0001437749-22-005273.txt : 20220304 0001437749-22-005273.hdr.sgml : 20220304 20220304130640 ACCESSION NUMBER: 0001437749-22-005273 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220304 DATE AS OF CHANGE: 20220304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATIONAL RESEARCH CORP CENTRAL INDEX KEY: 0000070487 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 470634000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35929 FILM NUMBER: 22713244 BUSINESS ADDRESS: STREET 1: 1245 Q STREET CITY: LINCOLN STATE: NE ZIP: 68508 BUSINESS PHONE: 4024752525 MAIL ADDRESS: STREET 1: 1245 Q STREET CITY: LINCOLN STATE: NE ZIP: 68508 10-K 1 nrc20211231_10k.htm FORM 10-K nrc20211231_10k.htm
0000070487 National Research Corporation false --12-31 FY 2021 94 120 0.01 0.01 2,000,000 2,000,000 0 0 0 0 0.001 0.001 110,000,000 60,000,000 30,898,600 30,775,154 25,361,409 25,390,968 5,537,191 5,384,186 87,203 227,902 6,005 0.78 180,112 630,373 6,793 0.21 153,005 116,753 0.48 3 5 3 10 3 5 1 5 7 40 0 0 0 0 0 1 1 0 0 1 1 1 0 0 30,000,000 15,000,000 0 0 1.10 3.00 100,000 1 10 3 5 10 0 5 0 1 1 00000704872021-01-012021-12-31 iso4217:USD 00000704872021-06-30 xbrli:shares 00000704872022-02-25 thunderdome:item 00000704872021-12-31 00000704872020-12-31 iso4217:USDxbrli:shares 00000704872020-01-012020-12-31 00000704872019-01-012019-12-31 0000070487us-gaap:CommonStockMember2018-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2018-12-31 0000070487us-gaap:RetainedEarningsMember2018-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-31 0000070487us-gaap:TreasuryStockMember2018-12-31 00000704872018-12-31 0000070487us-gaap:TreasuryStockMember2019-01-012019-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-31 0000070487us-gaap:RetainedEarningsMember2019-01-012019-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-31 0000070487us-gaap:CommonStockMember2019-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000070487us-gaap:RetainedEarningsMember2019-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0000070487us-gaap:TreasuryStockMember2019-12-31 00000704872019-12-31 0000070487us-gaap:TreasuryStockMember2020-01-012020-12-31 0000070487us-gaap:CommonStockMember2020-01-012020-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0000070487us-gaap:RetainedEarningsMember2020-01-012020-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-31 0000070487us-gaap:CommonStockMember2020-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000070487us-gaap:RetainedEarningsMember2020-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0000070487us-gaap:TreasuryStockMember2020-12-31 0000070487us-gaap:TreasuryStockMember2021-01-012021-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0000070487us-gaap:RetainedEarningsMember2021-01-012021-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-31 0000070487us-gaap:CommonStockMember2021-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000070487us-gaap:RetainedEarningsMember2021-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000070487us-gaap:TreasuryStockMember2021-12-31 utr:Y 0000070487srt:MinimumMember2021-12-31 0000070487srt:MaximumMember2021-12-31 0000070487nrc:DirectExpensesMember2021-01-012021-12-31 0000070487nrc:DirectExpensesMember2020-01-012020-12-31 0000070487nrc:DirectExpensesMember2019-01-012019-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-31 0000070487us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2021-01-012021-12-31 0000070487us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2021-01-012021-12-31 0000070487us-gaap:ComputerEquipmentMembersrt:MinimumMember2021-01-012021-12-31 0000070487us-gaap:ComputerEquipmentMembersrt:MaximumMember2021-01-012021-12-31 0000070487us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MinimumMember2021-01-012021-12-31 0000070487us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MaximumMember2021-01-012021-12-31 0000070487us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2021-01-012021-12-31 0000070487us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2021-01-012021-12-31 xbrli:pure 0000070487nrc:CanadianSubsidiaryMember2021-12-31 0000070487nrc:CanadianSubsidiaryMember2021-01-012021-12-31 0000070487nrc:CyberAttackMembernrc:RecoveriesReceivedDirectByTheCompanyMember2020-01-012020-12-31 0000070487nrc:CyberAttackMembernrc:RecoveriesPaidDirectlyByInsurerToOutsideVendorMember2020-01-012020-12-31 0000070487nrc:CyberAttackMembernrc:ReimbursementForLostRevenueMember2020-01-012020-12-31 0000070487us-gaap:OtherIncomeMembernrc:PropertyDamageExcludingCyberAttackMember2020-01-012020-12-31 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000070487us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000070487us-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-31 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-31 0000070487us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-31 0000070487us-gaap:FairValueMeasurementsRecurringMember2020-12-31 0000070487us-gaap:CommonClassAMember2021-01-012021-12-31 0000070487us-gaap:CommonClassAMember2020-01-012020-12-31 0000070487us-gaap:CommonClassAMember2019-01-012019-12-31 0000070487us-gaap:CommonStockMember2021-01-012021-12-31 0000070487us-gaap:CommonStockMember2020-01-012020-12-31 0000070487us-gaap:CommonStockMember2019-01-012019-12-31 0000070487nrc:PatientWisdomIncMember2021-01-042021-01-04 0000070487nrc:PatientWisdomIncMember2021-01-04 0000070487nrc:PatientWisdomIncMemberus-gaap:CustomerRelationshipsMember2021-01-04 0000070487nrc:PatientWisdomIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-01-04 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2021-01-012021-12-31 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-12-31 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-12-31 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2021-01-012021-12-31 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2020-01-012020-12-31 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2019-01-012019-12-31 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2021-01-012021-12-31 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-12-31 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-12-31 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2021-01-012021-12-31 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-12-31 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-12-31 0000070487us-gaap:OtherCurrentAssetsMember2021-12-31 0000070487us-gaap:OtherCurrentAssetsMember2020-12-31 0000070487us-gaap:LongTermContractWithCustomerMember2022-01-012021-12-31 0000070487us-gaap:LongTermContractWithCustomerMember2023-01-012021-12-31 0000070487us-gaap:LongTermContractWithCustomerMember2024-01-012021-12-31 0000070487us-gaap:LongTermContractWithCustomerMember2021-12-31 0000070487us-gaap:FurnitureAndFixturesMember2021-12-31 0000070487us-gaap:FurnitureAndFixturesMember2020-12-31 0000070487us-gaap:ComputerEquipmentMember2021-12-31 0000070487us-gaap:ComputerEquipmentMember2020-12-31 0000070487us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-31 0000070487us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-12-31 0000070487us-gaap:BuildingAndBuildingImprovementsMember2021-12-31 0000070487us-gaap:BuildingAndBuildingImprovementsMember2020-12-31 0000070487us-gaap:LeaseholdImprovementsMember2021-12-31 0000070487us-gaap:LeaseholdImprovementsMember2020-12-31 0000070487us-gaap:LandMember2021-12-31 0000070487us-gaap:LandMember2020-12-31 0000070487nrc:IncludingAssetsHeldUnderCapitalLeaseMember2021-01-012021-12-31 0000070487nrc:IncludingAssetsHeldUnderCapitalLeaseMember2020-01-012020-12-31 0000070487nrc:IncludingAssetsHeldUnderCapitalLeaseMember2019-01-012019-12-31 0000070487nrc:TradeNames1Member2021-12-31 0000070487us-gaap:CustomerRelationshipsMembersrt:MinimumMember2021-01-012021-12-31 0000070487us-gaap:CustomerRelationshipsMembersrt:MaximumMember2021-01-012021-12-31 0000070487us-gaap:CustomerRelationshipsMember2021-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2021-01-012021-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-31 0000070487us-gaap:TradeNamesMembersrt:MinimumMember2021-01-012021-12-31 0000070487us-gaap:TradeNamesMembersrt:MaximumMember2021-01-012021-12-31 0000070487us-gaap:TradeNamesMember2021-12-31 0000070487nrc:TradeNames1Member2020-12-31 0000070487us-gaap:CustomerRelationshipsMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:CustomerRelationshipsMembersrt:MaximumMember2020-01-012020-12-31 0000070487us-gaap:CustomerRelationshipsMember2020-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2020-12-31 0000070487us-gaap:TradeNamesMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:TradeNamesMembersrt:MaximumMember2020-01-012020-12-31 0000070487us-gaap:TradeNamesMember2020-12-31 0000070487nrc:CanadianSubsidiaryMember2020-01-012020-12-31 0000070487nrc:TermLoanMember2021-12-31 0000070487nrc:TermLoanMember2020-12-31 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2021-12-31 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-05-28 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2020-05-28 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:DelayedDrawTermLoanMember2021-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:DelayedDrawTermLoanMember2020-05-28 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2021-01-012021-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2021-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-01-012021-12-31 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-12-31 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2021-01-012021-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2021-01-012021-12-31 0000070487nrc:DirectorPlan2004Memberus-gaap:CommonStockMember2021-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:DirectorMember2021-01-012021-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:DirectorMember2020-01-012020-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:MaximumMembersrt:DirectorMember2021-01-012021-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:MinimumMembersrt:DirectorMember2021-01-012021-12-31 0000070487nrc:DirectorPlan2004Member2021-12-31 0000070487nrc:The2006EquityIncentivePlanMemberus-gaap:CommonStockMember2021-12-31 0000070487nrc:The2006EquityIncentivePlanMembersrt:MinimumMember2021-01-012021-12-31 0000070487nrc:The2006EquityIncentivePlanMembersrt:MaximumMember2021-01-012021-12-31 0000070487nrc:The2006EquityIncentivePlanMember2021-12-31 0000070487nrc:CommonStockOptionsMember2021-01-012021-12-31 0000070487nrc:CommonStockOptionsMember2020-01-012020-12-31 0000070487nrc:CommonStockOptionsMember2019-01-012019-12-31 0000070487us-gaap:CommonStockMember2021-01-012021-12-31 0000070487us-gaap:CommonStockMember2019-01-012019-12-31 0000070487nrc:CommonStockOptionsMember2020-12-31 0000070487nrc:CommonStockOptionsMember2021-12-31 0000070487us-gaap:EmployeeStockOptionMember2021-12-31 0000070487us-gaap:EmployeeStockOptionMember2021-01-012021-12-31 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-31 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2021-01-012021-12-31 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2019-01-012019-12-31 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2020-01-012020-12-31 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2021-12-31 0000070487nrc:NonvestedMember2021-01-012021-12-31 0000070487nrc:NonvestedMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0000070487nrc:NonvestedMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000070487nrc:NonvestedMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-31 0000070487us-gaap:RestrictedStockMember2020-01-012020-12-31 0000070487us-gaap:RestrictedStockMember2021-01-012021-12-31 0000070487us-gaap:RestrictedStockMember2019-01-012019-12-31 0000070487us-gaap:CommonStockMember2020-12-31 0000070487us-gaap:CommonStockMember2021-12-31 0000070487nrc:NonvestedMember2021-12-31 0000070487us-gaap:OtherCurrentLiabilitiesMember2021-12-31 0000070487us-gaap:OtherCurrentLiabilitiesMember2020-12-31 0000070487us-gaap:OtherNoncurrentLiabilitiesMember2021-12-31 0000070487us-gaap:OtherNoncurrentLiabilitiesMember2020-12-31 0000070487nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember2021-12-31 0000070487nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember2020-12-31 0000070487nrc:FurnitureAndEquipmentHeldUnderFinanceLeasesMember2021-12-31 0000070487nrc:FurnitureAndEquipmentHeldUnderFinanceLeasesMember2020-12-31 0000070487nrc:ComputerEquipmentHeldUnderFinanceLeasesMember2021-12-31 0000070487nrc:ComputerEquipmentHeldUnderFinanceLeasesMember2020-12-31 0000070487nrc:ComputerSoftwareHeldUnderFinanceLeasesMember2021-12-31 0000070487nrc:ComputerSoftwareHeldUnderFinanceLeasesMember2020-12-31 0000070487nrc:AssetsHeldUnderFinanceLeasesMember2021-12-31 0000070487nrc:AssetsHeldUnderFinanceLeasesMember2020-12-31 0000070487nrc:AllinaHealthMember2021-01-012021-12-31 0000070487nrc:AmeritasLifeInsuranceCorpMember2021-01-012021-12-31 0000070487nrc:AmeritasLifeInsuranceCorpMember2020-01-012020-12-31 0000070487nrc:AmeritasLifeInsuranceCorpMember2019-01-012019-12-31 0000070487nrc:PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMembernrc:IMAFinancialGroupMember2020-01-012020-12-31 0000070487nrc:PracticingExcellencecomMember2021-01-012021-12-31 0000070487nrc:PracticingExcellencecomMember2020-01-012020-12-31 0000070487nrc:PracticingExcellencecomMember2019-01-012019-12-31 0000070487country:US2021-01-012021-12-31 0000070487country:US2020-01-012020-12-31 0000070487country:US2019-01-012019-12-31 0000070487country:CA2021-01-012021-12-31 0000070487country:CA2020-01-012020-12-31 0000070487country:CA2019-01-012019-12-31 0000070487country:US2021-12-31 0000070487country:US2020-12-31 0000070487country:US2019-12-31 0000070487country:CA2021-12-31 0000070487country:CA2020-12-31 0000070487country:CA2019-12-31
 

 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021     

or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  
 

For the transition period from ________ to ________

Commission File Number 001-35929

   National Research Corporation      

(Exact name of Registrant as specified in its charter)

 

Delaware

 

47-0634000

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

 

1245 Q Street, Lincoln, Nebraska          68508

 
 

(Address of principal executive offices) (Zip Code)

 

 

 

(402) 475-2525

 
 

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.001 par value

NRC

The NASDAQ stock market

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer     

☒

 

Non-accelerated filer

☐

Smaller reporting company

☐

 
  

Emerging growth company

☐

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes ☐    No  ☒ 

 

Aggregate market value of the common stock held by non-affiliates of the registrant at June 30, 2021: $533,334,729.

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

 

Common Stock, $.001 par value, outstanding as of February 25, 2022: 25,194,447

 

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Proxy Statement for the 2022 Annual Meeting of Shareholders are incorporated by reference into Part III.

 

 
Table of Contents

 

 

TABLE OF CONTENTS

 

   

Page

PART I
     

Item 1.

Business

1

Item 1A.

Risk Factors

7

Item 1B.

Unresolved Staff Comments

13

Item 2.

Properties

13

Item 3.

Legal Proceedings

13

Item 4.

Mine Safety Disclosures

13
     

PART II
     

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

14

Item 6.

[Reserved]

15

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 7A.

Quantitative and Qualitative Disclosure About Market Risk

22

Item 8.

Financial Statements and Supplementary Data

23

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

52

Item 9A.

Controls and Procedures

52

Item 9B.

Other Information

52

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

52
     

PART III
     

Item 10.

Directors, Executive Officers and Corporate Governance

53

Item 11.

Executive Compensation

53

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

53

Item 13.

Certain Relationships and Related Transactions, and Director Independence

54

Item 14.

Principal Accountant Fees and Services

54
     

PART IV
     

Item 15.

Exhibits

55

Item 16.

Form 10-K Summary

56

Signatures

58

 

i
Table of Contents
 
 

PART I

 

Item 1.

Business

 

Special Note Regarding Forward-Looking Statements

 

Certain matters discussed in this Annual Report on Form 10-K are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified as such because the context of the statement includes phrases such as National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), “believes,” “expects,” “may,” “could,” “anticipates,” or the use of words such as “would,” “may,” “could,” or “should,” or other words of similar import. Similarly, statements that describe our future plans, objectives or goals are also forward-looking statements. In this Annual Report on Form 10-K, statements regarding the future impact of adopting new accounting standards, value and utility of, and market demand for, our service offerings, future opportunities for growth with respect to new and existing clients, our future ability to compete and the types of firms with which we will compete, future consolidation in the healthcare industry, future adequacy of our liquidity sources, future revenue sources, future revenue growth, future revenue estimates used to calculate recurring contract value, future capital expenditures and the timing, amount, and sources of cash to fund such capital expenditures, future stock repurchases and dividends, the expected impact of pending claims and contingencies, the future outcome of uncertain tax positions, our future use of owned and leased real property, the source of funds for future payments of deferred purchase price obligations and other cash expenses, the future phase out of LIBOR and applicable replacement benchmark rates and the expected impact of the COVID-19 pandemic and related government mandates and recommendations, among others, are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties which could cause actual results or outcomes to differ materially from those currently anticipated. Factors that could affect actual results or outcomes include, without limitation, the following factors:

 

 

●

The likelihood that the COVID-19 pandemic will adversely affect our operations, sales, earnings, financial condition and liquidity;

 

 

●

The possibility of non-renewal of our client service contracts, reductions in services purchased or prices, and failure to retain key clients;

 

 

●

Our ability to compete in our markets, which are highly competitive with new market entrants, and the possibility of increased price pressure and expenses;

 

 

●

The effects of an economic downturn;

 

 

●

The impact of consolidation in the healthcare industry;

 

 

●

The impact of federal healthcare reform legislation or other regulatory changes;

 

 

●

Our ability to attract and retain key managers and other personnel;

 

 

●

The possibility that our intellectual property and other proprietary information technology could be copied or independently developed by our competitors;

 

 

●

The possibility for failures or deficiencies in our information technology platform;

 

 

●

The possibility that we or our third-party providers could be subject to cyber-attacks, security breaches or computer viruses; and 

 

 

●

The factors set forth under the caption “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission.

 

Shareholders, potential investors and other readers are urged to consider these and other factors in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included are only made as of the date of this Annual Report on Form 10-K and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as required by the federal securities laws.

 

1
Table of Contents

 

General

 

Our purpose is to establish human understanding by enabling our clients to understand what matters most to each person they serve. We are a leading provider of analytics and insights that facilitate measurement and improvement of patient engagement and customer loyalty for healthcare organizations. Our heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for and design experiences that inspire loyalty and trust, while also facilitating regulatory compliance and the shift to population-based health management. Our ability to measure what matters most and systematically capture, analyze and deliver insights based on self-reported information from patients, families and consumers is critical in today’s healthcare market. We believe that access to and analysis of our extensive consumer-driven information is becoming more valuable as healthcare providers increasingly need to more deeply understand and engage the people they serve to build customer loyalty.

 

Our expertise includes the efficient capture, transmittal, benchmarking, analysis and interpretation of critical data elements from millions of healthcare consumers. Using our solutions, our clients gain insights into what people think and feel about their organizations in real-time, allowing them to build on their strengths and resolve service issues with greater speed and personalization. We also provide legacy experience-based solutions and shared intelligence from industry thought leaders and the nation’s largest member network focused on healthcare governance and strategy to member boards and executives.

 

Our portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management and brand loyalty. We partner with clients across the continuum of healthcare services. We believe this cross-continuum positioning is a unique and an increasingly important capability as evolving payment models drive healthcare providers and payers towards a more collaborative and integrated service model.

 

We have a broad and diversified client base that is distributed primarily across the United States. Our ten largest clients collectively accounted for 14%, 14%, and 16% of our total revenue in 2021, 2020 and 2019, respectively. Approximately 2%, 2% and 3% of our revenue was derived from foreign customers in 2021, 2020, and 2019, respectively.

 

We have achieved a market leadership position through our more than 40 years of industry innovation and experience, as well as our long-term, recurring revenue relationships (solutions that are used or required by a client each year) with many of the healthcare industry’s largest organizations. Since our founding in 1981, we have focused on meeting the evolving information needs of the healthcare industry through internal product development, as well as select acquisitions. We are a Delaware corporation headquartered in Lincoln, Nebraska.

 

Human Understanding Solutions

 

Our portfolio of solutions collectively provide a comprehensive set of capabilities that enable healthcare providers to collect, measure and analyze data collected across the patient journey to understand the preferences, experiences and needs of the people they serve. Our digital solutions consist of three primary solution categories which can be implemented both collectively as an enterprise solution or individually to meet specific needs within the organization. The primary solution categories include Market Insights solutions, Transparency solutions, and Experience solutions.

 

Market Insights Solutions – Our Market Insights solutions are subscription-based services that allow for improved tracking of awareness, perception, and consistency of healthcare brands; real-time assessment of competitive differentiators; and enhanced segmentation tools to evaluate the needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. Market Insights is the largest U.S. healthcare consumer database of its kind, measuring the opinions and behaviors of approximately 300,000 healthcare consumers across the contiguous United States annually. Our Market Insights is a syndicated survey that provides clients with an independent third-party source of information that is used to understand consumer perception and preferences and optimize marketing strategies. Our Market Insights solutions provide clients with on-demand tools to measure brand value and build brand equity in their markets, evaluate and optimize advertising efficacy and consumer recall, and tailor research to obtain the real time voice of customer feedback to support branding and loyalty initiatives.

 

2
Table of Contents

 

Experience Solutions – Our Experience solutions are provided on a subscription basis via a cross-continuum multi-mode digital platform that collects and measures data and then delivers business intelligence that our clients utilize to improve patient experience, engagement and loyalty. Patient experience data can also be collected on a periodic basis using CAHPS compliant mail and telephone survey methods for regulatory compliance purposes and to monitor and measure improvement in CAHPS survey scores. Consumer Assessment of Healthcare Providers and Systems (“CAHPS”) survey data can be collected and measured as an integrated service within our digital platform or independently as a legacy service offering. Our Experience solutions provide healthcare systems the ability to receive and take action on customer and employee feedback across all care settings in real-time. Experience solutions include patient experience, workforce engagement, health risk assessments, care transition, and improvement tools. These solutions enable clients to comply with regulatory requirements and to improve their reimbursement under value-based purchasing models. More importantly, our Experience solutions provide quantitative and qualitative real-time feedback, improvement plans, and coaching insights.   By illuminating the complete care journey in real time, our clients are able to ensure each individual receives the care, respect, and experience he or she deserves. Developing a longitudinal profile of what healthcare customers want and need allows for organizational improvement and increased customer loyalty.

 

Our Experience solutions also include the Transitions solution to drive effective communication between healthcare providers and patients in the critical 24-72 hours post discharge using an automated discharge call workflow supported by our digital platform. Through preference-based communications and real-time alerts, these solutions enable organizations to identify and manage high-risk patients to reduce readmissions, increase patient satisfaction and support safe care transitions. Tracking, trending and benchmarking tools isolate the key areas for process improvement allowing organizations to implement changes and reduce future readmissions.

 

Transparency Solutions – Our Transparency solutions allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs better consumer decision-making. Our Star Ratings solution enables clients to publish a five-star rating metric and verified patient feedback derived from actual patient survey data to complement their online physician information. Sharing this feedback not only results in better-informed consumer decision-making but also has the ability to drive new patient acquisition and grow online physician reputation. Our Reputation Monitoring solution alerts clients to ratings and reviews on third-party websites and provides workflows for response and service recovery. These solutions raise physician awareness of survey results and provide access to improvement resources and educational development opportunities designed to improve the way care is delivered.

 

The Governance Institute

 

Our Governance solutions, branded as The Governance Institute (“TGI”), serves not-for-profit health system boards of directors, executives, and physician leadership. TGI’s subscription-based, value-driven membership services are provided through national conferences, publications, advisory services, and an online portal designed to improve the effectiveness of hospital and healthcare systems by continually strengthening their board governance, strategic planning, medical leadership, management performance and customer loyalty. TGI also conducts research studies and tracks industry trends showcasing emerging healthcare trends and best practice solutions of healthcare system boards across the country. TGI thought leadership helps our client board members and executives inform and guide their organization’s strategic priorities in alignment with the rapidly changing healthcare market.

 

For additional information on our operating segment and our revenue and assets by geographic area, see Note 13, “Segment Information,” to our consolidated financial statements.

 

Markets

 

Growth Strategy

 

We believe that the value proposition of our current solutions, combined with the favorable alignment of our solutions with emerging market demand, positions us to benefit from multiple growth opportunities. We believe that we can accelerate our growth through (1) increasing scope of services and sales of our existing solutions to our existing clients (or cross-selling), (2) winning additional new clients through market share growth in existing market segments, (3) developing and introducing new solutions to new and existing clients, and (4) pursuing acquisitions of, or investments in, firms providing products, solutions or technologies which complement ours.

 

Increasing contract value with existing clients. Approximately 32% of our existing clients purchase more than one of our solutions. Our sales organization actively identifies and pursues cross-sell opportunities for clients to add additional solutions in order to accelerate our growth. Organic contract value growth is also realized by the increased scope of solution adoption as the size of client organizations increase from market expansion and consolidation.

 

3
Table of Contents

 

Adding new clients. We believe that there is an opportunity to add new clients across all existing market segments. Our sales organization is actively identifying and engaging new client prospects with a focus on demonstrating the economic value derived from adopting the portfolio of solutions in alignment with the prospect’s strategic objectives.

 

Adding new solutions. The need for effective solutions in the market segments that we serve is evolving to align with emerging healthcare consumerism trends. The evolving market creates an opportunity for us to introduce new solutions that leverage and extend our existing core competencies. We believe that there is an opportunity to drive sales growth with both existing and new clients, across all of the market segments that we serve, through the introduction of new solutions.

 

Pursue strategic acquisitions and investments. We have historically complemented our organic growth with strategic acquisitions, having completed eight such transactions over the past nineteen years. These transactions have added new capabilities and access to market segments that are adjacent and complementary to our existing solutions and market segments. We believe that additional strategic acquisition and/or investment opportunities will exist from time to time to complement our organic growth by further expanding our service capabilities, technology offerings and end markets.

 

We generate the majority of our revenue from the renewal of subscription-based client service agreements, supplemented by sales of additional solutions to existing clients and the addition of new clients. Our sales activities are carried out by our direct sales organization staffed with professional, trained sales associates.

 

We engage in marketing activities that enhance our brand visibility in the marketplace, generate demand for our solutions and engage existing clients. Strategic campaigns and programs focus on (1) ensuring coverage of prospective clients via targeted advertising and account-based campaigns, (2) elevating client value evidence and success stories to an executive level profile, (3) engaging key stakeholders with content, programming and events and (4) amplifying thought leadership through public and media relations programs that include earning placement in national media and trade publications, securing podium presentations at key industry events and winning awards on behalf of us and our executives.

 

Competition

 

The healthcare information and market research services industry is highly competitive. We have traditionally competed with healthcare organizations’ internal marketing, market research, and/or quality improvement departments which create their own performance measurement tools, and with relatively small specialty research firms which provide survey-based healthcare market research and/or performance assessment. Our primary competitors among such specialty firms include Press Ganey, which we believe has significantly higher annual revenue than us, and several other organizations that we believe have less annual revenue than us. We also compete with market research firms and technology solutions which provide survey-based, general market research or voice of the customer feedback capabilities and firms that provide services or products that complement healthcare performance assessments such as healthcare software or information systems.

 

We believe the primary competitive factors within our market include quality of service, timeliness of delivery, unique service capabilities, credibility of provider, industry experience, and price. We believe that our industry leadership position, exclusive focus on the healthcare industry, cross-continuum presence, comprehensive portfolio of solutions and relationships with leading healthcare payers and providers position us to compete in this market.

 

Although only a few of these competitors have offered specific services that compete directly with our solutions, many of these competitors have substantially greater financial, information gathering, and marketing resources than us and could decide to increase their resource commitments to our market. There are relatively few barriers to entry into our market, and we expect increased competition in our market which could adversely affect our operating results through pricing pressure, increased marketing expenditures, and market share losses, among other factors. There can be no assurance that we will continue to compete successfully against existing or new competitors.

 

We believe that our competitive strengths include the following:

 

A leading provider of patient experience solutions for healthcare providers, payers and other healthcare organizations. Our history is based on capturing the voice of the consumer in healthcare markets. Our solutions build on the “Eight Dimensions of Patient-Centered Care,” a philosophy developed by noted patient advocate Harvey Picker, who believed patients’ experiences are integral to quality healthcare. This foundation has been enhanced through our digital platform offering that provides the delivery of data and insights on a real time basis to understand what matters most to each individual. Based on our more than 40 years of experience, we are able to deliver unique and relevant healthcare domain expertise to the clients we serve.

 

4
Table of Contents

 

Established client base of leading healthcare organizations. Our client portfolio encompasses a majority of the leading healthcare systems across the United States. Over 275 of the top 400 healthcare systems based on net patient revenue are currently using one or more of our solutions. Our client base provides a unique network effect to share best practices among existing clients and to attract new clients. Our existing client base also provides a significant organic growth opportunity to upsell and cross sell additional solutions.

 

Highly scalable and visible revenue model. Our solutions are offered primarily through fixed price, subscription-based service agreements. The solutions we provide are also recurring in nature, which enables an ongoing relationship with our clients and favorable retention. This combination of subscription-based revenue, a base of ongoing client renewals and automated platforms creates a highly visible and scalable revenue model.

 

Comprehensive portfolio of solutions. We offer a portfolio of solutions that provide insights across the patient journey, which is unique in the healthcare industry. Our solutions enable the collection of data and insights from individuals prior to receiving care and then throughout their care journey from first encounter to after completion of their care. The data and insights provided through our solutions enable our clients to better understand what matters most to each person they serve to meet expectations and increase customer loyalty.

 

Exclusive focus on healthcare. We focus exclusively on healthcare and serving the unique needs of healthcare organizations across the continuum, which we believe gives us a distinct competitive advantage compared to other survey and analytics software providers. Our value proposition incorporates the benefits to clients derived from our deep subject matter expertise that has been built from helping healthcare organizations over the past 40 years. Our platform includes features and capabilities built specifically for healthcare providers, including a library of performance improvement content which can be tailored to the provider based on their specific customer feedback profile.

 

Experienced senior management team led by our founder. Our senior management team has extensive industry and leadership experience. Michael D. Hays, our Chief Executive Officer and President, founded NRC Health in 1981. Prior to launching the Company, Mr. Hays served as Vice President and as a Director of SRI Research Center, Inc. (now known as the Gallup Organization). Our Chief Financial Officer, Kevin Karas, CPA, has extensive financial experience having served as CFO at two previous companies, along with healthcare experience at Rehab Designs of America, Inc. and NovaCare, Inc. Jona Raasch has served as our Chief Operating Officer for most of the last 30 years and as Chief Executive Officer of the Governance Institute for more than 15 years.  Helen Hrdy was appointed as our Chief Growth Officer in 2020.  Prior to this position Ms. Hrdy served as our Senior Vice President, Customer Success, for eight years.

 

Resources

 

Our success depends in part upon our data collection processes, research methods, data analysis techniques and internal systems, and procedures that we have developed specifically to serve clients in the healthcare industry. We have no patents for most of our intellectual property. Consequently, we rely on a combination of copyright and trade secret laws and associate nondisclosure agreements to protect our systems, survey instruments and procedures. There can be no assurance that the steps we have taken to protect our rights will be adequate to prevent misappropriation of such rights or that third parties will not independently develop functionally equivalent or superior systems or procedures. We believe that our systems and procedures and other proprietary rights do not infringe upon the proprietary rights of third parties. There can be no assurance, however, that third parties will not assert infringement claims against us in the future or that any such claims will not result in protracted and costly litigation, regardless of the merits of such claims or whether we are ultimately successful in defending against such claims.

 

Government Regulation

 

According to the Centers for Medicare and Medicaid Services (“CMS”), health expenditures in the United States were approximately $4.1 trillion in 2020, or $12,530 per person. In total, health spending accounted for 19.7% of the nation’s Gross Domestic Product in 2020. Addressing this growing expenditure burden continues to be a major policy priority at both federal and state levels. In addition, increased co-pays and deductibles in healthcare plans have focused even more consumer attention on health spending and affordability. In the public sector, Medicare provides health coverage for individuals aged 65 and older, while Medicaid provides coverage for low-income families and other individuals in need. Both programs are administered by the CMS. With the aging of the U.S. population, Medicare enrollment has increased significantly.  In addition, longer life spans and greater prevalence of chronic illnesses among both the Medicare and Medicaid populations have placed tremendous demands on the health care system.

 

5
Table of Contents

 

An increasing percentage of Medicare reimbursement and reimbursement from commercial payers has been determined under value payment models, based on factors such as patient readmission rates and provider adherence to certain quality-related protocols. At the same time, many hospitals and other providers are creating new models of care delivery to improve patient experience, reduce cost and provide better clinical outcomes. These new models are based on sharing financial risk and managing the health and behaviors of large populations of patients and consumers. This transformation towards value-based payment models and increased engagement of healthcare consumers is resulting in a greater need for existing healthcare providers to deliver more customer-centric healthcare. At the same time, organizations that have successfully developed effective customer service models and brand loyalty in other industry verticals are entering the healthcare services market.

 

We believe that our current portfolio of solutions is uniquely aligned to address these healthcare market trends and related business opportunity. We provide tools and solutions to capture, interpret and improve the CAHPS data required by CMS as well as real time feedback that enables clients to better understand what matters most to people at key moments in their relationship with a health organization. Our solutions enable our clients to both satisfy patient survey compliance requirements and design experiences to build loyalty and improve the wellbeing of the people and communities they care for.

 

Human Capital

 

As of December 31, 2021, we employed a total of 511 associates, 10 of those were employed in Canada. None of our associates are represented by a collective bargaining unit. As a result of the COVID-19 pandemic, the majority of our associates are working remotely with very successful results. We attract a passionate team of associates who care deeply about making a difference in advancing “Human Understanding” in healthcare. We consider our relationships with our associates to be good.

 

We are committed to providing a workplace free of harassment or discrimination based on race, color, religion, sex, sexual orientation, gender identity, national origin, genetic information, ancestry, veteran status, or disability. We are an equal opportunity employer committed to inclusion and diversity.

 

Available Information

 

More information regarding NRC Health is available on our website at www.nrchealth.com. We are not including the information contained on or available through our website as part of, or incorporating such information by reference into, this Annual Report on Form 10-K. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports are made available to the public at no charge through a link appearing on our website. We provide access to such materials through our website as soon as reasonably practicable after electronically filing such material with, or furnishing it to, the Securities and Exchange Commission. Reports and amendments posted on our website do not include access to exhibits and supplemental schedules electronically filed with the reports or amendments.

 

6
Table of Contents

 

Item 1A.

Risk Factors

 

You should carefully consider each of the risks described below, together with all of the other information contained in this Annual Report on Form 10-K, before making an investment decision with respect to our securities. If any of the following risks develop into actual events, our business, financial condition or results of operations could be materially and adversely affected and you may lose all or part of your investment.

 

Risks Related to our Business

 

We could be negatively impacted by the Coronavirus or “COVID-19” outbreak or other similar outbreaks.

 

The outbreak of COVID-19, and the associated responses, have impacted our business in a variety of ways. Governments have implemented business and travel restrictions and recommended social distancing and other guidelines. Many businesses, including many of our clients, have de-emphasized external business opportunities and restricted in-person meetings while shifting their attention toward addressing COVID-19 planning, business disruptions, higher costs, and revenue shortfalls. Although the impact on our healthcare clients has varied, many of our clients have experienced decreased revenues, contracting margins, and cash losses.  Some clients’ cost reducing measures have included and could continue to include reducing or eliminating the services they purchase from us. While these circumstances did not significantly impact our financial position or results of operations in 2020 and 2021, the negative impact could continue to increase. 

 

We rely on third-party service providers and business partners, for services or supplies that are critical to providing our clients’ services. These include activities such as internet, cloud data storage, information technology services, and survey related services. These third parties are also subject to risks and uncertainties related to the COVID-19 pandemic, which may interfere with their ability to provide their services in a timely manner and in accordance with the agreed-upon terms or our agreements, which could interfere with our ability to operate our business.

 

At NRC, the vast majority of our associates are working remotely, and to date we have been capable of providing our services without significant disruption. We have made our facilities available for associates to return to work effective July 1, 2021 at their discretion. Historically, we have relied on national travel as part of our sales efforts, but as a result of the pandemic we had placed a temporary hold on all company related travel. We modified our travel policy and limited travel did resume in the third quarter of 2021. To date, we are still capable of providing our services without interruption and without significant changes to our internal control over financial reporting. However, we may need to develop or adapt to new ways of doing business that challenge our leadership, our associate training, our human resources, and our business practices, and we cannot assure you that we will be successful in doing so. The short and long-term costs associated with these potential changes are difficult to quantify. For these and other reasons, the outbreak and associated responses could negatively affect our business, and the impact could be material.

 

To the extent the COVID-19 pandemic adversely affects the Company’s business, results of operations, financial condition and stock price, it may also have the effect of heightening many of the other risks described in this Part I, Item 1A of this Form 10-K.

 

We depend on contract renewals, including retention of key clients, for a large share of our revenue and our operating results could be adversely affected.

 

We expect that a substantial portion of our revenue for the foreseeable future will continue to be derived from renewable service contracts. Substantially all contracts are renewable annually at the option of our clients, although contracts with clients under unit-based arrangements generally have no minimum purchase commitments. Client contracts are generally cancelable on short notice without penalty, however we are entitled to payment for services through the cancellation date. To the extent that clients fail to renew or defer their renewals, we anticipate our results may be materially adversely affected. We rely on a limited number of key clients for a substantial portion of our revenue. Our ten largest clients collectively accounted for 14%, 14%, and 16% of our total revenue in 2021, 2020, and 2019, respectively. Our ability to secure renewals depends on, among other things, our ability to gather and analyze performance data in a consistent, high-quality, and timely fashion. In addition, the service needs of our clients are affected by accreditation requirements, enrollment in managed care plans, the level of use of satisfaction measures in healthcare organizations’ overall management and compensation programs, the size of operating budgets, clients’ operating performance, industry and economic conditions, and changes in management or ownership. As these factors are beyond our control, we cannot ensure that we will be able to maintain our renewal rates. Any material decline in renewal rates from existing levels would have an adverse effect on our revenue and a corresponding effect on our operating and net income.

 

7
Table of Contents

 

We operate in a highly competitive market and could experience increased price pressure and expenses as a result.

 

The healthcare information and market research services industry is highly competitive. We have traditionally competed with healthcare organizations’ internal marketing, market research and/or quality improvement departments that create their own performance measurement tools, and with relatively small specialty research firms that provide survey-based healthcare market research and/or performance assessment. Our primary competitors among such specialty firms include Press Ganey, which we believe has significantly higher annual revenue than us, and three or four other firms that we believe have lower annual revenue than us. We also compete with market research firms and technology solutions which provide survey-based, general market research or voice of the customer feedback capabilities and firms that provide services or products that complement healthcare performance assessments, such as healthcare software or information systems. Although only a few of these competitors have offered specific services that compete directly with our services, many of these competitors have substantially greater financial, information gathering, and marketing resources than us and could decide to increase their resource commitments to our market. There are relatively few barriers to entry into our market, and we expect increased competition in our market which could adversely affect our operating results through pricing pressure, increased marketing expenditures, and market share losses, among other factors. There can be no assurance that we will continue to compete successfully against existing or new competitors.

 

Because our clients are concentrated in the healthcare industry, our revenue and operating results may be adversely affected by changes in regulations, a business downturn or consolidation with respect to the healthcare industry.

 

Substantially all of our revenue is derived from clients in the healthcare industry. As a result, our business, financial condition and results of operations are influenced by conditions affecting this industry, including changing political, economic, competitive and regulatory influences that may affect the procurement practices and operation of healthcare providers and payers. Future legislative changes, including additional provisions to control healthcare costs, improve healthcare quality and expand access to health insurance, could result in lower reimbursement rates and otherwise change the environment in which providers and payers operate. In addition, large private purchasers of healthcare services are placing increasing cost pressure on providers. Healthcare providers may react to these cost pressures and other uncertainties by curtailing or deferring purchases, including purchases of our services.

 

Moreover, there has been consolidation of companies in the healthcare industry, a trend which we believe will continue to grow. Consolidation in this industry, including the potential acquisition of certain of our clients, could adversely affect aggregate client budgets for our services, could result in clients performing more marketing, market research and/or quality improvement functions internally or could result in the termination of a client’s relationship with us. The impact of these developments on the healthcare industry is difficult to predict and could have an adverse effect on our revenue and a corresponding effect on our operating and net income.

 

We rely on third parties for data collection and other services whose actions could have a material adverse effect on our business.

 

We outsource certain operations and engage third parties to perform work needed to fulfill our client services. For example, we use vendors to perform certain printing, mailing, information transmittal and other services related to our survey operations. If any of these vendors cease to operate or fail to adequately perform the contracted services and alternative resources and processes are not utilized in a timely manner, our business could be adversely affected. The loss of any of our key vendors could impair our ability to perform our client services and result in lower revenues and income. It would also be time-consuming and expensive to replace, either directly or through other vendors, the services performed by these vendors, which could adversely impact revenues, expenses and net income. Furthermore, our ability to monitor and direct our vendors’ activities is limited. If their actions and business practices violate policies, regulations or procedures otherwise considered illegal, we could be subject to reputational damage or litigation which would adversely affect our business.

 

We face several risks relating to our ability to collect the data on which our business relies.

 

Our ability to provide timely and accurate performance measurement and improvement services to our clients depends on our ability to collect large quantities of high-quality data through surveys and interviews. If our mail survey operations are disrupted and we are unable to mail our surveys in a timely manner, then our revenue and net income could be negatively impacted. If receptivity to our survey and interview methods by respondents declines, or, for some other reason, their willingness to complete and return surveys declines, or if we, for any reason, cannot rely on the integrity of the data we receive, then our revenue could be adversely affected with a corresponding effect on our operating and net income. We also rely on third-party panels of pre-recruited consumer households to produce our Market Insights in a timely manner. If we are not able to continue to use these panels, or the time period in which we use these panels is altered and we cannot find alternative panels on a timely, cost-competitive basis, we could face an increase in our costs or an inability to effectively produce our Market Insights. In either case, our operating and net income could be negatively affected.

 

8
Table of Contents

 

If intellectual property and other proprietary information technology were copied or independently developed by our competitors, our operating results could be negatively affected.

 

Our success depends in part upon our data collection process, research methods, data analysis techniques, and internal systems and procedures that we have developed specifically to serve clients in the healthcare industry. We have no patents for most of our intellectual property. Consequently, we rely on a combination of copyright, trade secret laws and associate nondisclosure agreements to protect our systems, survey instruments and procedures. We cannot assure you that the steps we have taken to protect our rights will be adequate to prevent misappropriation of such rights, or that third parties will not independently develop functionally equivalent or superior systems or procedures. We believe that our systems and procedures and other proprietary rights do not infringe upon the proprietary rights of third parties. We cannot assure you, however, that third parties will not assert infringement claims against us in the future, or that any such claims will not result in protracted and costly litigation, regardless of the merits of such claims, or whether we are ultimately successful in defending against such claims.

 

Failures or deficiencies in our information technology platform could negatively impact our operating results.

 

Our ability to provide client service is dependent, to a significant extent, upon the technology that we develop internally. Investment in the enhancement of existing and development of new information technology processes is costly and affects our ability to successfully serve our clients. The failure or deficiency of the technology we develop could negatively impact the willingness or ability for our clients to use our services and our ability to perform our services. Our failure to anticipate clients’ expectation and needs, adapt to emerging technological trends, or design efficient and effective information technology platforms, could result in lower utilization, loss of customers, damage to customer relationships, reduced revenue and profits, refunds to customers and damage to our reputation. Although we have procedures to monitor the efficacy of our information technology platforms, the procedures may not prevent failures or deficiencies in the information technology platforms we develop, we may not adapt quickly enough and may incur significant costs and delays that could harm our business. Additional costs could be incurred to further develop and improve our information technology platforms.

 

Our business and operating results could be adversely affected if we experience business interruptions or failure of our information technology and communication systems.

 

Our ability to provide timely and accurate performance measurement and improvement services to our clients depends on the efficient and uninterrupted operation of our information technology and communication systems, and those of our external service providers. Our systems and those of our external service providers could be exposed to damage or interruption from fire, natural disasters, energy loss, telecommunication failure, security breach and computer viruses. An operational failure or outage in our information technology and communication systems or those of our external service providers, could result in loss of customers, damage to customer relationships, reduced revenue and profits, refunds of customer charges and damage to our reputation and may result in additional expense to repair or replace damaged equipment and recover data loss resulting from the interruption. Although we have taken steps to prevent system failures and have back-up systems and procedures to prevent or reduce disruptions, such steps may not prevent an interruption of services and our disaster recovery planning may not account for all contingencies. Additionally, our insurance may not adequately compensate us for all losses or failures that may occur. Any one of the above situations could have a material adverse effect on our business, financial condition, results of operations and reputation.

 

If we sustain cyber-attacks or other privacy or data security incidents that result in security breaches that disrupt our operations or result in the unintended dissemination of protected personal information or proprietary or confidential information, we could suffer a loss of revenue and increased costs, exposure to significant liability, reputational harm and other serious negative consequences. 

 

In connection with our client services, we receive, process, store and transmit sensitive business information and, in certain circumstances, personal medical information of our clients’ patients, electronically over the internet. We may become the target of attempted cyber-attacks and other security threats and may be subject to breaches of the information technology systems we use. Experienced computer programmers and hackers may be able to penetrate our security controls and access, misappropriate or otherwise compromise protected personal information or proprietary or confidential information or that of third-parties, create system disruptions or cause system shutdowns that could negatively affect our operations. They also may be able to develop and deploy viruses, worms, ransomware, and other malicious software programs that attack our systems or otherwise exploit any security vulnerabilities.

 

9
Table of Contents

 

We were the target of an external cyber-attack in February 2020 (the “February incident”) which resulted in a temporary suspension of our services to clients.  We will likely continue to be the target of other attempted cyber-attacks and security threats. Such cyber-attacks may subject us to litigation and regulatory risk, civil and criminal penalties, additional costs and diversion of management attention due to investigation, remediation efforts and engagement of third party consultants and legal counsel in connection with such incidents, payment of “ransoms” to regain access to our systems and information, loss of clients, damage to client relationships, reduced revenue and profits, refunds of client charges and damage to our reputation, any of which could have a material adverse effect on our business, cash flows, financial condition and results of operations. While we have contingency plans and insurance coverage for potential liabilities of this nature, they may not be sufficient to cover all claims and liabilities and in some cases are subject to deductibles and layers of self-insured retention.

 

We cannot ensure that we will be able to identify, prevent or contain the effects of cyber-attacks or other cybersecurity risks that bypass our security measures or disrupt our information technology systems or business. We have security technologies, processes and procedures in place to protect against cybersecurity risks and security breaches. However, hardware, software or applications we develop or procure from third parties may contain defects in design, manufacturer defects or other problems that could unexpectedly compromise information security. In addition, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently, are becoming increasingly sophisticated, and may not immediately produce signs of intrusion, we may be unable to anticipate these techniques, timely discover or counter them or implement adequate preventative measures.

 

In addition, we use third-party technology, systems and services for a variety of reasons, including, without limitation, encryption and authentication technology, employee email, content delivery to clients, back-office support, and other functions that in some cases involve processing, storing and transmitting large amounts of data for our business. These third-party providers may also experience security breaches or interruptions to their information technology hardware and software infrastructure and communications systems that could adversely impact us.

 

Under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, implementing regulations promulgated by the U.S. Department of Health and Human Services, or “HHS,” including what are referred to as the “Privacy Rule” and the “Security Rule” (collectively, “HIPAA”), we face potential liability related to the privacy of health information we obtain.  We are required through our contracts with our clients and by HIPAA to protect the privacy and security of certain health information and to make certain disclosures to our clients or to the public if this information is unlawfully accessed. 

 

Changes in privacy and information security laws and standards may require we incur significant expense to ensure compliance due to increased technology investment and operational procedures. Noncompliance with any privacy or security laws and regulations, including, without limitation, HIPPA, or any security breach, cyber-attack or cybersecurity breach, and any incident involving the misappropriation, loss or other unauthorized disclosure or use of, or access to, sensitive or confidential information, whether by us or by one of our third-party service providers, could require us to expend significant resources to continue to modify or enhance our protective measures and to remediate any damage. In addition, this could negatively affect our operations, cause system disruptions, damage our reputation, cause client losses and contract breaches, and could also result in regulatory enforcement actions, material fines and penalties, litigation or other actions that could have a material adverse effect on our business, cash flows, financial condition and results of operations.  Even if cyber-attacks or other cybersecurity breaches do not result in noncompliance with privacy or security laws, the perception that such noncompliance may have occurred by our clients or in the news media may have an adverse impact on our stock price and could result in damage to our reputation or loss of clients, which could have a material adverse effect on our business, cash flows, financial condition and results of operations.

 

Reputational harm could have a material adverse effect on our business, financial condition and results of operations.

 

Our ability to maintain a good reputation is critical to selling our services. Our reputation could be adversely impacted by any of the following (whether or not valid): the failure to maintain high ethical and social standards; the failure to perform our client services in a timely manner; violations of laws and regulations; failure to adequately preserve information security; and the failure to maintain an effective system of internal controls or to provide accurate and timely financial information. Damage to our reputation or loss of our clients’ confidence in our services for any of these, or any other reasons, could adversely impact our business, revenues, financial condition, and results of operations, as well as require additional resources to rebuild our reputation.

 

10
Table of Contents

 

Our operations are subject to laws and regulations that impose significant compliance costs and create reputational and legal risk.

 

Due to the nature of the services we offer, we are subject to significant commercial, trade and privacy regulations. We cannot predict the nature, scope or effect of future regulatory requirements to which our operations might be subject or the manner in which existing laws might be administered or interpreted, which could have a material and negative impact on our business and our results of operation. For example, recent years have seen an increase in the development or enforcement of legislation related to healthcare reform, privacy, trade compliance and anti-corruption. Additionally, some of the services we provide include information our clients need to fulfill regulatory reporting requirements. If our services result in errors or omissions in our clients’ regulatory reporting, we may be subject to loss of clients, reputational harm or litigation, each potentially adversely impacting our business. Furthermore, although we maintain a variety of internal policies and controls designed to educate, discourage, prevent and detect violations of such laws, we cannot guarantee that such actions will be effective or sufficient or that individual employees will not engage in inappropriate behavior in breach of our policies. Such conduct, or even an allegation of misbehavior, could result in material adverse reputational harm, costly investigations, severe criminal or civil sanctions, or could disrupt our business, and could negatively affect our results of operations or financial condition.

 

Our growth strategy includes future acquisitions and/or investments which involve inherent risk.

 

In order to expand services or technologies to existing clients and increase our client base, we have historically, and may in the future, make strategic business acquisitions and/or investments that we believe complement our business. Acquisitions have inherent risks which may have material adverse effects on our business, financial condition, or results of operations, including, among other things: (1) failure to successfully integrate the purchased operations, technologies, products or services and maintain uniform standard controls, policies and procedures; (2) substantial unanticipated integration costs; (3) loss of key associates including those of the acquired business; (4) diversion of management’s attention from other operations; (5) failure to retain the customers of the acquired business; (6) failure to achieve any projected synergies and performance targets; (7) additional debt and/or assumption of known or unknown liabilities; (8) dilutive issuances of equity securities; and (9) a write-off of goodwill, software development costs, client lists, other intangibles and amortization of expenses. If we fail to successfully complete acquisitions or integrate acquired businesses, we may not achieve projected results and there may be a material adverse effect on our business, financial condition and results of operations.

 

Risks Related to our Common Stock

 

Our principal shareholders effectively control the Company.

 

A majority of our common stock and voting power was historically owned and/or held by Michael D. Hays, our Chief Executive Officer and President. However, over the years Mr. Hays, for estate planning purposes, gifted and/or transferred almost all of his directly owned shares to trusts for the benefit of his family. Currently, the principal holders of shares previously owned by Mr. Hays are the Common Property Trust and the Amandla MK Trust (collectively the “Trusts”).

 

As of February 25, 2022, approximately 42.6% of our outstanding common stock was owned by the Trusts and approximately 52.4% of our outstanding common stock was held by the Trusts and other entities owned or controlled by members of Mr. Hays’ family. As a result, the Trusts and these other entities have the power to indirectly control decisions such as whether to issue additional shares or declare and pay dividends and can control matters requiring shareholder approval, including the election of directors and the approval of significant corporate matters such as change of control transactions. The effects of such influence could be to delay or prevent a change of control of the Company unless the terms are approved by the Trusts and these other entities.

 

11
Table of Contents

 

The market price of our common stock may be volatile and shareholders may be unable to resell shares at or above the price at which the shares were acquired.

 

The market price and trading volume of our common stock has historically been and may continue to be highly volatile, and investors in our common stock may experience a decrease in the value of their shares, including decreases that are in response to factors beyond our control, including, but not limited to:

 

 

●

Variations in our financial performance and that of similar companies;
 

●

Regulatory and other developments that may impact the demand for our services;
 

●

Reaction to our press releases, public announcements and filings with the Securities and Exchange Commission;
 

●

Client, market and industry perception of our services and performance;
 

●

Actions of our competitors;
 

●

Changes in earnings estimates or recommendations by analysts who follow our stock;
 

●

Loss of key personnel;
 

●

Investor, management team or large stockholder sales of our stock;
 

●

Changes in accounting principles; and
 

●

Variations in general market, economic and political conditions or financial markets.

 

Any of these factors, among others, may result in changes in the trading volume and/or market price of our common stock. Following periods of volatility in the market price of securities, shareholders have often filed securities class-action lawsuits. Our involvement in a class-action lawsuit would result in substantial legal fees and divert our senior management’s attention from operating our business, which could harm our business and net income.

 

General Risk Factors

 

Our operating results may fluctuate and this may cause our stock price to decline.

 

Our overall operating results may fluctuate as a result of a variety of factors, including the size and timing of orders from clients, client demand for our services (which, in turn, is affected by factors such as accreditation requirements, enrollment in managed care plans, operating budgets and clients’ operating performance), the hiring and training of additional staff, expense increases, and industry and general economic conditions. Because a significant portion of our overhead is fixed in the short-term, particularly some costs associated with owning and occupying our building and full-time personnel expenses, our results of operations may be materially adversely affected in any particular period if revenue falls below our expectations. These factors, among others, make it possible that in some future period our operating results may be below the expectations of securities analysts and investors which would have a material adverse effect on the market price of our common stock.

 

Our business and operating results could be adversely affected if we are unable to attract or retain key managers and other personnel.

 

Our future performance may depend, to a significant extent, upon the efforts and ability of our key personnel who have expertise in gathering, interpreting and marketing survey-based performance information for healthcare markets. Although client relationships are managed at many levels within our company, the loss of the services of Michael D. Hays, our Chief Executive Officer and President, or one or more of our other senior managers, could have a material adverse effect, at least in the short to medium term, on most significant aspects of our business, including strategic planning, product development, and sales and customer relations. Our success will also depend on our ability to hire, train and retain skilled personnel in all areas of our business. Competition for qualified personnel in our industry is intense, and many of the companies that compete with us for qualified personnel have substantially greater financial and other resources than us. Furthermore, we expect competition for qualified personnel to become more intense as competition in our industry increases. We cannot assure you that we will be able to recruit, retain and motivate a sufficient number of qualified personnel to compete successfully.

 

Like many other companies, we experienced higher attrition rates in 2021. We may incur higher costs to attract, train and retain these associates. Attrition in our sales and service areas can also impact our ability to retain and attract new business. We may need to develop or adapt to new ways of doing business that challenge our leadership, our associate training, our human resources, and our business practices, and we cannot assure you that we will be successful in doing so. The short and long-term costs associated with these potential changes are difficult to quantify. 

 

12
Table of Contents

 

Failure to comply with public company regulations could adversely impact our profitability.

 

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Act Wall Street Reform and Consumer Protection Act, the listing requirements of NASDAQ and other applicable securities rules and regulations. Additionally, laws, regulations and standards relating to corporate governance and public disclosure are subject to varying interpretations and continue to develop and change. If we misinterpret or fail to comply with these rules and regulations, our legal and financial compliance costs and net income may be adversely affected.

 

 

Item 1B.

Unresolved Staff Comments

 

We have no unresolved staff comments to report pursuant to this item.

 

Item 2.

Properties

 

Our headquarters is located in an owned office building in Lincoln, Nebraska, of which 62,000 square feet have been used for operations. Our credit facilities are secured by this property and our other assets. We are currently renovating the building and expect renovations to complete in early 2023. In February 2021, we began leasing 19,300 square feet of space in Lincoln, Nebraska for our survey programming, printing and distribution previously housed at our headquarters.

 

We are leasing 4,000 square feet of office space in Markham, Ontario, 6,500 square feet of office space in Atlanta, Georgia, 1,000 square feet of office space in Bethel, Connecticut and 100 square feet of office space in Nashville, Tennessee as a month-to month lease. We are also subleasing as a sublessor 4,300 square feet of office space in Seattle, Washington. In January 2022, the leased space in Atlanta, Georgia will be reduced to a 300 square feet month-to-month lease. Due to our decision to close the Canadian office, the Markham, Ontario lease will also be terminated in late 2022.

 

Item 3.

Legal Proceedings

 

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. For additional information, see Note 1, under the heading “Commitments and Contingencies,” to our consolidated financial statements. Regardless of the final outcome, any legal proceedings, claims, inquiries and investigations, however, can impose a significant burden on management and employees, may include costly defense and settlement costs, and could cause harm to our reputation and brand, and other factors.

 

Item 4.

Mine Safety Disclosures

 

Not applicable.

 

13
Table of Contents

 

PART II

 

Item 5.

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Currently we have one class of outstanding capital stock, which is our Common Stock, par value $.001 per share (“Common Stock”). Our Common Stock trades on the NASDAQ Global Select Market under the symbol “NRC”.

 

Cash dividends in the aggregate amount of $12.2 million were declared in 2021 with $9.2 million paid in 2021 and the remaining $3.0 million paid in January 2022. Cash dividends in the aggregate amount of $5.3 million were declared and paid in 2020. Cash dividends in the aggregate amount of $19.4 million were declared in 2019 with $14.2 million paid in 2019 and the remaining $5.2 million paid in January 2020. The payment and amount of future dividends, if any, is at the discretion of our Board of Directors and will depend on our future earnings, financial condition, general business conditions, alternative uses of our earnings and cash and other factors.

 

On February 16, 2022, there were approximately 11 shareholders of record and approximately 11,814 beneficial owners of our Common Stock.

 

Our Board of Directors has authorized a stock repurchase program that initially provided for the repurchase of up to 2,250,000 shares of our Common Stock.

 

The table below summarizes repurchases of Common Stock during the three-month period ended December 31, 2021.

 

Period

  

Total Number

of Shares

Purchased

    

Average Price

Paid per Share

    

Total Number of Shares

Purchased as Part of

Publicly Announced

Plans or Programs(1)

    

Maximum Number of

Shares that May Yet Be

Purchased Under the

Plans or Programs(1)

  
                                 

Oct 1 – Oct 31, 2021

     --       --       --       280,491  

Nov 1 – Nov 30, 2021

     24,298       41.48       24,298       256,193  

Dec 1 – Dec 31, 2021

    
94,846
 (2)     41.53       87,250       168,943  

 

(1)Shares were repurchased pursuant to a repurchase plan originally announced on February 14, 2006. The repurchase plan was subsequently amended to permit the repurchase of up to 2,250,000 shares of Common Stock.

(2)Includes 7,596 shares of Common Stock that were owned by an associate and surrendered to us as payment of the exercise price for, and to satisfy tax withholding obligations in connection with, the exercise of stock options.

 

See Item 12 in Part III of this Annual Report on Form 10-K for certain information concerning shares of our Common Stock authorized for issuance under our equity compensation plans.

 

14
Table of Contents

 

The following graph compares the cumulative 5-year total return provided shareholders on our Common Stock relative to the cumulative total returns of the NASDAQ Composite Index and the Russell 2000 Index. An investment of $100 (with reinvestment of all dividends) is assumed to have been made in our Common Stock and in each of the indexes on December 31, 2016, and our relative performance is tracked through December 31, 2021. 

 

                              graph6.jpg
 

 

The stock price performance included in this graph is not necessarily indicative of future stock price performance.

 

 

   

12/16

    

12/17

    

12/18

    

12/19

    

12/20

    

12/21

  
                                                 

National Research Corporation Common Stock (1)

     100.00       199.11       209.79       368.11       239.77       235.38  

NASDAQ Composite

     100.00       129.64       125.96       172.17       249.51       304.85  

Russell 2000

     100.00       114.65       102.02       128.06       153.62       176.39  

 

(1)Prior to a recapitalization that took place in 2018, our Common Stock was referred to as Class A Common Stock.

 

Item 6.

[Reserved]

 

15
Table of Contents

 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations 

 

The following discussion and analysis provides a summary of significant factors relevant to our financial performance and condition. It should be read in conjunction with the consolidated financial statements and accompanying notes included in Part II, Item 8 of this Form 10-K. This section of this Form 10-K generally discusses 2021 and 2020 items and year-to-year comparisons between 2021 and 2020. Discussions of 2019 items and year-to-year comparisons between 2020 and 2019 are not included in this Form 10-K, and can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

 

Overview

 

Our purpose is to establish human understanding by enabling our clients to understand what matters most to each person they serve. We are a leading provider of analytics and insights that facilitate measurement and improvement of patient engagement and customer loyalty for healthcare organizations. Our heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for and design experiences that inspire loyalty and trust, while also facilitating regulatory compliance and the shift to population-based health management. Our ability to measure what matters most and systematically capture, analyze and deliver insights based on self-reported information from patients, families and consumers is critical in today’s healthcare market. We believe that access to and analysis of our extensive consumer-driven information is becoming more valuable as healthcare providers increasingly need to more deeply understand and engage the people they serve to build customer loyalty.

 

Our portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. We partner with clients across the continuum of healthcare services. We believe this cross-continuum positioning is a unique and an increasingly important capability as evolving payment models drive healthcare providers and payers towards a more collaborative and integrated service model.

 

The outbreak of COVID-19, and the associated responses, have impacted our business in a variety of ways. Governments have implemented business and travel restrictions and recommended social distancing and other guidelines. Many businesses, including many of our clients, have de-emphasized external business opportunities and restricted in-person meetings while shifting their attention toward addressing COVID-19 planning, business disruptions, higher costs, and revenue shortfalls. At NRC, the vast majority of our associates are working remotely, and to date we have been capable of providing our services without significant disruption. We have made our facilities available for associates to return to work effective July 1, 2021 at their discretion. Historically, we have relied on national travel as part of our sales efforts, but as a result of the pandemic we had placed a temporary hold on all company related travel. We modified our travel policy and limited travel did resume in the third quarter of 2021. The duration and severity of the COVID-19 pandemic and associated impacts on our business, including the impact on our revenue, expenses, and cash flows, cannot be predicted at this time. Like many other companies, we experienced higher attrition rates in 2021. We may incur higher costs to attract, train and retain these associates. Attrition in our sales and service areas can also impact our ability to retain and attract new business. Based on the foregoing, we do not expect our recent revenue and earnings growth to be indicative of future expectations. We do, however, expect to have adequate sources of liquidity to meet our current and expected needs for the foreseeable future. 

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements requires management to make estimates and assumptions that affect amounts reported therein. The following areas are considered critical accounting estimates because they involve significant judgments or assumptions, involve complex or uncertain matters or they are susceptible to change and the impact could be material to our financial condition or operating results:

 

 

●

Revenue recognition; and
 

●

Valuation of goodwill and identifiable intangible assets.

 

Revenue Recognition

 

We derive a majority of our revenue from annually renewable subscription-based service agreements with our customers. Such agreements are generally cancelable on short or no notice without penalty.  We also derive revenue from fixed, non-subscription arrangements.  Our revenue recognition policy requires management to estimate, among other factors, the future contract consideration we expect to receive under variable consideration subscription arrangements as well as future total estimated contract costs over the contract term with respect to fixed, non-subscription arrangements. If management made different judgments and estimates, then the amount and timing of revenue for any period could differ from the reported revenue.  See Notes 1 and 3 to our consolidated financial statements for a description of our revenue recognition policies. 

 

16
Table of Contents

 

Valuation of Goodwill and Identifiable Intangible Assets

 

Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment with other long-lived assets in the related asset group whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review intangible assets with indefinite lives for impairment annually as of October 1 and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  This review requires management to assess qualitative factors to determine whether an impairment may have occurred, which inherently involves management’s judgment.  This assessment also requires a determination of the fair value of the asset, which often includes several significant estimates and assumptions, including future cash flow estimates, determination of appropriate discount rates, and other assumptions that management believed reasonable under the circumstances.  Changes in these estimates and assumptions could materially affect the determination of fair value and/or impairment of goodwill or other intangible assets.  See Notes 1 and 6 to our consolidated financial statements for a description of our goodwill and intangible asset valuation and impairment policies and associated impacts for the reported periods.

 

In March 2021, we changed our operating segments from six to one to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker. In connection with the revision to our operating segments, we performed an interim qualitative analysis immediately before and after the reorganization and concluded that the fair value of our reporting units likely exceeded the carrying values and no impairments were recorded. Following the reorganization, we considered the current and expected future economic and market conditions, including the impact of the COVID-19 pandemic, on our reporting unit. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has not occurred which would require an additional interim impairment test to be performed as it is not more likely than not that an impairment loss had been incurred at December 31, 2021.

 

17
Table of Contents

 

 

 

Key Financial Metrics and Results of Operations

 

The following table sets forth, for the periods indicated, selected financial information derived from our consolidated financial statements and the percentage change in such items versus the prior comparable period, as well as other key financial metrics. The discussion that follows the information should be read in conjunction with our consolidated financial statements.

 

Due to changes in our corporate reporting structure in 2021, certain associates moved between departments. As a result, the related salaries and benefits and company incentive expenses are included in Selling, general and administrative expenses in the 2021 periods instead of Direct as in the 2020 periods. The total amount of the reclassified expenses approximates $1.9 million in 2021.

 

   

(In thousands, except percentages)
Year Ended December 31,

    

Percentage

Increase (Decrease)

  
   

2021

    

2020

    

2019

    

2021 over

2020

    

2020 over

2019

  

Revenue

   $ 147,954     $ 133,277     $ 127,982       11.0       4.1  

Direct expenses

     52,350       49,187       46,435       6.4       5.9  

Selling, general, and administrative

     38,960       34,441       32,973       13.1       4.5  

Depreciation, amortization and impairment

     6,374       7,505       5,539       (15.1

)

     35.5  

Operating income

     50,270       42,677       43,035       17.8       (0.8

)

Total other income (expense)

     (1,649

)

     (1,210

)

     (2,516

)

     36.3       (51.9

)

Provision for income taxes

     11,155       4,207       8,113       165.2       (48.1

)

Effective Tax Rate

     22.9

%

     10.1

%

     20.0

%

     12.8       (9.9

)
                                         

Operating margin

     34.0

%

     32.0

%

     33.6

%

     2.0       (1.6

)

Recurring Contact Value

   $ 150,937     $ 145,079     $ 136,763       4.0       6.1  

Cash provided by operating activities

     46,344       40,636       40,917       14.0       (0.7

)

 

Revenue. Revenue in 2021 increased compared to 2020, primarily due to new customer sales, as well as increases in sales to the existing client base. During 2020, we also experienced revenue reductions from COVID-19 as some clients reduced or eliminated services they purchased from us as cost reducing measures, which increased our revenue growth in 2021. We expect our revenue growth in 2022 to align more closely in relation to our recurring contract value growth.

 

Direct expenses. Direct expenses increased in 2021 compared to 2020 due to growth in volume-based data collection costs to support the growth in revenue partially offset by decreased postage, printing, and paper costs primarily resulting from increased use of digital survey methodologies. Conference expenses also increased due to additional conferences being held in 2021 compared to 2020 and shift to allow live or virtual attendance at conferences. Variable expenses as a percentage of revenue have leveled with changes in survey methodologies at 14.4% and 14.2% in 2021 and 2020, respectively. Fixed expenses increased primarily as a result of increased salary and benefit costs to attract and retain associates, contracted services and software and platform hosting expenses.

 

Selling, general and administrative expenses. Selling, general and administrative expenses increased in 2021 compared to 2020 primarily due to increases in salary and benefit costs to attract and retain associates, public company and other legal and accounting costs, contracted services, software and platform hosting expenses and other taxes due to a favorable tax ruling in 2020 reversing sales tax expense.

 

18
Table of Contents

 

Depreciation, amortization and impairment. Depreciation, amortization and impairment expenses decreased in 2021 compared to 2020 primarily due to additional depreciation and impairment expense in 2020 from shortening the estimated useful lives of certain building assets and a goodwill impairment adjustment for the Canadian reporting unit. This was partially offset by our transformation to a distributed workforce environment, which includes building renovation costs for our headquarters, as well as subleasing a remote office location at a discounted rate, which resulted in an ROU asset impairment in 2021.

 

Operating income and margin. Operating income and margin grew due to leveraging the revenue growth through the efficiencies inherent within our subscription model as well as the discipline in managing our cost structure.

 

Total other income (expense). Total other income (expense) increased in total net (expense) primarily due to revaluation on intercompany transactions due to changes in the Canadian to U.S. dollar foreign exchange rate partially offset by lower interest expense due to the declining balance on our term loan.

 

Provision for income taxes and effective tax rate. Provision for income taxes and effective tax rate grew in 2021 compared to 2020 primarily due to decreased tax benefits from the exercise and vesting of share-based compensation awards and higher state income taxes.

 

Recurring Contact Value. Recurring contract value grew as sales continued to exceed loss and downsells. Retention rates grew in 2021 compared to 2020, but sales declined due to the difficulties of selling to our clients during the COVID-19 pandemic as well as increased turnover within our sales force. Our recurring contract value growth declined in 2021 in comparison to 2020 due in part to our strategy to focus on growing our digital core solutions, and therefore, the decision was made to eliminate certain legacy offerings. Our recurring contract value metric represents the total revenue projected under all renewable contracts for their respective next annual renewal periods, assuming no upsells, downsells, price increases, or cancellations, measured as of the most recent quarter end.

 

Cash provided by operating activities. Cash provided by operating activities grew mainly due to growth in cash collections on trades accounts receivable, change in income taxes receivable and payable, and growth in deferred revenue primarily due to timing of initial billings on new and renewal contracts.

 

Liquidity and Capital Resources

 

Our Board of Directors has established priorities for capital allocation, which prioritize funding of innovation and growth investments, including merger and acquisition activity as well as internal projects. The secondary priority is capital allocation for quarterly dividends and share repurchases. We believe that our existing sources of liquidity, including cash and cash equivalents, borrowing availability, and operating cash flows will be sufficient to meet our projected capital and debt maturity needs for the foreseeable future.

 

As of December 31, 2021, our principal sources of liquidity included $54.4 million of cash and cash equivalents, up to $30 million of unused borrowings under our line of credit and up to $15 million on our delayed draw term note. Of this cash, $6.5 million was held in Canada. The delayed draw term note can only be used to fund permitted future business acquisitions or repurchasing our Common Stock.

 

Our cash flows from operating activities consist of net income adjusted for non-cash items including depreciation and amortization, deferred income taxes, share-based compensation and related taxes, reserve for uncertain tax positions, loss on disposal of property and equipment and the effect of working capital changes. Cash provided by operating activities grew mainly due to strong cash collections on trades accounts receivable, change in income taxes receivable and payable, decreases in deferred contract costs due to the changes in the costs to acquire new sales and growth in deferred revenue primarily due to timing of initial billings on new and renewal contracts. This was partially offset by decreased depreciation, amortization and impairment and increased accrued expenses, wages, and bonuses.

 

We had a working capital surplus of $33.3 million and $22.4 million on December 31, 2021 and 2020, respectively. The change was primarily due to increases in cash and cash equivalents and prepaid expenses, partially offset by increases in dividends payable, accrued expenses and deferred revenue. Dividends payable increased due to timing of declaration and payments of dividends. Prepaid expenses and accrued expenses increased due to timing of payment for services and supplies. Our working capital is significantly impacted by our large deferred revenue balances which will vary based on the timing and frequency of billings on annual agreements.

 

Cash used in investing activities consisted of acquisition consideration for our January 2021 acquisition of PatientWisdom and purchases of property and equipment including computer software and hardware, leasehold and building improvements and furniture and equipment.

 

19
Table of Contents

 

Cash used in financing activities consisted of payments for borrowings under the term note and finance lease obligations. We also used cash to pay payroll tax withholdings related to share-based compensation, repurchase of shares for treasury, and to pay dividends on common stock. This was partially offset by the proceeds from the exercise of share-based awards.

 

Our material cash requirements include the following contractual and other obligations:

 

Dividends

 

Cash dividends in the aggregate amount of $12.2 million were declared in 2021 with $9.2 million paid in 2021 and the remaining $3.0 million paid in January 2022.The dividends were paid from cash on hand. Our board of directors considers whether to declare a dividend and the amount of any dividends declared on a quarterly basis.

 

Acquisition Consideration

 

On January 4, 2021, we acquired substantially all assets and assumed certain liabilities of PatientWisdom, Inc., a company with a health engagement solution that will further our purpose of operationalizing human understanding through tangible and actionable insights. $3.0 million of the total $5.0 million all-cash consideration was paid at closing. We paid the remaining $2.0 million in January 2022. All payments were made with cash on hand.

 

Capital Expenditures

 

We paid cash of $5.5 million for capital expenditures in the year ended December 31, 2021. These expenditures consisted mainly of computer software development for our Human Understanding solutions and building renovations to our headquarters of $2.8 million and $1.8 million, respectively. Future costs related to our headquarters building renovations are estimated at $15 million and $7 million in 2022 and 2023, respectively.

 

Debt

 

Our amended and restated credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-down term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). We may use the Delayed Draw Term Loan to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit to fund ongoing working capital needs and for other general corporate purposes.

 

The Term Loan has an outstanding balance of $26.6 million and is payable in monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%.  

 

Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.35% at December 31, 2021). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. As of December 31, 2021, and 2020, the Line of Credit did not have a balance. There were no borrowings on the Line of Credit during 2021. There have been no borrowings on the Delayed Draw Term Loan since origination.

 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the term(s) of the Credit Facilities. All obligations under the Credit Facilities are guaranteed by our subsidiary. As of December 31, 2021, we were in compliance with our financial covenants.

 

20
Table of Contents

 

The Credit Facilities are secured, subject to permitted liens and other agreed upon exceptions, by a first-priority lien on and perfected security interest in substantially all of our and our guarantors’ present and future assets (including, without limitation, fee-owned real property, and limited, in the case of the equity interests of foreign subsidiaries, to 65% of the outstanding equity interests of such subsidiaries).

 

Leases

 

We have lease arrangements for certain computer, office, printing and inserting equipment as well as office and data center space. As of December 31, 2021, we had fixed lease payments of $531,000 and $488,000 for operating and finance leases, respectively payable within 12 months. A summary of our operating and finance lease obligations as of December 31, 2021 can be found in Note 10, "Leases", to the Consolidated Financial Statements contained in this report.

 

Taxes 

 

The liability for gross unrecognized tax benefits related to uncertain tax positions was $1.1 million as of December 31, 2021. See Note 7, "Income Taxes", to the Consolidated Financial Statements contained in this report for income tax related information.

 

As of December 31, 2021, the balance of the deemed repatriation tax payable imposed by the U.S. Tax Cuts and Jobs Act of 2017 (the Act”) was $182,000, which we expect to pay by the end of 2022.

 

We generally do not make unconditional, non-cancelable purchase commitments. We enter into purchase orders in the normal course of business, but these purchase obligations do not exceed one year.

 

Stock Repurchase Program

 

Our Board of Directors authorized the repurchase of up to 2,250,000 shares of Common Stock in the open market or in privately negotiated transactions under a stock repurchase program. We repurchase shares of our common stock from time to time after considering market conditions and in accordance with repurchase limits authorized by our Board. During 2021, we repurchased 111,548 shares of our Common Stock under this authorization for an aggregate of $4.6 million. As of December 31, 2021, the remaining number of shares of Common Stock that could be purchased under this authorization was 168,943 shares, which we expect to repurchase during 2022.

 

Recent Accounting Pronouncements

 

See Note 1 to our consolidated financial statements for a description of recently issued accounting pronouncements.

 

21
Table of Contents

 

Item 7A.

Quantitative and Qualitative Disclosure About Market Risk

 

Our primary market risk exposures are changes in foreign currency exchange rates and interest rates.

 

Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Foreign currency translation gains (losses) were $24,000, ($190,000), and $707,000 in 2021, 2020, and 2019, respectively. Gains and losses related to transactions denominated in a currency other than the functional currency of the countries in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income and amounted to $10,000, ($333,000), and ($483,000) in 2021, 2020, and 2019, respectively. The change is primarily the result of exchange rate fluctuation applied to an intercompany loan from our Canadian subsidiary which was paid off in September 2020. A portion of our cash in our Canadian subsidiary is denominated in foreign currencies, where fluctuations in exchange rates will impact our cash balances in U.S. dollar terms. A sensitivity analysis assuming a hypothetical 10% change in the value of the U.S. dollar versus the Canadian dollar would impact our reported cash balance by approximately $648,000. We have not entered into any foreign currency hedging transactions. We do not purchase or hold any currency exchange related derivative financial instruments. We do not expect any foreign currency exposure after the anticpated closure of our Canadian office by the end of 2022.

 

We are exposed to interest rate risk with both our fixed-rate Term Loan and variable rate Line of Credit. Interest rate changes for borrowings under our fixed-rate Term Loan would impact the fair value of such debt, but do not impact earnings or cash flow. At December 31, 2021, our fixed-rate Term Loan totaled $26.6 million. Based on a sensitivity analysis, a one percent per annum change in market interest rates as of December 31, 2021, would impact the estimated fair value of our fixed-rate Term Loan outstanding at December 31, 2021 by approximately $647,000.

 

Borrowings under our Line of Credit and Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day LIBOR plus 225 basis points. Borrowings under the Line of Credit and Delayed Draw Term Note may not exceed $30.0 million and $15.0 million, respectively. There were no borrowings outstanding under the Line of Credit at December 31, 2021, or at any time during 2021. There were no borrowings outstanding under the Delayed Draw Term Note at December 31, 2021, or at any time during 2021. A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to the average daily borrowings and the maximum borrowings available under the Line of Credit for 2021 indicated that such a movement would not have a material impact on our consolidated financial position, results of operations or cash flows. We have not entered into any interest rate swaps or hedging transactions.

LIBOR is currently expected to be phased out beginning in 2021 through 2023. The one-week and two-month LIBOR rates were retired on December 31, 2021. The overnight, one-month, three-month, six-month and 12-month LIBOR rates are expected to be published through June 2023. We are required to pay interest on borrowings under our Line of Credit and Delayed Draw Term Loan at floating rates based on the one-month LIBOR. Future debt that we may incur may also require that we pay interest based upon LIBOR. Under the terms of our Credit Agreement with FNB, if LIBOR becomes unavailable during the term of the agreement, FNB may, in its discretion and in a manner consistent with market practice, designate a substitute index. We currently expect that the determination of interest under our Credit Agreement would be revised as to provide for an interest rate that approximates the existing interest rate as calculated in accordance with LIBOR. Despite our current expectations, we cannot be sure that when LIBOR is phased out or transitioned, the changes to the determination of interest under our agreements would approximate the current calculation in accordance with LIBOR. We do not know what standard, if any, will replace LIBOR when it is phased out or transitioned.

 

22
Table of Contents

 

Item 8.

Financial Statements and Supplementary Data

 

23
Table of Contents

 

Report of Independent Registered Public Accounting Firm

 

 

To the Shareholders and the Board of Directors

National Research Corporation:

 

Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting

 

We have audited the accompanying consolidated balance sheets of National Research Corporation and subsidiary (the Company) as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021 based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

Basis for Opinions

 

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s consolidated financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

 

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

 

Definition and Limitations of Internal Control Over Financial Reporting

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

24
Table of Contents

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Sufficiency of audit evidence over new and modified subscription-based service agreement terms

 

As discussed in Notes 1 and 3 to the consolidated financial statements, revenue consists of service arrangement contracts with customers that can include more than one separately identifiable performance obligation. The Company’s revenue for the year ended December 31, 2021 included $137.0 million for subscription-based service agreements, a portion of which was revenue from new and modified subscription-based service agreements, that was recognized ratably over the subscription period and which agreements are renewable at the option of the customer. Subscription-based service agreements represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period.

 

We identified the evaluation of the sufficiency of audit evidence over the key terms within new and modified subscription-based service agreements as a critical audit matter. Specifically, the nature and extent of procedures performed over the key terms within the new and modified subscription-based service agreements required subjective auditor judgment as recognition of revenue by the Company is dependent on the accuracy of the key terms within the related information technology (IT) application used to calculate revenue. The key terms within the new subscription-based service agreements included the description of service, transaction price, renewal price and contract term, and the key terms within the modified subscription-based service agreements were the transaction price and contract term.

 

The following are the primary procedures we performed to address this critical audit matter. We applied auditor judgment to determine the nature and extent of procedures to be performed over the accuracy of key terms within the IT application, including the identification of key terms. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s subscription-based service revenue process, including controls related to the key terms within the new and modified subscription-based service agreements. We also tested certain internal controls over the accurate input of the underlying key terms of the subscription-based service agreement into the related IT application. For a sample of revenue transactions, we compared the key terms used in the revenue calculation to the underlying contract with the customer. We evaluated the sufficiency of audit evidence obtained over the key terms within new and modified subscription-based service agreements by assessing the results of procedures performed, including the appropriateness of the nature and extent of audit effort.

 

 

/s/ KPMG LLP

 

We have served as the Company’s auditor since 1997.

 

Lincoln, Nebraska

March 4, 2022

 

25
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

 

  

2021

  

2020

 

Assets

        

Current assets:

        

Cash and cash equivalents

 $54,361  $34,690 

Trade accounts receivable, less allowance for doubtful accounts of $94 and $120, respectively

  13,728   13,923 

Prepaid expenses

  3,884   2,645 

Income taxes receivable

  752   1,235 

Other current assets

  982   1,619 

Total current assets

  73,707   54,112 
         

Net property and equipment

  12,391   11,726 

Intangible assets, net

  1,790   1,410 

Goodwill

  61,614   57,255 

Operating lease right-of-use assets

  975   1,308 

Deferred contract costs, net

  3,772   4,555 

Deferred income taxes

  14   -- 

Other

  3,277   3,057 
         

Total assets

 $157,540  $133,423 
         

Liabilities and Shareholders’ Equity

        

Current liabilities:

        

Current portion of notes payable, net of unamortized debt issuance costs

 $4,278  $4,061 

Accounts payable

  1,943   1,095 

Accrued wages and bonuses

  7,139   6,460 

Accrued expenses

  5,450   3,184 

Dividends payable

  3,044   -- 

Deferred revenue

  17,213   15,585 

Other current liabilities

  1,321   1,296 

Total current liabilities

  40,388   31,681 
         

Notes payable, net of current portion and unamortized debt issuance costs

  22,269   26,547 

Deferred income taxes

  7,002   7,265 

Other long-term liabilities

  2,544   3,615 

Total liabilities

  72,203   69,108 
         

Shareholders’ equity:

        

Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued

  --   -- 

Common stock, $0.001 par value; authorized 110,000,000 shares in 2021 and 60,000,000 shares in 2020, issued 30,898,600 in 2021 and 30,775,154 in 2020, outstanding 25,361,409 in 2021 and 25,390,968 in 2020

  31   31 

Additional paid-in capital

  173,942   171,785 

Retained earnings (accumulated deficit)

  (36,112

)

  (61,375

)

Accumulated other comprehensive loss, foreign currency translation adjustment

  (2,375

)

  (2,399

)

Treasury stock, at cost; 5,537,191 Common shares in 2021 and 5,384,186 Common shares
in 2020

  (50,149

)

  (43,727

)

Total shareholders’ equity

  85,337   64,315 
         

Total liabilities and shareholders’ equity

 $157,540  $133,423 

 

See accompanying notes to consolidated financial statements.

 

26
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except share amounts)

 

  

2021

  

2020

  

2019

 
             

Revenue

 $147,954  $133,277  $127,982 
             

Insurance recoveries

  --   533   -- 
             

Operating expenses:

            

Direct

  52,350   49,187   46,435 

Selling, general and administrative

  38,960   34,441   32,973 

Depreciation, amortization and impairment

  6,374   7,505   5,539 

Total operating expenses

  97,684   91,133   84,947 
             

Operating income

  50,270   42,677   43,035 
             

Other income (expense):

            

Interest income

  14   18   37 

Interest expense

  (1,667

)

  (1,813

)

  (2,091

)

Other, net

  4   585   (462

)

             

Total other income (expense)

  (1,649

)

  (1,210

)

  (2,516

)

             

Income before income taxes

  48,621   41,467   40,519 
             

Provision for income taxes

  11,155   4,207   8,113 
             

Net income

 $37,466  $37,260  $32,406 
             

Earnings per share of common stock:

            

Basic earnings per share

 $1.47  $1.48  $1.30 

Diluted earnings per share

 $1.46  $1.45  $1.26 
             

Weighted average shares and share equivalents outstanding

            

Basic

  25,422   25,170   24,809 

Diluted

  25,640   25,696   25,653 

 

See accompanying notes to consolidated financial statements.

 

27
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

 

  

2021

  

2020

  

2019

 
             

Net income

 $37,466  $37,260  $32,406 
             

Other comprehensive income (loss):

            

Cumulative translation adjustment

 $24  $(190

)

 $707 

Other comprehensive income (loss)

 $24  $(190

)

 $707 
             

Comprehensive income

 $37,490  $37,070  $33,113 

 

See accompanying notes to consolidated financial statements.

 

28
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands except share and per share amounts)

 

  

Common

Stock

  

Additional

Paid-in

Capital

  

Retained

Earnings

(Accumulated

Deficit)

  

Accumulated

Other

Comprehensive

Income (Loss)

  

Treasury

Stock

  

Total

 

Balances at December 31, 2018

 $30  $157,312  $(106,339

)

 $(2,916

)

 $(29,004

)

 $19,083 

Purchase of 87,203 shares of treasury stock

  --   --   --   --   (4,722

)

  (4,722

)

Issuance of 227,902 common shares for the exercise of stock options

  --   3,618   --   --   --   3,618 

Issuance of 6,005 restricted common shares

  --   --   --   --   --   -- 

Non-cash stock compensation expense

  --   1,224   --   --   --   1,224 

Dividends declared of $0.78 per common share

  --   --   (19,424

)

  --   --   (19,424

)

Other comprehensive income, foreign currency translation adjustment

  --   --   --   707   --   707 

Net income

  --   --   32,406   --   --   32,406 

Balances at December 31, 2019

 $30  $162,154  $(93,357

)

 $(2,209

)

 $(33,726

)

 $32,892 

Purchase of 180,112 shares of treasury stock

  --   --   --   --   (10,001

)

  (10,001

)

Issuance of 630,373 common shares for the exercise of stock options

  1   8,951   --   --   --   8,952 

Forfeiture of 6,793 restricted common shares

  --   --   --   --   --   -- 

Non-cash stock compensation expense

  --   680   --   --   --   680 

Dividends declared of $0.21 per common share

  --   --   (5,278

)

  --   --   (5,278

)

Other comprehensive loss, foreign currency translation adjustment

  --   --   --   (190

)

  --   (190

)

Net income

  --   --   37,260   --   --   37,260 

Balances at December 31, 2020

 $31  $171,785  $(61,375

)

 $(2,399

)

 $(43,727

)

 $64,315 

Purchase of 153,005 shares treasury stock

  --   --   --   --   (6,422

)

  (6,422

)

Issuance of 116,753 common shares for the exercise of stock options

  --   1,534   --   --   --   1,534 

Non-cash stock compensation expense

  --   623   --   --   --   623 

Dividends declared of $0.48 per common share

  --   --   (12,203

)

  --   --   (12,203

)

Other comprehensive income, foreign currency translation adjustment

  --   --   --   24   --   24 

Net income

  --   --   37,466   --   --   37,466 

Balances at December 31, 2021

 $31  $173,942  $(36,112

)

 $(2,375

)

 $(50,149

)

 $85,337 

 

See accompanying notes to consolidated financial statements.

 

29
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

  

2021

  

2020

  

2019

 

Cash flows from operating activities:

            

Net income

 $37,466  $37,260  $32,406 

Adjustments to reconcile net income to net cash provided by operating activities:

            

Depreciation, amortization and impairment

  6,374   7,505   5,539 

Deferred income taxes

  (277

)

  (134

)

  1,099 

Reserve for uncertain tax positions

  310   185   39 

Gain on insurance recoveries for damaged property

  --   (260

)

  -- 

Loss on disposal of property and equipment

  7   12   (6

)

Non-cash share-based compensation expense

  623   680   1,224 

Change in assets and liabilities:

            

Trade accounts receivable

  343   (2,271

)

  311 

Prepaid expenses and other current and long-term assets

  (842

)

  (827

)

  (529

)

Operating lease assets and liability, net

  (34

)

  16   (8

)

Deferred contract costs, net

  783   (351

)

  (719

)

Accounts payable

  4   (247

)

  647 

Accrued expenses, wages and bonuses

  (285

)

  1,370   806 

Income taxes receivable and payable

  484   (1,529

)

  11 

Deferred revenue

  1,388   (773

)

  97 

Net cash provided by operating activities

  46,344   40,636   40,917 
             

Cash flows from investing activities:

            

Purchases of property and equipment

  (5,514

)

  (3,984

)

  (4,656

)

Acquisition consideration

  (3,000

)

  --   -- 

Insurance proceeds for damaged property

  --   260   -- 

Net cash used in investing activities

  (8,514

)

  (3,724

)

  (4,656

)

             

Cash flows from financing activities:

            

Borrowings on line of credit

  --   --   21,000 

Payments on line of credit

  --   --   (21,000

)

Payments on notes payable

  (4,093

)

  (3,568

)

  (3,715

)

Payment of debt issuance costs

  --   (36

)

  -- 

Payments on finance lease obligations

  (493

)

  (332

)

  (229

)

Proceeds from the exercise of stock options

  446   1,734   -- 

Payment of payroll tax withholdings on share-based awards exercised

  (721

)

  (2,784

)

  (1,103

)

Repurchase of shares for treasury

  (4,142

)

  --   -- 

Payment of dividends on common stock

  (9,159

)

  (10,517

)

  (31,299

)

Net cash used in financing activities

  (18,162

)

  (15,503

)

  (36,346

)

             

Effect of exchange rate changes on cash

  3   (236

)

  611 

Net increase (decrease) in cash and cash equivalents

  19,671   21,173   526 

Cash and cash equivalents at beginning of period

  34,690   13,517   12,991 

Cash and cash equivalents at end of period

 $54,361  $34,690  $13,517 
             

Supplemental disclosure of cash paid for:

            

Interest expense, net of capitalized amounts

 $1,554  $1,735  $2,014 

Income taxes

 $10,644  $5,217  $6,946 

Supplemental disclosure of non-cash investing and financing activities:

            

Finance lease obligations originated for property and equipment

 $40  $817  $192 

Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans

 $1,088  $7,217  $3,618 

Deferred acquisition consideration

 $1,950  $--  $-- 

 

See accompanying notes to consolidated financial statements.

 

30
Table of Contents

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

(1)

Summary of Significant Accounting Policies

 

Description of Business and Basis of Presentation

 

National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our purpose is to enable human understanding. Our solutions enable health care organizations to understand what matters most to each person they serve. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Translation of Foreign Currencies

 

Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.

 

Revenue Recognition

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 3 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

●

Identify the contract, or contracts, with a customer;

 

●

Identify the performance obligations in the contract;

 

●

Determine the transaction price;

 

●

Allocate the transaction price to the identified performance obligations; and

 

●

Recognize revenue when, or as, we satisfy the performance obligations.

 

31
Table of Contents
 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve- month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch-up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.

  

 

32
Table of Contents
 

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. We deferred incremental costs of obtaining a contract of $1.9 million, $3.7 million and $3.6 million in the years ended December 31, 2021, 2020 and 2019, respectively. Deferred contract costs, net of accumulated amortization was $3.8 million and $4.6 million at December 31, 2021 and 2020, respectively. Total amortization by expense classification for the years ended December 31, 2021, 2020 and 2019 was as follows:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Direct expenses

 $157  $272  $34 

Selling, general and administrative expenses

 $2,494  $2,970  $2,874 

Total amortization

 $2,651  $3,242  $2,908 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $31,000, $63,000 and $22,000 for the years December 31, 2021, 2020 and 2019, respectively.

 

Trade Accounts Receivable

 

The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

The following table provides the activity in the allowance for doubtful accounts for the years ended December 31, 2021, 2020 and 2019 (in thousands):

 

  

Balance at

Beginning

of Year

  

Bad Debt

Expense

  

Write-offs,

net of

Recoveries

  

Balance

at End

of Year

 
                 

Year Ended December 31, 2019

 $175  $75  $106  $144 

Year Ended December 31, 2020

 $144  $46  $70  $120 

Year Ended December 31, 2021

 $120  $38  $64  $94 

 

33
Table of Contents
 

Property and Equipment

 

Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.

 

We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.8 million and $2.7 million of costs incurred for the development of internal-use software for the years ended December 31, 2021 and 2020, respectively.

 

When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of three to ten years for furniture and equipment, three to five years for computer equipment, one to five years for capitalized software, and seven to forty years for our office building and related improvements. Software licenses are amortized over the term of the license.

 

Impairment of Long-Lived Assets and Amortizing Intangible Assets

 

Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended December 31, 2021, 2020, or 2019.

 

Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result may trigger an impairment review:

 

 

●

Significant underperformance in comparison to historical or projected operating results;

 

●

Significant changes in the manner or use of acquired assets or our overall strategy;

 

●

Significant negative trends in our industry or the overall economy;

 

●

A significant decline in the market price for our common stock for a sustained period; and

 

●

Our market capitalization falling below the book value of our net assets.

 

Goodwill and Intangible Assets

 

Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review intangible assets with indefinite lives for impairment annually as of October 1 and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.

 

34
Table of Contents
 

When performing the impairment assessment, we will first assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did not recognize any impairments related to indefinite-lived intangibles during 2021, 2020 or 2019.

 

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. All of our goodwill is allocated to our reporting unit, which is the same as our operating segment. Goodwill is reviewed for impairment at least annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable.

 

We review goodwill for impairment by first assessing qualitative factors to determine whether any impairment may exist. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of October 1, 2021 and determined the fair value of our reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended December 31, 2021 or 2019. A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to September 2022, during December 2020 we chose not to enter into a new contract with this customer or otherwise extend the term of the contract beyond September 2022. We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at December 31, 2020. We recognized an impairment of $714,000 for the excess of the then Canada reporting unit’s carrying value over the fair value, using discounted cash flows.

 

In March 2021, we changed our operating segments from six to one to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker. In connection with this change, our previous reporting units were combined into one reporting unit. We performed an interim qualitative analysis immediately before and after the reorganization and concluded that the fair value of our reporting units likely exceeded the carrying values and no impairments were recorded. Following the reorganization, we considered the current and expected future economic and market conditions, including the impact of the COVID-19 pandemic, on our reporting unit. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has not occurred which would require an additional interim impairment test to be performed as it is not more likely than not that an impairment loss had been incurred at December 31, 2021.

 

Insurance Recoveries

 

We record insurance recoveries when the realization of the claim is probable. In 2020 we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in February 2020 (the “February incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the February incident did not have a significant impact on our consolidated financial statements. In 2020, we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.

 

Income Taxes

 

We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended December 31, 2021, 2020, and 2019, we recorded income tax benefits relating to these tax credits of $10,000, $45,000, and $24,000, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.

 

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

 

35
Table of Contents
 

In 2021, we adopted ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The adoption of this standard had no material impact to our consolidated financial statements.

 

Share-Based Compensation

 

All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Amounts charged against income, before income tax benefit

 $623  $680  $1,224 

Amount of related income tax benefit

  (919

)

  (6,764

)

  (2,081

)

Net (benefit) expense to net income

 $(296

)

 $(6,084

)

 $(857

)

 

We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents were $6.3 million and $5.0 million as of December 31, 2021, and 2020, respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances may exceed federally insured limits.

 

Leases

 

We determine whether a lease is included in an agreement at inception. We recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for our operating leases under which we are lessee. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 

36
Table of Contents
 

Due to remote working arrangements, we reassessed our office needs and subleased our Seattle location under an agreement considered to be an operating lease beginning in May 2021. We have not been legally released from our primary obligations under the original lease and therefore we continue to account for the original lease separately. We recorded an ROU asset impairment charge in 2021 of $324,000, which was the amount by which the carrying value of the Seattle office lease ROU asset exceeded the fair value. We estimated the fair value based on the discounted cash flows of estimated net rental income for the office space subleased. The ROU asset impairment charge is included in depreciation, amortization and impairment expenses. There were no ROU asset impairment charges in 2020 or 2019. Rent income from the sublessee are included in the statement of operations on a straight-line basis as an offset to rent expense associated with the original operating lease included in other expenses.

 

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

The following details our financial assets within the fair value hierarchy at December 31, 2021 and 2020:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of December 31, 2021

                

Money Market Funds

 $6,306  $--  $--  $6,306 

Total Cash Equivalents

 $6,306  $--  $--  $6,306 
                 

As of December 31, 2020

                

Money Market Funds

 $5,015  $--  $--  $5,015 

Total Cash Equivalents

 $5,015  $--  $--  $5,015 

 

There were no transfers between levels during the years ended December 31, 2021 and 2020.

 

Our long-term debt described in Note 8 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.

 

The following are the carrying amount and estimated fair values of long-term debt:

 

  

December 31,

2021

  

December 31,

2020

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $26,620  $30,713 

Estimated fair value of long-term debt

 $27,708  $32,943 

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). We estimated the fair value of the Seattle office ROU using discounted cash flows of the sublease based on management’s most recent projections, which are considered level 3 inputs in the fair value hierarchy and recorded an ROU asset impairment charge of $324,000 during 2021. As of December 31, 2021 and 2020, there was no indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill in December 2020 as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level 3 inputs in the fair value hierarchy.

 

37
Table of Contents
 

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do not believe the final disposition of claims at December 31, 2021 will have a material adverse effect on our consolidated financial position, results of operations or liquidity.

 

We became self-insured for group medical and dental insurance on January 1, 2019.   We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance. We do not self-insure for any other types of losses, and therefore do not carry any additional excess loss insurance. In addition, we had aggregate claims loss coverage with a minimum aggregate deductible of $3.2 million and $2.8 million, in 2021 and 2020, respectively. We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but not reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a third-party actuarial IBNR analysis.  As of December 31, 2021 and 2020, our accrual related to self-insurance was $406,000 and $418,000, respectively.

 

Earnings Per Share

 

Basic net income per share was computed using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

We had 127,185, 65,127 and 16,221 options of Common Stock for the years ended December 31, 2021, 2020 and 2019, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.

 

  

2021

  

2020

  

2019

 
  

(In thousands, except per share data)

 

Numerator for net income per share - basic:

            

Net income

 $37,466  $37,260  $32,406 

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (18

)

  (57

)

  (109

)

Net income attributable to common shareholders

 $37,448  $37,203  $32,297 

Denominator for net income per share - basic:

            

Weighted average common shares outstanding – basic

  25,422   25,170   24,809 

Net income per share – basic

 $1.47  $1.48  $1.30 

Numerator for net income per share - diluted:

            

Net income attributable to common shareholders for basic computation

 $37,448  $37,203  $32,297 

Denominator for net income per share - diluted:

            

Weighted average common shares outstanding – basic

  25,422   25,170   24,809 

Weighted average effect of dilutive securities – stock options

  218   526   844 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,640   25,696   25,653 

Net income per share – diluted

 $1.46  $1.45  $1.26 

 

38
Table of Contents
 

Recent Accounting Pronouncements Not Yet Adopted

 

In March 2020, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate. 

 

In October 2021, FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The amendment requires an acquirer in a business combination apply Topic 606 to recognize and measure contract assets in revenue contracts acquired in a business combination rather than fair value. The amendment is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the timing and the impact of adopting this new guidance on our consolidated financial statements.

 

 
 

(2) 

ACQUISITION

 

On January 4, 2021, we acquired substantially all assets and assumed certain liabilities of PatientWisdom, Inc., a company with a health engagement solution that will further our purpose of operationalizing human understanding through tangible and actionable insights. $3.0 million of the total $5.0 million all-cash consideration was paid at closing. We paid the remaining $2.0 million in January 2022. All payments were made with cash on hand. The acquisition was accounted for as a business combination, using the acquisition method of accounting, which requires, among other things, certain assets acquired and liabilities assumed to be recognized at their fair values as of the acquisition date. The following table summarizes the fair value of assets acquired and liabilities assumed at the acquisition date.

 

Amount of Identified Assets Acquired and Liabilities Assumed

 
  

($ in thousands)

 

Current Assets

 $184 

Property and equipment

  10 

Customer related

  100 

Technology

  600 

Goodwill

  4,340 

Total assets acquired

 $5,234 

Current liabilities

  284 

Net assets acquired

 $4,950 

 

The identifiable intangible assets are being amortized over their estimated useful lives of 5 years. The goodwill and identifiable intangible assets are deductible for tax purposes. Goodwill related to the acquisition was primarily attributable to anticipated synergies and other intangibles that do not qualify for separate recognition.

 

The financial results associated with the PatientWisdom assets we acquired and liabilities we assumed are included in our consolidated financial statements from the date of acquisition, although the amounts are insignificant for 2021. Pro-forma information has not been presented because the amounts for 2021 are insignificant. Acquisition-related costs of $119,000 are included in selling, general and administrative expenses for the year ended December 31, 2021.

 

39
Table of Contents

 

 

(3)

Contracts with Customers

 

The following table disaggregates revenue for the years ended December 31, 2021, 2020 and 2019 based on timing of revenue recognition (In thousands):

 

  

2021

  

2020

  

2019

 

Subscription services recognized ratably over time

 $137,008  $122,499  $114,216 

Services recognized at a point in time

  3,216   2,932   4,992 

Fixed, non-subscription recognized over time

  3,065   2,907   3,248 

Unit price services recognized over time

  4,665   4,939   5,526 

Total revenue

 $147,954  $133,277  $127,982 

 

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):

 

  

December 31,

2021

  

December 31,

2020

 

Accounts receivables

 $13,728  $13,923 

Contract assets included in other current assets

 $99  $311 

Deferred revenue

 $(17,213

)

 $(15,585

)

 

Significant changes in contract assets and contract liabilities during the years ended December 31, 2021 and 2020 are as follows (in thousands):

 

  

2021

  

2020

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(15,631

)

 $-  $(16,083

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   16,694   -   15,338 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (311

)

  -   (103

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

  -   326   -   (24

)

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  99   -   311   - 

 

We have elected to apply the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at December 31, 2021 approximated $2.9 million of which $1.3 million, $1.1 million, and $587,000 is expected to be recognized during 2022, 2023, and 2024, respectively.

 

40
Table of Contents

 

 

(4)

Equity Investments

 

We make equity investments to promote business and strategic objectives. For investments that do not have a readily determinable fair value, we apply either cost or equity method of accounting depending on the nature of our investment and our ability to exercise significant influence. Investments are periodically analyzed to determine whether or not there are any indicators of impairment and written down to fair value if the investment has incurred an other than temporary impairment. Our investment of $1.3 million in convertible preferred stock of PracticingExcellence.com, Inc., a privately-held Delaware corporation (“PX”) is included in non-current assets. It is not practicable for us to estimate fair value at each reporting date due to the cost and complexity of the calculations for this non-public entity. Therefore, it is carried at cost less impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, if any. We have a seat on PX's board of directors and our investment, which is not considered to be in-substance common stock, represents approximately 15.1% of the issued and outstanding equity interests in PX.

 

 
 

(5)

Property and Equipment

 

At December 31, 2021, and 2020, property and equipment consisted of the following:

 

  

2021

  

2020

 
  

(In thousands)

 

Furniture and equipment

 $4,901  $4,808 

Computer equipment

  2,672   2,638 

Computer software

  27,828   27,087 

Building

  9,271   7,515 

Leaseholds

  502   232 

Land

  425   425 

Property and equipment at cost

  45,599   42,705 

Less accumulated depreciation and amortization

  33,208   30,979 

Net property and equipment

 $12,391  $11,726 

 

Depreciation and amortization expense related to property and equipment, including assets under capital lease, for the years ended December 31, 2021, 2020, and 2019 was $5.7 million, $6.5 million, and $5.4 million, respectively. There were no significant impairments in property and equipment during 2021, 2020, and 2019. However, we did shorten the useful lives of certain assets to reflect our best estimate of when assets are expected to be disposed of or replaced.

 

41
Table of Contents

 

 

(6)

Goodwill and Intangible Assets

 

Goodwill and intangible assets consisted of the following at December 31, 2021:

 

  

Gross

  

Accumulated

Impairment

  

Net

 
  

(In thousands)

 

Goodwill

 $62,328  $(714

)

 $61,614 

 

  

Useful Life

  

Gross

  

Accumulated

Amortization

  

Net

 
  

(In years)

      

(In thousands)

     

Non-amortizing intangible assets:

                

Indefinite trade name

      1,191       1,191 

Amortizing intangible assets:

                

Customer related

  5-15   9,445   9,325   120 

Technology

  7   1,959   1,480   479 

Trade names

  5-10   1,572   1,572   -- 

Total amortizing intangible assets

      12,976   12,377   599 

Total intangible assets other than goodwill

     $14,167  $12,377  $1,790 

 

Goodwill and intangible assets consisted of the following at December 31, 2020:

 

  

Gross

  

Accumulated

Impairment

  

Net

 
  

(In thousands)

 

Goodwill

 $57,969  $(714

)

 $57,255 

 

  

Useful Life

  

Gross

  

Accumulated

Amortization

  

Net

 
  

(In years)

      

(In thousands)

     

Non-amortizing intangible assets:

                

Indefinite trade name

      1,191       1,191 

Amortizing intangible assets:

                

Customer related

  5-15   9,344   9,256   88 

Technology

  7   1,360   1,229   131 

Trade names

  5-10   1,572   1,572   -- 

Total amortizing intangible assets

      12,276   12,057   219 

Total intangible assets other than goodwill

     $13,467  $12,057  $1,410 

 

The following represents a summary of changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 (in thousands):

 

Balance as of December 31, 2019

 $57,935 

Impairment

  (714

)

Foreign currency translation

  34 

Balance as of December 31, 2020

 $57,255 

Goodwill acquired

  4,340 

Foreign currency translation

  19 

Balance at December 31, 2021

 $61,614 

 

As discussed in Note 1, we recorded an impairment of $714,000 to the Canada reporting unit’s goodwill in December 2020.

 

Aggregate amortization expense for customer related intangibles, trade names, and technology for the years ended December 31, 2021, 2020 and 2019 was $320,000, $318,000, and $374,000, respectively. Estimated future amortization expense for 2022, 2023, 2024 and 2025 is $180,000, $140,000, $140,000 and $139,000, respectively.

 

42
Table of Contents

 

 

(7)

Income Taxes

 

For the years ended December 31, 2021, 2020, and 2019, income before income taxes consists of the following:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

U.S. Operations

 $48,145  $41,357  $40,045 

Foreign Operations

  476   110   474 

Income before income taxes

 $48,621  $41,467  $40,519 

 

Income tax expense consisted of the following components:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Federal:

            

Current

 $9,092  $3,546  $5,574 

Deferred

  (224

)

  (308

)

  718 

Total

 $8,868  $3,238  $6,292 
             

Foreign:

            

Current

 $143  $225  $94 

Deferred

  (17

)

  (6

)

  33 

Total

 $126  $219  $127 
             

State:

            

Current

 $2,197  $578  $1,322 

Deferred

  (36

)

  172   372 

Total

 $2,161  $750  $1,694 
             

Total

 $11,155  $4,207  $8,113 

 

As a result of the Tax Cut and Jobs Act (the “Tax Act”), we determined that we would no longer indefinitely reinvest the earnings of our Canadian subsidiary. Our Canadian subsidiary declared a deemed dividend to the Company for $9.6 million in 2020. Additionally, a withholding tax of 5% was paid for the dividend distribution.

 

We received notice in December 2019, that we met qualification requirements for the Nebraska Advantage LB312 Act (“NAA”) related to certain investment and full-time equivalent employee thresholds in the year ended 2017. NAA provides direct refunds of sales tax on qualified property, as well as investment credits and employment credits that can be claimed through credits of Nebraska income tax, employment tax, and sales tax on non-qualified property. We expect to receive direct refunds of Nebraska sales tax on qualified property incurred from 2014 to 2023. Investment credits started to accumulate in 2014 and can be earned through 2023. These credits can be claimed against Nebraska income taxes or through sales tax on non-qualified property through 2028. The employment credits are earned from 2017 through 2023, and they can be claimed against Nebraska payroll taxes through 2028. In 2019, we recorded cumulative adjustments for direct refunds and credits earned through the year ending December 31, 2019, which reduced operating expenses by approximately $1.9 million. For the year ended December 31, 2021 and 2020, adjustments for credits reduced operating expenses by approximately $473,000 and $435,000, respectively. In addition, income tax credits of $10,000, $45,000 and $24,000 were recorded as a reduction to income tax expense for the years ended December 31, 2021, 2020 and 2019, respectively.

 

43
Table of Contents
 

The differences between income taxes expected at the U.S. federal statutory income tax rate of 21 percent and the reported income tax (benefit) expense are summarized as follows:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Expected federal income taxes

 $10,210  $8,708  $8,509 

Foreign tax rate differential

  26   6   26 

State income taxes, net of federal benefit and state tax credits

  1,531   607   1,344 

Share-based compensation

  (660

)

  (5,713

)

  (1,579

)

Compensation limit for covered employees

  --   463   -- 

Federal tax credits

  (272

)

  (261

)

  (419

)

Uncertain tax positions

  254   157   34 

Nondeductible expenses (income) related to recapitalization

  --   --   (24

)

Goodwill Impairment

  --   184   -- 

Withholding tax on repatriation of foreign earnings

  8   18   107 

GILTI

  --   10   13 

Other

  58   28   102 
  $11,155  $4,207  $8,113 

 

Deferred tax assets and liabilities at December 31, 2021 and 2020, were comprised of the following:

 

  

2021

  

2020

 
  

(In thousands)

 

Deferred tax assets:

        

Allowance for doubtful accounts

 $24  $29 

Accrued expenses

  687   696 

Share-based compensation

  740   735 

Accrued bonuses

  267   145 

Employer payroll tax deferral

  200   323 

Uncertain tax positions

  161   104 

Other

  66   11 

Gross deferred tax assets

  2,145   2,043 

Less valuation allowance

  --   -- 

Deferred tax assets

  2,145   2,043 

Deferred tax liabilities:

        

Prepaid expenses

  89   93 

Deferred contract costs

  945   1,111 

Property and equipment

  1,579   1,725 

Intangible assets

  6,338   6,109 

Repatriation withholding

  182   174 

Other

  --   96 

Deferred tax liabilities

  9,133   9,308 

Net deferred tax liabilities

 $(6,988

)

 $(7,265

)

 

In March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we had deferred $1.3 million of employer social security tax payments as of December 31, 2020. In accordance with the CARES Act, we paid half of this liability in December 2021, and we expect to pay the remaining $656,000 in December 2022. We have had no other impacts to our consolidated financial statements or related disclosures from the CARES Act.

 

44
Table of Contents
 

In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider projected future taxable income, carry-back opportunities, and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods which the deferred tax assets are deductible, we believe it is more likely than not that we will realize the benefits of these deductible differences excluding the foreign tax credit carryforward. In 2020, we wrote off the deferred tax asset for prior year foreign tax credit carryforwards of $535,000 and the related valuation allowance. We made the assessment that due to our Canadian subsidiary’s decreased projected future income and the lower US tax rate compared to the Canadian tax rate, it was unlikely we would realize this asset.

 

We had an unrecognized tax benefit at December 31, 2021 and 2020, of $1.1 million and $768,000, respectively, excluding interest of $19,000 and $15,000 at December 31, 2021 and 2020, respectively. Of these amounts, $918,000 and $668,000 at December 31, 2021 and 2020, respectively, represents the net unrecognized tax benefits that, if recognized, would favorably impact the effective income tax rate. The change in the unrecognized tax benefits for 2021 and 2020 was as follows:

 

  

(In thousands)

 

Balance of unrecognized tax benefits at December 31, 2019

 $592 

Reductions due to lapse of applicable statute of limitations

  (34

)

Reductions due to tax positions of prior years

  4 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  206 

Balance of unrecognized tax benefits at December 31, 2020

 $768 

Reductions due to lapse of applicable statute of limitations

  (38

)

Additions due to tax positions of prior years

  -- 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  345 

Balance of unrecognized tax benefits at December 31, 2021

 $1,075 

 

We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Canada federal and provincial jurisdictions. Tax years 2018 and forward remain subject to U.S. federal examination. Tax years 2015 and forward remain subject to state examination. Tax years 2017 and forward remain subject to Canadian federal and provincial examination.

 

 
 

(8)

Notes Payable

 

Our long-term debt consists of the following:  

 

  

2021

  

2020

 
  

(In thousands)

 

Term Loans

 $26,620  $30,713 

Less: current portion

  (4,278

)

  (4,061

)

Less: unamortized debt issuance costs

  (73

)

  (105

)

Notes payable, net of current portion

 $22,269  $26,547 

 

Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on May 28, 2020 and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-down term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan may be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The May 2020 amendment increased the Line of Credit from $15,000,000 to $30,000,000.

 

The Term Loan is payable in monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%. Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.35% at December 31, 2021). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. As of December 31, 2021, and December 31, 2020, the Line of Credit did not have a balance. We did not borrow on the Line of Credit during 2021. We have not borrowed on the Delayed Draw Term Loan since origination.

 

45
Table of Contents
 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the term(s) of the Credit Facilities. As of December 31, 2021, we were in compliance with our financial covenants. 

 

Scheduled maturities of notes payable at December 31, 2021 are as follows:

 

2022

 $4,306 

2023

  4,529 

2024

  4,762 

2025

  13,023 

 

 

 

(9)

Share-Based Compensation

 

We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur.

 

Our 2004 Non-Employee Director Stock Plan, as amended (the “2004 Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock. The 2004 Director Plan provides for grants of nonqualified stock options to each of our directors who we do not employ. On the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately one year following the date of grant and option terms are generally the earlier of ten years following the date of grant, or three years from the termination of the outside director’s service. At December 31, 2021, there were 780,330 shares of Common Stock available for issuance pursuant to future grants under the 2004 Director Plan. We have accounted for grants of 2,219,670 shares of Common Stock under the 2004 Director Plan using the date of grant as the measurement date for financial accounting purposes.

 

Our 2006 Equity Incentive Plan (the “2006 Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of Common Stock. Stock options granted may be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally five to ten years following the date of grant. At December 31, 2021, there were 806,537 shares of Common Stock available for issuance pursuant to future grants under the 2006 Equity Incentive Plan. We have accounted for grants of 993,463 shares of Common Stock and restricted stock under the 2006 Equity Incentive Plan using the date of grant as the measurement date for financial accounting purposes.

 

46
Table of Contents
 

During 2021, 2020 and 2019, we granted options to purchase 101,091, 70,471, and 100,615 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

 

  

2021

  

2020

  

2019

 

Expected dividend yield at date of grant

  2.15

%

  1.84

%

  2.60

%

Expected stock price volatility

  34.85

%

  33.62

%

  34.01

%

Risk-free interest rate

  0.91

%

  1.35

%

  2.38

%

Expected life of options (in years)

  7.01   7.39   7.46 

 

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.

 

The following table summarizes stock option activity under 2006 Equity Incentive Plan and the 2004 Director Plan for the year ended December 31, 2021:

 

  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Common Stock

                

Outstanding at December 31, 2020

  600,571  $25.31         

Granted

  101,091  $44.96         

Exercised

  (116,753

)

 $13.14      $3,535 

Expired

  (22,837

)

  9.74         

Forfeited

  (84,432

)

 $38.38         

Outstanding at December 31, 2021

  477,640  $30.88   5.97  $6,337 

Exercisable at December 31, 2021

  249,488  $23.99   4.82  $4,805 

 

The following table summarizes information related to stock options for the years ended December 31, 2021, 2020 and 2019:

 

  

2021

  

2020

  

2019

 

Weighted average grant date fair value of stock options granted

 $12.55  $18.67  $11.99 

Intrinsic value of stock options exercised (in thousands)

 $3,535  $25,912  $8,280 

Intrinsic value of stock options vested (in thousands)

 $4,805  $1,965  $1,891 

 

As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock option awards was approximately $1.1 million which was expected to be recognized over a weighted average period of 2.37 years.

 

There was $446,000 and $1.7 million in cash received from stock options exercised for the years ended December 31, 2021 and 2020, respectively and no cash received from options exercised in 2019. We recognized $607,000, $680,000, and $934,000 of non-cash compensation for the years ended December 31, 2021, 2020, and 2019, respectively, related to options, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from stock options exercised was $862,000, $6.3 million, and $1.9 million for the years ended December 31, 2021, 2020, and 2019, respectively.

 

47
Table of Contents
 

During 2021 and 2019 we granted 12,698 and 6,005 non-vested shares of Common Stock, respectively, under the 2006 Equity Incentive Plan. No shares of non-vested Common Stock were granted during the year ended December 31, 2020. As of December 31, 2021, we had 12,698 non-vested shares of Common Stock outstanding under the 2006 Equity Incentive Plan. These shares vest over five years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or not vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized $17,000, $23,000, and $290,000 of non-cash compensation for the years ended December 31, 2021, 2020, and 2019, respectively, related to this non-vested stock, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from vesting of restricted stock was $235,000 for the year ended December 31, 2020. No restricted stock vested during the year end December 31, 2021 and 2019.

 

The following table summarizes information regarding non-vested stock granted to associates under the 2006 Equity Incentive Plans for the year ended December 31, 2021:

 

  

Common Stock

Outstanding

  

Common Stock

Weighted

Average Grant

Date Fair Value

Per Share

 

Outstanding at December 31, 2020

  6,005  $38.30 

Granted

  12,698  $42.92 

Vested

  --  $-- 

Forfeited

  (6,005

)

 $38.30 

Outstanding at December 31, 2021

  12,698  $42.92 

 

As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock awards was approximately $436,000 and is expected to be recognized over a weighted average period of 4.00 years.

 

 
 

(10)

Leases

 

We lease printing, computer, other equipment and office space in the United States and Canada. The leases remaining terms as of December 31, 2021 range from less than one year to 4.93 years.

 

Certain equipment and office lease agreements include provisions for periodic adjustments to rates and charges. The rates and charges are adjusted based on actual usage or actual costs for internet, common area maintenance, taxes or insurance, as determined by the lessor and are considered variable lease costs.

 

The components of lease expense for the years ended December 31, 2021, 2020 and 2019 included (in thousands):

 

  

2021

  

2020

  

2019

 

Operating leases

 $669  $600  $781 

Finance leases:

            

Asset amortization

  489   355   252 

Interest on lease liabilities

  34   37   39 

Variable lease cost

  99   62   86 

Short-term lease cost

  59   42   42 

Sublease income

  (81

)

  --   -- 

Total net lease cost

 $1,269  $1,096  $1,200 

 

In 2020, we adjusted the useful life of the operating right of use assts associated with our Atlanta, Georgia and Markham, Ontario office leases based on the expectation that we will vacate the office space before the end of the lease term.

 

48
Table of Contents
 

Supplemental balance sheet information related to leases (in thousands):

  

  

December 31,

2021

  

December 31,

2020

 

Operating leases:

        

Operating ROU assets

 $975  $1,308 
         

Current operating lease liabilities

  493   461 

Noncurrent operating lease liabilities

  820   896 

Total operating lease liabilities

 $1,313  $1,357 

 

  

December 31,

2021

  

December 31,

2020

 

Finance leases:

        

Furniture and equipment

 $1,042  $1,014 

Computer Equipment

  659   662 

Computer Software

  207   207 

Property and equipment under finance lease, gross

  1,908   1,883 

Less accumulated amortization

  (1,074

)

  (605

)

Property and equipment under finance lease, net

 $834  $1,278 
         

Current obligations of finance leases

 $470  $493 

Noncurrent obligations of finance leases

  348   778 

Total finance lease liabilities

 $818  $1,271 
         

Weighted average remaining lease term (in years):

        

Operating leases

  2.80   3.68 

Finance leases

  1.93   2.69 
         

Weighted average discount rate:

        

Operating leases

  3.85

%

  4.40

%

Finance leases

  3.42

%

  3.38

%

 

Supplemental cash flow and other information related to leases were as follows (in thousands):

 

  

2021

  

2020

  

2019

 

Cash paid for amounts included in the measurement of lease liabilities:

            

Operating cash flows from operating leases

 $680  $596  $789 

Operating cash flows from finance leases

  34   36   38 

Financing cash flows from finance leases

  493   332   229 
             

ROU assets obtained in exchange for operating lease liabilities

  560   276   16 

ROU assets obtained in exchange for finance lease liabilities

  40   817   192 

 

Undiscounted payments under non-cancelable finance and operating leases at December 31, 2021 were as follows (in thousands):

 

  

Finance Leases

  

Operating Leases

 

2022

 $488  $531 

2023

  315   513 

2024

  23   227 

2025

  10   118 

2026

  10   -- 

Thereafter

  --   -- 

Total minimum lease payments

  846   1,389 

Less: Amount representing interest

  (28

)

  (76

)

Present value of minimum lease payments

  818   1,313 

Current portion

  (470

)

  (493

)

Lease obligations, net of current portion

 $348  $820 

 

49
Table of Contents
 

Undiscounted cash receipts due under the sublease agreement at December 31, 2021 are as follows (in thousands):

 

  

Operating Lease

 

2022

 $118 

2023

  122 

2024

  127 

2025

  65 

Total minimum lease receipts

 $432 

 

 
 

(11)

Related Party

 

A director who began serving on our board in May 2021, served as chief executive officer of Allina Health during 2021, a not-for-profit healthcare system. In connection with its routine business operations, Allina Health purchases certain of our products and services. Total revenue we earned from Allina Health in year ended December 31, 2021 approximated $1.7 million.

 

A director, who served on our board through October 2021, also served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) until January 2020 and continued to serve on the board of directors of Ameritas until October 2021. In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $278,000, $248,000, and $242,000 in 2021, 2020, and 2019 respectively.

 

A director, who served on our board through May 2020, also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during 2020 we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. Total payments for these services totaled $1.1 million in 2020.

 

During 2017, we acquired a cost method investment in convertible preferred stock of Practicing Excellence.com, Inc., a privately-held Delaware Corporation (“PX”), which is included in other non-current assets and is carried at cost, adjusted for changes resulting from observable price changes in orderly transactions of the same investment in PX, if any.  We also have an agreement with PX which commenced in 2016 under which we act as a reseller of PX services and PX receives a portion of the revenues. The total revenue earned from the PX reseller agreement in the years ended December 31, 2021, 2020, and 2019 was $35,000, $294,000, and $578,000, respectively. We no longer earn revenue under this agreement after June 30, 2021 due to termination of the reseller agreement.

 

 
 

(12)

Associate Benefits

 

We sponsor a qualified 401(k) plan covering substantially all associates with no eligibility service requirement. Under the 401(k) plan, we match 25.0% of the first 6.0% of compensation contributed by each associate. Employer contributions, which are discretionary, vest to participants at a rate of 20% per year. We contributed $531,000, $521,000, and $447,000 in 2021, 2020, and 2019, respectively, as a matching percentage of associate 401(k) contributions.

 

 

 

(13)

Segment Information

 

In March 2021, we changed our operating segments from six to one to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker.

 

50
Table of Contents
 

The table below presents entity-wide information regarding our revenue and assets by geographic area (in thousands):

 

  

2021

  

2020

  

2019

 

Revenue:

            

United States

 $144,987  $130,305  $124,369 

Canada

  2,967   2,972   3,613 

Total

 $147,954  $133,277  $127,982 

Long-lived assets:

            

United States

 $83,722  $77,448  $78,906 

Canada

  111   1,863   2,622 

Total

 $83,833  $79,311  $81,528 

Total assets:

            

United States

 $153,879  $128,319  $95,668 

Canada

  3,661   5,104   15,017 

Total

 $157,540  $133,423  $110,685 

 
51
Table of Contents

 

 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Not applicable.

 

Item 9A.

Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2021. Based upon their evaluation of these disclosure controls and procedures, the Chief Executive Officer and the Chief Financial Officer concluded that the disclosure controls and procedures were effective as of December 31, 2021.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, however, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies of procedures may deteriorate.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our internal control over financial reporting using the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on such evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2021.

 

The effectiveness of our internal control over financial reporting as of December 31, 2021, has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their report, a copy of which is included in this Annual Report on Form 10-K.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B.

Other Information

 

We have no other information to report pursuant to this item.

 

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not applicable.

 

 

52
Table of Contents

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance

 

The information required by this Item with respect to directors, executive officers and Section 16 compliance is included under the captions “Election of Directors,” “Corporate Governance – Committees”, “Information About Our Executive Officers” and “Delinquent Section 16(a) Reports,” respectively, in our definitive Proxy Statement for our 2022 Annual Meeting of Shareholders (“Proxy Statement”) and is hereby incorporated herein by reference. The information required by this Item with respect to audit committees and audit committee financial experts is included under the caption “Corporate Governance” in the Proxy Statement and is incorporated herein by reference.

 

We have adopted a Code of Business Conduct and Ethics that applies to all of our associates, including our Chief Executive Officer and Chief Financial Officer and other persons performing similar functions. We have posted a copy of the Code of Business Conduct and Ethics on our website at www.nrchealth.com, and such Code of Business Conduct and Ethics is available, in print, without charge, to any shareholder who requests it from our Secretary. We intend to satisfy the disclosure requirements under Item 5.05 of Form 8-K regarding amendments to, or waivers from, the Code of Business Conduct and Ethics by posting such information on our website at www.nrchealth.com. We are not including the information contained on our website as part of, or incorporating it by reference into, this report.

 

Item 11. 

Executive Compensation

 

The information required by this Item is included under the captions “Compensation Discussion and Analysis,” “2021 Summary Compensation Table,” “Grants of Plan-Based Awards in 2021,” “Outstanding Equity Awards at December 31, 2021,” “2021 Director Compensation,” “Compensation Committee Report,” “Corporate Governance-Transactions with Related Persons,” “Compensation Committee Interlocks and Insider Participation” and “CEO Pay Ratio” in the Proxy Statement and is hereby incorporated herein by reference.

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

 

The information required by this Item with respect to security ownership of certain beneficial owners and management is included under the caption “Principal Shareholders” in the Proxy Statement and is hereby incorporated by reference.

 

The following table sets forth information with respect to compensation plans under which equity securities of the Company are authorized for issuance as of December 31, 2021. 

 

Plan Category Common Shares

  

Number of

Securities to be

issued upon

the exercise of

outstanding

options,

warrants and

rights

    

Weighted-

average

exercise price

of

outstanding

options,

warrants and

rights

    

Number of

securities

remaining available

for future issuance

under equity

compensation

plans (excluding

securities reflected

in the first column)

  

Equity compensation plans approved by security holders(1)

     477,640     $ 30.88       1,586,867  (2)

Equity compensation plans not approved by security holders

     --       --       --  

Total

     477,640     $ 30.88       1,586,867  

 

 

(1)

Includes our 2006 Equity Incentive Plan and 2004 Director Plan.
 

(2)

Under the 2006 Equity Incentive Plan, we had authority to award up to 325,181 additional shares of restricted Common Stock provided that the total of such shares awarded may not exceed the total number of shares remaining available for issuance under the 2006 Equity Incentive Plan, which totaled 806,537 shares of Common Stock as of December 31, 2021. The Director Plan provides for granting options for 3,000,000 shares of Common Stock. Option awards through December 31, 2021 totaled 2,196,833 shares of Common Stock. 

 

53
Table of Contents

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

 

The information required by this Item is included under the caption “Corporate Governance” in the Proxy Statement and is hereby incorporated by reference.

 

Item 14.

Principal Accountant Fees and Services

 

The information required by this Item is included under the caption “Miscellaneous — Independent Registered Public Accounting Firm” in the Proxy Statement and is hereby incorporated by reference.

 

54
Table of Contents

 

PART IV

 

Item 15.

Exhibits, Financial Statement Schedules

 

1.

Consolidated financial statements. The consolidated financial statements listed in the accompanying index to the consolidated financial statements are filed as part of this Annual Report on Form 10-K.

 

2.

Financial statement schedules. All financial statement schedules have been omitted because they are not applicable or the required information is included in the consolidated financial statements and the related notes thereto.

 

3.

Exhibits. The exhibits listed in the exhibit index below are filed as part of this Annual Report on Form 10-K.

 

EXHIBIT INDEX

 

Exhibit
Number

Exhibit Description
   

(3.1)

Certificate of Incorporation of National Research Corporation, effective June 30, 2021 [Incorporated by reference to Exhibit 3.3 to National Research Corporation’s Current Report on Form 8-K dated June 29, 2021, and filed on July 2, 2021 (File No. 001-35929)]
   

(3.2)

Bylaws of National Research Corporation, as amended to date [Incorporated by reference to Exhibit 3.4 to National Research Corporation’s Current Report on Form 8-K dated June 29, 2021 and filed on July 2, 2021 (File No. 001-35929)]
   

(4.1)

Certificate of Incorporation of National Research Corporation, effective June 30, 2021 [Incorporated by reference to Exhibit 3.3 to National Research Corporation’s Current Report on Form 8-K dated June 29, 2021, and filed on July 2, 2021 (File No. 001-35929)]
   

(4.2)

Bylaws of National Research Corporation, as amended to date [Incorporated by reference to Exhibit 3.4 to National Research Corporation’s Current Report on Form 8-K dated June 29, 2021 and filed on July 2, 2021 (File No. 001-35929)]
   

(4.3)**

Description of the Securities of the Registrant.
   

(10.1)

Amended and Restated Credit Agreement dated May 28, 2020, between National Research Corporation and First National Bank of Omaha [Incorporated by reference to Exhibit 10.1 to National Research Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and filed on August 7, 2020 (File No. 001-35929)]
   

(10.2)*

National Research Corporation 2004 Non-Employee Director Stock Plan, as amended [Incorporated by reference to Appendix A to National Research Corporation’s Proxy Statement for the 2018 Annual Meeting of Shareholders filed on April 27, 2018 (File No. 001-35929)]
   

(10.3)*

Form of Nonqualified Stock Option Agreement used in connection with the National Research Corporation 2006 Equity Incentive Plan [Incorporated by reference to Exhibit 10.14 to National Research Corporation’s Annual Report on Form 10-K for the year ended December 31, 2006 and filed on April 2, 2007 (File No. 000-29466)]
   

(10.4)*

Form of Restricted Stock Agreement used in connection with the National Research Corporation 2006 Equity Incentive Plan [Incorporated by reference to Exhibit 10.15 to National Research Corporation’s Annual Report on Form 10-K for the year ended December 31, 2006 and filed on April 2, 2007 (File No. 000-29466)]
   

(10.5)*

National Research Corporation 2006 Equity Incentive Plan, [Incorporated by reference to Appendix A to National Research Corporation’s Proxy Statement for the 2006 Annual Meeting of Shareholders filed on April 3, 2006 (File No. 000-29466)]

 

55
Table of Contents

 

Exhibit
Number

Exhibit Description
   

(10.6)*

Form of Grant used in connection with the National Research Corporation 2004 Non-Employee Director Stock Plan, as amended [Incorporated by reference to Exhibit 10.1 to National Research Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and filed on November 5, 2021 (File No. 001-35929)]
   

(21)**

Subsidiary of National Research Corporation
   

(23)**

Consent of Independent Registered Public Accounting Firm
   

(31.1)**

Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   

(31.2)**

Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   

(32)**

Certification of Periodic Financial Report by the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
   

(101)**

Financial statements from the Annual Report on Form 10-K of National Research Corporation for the year ended December 31, 2021, formatted in Inline eXtensible Business Reporting Language (iXBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Shareholders’ Equity, (v) the Consolidated Statements of Cash Flows, (vi) the Notes to the Consolidated Financial Statements, and (vii) document and entity information.
   

(104)**

Cover Page Interactive Data File (formatted in the Inline XBRL and contained in Exhibit 101).

 

 

*

A management contract or compensatory plan or arrangement.

 

**

Filed herewith.

 

Item 16.

Form 10-K Summary

 

None.

 

56
Table of Contents

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

Page in

this
Form 10-K
   

Report of Independent Registered Public Accounting Firm (KPMG LLP, PCAOB ID: 185)

24
   

Consolidated Balance Sheets as of December 31, 2021 and 2020

26
   

Consolidated Statements of Income for the Three Years Ended December 31, 2021

27
   

Consolidated Statements of Comprehensive Income for the Three Years Ended December 31, 2021

28
   

Consolidated Statements of Shareholders’ Equity for the Three Years Ended December 31, 2021

29
   

Consolidated Statements of Cash Flows for the Three Years Ended December 31, 2021

30
   

Notes to Consolidated Financial Statements

31

 

 

All other financial statement schedules are omitted since the required information is not present or is not present in amounts sufficient to require submission of the schedules, or because the information required is included in the consolidated financial statements and notes thereto.

 

57
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 4th day of March 2022.

 

 

NATIONAL RESEARCH CORPORATION

  
       
 

By:

/s/ Michael D. Hays

  
   

Michael D. Hays

  
   

Chief Executive Officer and President

  

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

 

Signature

  

Title

  

Date
         

/s/ Michael D. Hays

  

Chief Executive Officer, President and Director

  

March 4, 2022

Michael D. Hays

  

(Principal Executive Officer)

    
         
         

/s/ Kevin R. Karas

  

Senior Vice President Finance, Chief Financial

  

March 4, 2022

Kevin R. Karas

  

Officer, Treasurer and Secretary (Principal

    
   

Financial and Accounting Officer)

    
         

/s/ Donald M. Berwick

  

Director

  

March 4, 2022

Donald M. Berwick

        
         
         

/s/ John N. Nunnelly

  

Director

  

March 4, 2022

John N. Nunnelly

        
         
         

/s/ Penny A. Wheeler

  

Director

  

 March 4, 2022

Penny A. Wheeler

        
         
         

/s/ Stephen H. Lockhart

  

Director

  

March 4, 2022

Stephen H. Lockhart

        

 

58
EX-4.3 2 ex_337775.htm EXHIBIT 4.3 HTML Editor

Exhibit 4.3

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

As of December 31, 2021, National Research Corporation (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $.001 (“Common Stock”).

 

The summary of the general terms and provisions of the Common Stock set forth below does not purport to be complete and is subject to and qualified by reference to the Company’s Certificate of Incorporation and Bylaws, each of which is incorporated by reference as exhibits to the Annual Report on Form 10-K. For additional information, please read the Certificate and Bylaws and the applicable provisions of the Delaware General Corporation Law (“DGCL”).

 

Authorized Capital Stock

 

Our authorized capital stock consists of 112,000,000 shares, consisting of: (i) 110,000,000 shares of Common Stock, par value $0.001 per share, and (ii) 2,000,000 shares of Preferred Stock, par value $0.01 per share. As of February 25, 2022, 25,194,447 shares of Common Stock were issued and outstanding, and no shares of our preferred stock were issued and outstanding.

 

Common Stock

 

After all cumulative dividends have been paid or declared and set apart for payment on any shares of preferred stock that are outstanding, the Common Stock is entitled to such dividends as may be declared from time to time by our board of directors in accordance with applicable law.

 

Except as provided under the DGCL, and except as may be determined by our board of directors with respect to any series of preferred stock, only the holders of Common Stock shall be entitled to vote for the election of directors of the Company and on all other matters. Holders of Common Stock are entitled to one vote for each share of Common Stock held by them on all matters properly submitted to a vote of shareholders. Shareholders have no cumulative voting rights, which means that the holders of shares entitled to exercise more than 50% of the voting power are able to elect all of the directors to be elected.

 

All shares of Common Stock are entitled to participate equally in distributions in liquidation, subject to the prior rights of any preferred stock which may be outstanding. Holders of Common Stock have no preemptive rights to subscribe for or purchase shares of our capital stock. There are no conversion rights, sinking fund or redemption provisions applicable to Common Stock. The outstanding shares of our Common Stock are fully paid and nonassessable.

 

Our Common Stock is listed on the NASDAQ Global Select Market under the trading symbol “NRC.” The transfer agent for our Common Stock is American Stock Transfer & Trust Company LLC.

 

Preferred Stock

 

Pursuant to our Certificate of Incorporation, the board of directors has the authority, without further action by the shareholders, to issue up to 2,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including, dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of our Common Stock. The board of directors, without shareholder approval, can issue preferred stock with voting, conversion, or other rights that could adversely affect the voting power and other rights of the holders of Common Stock. As a result, preferred stock could be issued quickly with terms calculated to delay or prevent a change of control of the company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our Common Stock and may adversely affect the voting and other rights of the holders of Common Stock.

 

As of the date of the Annual Report on Form 10-K of which this Exhibit is a part, no shares of preferred stock are outstanding.

 

Anti-Takeover Effects of Various Provisions of Delaware Law and Our Certificate of Incorporation and Bylaws

 

Our Certificate of Incorporation and Bylaws contain certain provisions that could have the effect of delaying, deferring, or preventing another party from acquiring control of us. These provisions, summarized below, may make it more difficult for a potential acquirer to acquire us in a transaction that is not negotiated with our board of directors and could discourage coercive takeover practices and inadequate takeover bids.

 

Director Classes and Terms; Vacancies. Under our Certificate of Incorporation and Bylaws, our board of directors is divided into three classes, with staggered terms of three years each. Each year the term of one class expires. The Certificate of Incorporation provides that any vacancies on the board of directors shall be filled only by the affirmative vote of a majority of the directors in office, even if less than a quorum. However, if the vacant office was held by a director elected by a voting group of stockholders, only the remaining directors elected by that voting group shall fill the vacancy. Any director so elected will serve until the next election of the class for which such director is chosen and until his or her successor is duly elected and qualified.

 

Removal of Directors. Our Certificate of Incorporation provides that any directors may be removed from office, but only for cause by the affirmative vote of at least 66-2/3% of the voting power of the then outstanding shares of stock of the voting group of stockholders that elected the director to be removed. However, if at least two-thirds of the board of directors plus one director vote to remove a director, such director may be removed without cause by a majority of the voting power of our outstanding shares of capital stock entitled to vote thereon.

 

Special Meetings of Stockholders. In addition, our Bylaws establish a procedure that shareholders seeking to call a special meeting of shareholders must satisfy. This procedure involves notice to us, our receipt of written demands for a special meeting from holders of 10% or more of the issued and outstanding shares of Common Stock, a review of the validity of such demands by an independent inspector appointed by us, and the fixing of the record and meeting dates by the board of directors.

 

Postponement and Adjournment of Shareholder Meetings. Our Bylaws also provide the board of directors with discretion in postponing shareholder meetings, including, within some limits, special meetings of shareholders. Additionally, the chief executive officer or the board of directors, acting by resolution, may adjourn a shareholder meeting at any time prior to the transaction of business at such meeting. Our Bylaws also contain strict time deadlines, procedures, and other criteria applicable to bringing business before a meeting, such as shareholders seeking to nominate a person for election as a director, including with respect to our proxy access provisions (whereby a shareholder, or a group of up to 20 shareholders, that have held at least 3% of our outstanding Common Stock for at least three years, may submit director nominees for inclusion in our future proxy statements).

 

 
 

 

Amendment to Certificate of Incorporation or Bylaws. The approval of a 66 2/3% super-majority of the voting power of the then outstanding shares of our capital stock entitled to vote is required to amend certain provisions of our Certificate of Incorporation and certain provisions of our Bylaws, including provisions regarding the number, classification, tenure, and removal of directors.

 

Limitations on Liability and Indemnification of Directors and Officers. Our Certificate of Incorporation limits the liability of our directors to the fullest extent permitted by the DGCL. Our Certificate of Incorporation includes a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the Company or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL (providing for liability of directors for unlawful payment of dividends or unlawful stock purchases or redemptions), or (iv) for any transaction from which the director derived an improper personal benefit. Our Certificate of Incorporation further provides, that if the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. Our Bylaws provide for the indemnification of our directors and officers and authorize us to carry directors’ and officers’ insurance for the benefit of our directors, officers, employees and agents. We believe that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive officers.

 

Business Combinations with Interested Stockholders. Section 203 of the DGCL prohibits, in certain circumstances, a Delaware corporation that has either shares of voting stock listed on a national securities exchange or more than 2,000 record holders of voting stock, from engaging in a “business combination” with an “interested stockholder” for a period of three years following the date that such stockholder became an interested stockholder, unless (i) prior to the date of the transaction, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder, (ii) upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding certain shares, or (iii) at or subsequent to that time, the business combination is approved by the board of directors and by the affirmative vote of holders of at least 66 2/3% of the corporation’s outstanding voting stock that is not owned by the interested stockholder. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an “interested stockholder” is a person who, together with that person’s affiliates and associates, owns, or within the previous three years owned, 15% or more of the corporation’s outstanding voting stock. Our Certificate of Incorporation includes a provision expressly electing not to be governed by Section 203 of the DGCL. However, since the Company’s voting stock is listed on a national securities exchange, under the DGCL, such provision will not take effect until twelve months after the effective date of our Certificate of Incorporation. Following such twelve month period, the Company will not be subject to any restrictions imposed by DGCL Section 203.

 

These provisions of our Certificate of Incorporation and Bylaws and the DGCL could have the effect of delaying or preventing a change of control of the Company.

 

 
 EX-21 3 ex_335803.htm EXHIBIT 21

 

Exhibit 21

 

Subsidiary of National Research Corp.

 

National Research Corporation’s subsidiary as of December 31, 2021 is listed below:

 

Subsidiary

Jurisdiction of organization
   

National Research Corporation Canada 

Ontario

 

 
 EX-23 4 ex_335798.htm EXHIBIT 23

 

Exhibit 23

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

National Research Corporation:

 

We consent to the incorporation by reference in the registration statements (File Nos. 333-120530, 333-137763, 333-137769, 333-173097, 333-189139, 333-189140, 333-189141, 333-209934, 333-226715, and 333-226716) on Forms S-8 and (File Nos. 333-120529, 333-211190, and 333-232534) on Form S-3 of our report dated March 4, 2022, with respect to the consolidated financial statements of National Research Corporation and the effectiveness of internal control over financial reporting.

 

 

 

 

/s/ KPMG LLP

 

Lincoln, Nebraska

March 4, 2022

 

 
 EX-31.1 5 ex_335797.htm EXHIBIT 31.1

 

Exhibit 31.1

 

Certification of Chief Executive Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

 

I, Michael D. Hays, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of National Research Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 4, 2022

By:

/s/ Michael D. Hays

  
   

Michael D. Hays

  
   

Chief Executive Officer and President

  

 

 
 EX-31.2 6 ex_335796.htm EXHIBIT 31.2

 

Exhibit 31.2

 

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

 

I, Kevin R. Karas, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of National Research Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 4, 2022

By:

/s/ Kevin R. Karas

  
   

Kevin R. Karas

  
   

Chief Financial Officer

  

 

 
 EX-32 7 ex_335795.htm EXHIBIT 32

 

Exhibit 32

 

 

Certification Pursuant to 18 U.S.C. Section 1350
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the accompanying Annual Report on Form 10-K of National Research Corporation (the “Company”) for the year ended December 31, 2021 (the “Report”), I, Michael D. Hays, Chief Executive Officer and President of the Company, and I, Kevin R. Karas, Chief Financial Officer, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, based on my knowledge, that:

 

 

1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

   

/s/ Michael D. Hays

  
   

Michael D. Hays

  
   

Chief Executive Officer and President

  

 

     
   

/s/ Kevin R. Karas

  
   

Kevin R. Karas

  
   

Chief Financial Officer

  

 

   

Date: March 4, 2022

  

 

 

 

A signed original of this written statement required by Section 906 has been provided to National Research Corporation and will be retained by National Research Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

 
 EX-101.SCH 8 nrc-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Income link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Income link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Acquisition link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Contracts With Customers link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Equity Investments link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Goodwill and Intangible Assets link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Notes Payable link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Leases link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 11 - Related Party link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 12 - Associate Benefits link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 13 - Segment Information link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Acquisition (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 3 - Contracts With Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Goodwill and Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 8 - Notes Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 9 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 10 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 13 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 2 - Acquisition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 2 - Acquisition - Fair Value of Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 3 - Contracts With Customers 1 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 3 - Contracts With Customers 2 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 4 - Equity Investments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 6 - Goodwill and Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 7 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 7 - Income Taxes - Income Before Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 7 - Income Taxes - Income Tax Expense (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 7 - Income Taxes - Income Tax Reconciliation (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 8 - Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 8 - Notes Payable - Summary of Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 9 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 9 - Share-based compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 9 - Share-based Compensation - Non-vested Stock (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 10 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 10 - Leases - Lease Expense (Details) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Sublease (Details) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note 11 - Related Party (Details Textual) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note 12 - Associate Benefits (Details Textual) link:calculationLink link:definitionLink link:presentationLink 072 - Disclosure - Note 13 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 073 - Disclosure - Note 13 - Segment Information - Assets by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 9 nrc-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 nrc-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 nrc-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Expected dividend yield at date of grant us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Intangible assets Note To Financial Statement Details Textual Significant Accounting Policies Note 1 - Summary of Significant Accounting Policies Expected federal income taxes Note 2 - Acquisition Risk-free interest rate us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets Current Assets Note 3 - Contracts With Customers Note 5 - Property and Equipment Note 6 - Goodwill and Intangible Assets Note 7 - Income Taxes Note 8 - Notes Payable Note 9 - Share-based Compensation Income Tax Disclosure [Text Block] Note 10 - Leases Note 13 - Segment Information Nondeductible expenses (income) related to recapitalization Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to recapitalization. us-gaap_SelfInsuranceReserveCurrent Self Insurance Reserve, Current Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate The interest rate applicable to the portion of the carrying amount of debt instrument borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time. Expected stock price volatility Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) Schedule of Maturities of Long-term Debt [Table Text Block] Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) Schedule of Debt [Table Text Block] Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) Note 2 - Acquisition - Fair Value of Assets and Liabilities (Details) Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) Expected life of options (in years) (Year) Other current liabilities Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Note 5 - Property and Equipment - Summary of Property and Equipment (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred, Total Lease, Cash flow [Table Text Block] Tabular disclosure of supplemental cash flow and other information related to leases. Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) nrc_GainOnPropertyInsuranceRecoveries Gain on insurance recoveries for damaged property The net amount by which an insurance settlement exceeds net book value of property damaged from an event, such as a natural catastrophe, explosion or fire. Note 7 - Income Taxes - Income Before Income Taxes (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 7 - Income Taxes - Income Tax Expense (Details) Note 7 - Income Taxes - Income Tax Reconciliation (Details) us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Business Combination, Consideration Transferred, Liabilities Incurred Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) Note 8 - Notes Payable - Summary of Notes Payable (Details) Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details) Insurance recoveries The amount recovered from insurance for lost revenues that are reported as a separate line item. Share-based Payment Arrangement, Activity [Table Text Block] Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Other comprehensive income, foreign currency translation adjustment Granted (in dollars per share) Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Note 9 - Share-based compensation - Stock Option Activity (Details) Note 9 - Share-based Compensation - Non-vested Stock (Details) Forfeited (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding (in dollars per share) Outstanding (in dollars per share) Note 10 - Leases - Lease Expense (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited (in shares) Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Outstanding (in shares) Outstanding (in shares) Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) Note 10 - Leases - Undiscounted Payments Under Sublease (Details) Schedule of Nonvested Share Activity [Table Text Block] Note 13 - Segment Information - Assets by Geographic Area (Details) Notes To Financial Statements Granted (in shares) Notes To Financial Statements [Abstract] First National Bank of Omaha [Member] Related to the entity First National Bank of Omaha. Other comprehensive income (loss): Weighted average exercise price (in dollars per share) Exercisable, weighted average remaining contractual term (Year) Current portion of notes payable, net of unamortized debt issuance costs Exercisable, aggregate intrinsic value Intrinsic value of stock options exercised (in thousands) Exercisable, number of options (in shares) Outstanding, weighted average remaining contractual term (Year) Outstanding, aggregate intrinsic value Weighted average grant date fair value of stock options granted (in dollars per share) nrc_CostMethodInvestmentOwnershipPercentage Cost Method Investment, Ownership Percentage The percentage of ownership of common stock or equity participation in the investee accounted for under the cost method of accounting. us-gaap_GoodwillGross Goodwill, gross us-gaap_GoodwillImpairedAccumulatedImpairmentLoss Goodwill, accumulated impairment us-gaap_SecuredDebtCurrent Less: current portion us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Beginning balance, outstanding, weighted average exercise price (in dollars per share) Ending balance, outstanding, weighted average exercise price (in dollars per share) Forfeited, weighted average exercise price (in dollars per share) Deferred revenue Deferred revenue Expired, weighted average exercise price (in dollars per share) Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued expenses Accrued wages and bonuses nrc_ClaimsLossCoverageMinimumAggregateDeductible Claims Loss Coverage, Minimum Aggregate Deductible The amount of minimum aggregate deductible for claims loss coverage. Dividends payable Accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Beginning balance, outstanding, number of options (in shares) Ending balance, outstanding, number of options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired, number of options (in shares) Credit Facility [Axis] Credit Facility [Domain] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Finance lease obligations originated for property and equipment us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Weighted average effect of dilutive securities – stock options (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Weighted average shares and share equivalents outstanding Income taxes nrc_ContractWithCustomerLiabilityRevenueRecognizedFromDeferredRevenue Revenue recognized that was included in deferred revenue at beginning of year due to completion of services The amount of revenue recognized that was previously included in the balance of deferred revenue under contract with customer liabilities. Current liabilities: us-gaap_Assets Total assets Total assets nrc_DeferredTaxAssetsUncertainTaxPositions Uncertain tax positions Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from uncertain tax positions. us-gaap_OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss Estimated fair value of long-term debt Plan Name [Axis] Technology-Based Intangible Assets [Member] Plan Name [Domain] Compensation and Employee Benefit Plans [Text Block] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_SubleaseIncome Sublease income us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net income attributable to common shareholders us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions Share-based Payment Arrangement, Exercise of Option, Tax Benefit Customer Relationships [Member] Investment [Text Block] us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Amount of related income tax benefit Depreciation, amortization and impairment The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and the total loss recognized during the period from impairments. Recoveries Received Direct by the Company [Member] Related to recoveries received direct by the company. Reimbursement for Lost Revenue [Member] Related to reimbursement for lost revenue. Recoveries Paid Directly by Insurer to Outside Vendor [Member] Related to recoveries paid directly by insurer to outside vendor. us-gaap_DeferredIncomeTaxAssetsNet Deferred income taxes Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Direct, Selling, General and Administrative Expenses [Member] Related to direct, selling, general and administrative expenses. Property Damage Excluding Cyber Attack [Member] Related to property damage excluding cyber attack. Award Type [Domain] Award Type [Axis] us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-lived intangible assets, accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Finite-lived intangible assets, net Intangible assets, net Total intangible assets other than goodwill Numerator for net income per share - basic: Insurance proceeds for damaged property us-gaap_FiniteLivedIntangibleAssetsGross Finite-lived intangible assets, gross Common Stock Options [Member] Related to common stock options. Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value, Intrinsic Value of Exercised and Vested in Period, and Fair Value of Vested in Period [Table Text Block] Tabular disclosure of the weighted-average grant-date fair value, aggregate intrinsic value of equity options exercised and intrinsic value and fair value of options vested. Share-based Payment Arrangement, Option [Member] Foreign currency translation Goodwill acquired us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite trade name Business Combination Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation and amortization Less accumulated amortization Net property and equipment Net property and equipment Property and equipment under finance lease, net Goodwill Goodwill, net Goodwill Goodwill us-gaap_PropertyPlantAndEquipmentGross Property and equipment at cost Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Net income Net income Net income us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic Allocation of distributed and undistributed income to unvested restricted stock shareholders Cash flows from investing activities: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Equity Securities without Readily Determinable Fair Value, Amount us-gaap_RevenueFromRelatedParties Revenue from Related Parties Earnings per share of common stock: us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction CANADA Related Party Transactions Disclosure [Text Block] Provision for income taxes Income Tax Expense (Benefit), Total us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay us-gaap_CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value, Total Cash and cash equivalents us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax Net (benefit) expense to net income us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense Accrued expenses, wages and bonuses The net change during the reporting period in the aggregate amount of expenses and accrued compensation incurred but not yet paid. Amendment Flag Auditor Name Auditor Location Auditor Firm ID ICFR Auditor Attestation Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income City Area Code Use of Estimates, Policy [Policy Text Block] us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment, Total New Accounting Pronouncements, Policy [Policy Text Block] Purchase of shares of treasury stock (in shares) us-gaap_IncreaseDecreaseInIncomeTaxes Income taxes receivable and payable us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue Common stock, shares outstanding (in shares) Financing Receivable, Allowance for Credit Loss [Table Text Block] Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_IncreaseDecreaseInDeferredCharges Deferred contract costs, net Variable lease cost us-gaap_LeaseCost Total net lease cost us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current and long-term assets Operating leases Document Fiscal Period Focus us-gaap_OperatingLeaseCost Operating leases Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term lease cost Lease, Cost [Table Text Block] ROU assets obtained in exchange for finance lease liabilities Document Period End Date ROU assets obtained in exchange for operating lease liabilities Operating leases (Year) us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type us-gaap_AssetImpairmentCharges Asset Impairment Charges, Total Entity Small Business Entity Shell Company us-gaap_DividendsCommonStockCash Dividends declared common share Document Information [Line Items] Document Information [Table] Service [Member] Entity Public Float Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Entity Voluntary Filers us-gaap_BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs Entity Well-known Seasoned Issuer London Interbank Offered Rate (LIBOR) [Member] us-gaap_CapitalizedComputerSoftwareAdditions Capitalized Computer Software, Additions Variable Rate [Domain] us-gaap_LessorOperatingLeasePaymentsToBeReceived Total minimum lease receipts us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment, Long-Lived Asset, Held-for-Use, Total Uncertain tax positions The sum of the differences between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable uncertain tax positions. us-gaap_GoodwillImpairmentLoss Goodwill, Impairment Loss Impairment Variable Rate [Axis] Capitalized contract cost us-gaap_CapitalizedContractCostImpairmentLoss Capitalized Contract Cost, Impairment Loss us-gaap_IncreaseDecreaseInAccountsReceivable Trade accounts receivable Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key us-gaap_DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction, Total us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths 2022 Capitalized Contract Cost [Axis] Entity Registrant Name us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears 2023 Capitalized Contract Cost [Domain] us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears 2024 us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears 2025 Entity [Domain] us-gaap_CapitalizedContractCostAmortizationPeriod Capitalized Contract Cost, Amortization Period (Year) Legal Entity [Axis] Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Entity Address, Address Line One us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets, Total us-gaap_TreasuryStockValueAcquiredCostMethod Purchase of shares of treasury stock Entity Address, City or Town Entity Address, Postal Zip Code Supplemental disclosure of cash paid for: Entity Address, State or Province us-gaap_TreasuryStockValue Treasury stock, at cost; 5,537,191 Common shares in 2021 and 5,384,186 Common shares in 2020 us-gaap_AllowanceForDoubtfulAccountsReceivable Balance Balance Entity Common Stock, Shares Outstanding Trading Symbol Reserve for uncertain tax positions The current period expense charged against earnings to reserve for uncertain tax positions. Local Phone Number Shares of common stock for the exercise of stock options (in shares) Exercised, number of options (in shares) Purchasing Directors and Officers and Employment Practices Liability Insurance [Member] Represents information about purchasing directors and officers and employment practices liability insurance in a related party transaction. us-gaap_TableTextBlock Notes Tables IMA Financial Group [Member] Represents information pertaining to IMA Financial Group. us-gaap_GainLossOnDispositionOfAssets1 Loss on disposal of property and equipment us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) Issuance of restricted common shares, net of forfeitures (in shares) us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Director Plan 2004 [Member] Represents the 2004 director plan. Issuance of common shares for the exercise of stock options us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Related Party [Axis] The 2006 Equity Incentive Plan [Member] Represents the 2006 Equity Incentive plan. Related Party [Domain] Trade Names 1 [Member] Rights acquired through registration of a business name to gain or protect exclusive use thereof. Ameritas Life Insurance Corp [Member] Represents information about related party. Selling, general and administrative Bad debt expense nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsCumulative Share-based Compensation Arrangement by Share-based Payment Award, Options Grants Cumulative (in shares) Gross number of share options (or share units) granted for plan to date. Granted, number of options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, number of options (in shares) Line of Credit Facility, Lender [Domain] Nonvested [Member] Information pertaining to nonvested shares. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares) Number of nonvested restricted shares outstanding. Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholders’ equity us-gaap_InsuranceRecoveries Insurance Recoveries UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans The value of stock tendered to the company for cashless exercise of stock options in connection with equity incentive plans. Retained earnings (accumulated deficit) Money Market Funds [Member] Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense nrc_ExcessLossCoveragePerPerson Excess Loss Coverage Per Person Amount of excess loss coverage per covered person related to self-insurance group medical and dental insurance. nrc_NumberOfCustomers Number of Customers Number of customers accounting for a substantial portion of one reporting unit's revenue. Change in assets and liabilities: Canadian Subsidiary [Member] Related to Canadian Subsidiary. Intrinsic value of stock options vested (in thousands) Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently vested. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements nrc_StockOptionsExcludedFromComputationOfEarningsPerShareAmount Stock Options Excluded from Computation of Earnings Per Share, Amount (in shares) Stock options that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because the exercise price exceeds the fair market value. nrc_CumulativeTaxIncentives Cumulative Tax Incentives The amount of cumulative state tax incentives that reduced the operating expenses. Operating lease obligations, net of current portion Total operating lease liabilities Present value of minimum operating lease payments Current operating lease liabilities Current portion, operating leases us-gaap_IncomeTaxCreditsAndAdjustments Income Tax Credits and Adjustments Current obligations of finance leases Current portion, finance leases Noncurrent obligations of finance leases Finance leases obligations, net of current portion us-gaap_IntangibleAssetsGrossExcludingGoodwill Total intangible assets other than goodwill Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Operating leases, total minimum lease payments Financing cash flows from finance leases Payments on finance lease obligations us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Operating leases, less: Amount representing interest us-gaap_FinanceLeaseLiability Present value of minimum finance lease payments Total finance lease liabilities us-gaap_DeferredIncomeTaxExpenseBenefit Deferred income taxes us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2024, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2025, operating leases Fair Value Measurement, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Finite-Lived Intangible Asset, Expected Amortization, Year Two us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Finite-Lived Intangible Asset, Expected Amortization, Year Three us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Finite-Lived Intangible Asset, Expected Amortization, Year Four nrc_DefinedContributionPlanMaximumPercentageOfAnnualContributionEmployeeSubjectToMatch Defined Contribution Plan, Maximum Percentage of Annual Contribution Employee Subject to Match Maximum percentage of employee gross pay, by the terms of the plan, that the employer may apply a percentage match contribution to a defined contribution plan. us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2022, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2023, operating leases Increases due to invoicing of client, net of amounts recognized as revenue Amount of increase in obligation to transfer good or service to customer due to billings to customer in excess of revenue us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One Increases due to revenue recognized in the period with additional performance obligations before invoicing Amount of increase in right to consideration in exchange for good or service transferred to customer with right conditioned on satisfaction of other performance obligations. Accumulated other comprehensive loss, foreign currency translation adjustment Foreign Currency Transactions and Translations Policy [Policy Text Block] Deferred contract costs, net Capitalized Contract Cost, Net, Noncurrent Non-cash share-based compensation expense Other Lessee, Leases [Policy Text Block] Cyber Attack [Member] Represents cyber attack. us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) Earnings Per Share, Policy [Policy Text Block] Including Assets Held under Capital Lease [Member] Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, including long lived property, plant or equipment assets held by a lessee through a capital lease arrangement. Operating expenses: Income Tax, Policy [Policy Text Block] us-gaap_AssetsCurrent Total current assets Assets, fair value Share-based Payment Arrangement [Policy Text Block] Allina Health [Member] Information related to Allina Health, a not-for-profit healthcare system. Income taxes receivable us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Impairment of Intangible Assets (Excluding Goodwill), Total Treasury stock, shares (in shares) Common stock, $0.001 par value; authorized 110,000,000 shares in 2021 and 60,000,000 shares in 2020, issued 30,898,600 in 2021 and 30,775,154 in 2020, outstanding 25,361,409 in 2021 and 25,390,968 in 2020 Adjustments to reconcile net income to net cash provided by operating activities: Measurement Frequency [Axis] nrc_DeferredAcquisitionConsideration Deferred acquisition consideration The amount of consideration for a current period business acquisition that did not result in cash payments in the period but will be paid in a future period. Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Statistical Measurement [Domain] Operating cash flows from operating leases Maximum [Member] Supplemental disclosure of non-cash investing and financing activities: nrc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill Total assets acquired Amount of assets, including goodwill, acquired at the acquisition date. Commitments and Contingencies, Policy [Policy Text Block] Minimum [Member] nrc_SocialSecurityTaxPayableCurrent Social Security Tax Payable, Current Balance social security tax payable and outstanding that was deferred as a result of the CARES Act. Product and Service [Axis] Other current assets Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Deferred tax assets Statistical Measurement [Axis] Operating cash flows from finance leases Deferred Charges, Policy [Policy Text Block] Nonqualified Stock Options [Member] Represents nonqualified stock options. Contract assets included in other current assets Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued us-gaap_NumberOfReportingUnits Number of Reporting Units Preferred stock, shares issued (in shares) Interest expense, net of capitalized amounts Prepaid expenses Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] us-gaap_DeferredTaxAssetsOther Other us-gaap_NoncurrentAssets Long-lived assets Property, Plant and Equipment Disclosure [Text Block] Geographical [Axis] Goodwill and Intangible Assets, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] us-gaap_DeferredTaxAssetsGross Gross deferred tax assets Geographical [Domain] Preferred stock, shares authorized (in shares) us-gaap_DeferredIncomeTaxLiabilities Deferred tax liabilities Non-cash stock compensation expense Amount of increase (decrease) to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Preferred stock, par value (in dollars per share) nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet Operating lease assets and liability, net Amount of increase (decrease) in operating lease assets after deduction of operating lease liabilities. us-gaap_ProceedsFromInsuranceSettlementOperatingActivities Proceeds from Insurance Settlement, Operating Activities Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value Hierarchy and NAV [Axis] Amortization of Capitalized Contract Cost [Table Text Block] Tabular disclosure of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Accrued expenses Software and Software Development Costs [Member] Noncatastrophic Event [Domain] us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Cash flows from operating activities: Noncatastrophic Event [Axis] us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts Allowance for doubtful accounts Revenue [Policy Text Block] Statement [Line Items] Lessee, Lease, Balance Sheet Information [Table Text Block] Tabular disclosure of balance sheet information related lessee's lease . Allowance for doubtful accounts Furniture and Fixtures [Member] us-gaap_NumberOfOperatingSegments Number of Operating Segments Trade accounts receivable, less allowance for doubtful accounts of $94 and $120, respectively Accounts receivables us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Share-based compensation Computer Software Held under Finance Leases [Member] Computer software held by a lessee through a finance lease arrangement. Building and Building Improvements [Member] Computer Equipment Held under Finance Leases [Member] Computer equipment held by a lessee through a finance lease arrangement. us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses Accrued bonuses Furniture and Equipment Held under Finance Leases [Member] Furniture and equipment held by a lessee through a finance lease arrangement. Assets Held under Finance Leases [Member] Long lived property, plant or equipment assets held by a lessee through a finance lease arrangement. Lessee, Operating and Finance Lease, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of lessee's operating and finance lease liability. AOCI Attributable to Parent [Member] Additional paid-in capital Shareholders’ equity: Land [Member] Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] Other, net Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other income (expense) Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Current assets: Fair Value, by Balance Sheet Grouping [Table Text Block] Deferred tax assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_ContractWithCustomerAssetReclassifiedToReceivable Decreases due to completion of services (or portion of services) and transferred to accounts receivable Interest income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_Liabilities Total liabilities us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Change due to cumulative catch-up adjustments arising from changes in expected contract consideration Director [Member] us-gaap_OperatingIncomeLoss Operating income us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities us-gaap_DeferredTaxLiabilitiesOther Other Other income (expense): us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities us-gaap_DeferredTaxLiabilities Net deferred tax liabilities Effect of exchange rate changes on cash us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets Intangible assets Deferred income taxes Consolidated Entities [Axis] Consolidated Entities [Domain] Direct us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment of payroll tax withholdings on share-based awards exercised us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Property and equipment us-gaap_DeferredTaxLiabilitiesPrepaidExpenses Prepaid expenses Deferred tax liabilities: us-gaap_PaymentsOfDividendsCommonStock Payment of dividends on common stock us-gaap_CostsAndExpenses Total operating expenses us-gaap_PaymentsForRepurchaseOfCommonStock Repurchase of shares for treasury Direct Expenses [Member] Related to direct expenses. Retained Earnings [Member] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Revenue Revenue Title of Individual [Domain] us-gaap_CurrentStateAndLocalTaxExpenseBenefit Current Title of Individual [Axis] Treasury Stock [Member] us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations Total us-gaap_CurrentForeignTaxExpenseBenefit Current us-gaap_DeferredForeignIncomeTaxExpenseBenefit Deferred nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod Incremental Costs of Obtaining a Contract, Deferred During Period Represents the amount of incremental costs of obtaining a contract deferred during the period. Additional Paid-in Capital [Member] us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations Total Common Stock [Member] us-gaap_CurrentFederalTaxExpenseBenefit Current us-gaap_DeferredFederalIncomeTaxExpenseBenefit Deferred us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations Total Equity Components [Axis] Equity Component [Domain] Total carrying amount of long-term debt us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) us-gaap_RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Foreign Operations Other Current Assets [Member] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before income taxes us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic U.S. Operations us-gaap_LineOfCredit Long-term Line of Credit, Total us-gaap_PaymentsOfDebtIssuanceCosts Payment of debt issuance costs Timing of Transfer of Good or Service [Domain] Transferred at Point in Time [Member] us-gaap_DeferredFinanceCostsNet Less: unamortized debt issuance costs Transferred over Time [Member] us-gaap_SecuredDebt Term Loans Subscription Services [Member] Represents information pertaining to subscription services. Disaggregation of Revenue [Table Text Block] Leases Disclosure [Text Block] The entire disclosure for leases. Insurance Recoveries [Policy Text Block] The disclosure for accounting policies related to insurance recoveries. Timing of Transfer of Good or Service [Axis] Unit Price Services [Member] Represents information pertaining to unit price services. Revenue from Contract with Customer [Text Block] Fixed, Non-subscription Services [Member] Represents information pertaining to fixed, non-subscription services. Document Annual Report Accounts Receivable [Policy Text Block] nrc_DeferredTaxAssetPriorYearForeignTaxCreditCarryforwardsWriteOff Deferred Tax Asset, Prior Year Foreign Tax Credit Carryforwards, Write Off The amount of prior year foreign tax credit carryforwards deferred tax assets and valuation allowance written off. Computer Equipment [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance Balance of unrecognized tax benefits Balance of unrecognized tax benefits us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Credit Agreement [Member] Represents information pertaining to a credit agreement, providing a revolving credit facility, term loan facility, and delayed draw-down term facility. Document Transition Report Term Loan [Member] Represents information pertaining to a term loan. us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations Reductions due to lapse of applicable statute of limitations nrc_DeferredTaxAssetsEmployerPayrollTaxDeferral Employer payroll tax deferral Amount before allocation of valuation allowances of deferred tax asset attributable to employer payroll tax deferral. Selling, General and Administrative Expenses [Member] Entity Interactive Data Current Dividends declared per common share (in dollars per share) Delayed Draw Term Loan [Member] Represents information pertaining to a delayed draw term loan. Security Exchange Name us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Reductions due to tax positions of prior years us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Additions based on tax positions related to the current year Title of 12(b) Security Write-offs, net of recoveries us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued Other Current Liabilities and Other Noncurrent Liabilities [Member] Primary financial statement caption encompassing other current liabilities and other noncurrent liabilities. Other Income [Member] PatientWisdom, Inc. [Member] Related to PatientWisdom, Inc. Income Statement Location [Axis] Income Statement Location [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Compensation limit for covered employees Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation limits for covered employees. nrc_DeferredTaxLiabilitiesRepatriationWithholding Repatriation withholding Amount of deferred tax liability attributable to taxable temporary differences attributable to repatriation withholding. us-gaap_RepaymentsOfNotesPayable Payments on notes payable us-gaap_RepaymentsOfLinesOfCredit Payments on line of credit Diluted (in shares) Denominator for diluted earnings per share – adjusted weighted average shares (in shares) Borrowings on line of credit Asset Class [Axis] Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] Diluted earnings per share (in dollars per share) Net income per share – diluted (in dollars per share) Basic (in shares) Weighted average common shares outstanding – basic (in shares) Numerator for net income per share - diluted: Business Acquisition [Axis] Basic earnings per share (in dollars per share) Net income per share – basic (in dollars per share) Business Acquisition, Acquiree [Domain] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Long-term Contract with Customer [Member] Denominator for net income per share - basic: Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Domain] Income Statement [Abstract] us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other comprehensive income (loss) us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2024 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour 2025 nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold The maximum amount of quarterly dividends included in the fixed charge coverage calculation unless liquidity falls below a specified threshold. nrc_TaxBenefitRealizedRestrictedStockVested Tax Benefit Realized Restricted Stock Vested The tax benefit realized from the vesting of restricted stock during the period. us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Lessee, Operating Lease, Remaining Lease Term (Year) nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantAmount Share Based Compensation, Arrangement By Share Based Payment Award, Options Grant, Amount Represents the fair value granted for share based compensation arrangement to each non-employee director at the annual meeting or when joining the board us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2022 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2023 Interest on lease liabilities Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] us-gaap_FinanceLeaseLiabilityPaymentsDue Finance leases, total minimum lease payments Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Asset amortization us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive 2026, finance leases Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] GILTI Amount of tax expense (benefit) from the December 22, 2017 Tax Cut and Jobs Act related to the GILTI tax. Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Finance leases, less: Amount representing interest us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths 2022, finance leases us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo 2023, finance leases us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree 2024, finance leases us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour 2025, finance leases Schedule of Intangible Assets and Goodwill [Table Text Block] Finance leases Finance leases (Year) us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Cash flows from financing activities: us-gaap_IncomeTaxReconciliationOtherReconcilingItems Other Other long-term liabilities nrc_DeferredTaxLiabilitiesContractCosts Deferred contract costs Amount of deferred tax liability attributable to contract costs. Share-based compensation Withholding tax on repatriation of foreign earnings PracticingExcellence.com [Member] Related to the entity PracticingExcellence.com. us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Net assets acquired us-gaap_StockholdersEquity Total shareholders’ equity Balances Balances nrc_DeemedDividendPaidByForeignSubsidiary Deemed Dividend Paid by Foreign Subsidiary Represents the amount of deemed dividend paid by foreign subsidiary. Common Class A [Member] Current liabilities Class of Stock [Axis] Goodwill Impairment us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses Class of Stock [Domain] us-gaap_LongTermDebtNoncurrent Notes payable, net of current portion nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio The minimum fixed charge coverage ratio the borrower is required to maintain under a debt instrument agreement. Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_PaymentsToAcquireBusinessesGross Payments to Acquire Businesses, Gross Acquisition consideration Notes payable, net of current portion and unamortized debt issuance costs nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio The maximum cash flow leverage ratio the borrower is allowable to maintain under a debt instrument agreement. us-gaap_IncomeTaxReconciliationTaxCredits Federal tax credits State income taxes, net of federal benefit and state tax credits Foreign tax rate differential us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Property and equipment EX-101.PRE 12 nrc-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 13 graph6.jpg begin 644 graph6.jpg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�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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Feb. 25, 2022
Jun. 30, 2021
Document Information [Line Items]      
Entity Central Index Key 0000070487    
Entity Registrant Name National Research Corporation    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Document Transition Report false    
Entity File Number 001-35929    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 47-0634000    
Entity Address, Address Line One 1245 Q Street    
Entity Address, City or Town Lincoln    
Entity Address, State or Province NE    
Entity Address, Postal Zip Code 68508    
City Area Code 402    
Local Phone Number 475-2525    
Title of 12(b) Security Common Stock, $.001 par value    
Trading Symbol NRC    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 533,334,729
Entity Common Stock, Shares Outstanding   25,194,447  
Auditor Name KPMG LLP    
Auditor Location Lincoln, Nebraska    
Auditor Firm ID 185    
ICFR Auditor Attestation Flag true    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 54,361 $ 34,690
Trade accounts receivable, less allowance for doubtful accounts of $94 and $120, respectively 13,728 13,923
Prepaid expenses 3,884 2,645
Income taxes receivable 752 1,235
Other current assets 982 1,619
Total current assets 73,707 54,112
Net property and equipment 12,391 11,726
Intangible assets, net 1,790 1,410
Goodwill 61,614 57,255
Operating lease right-of-use assets 975 1,308
Deferred contract costs, net 3,772 4,555
Deferred income taxes 14  
Other 3,277 3,057
Total assets 157,540 133,423
Current liabilities:    
Current portion of notes payable, net of unamortized debt issuance costs 4,278 4,061
Accounts payable 1,943 1,095
Accrued wages and bonuses 7,139 6,460
Accrued expenses 5,450 3,184
Dividends payable 3,044  
Deferred revenue 17,213 15,585
Other current liabilities 1,321 1,296
Total current liabilities 40,388 31,681
Notes payable, net of current portion and unamortized debt issuance costs 22,269 26,547
Deferred income taxes 7,002 7,265
Other long-term liabilities 2,544 3,615
Total liabilities 72,203 69,108
Shareholders’ equity:    
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued 0 0
Common stock, $0.001 par value; authorized 110,000,000 shares in 2021 and 60,000,000 shares in 2020, issued 30,898,600 in 2021 and 30,775,154 in 2020, outstanding 25,361,409 in 2021 and 25,390,968 in 2020 31 31
Additional paid-in capital 173,942 171,785
Retained earnings (accumulated deficit) (36,112) (61,375)
Accumulated other comprehensive loss, foreign currency translation adjustment (2,375) (2,399)
Treasury stock, at cost; 5,537,191 Common shares in 2021 and 5,384,186 Common shares in 2020 (50,149) (43,727)
Total shareholders’ equity 85,337 64,315
Total liabilities and shareholders’ equity $ 157,540 $ 133,423
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Allowance for doubtful accounts $ 94 $ 120
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 110,000,000 60,000,000
Common stock, shares issued (in shares) 30,898,600 30,775,154
Common stock, shares outstanding (in shares) 25,361,409 25,390,968
Treasury stock, shares (in shares) 5,537,191 5,384,186
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue $ 147,954 $ 133,277 $ 127,982
Insurance recoveries   533  
Operating expenses:      
Direct 52,350 49,187 46,435
Selling, general and administrative 38,960 34,441 32,973
Depreciation, amortization and impairment 6,374 7,505 5,539
Total operating expenses 97,684 91,133 84,947
Operating income 50,270 42,677 43,035
Other income (expense):      
Interest income 14 18 37
Interest expense (1,667) (1,813) (2,091)
Other, net 4 585 (462)
Total other income (expense) (1,649) (1,210) (2,516)
Income before income taxes 48,621 41,467 40,519
Provision for income taxes 11,155 4,207 8,113
Net income $ 37,466 $ 37,260 $ 32,406
Earnings per share of common stock:      
Basic earnings per share (in dollars per share) $ 1.47 $ 1.48 $ 1.30
Diluted earnings per share (in dollars per share) $ 1.46 $ 1.45 $ 1.26
Weighted average shares and share equivalents outstanding      
Basic (in shares) 25,422 25,170 24,809
Diluted (in shares) 25,640 25,696 25,653
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Net income $ 37,466 $ 37,260 $ 32,406
Other comprehensive income (loss):      
Other comprehensive income, foreign currency translation adjustment 24 (190) 707
Other comprehensive income (loss) 24 (190) 707
Comprehensive income $ 37,490 $ 37,070 $ 33,113
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
Balances at Dec. 31, 2018 $ 30 $ 157,312 $ (106,339) $ (2,916) $ (29,004) $ 19,083
Purchase of shares of treasury stock         (4,722) (4,722)
Issuance of common shares for the exercise of stock options   3,618       3,618
Non-cash stock compensation expense   1,224       1,224
Dividends declared common share     (19,424)     (19,424)
Other comprehensive income, foreign currency translation adjustment       707   707
Net income     32,406     32,406
Balances at Dec. 31, 2019 30 162,154 (93,357) (2,209) (33,726) 32,892
Purchase of shares of treasury stock         (10,001) (10,001)
Issuance of common shares for the exercise of stock options 1 8,951       8,952
Non-cash stock compensation expense   680       680
Dividends declared common share     (5,278)     (5,278)
Other comprehensive income, foreign currency translation adjustment       (190)   (190)
Net income     37,260     37,260
Balances at Dec. 31, 2020 31 171,785 (61,375) (2,399) (43,727) 64,315
Purchase of shares of treasury stock         (6,422) (6,422)
Issuance of common shares for the exercise of stock options   1,534       1,534
Non-cash stock compensation expense   623       623
Dividends declared common share     (12,203)     (12,203)
Other comprehensive income, foreign currency translation adjustment       24   24
Net income     37,466     37,466
Balances at Dec. 31, 2021 $ 31 $ 173,942 $ (36,112) $ (2,375) $ (50,149) $ 85,337
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Shareholders' Equity (Parentheticals) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Purchase of shares of treasury stock (in shares) 153,005 180,112 87,203
Shares of common stock for the exercise of stock options (in shares) 116,753 630,373 227,902
Issuance of restricted common shares, net of forfeitures (in shares)   6,793 6,005
Dividends declared per common share (in dollars per share) $ 0.48 $ 0.21 $ 0.78
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net income $ 37,466,000 $ 37,260,000 $ 32,406,000
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation, amortization and impairment 6,374,000 7,505,000 5,539,000
Deferred income taxes (277,000) (134,000) 1,099,000
Reserve for uncertain tax positions 310,000 185,000 39,000
Gain on insurance recoveries for damaged property   (260,000)  
Loss on disposal of property and equipment 7,000 12,000 (6,000)
Non-cash share-based compensation expense 623,000 680,000 1,224,000
Change in assets and liabilities:      
Trade accounts receivable 343,000 (2,271,000) 311,000
Prepaid expenses and other current and long-term assets (842,000) (827,000) (529,000)
Operating lease assets and liability, net (34,000) 16,000 (8,000)
Deferred contract costs, net 783,000 (351,000) (719,000)
Accounts payable 4,000 (247,000) 647,000
Accrued expenses, wages and bonuses (285,000) 1,370,000 806,000
Income taxes receivable and payable 484,000 (1,529,000) 11,000
Deferred revenue 1,388,000 (773,000) 97,000
Net cash provided by operating activities 46,344,000 40,636,000 40,917,000
Cash flows from investing activities:      
Purchases of property and equipment (5,514,000) (3,984,000) (4,656,000)
Acquisition consideration (3,000,000)    
Insurance proceeds for damaged property   260,000  
Net cash used in investing activities (8,514,000) (3,724,000) (4,656,000)
Cash flows from financing activities:      
Borrowings on line of credit     21,000,000
Payments on line of credit     (21,000,000)
Payments on notes payable (4,093,000) (3,568,000) (3,715,000)
Payment of debt issuance costs   (36,000)  
Payments on finance lease obligations (493,000) (332,000) (229,000)
Proceeds from the exercise of stock options 446,000 1,734,000 0
Payment of payroll tax withholdings on share-based awards exercised (721,000) (2,784,000) (1,103,000)
Repurchase of shares for treasury (4,142,000)    
Payment of dividends on common stock (9,159,000) (10,517,000) (31,299,000)
Net cash used in financing activities (18,162,000) (15,503,000) (36,346,000)
Effect of exchange rate changes on cash 3,000 (236,000) 611,000
Net increase (decrease) in cash and cash equivalents 19,671,000 21,173,000 526,000
Cash and cash equivalents at beginning of period 34,690,000 13,517,000 12,991,000
Cash and cash equivalents at end of period 54,361,000 34,690,000 13,517,000
Supplemental disclosure of cash paid for:      
Interest expense, net of capitalized amounts 1,554,000 1,735,000 2,014,000
Income taxes 10,644,000 5,217,000 6,946,000
Supplemental disclosure of non-cash investing and financing activities:      
Finance lease obligations originated for property and equipment 40,000 817,000 192,000
Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans 1,088,000 $ 7,217,000 $ 3,618,000
Deferred acquisition consideration $ 1,950,000    
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

(1)

Summary of Significant Accounting Policies

 

Description of Business and Basis of Presentation

 

National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our purpose is to enable human understanding. Our solutions enable health care organizations to understand what matters most to each person they serve. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Translation of Foreign Currencies

 

Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.

 

Revenue Recognition

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 3 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

●

Identify the contract, or contracts, with a customer;

 

●

Identify the performance obligations in the contract;

 

●

Determine the transaction price;

 

●

Allocate the transaction price to the identified performance obligations; and

 

●

Recognize revenue when, or as, we satisfy the performance obligations.

 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve- month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch-up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.

  

 

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. We deferred incremental costs of obtaining a contract of $1.9 million, $3.7 million and $3.6 million in the years ended December 31, 2021, 2020 and 2019, respectively. Deferred contract costs, net of accumulated amortization was $3.8 million and $4.6 million at December 31, 2021 and 2020, respectively. Total amortization by expense classification for the years ended December 31, 2021, 2020 and 2019 was as follows:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Direct expenses

 $157  $272  $34 

Selling, general and administrative expenses

 $2,494  $2,970  $2,874 

Total amortization

 $2,651  $3,242  $2,908 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $31,000, $63,000 and $22,000 for the years December 31, 2021, 2020 and 2019, respectively.

 

Trade Accounts Receivable

 

The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

The following table provides the activity in the allowance for doubtful accounts for the years ended December 31, 2021, 2020 and 2019 (in thousands):

 

  

Balance at

Beginning

of Year

  

Bad Debt

Expense

  

Write-offs,

net of

Recoveries

  

Balance

at End

of Year

 
                 

Year Ended December 31, 2019

 $175  $75  $106  $144 

Year Ended December 31, 2020

 $144  $46  $70  $120 

Year Ended December 31, 2021

 $120  $38  $64  $94 

 

Property and Equipment

 

Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.

 

We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.8 million and $2.7 million of costs incurred for the development of internal-use software for the years ended December 31, 2021 and 2020, respectively.

 

When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of three to ten years for furniture and equipment, three to five years for computer equipment, one to five years for capitalized software, and seven to forty years for our office building and related improvements. Software licenses are amortized over the term of the license.

 

Impairment of Long-Lived Assets and Amortizing Intangible Assets

 

Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended December 31, 2021, 2020, or 2019.

 

Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result may trigger an impairment review:

 

 

●

Significant underperformance in comparison to historical or projected operating results;

 

●

Significant changes in the manner or use of acquired assets or our overall strategy;

 

●

Significant negative trends in our industry or the overall economy;

 

●

A significant decline in the market price for our common stock for a sustained period; and

 

●

Our market capitalization falling below the book value of our net assets.

 

Goodwill and Intangible Assets

 

Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review intangible assets with indefinite lives for impairment annually as of October 1 and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.

 

When performing the impairment assessment, we will first assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did not recognize any impairments related to indefinite-lived intangibles during 2021, 2020 or 2019.

 

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. All of our goodwill is allocated to our reporting unit, which is the same as our operating segment. Goodwill is reviewed for impairment at least annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable.

 

We review goodwill for impairment by first assessing qualitative factors to determine whether any impairment may exist. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of October 1, 2021 and determined the fair value of our reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended December 31, 2021 or 2019. A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to September 2022, during December 2020 we chose not to enter into a new contract with this customer or otherwise extend the term of the contract beyond September 2022. We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at December 31, 2020. We recognized an impairment of $714,000 for the excess of the then Canada reporting unit’s carrying value over the fair value, using discounted cash flows.

 

In March 2021, we changed our operating segments from six to one to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker. In connection with this change, our previous reporting units were combined into one reporting unit. We performed an interim qualitative analysis immediately before and after the reorganization and concluded that the fair value of our reporting units likely exceeded the carrying values and no impairments were recorded. Following the reorganization, we considered the current and expected future economic and market conditions, including the impact of the COVID-19 pandemic, on our reporting unit. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has not occurred which would require an additional interim impairment test to be performed as it is not more likely than not that an impairment loss had been incurred at December 31, 2021.

 

Insurance Recoveries

 

We record insurance recoveries when the realization of the claim is probable. In 2020 we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in February 2020 (the “February incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the February incident did not have a significant impact on our consolidated financial statements. In 2020, we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.

 

Income Taxes

 

We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended December 31, 2021, 2020, and 2019, we recorded income tax benefits relating to these tax credits of $10,000, $45,000, and $24,000, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.

 

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

 

In 2021, we adopted ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The adoption of this standard had no material impact to our consolidated financial statements.

 

Share-Based Compensation

 

All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Amounts charged against income, before income tax benefit

 $623  $680  $1,224 

Amount of related income tax benefit

  (919

)

  (6,764

)

  (2,081

)

Net (benefit) expense to net income

 $(296

)

 $(6,084

)

 $(857

)

 

We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents were $6.3 million and $5.0 million as of December 31, 2021, and 2020, respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances may exceed federally insured limits.

 

Leases

 

We determine whether a lease is included in an agreement at inception. We recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for our operating leases under which we are lessee. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 

Due to remote working arrangements, we reassessed our office needs and subleased our Seattle location under an agreement considered to be an operating lease beginning in May 2021. We have not been legally released from our primary obligations under the original lease and therefore we continue to account for the original lease separately. We recorded an ROU asset impairment charge in 2021 of $324,000, which was the amount by which the carrying value of the Seattle office lease ROU asset exceeded the fair value. We estimated the fair value based on the discounted cash flows of estimated net rental income for the office space subleased. The ROU asset impairment charge is included in depreciation, amortization and impairment expenses. There were no ROU asset impairment charges in 2020 or 2019. Rent income from the sublessee are included in the statement of operations on a straight-line basis as an offset to rent expense associated with the original operating lease included in other expenses.

 

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

The following details our financial assets within the fair value hierarchy at December 31, 2021 and 2020:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of December 31, 2021

                

Money Market Funds

 $6,306  $--  $--  $6,306 

Total Cash Equivalents

 $6,306  $--  $--  $6,306 
                 

As of December 31, 2020

                

Money Market Funds

 $5,015  $--  $--  $5,015 

Total Cash Equivalents

 $5,015  $--  $--  $5,015 

 

There were no transfers between levels during the years ended December 31, 2021 and 2020.

 

Our long-term debt described in Note 8 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.

 

The following are the carrying amount and estimated fair values of long-term debt:

 

  

December 31,

2021

  

December 31,

2020

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $26,620  $30,713 

Estimated fair value of long-term debt

 $27,708  $32,943 

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). We estimated the fair value of the Seattle office ROU using discounted cash flows of the sublease based on management’s most recent projections, which are considered level 3 inputs in the fair value hierarchy and recorded an ROU asset impairment charge of $324,000 during 2021. As of December 31, 2021 and 2020, there was no indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill in December 2020 as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level 3 inputs in the fair value hierarchy.

 

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do not believe the final disposition of claims at December 31, 2021 will have a material adverse effect on our consolidated financial position, results of operations or liquidity.

 

We became self-insured for group medical and dental insurance on January 1, 2019.   We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance. We do not self-insure for any other types of losses, and therefore do not carry any additional excess loss insurance. In addition, we had aggregate claims loss coverage with a minimum aggregate deductible of $3.2 million and $2.8 million, in 2021 and 2020, respectively. We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but not reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a third-party actuarial IBNR analysis.  As of December 31, 2021 and 2020, our accrual related to self-insurance was $406,000 and $418,000, respectively.

 

Earnings Per Share

 

Basic net income per share was computed using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

We had 127,185, 65,127 and 16,221 options of Common Stock for the years ended December 31, 2021, 2020 and 2019, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.

 

  

2021

  

2020

  

2019

 
  

(In thousands, except per share data)

 

Numerator for net income per share - basic:

            

Net income

 $37,466  $37,260  $32,406 

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (18

)

  (57

)

  (109

)

Net income attributable to common shareholders

 $37,448  $37,203  $32,297 

Denominator for net income per share - basic:

            

Weighted average common shares outstanding – basic

  25,422   25,170   24,809 

Net income per share – basic

 $1.47  $1.48  $1.30 

Numerator for net income per share - diluted:

            

Net income attributable to common shareholders for basic computation

 $37,448  $37,203  $32,297 

Denominator for net income per share - diluted:

            

Weighted average common shares outstanding – basic

  25,422   25,170   24,809 

Weighted average effect of dilutive securities – stock options

  218   526   844 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,640   25,696   25,653 

Net income per share – diluted

 $1.46  $1.45  $1.26 

 

Recent Accounting Pronouncements Not Yet Adopted

 

In March 2020, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate. 

 

In October 2021, FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The amendment requires an acquirer in a business combination apply Topic 606 to recognize and measure contract assets in revenue contracts acquired in a business combination rather than fair value. The amendment is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the timing and the impact of adopting this new guidance on our consolidated financial statements.

 

 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 2 - Acquisition
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

(2) 

ACQUISITION

 

On January 4, 2021, we acquired substantially all assets and assumed certain liabilities of PatientWisdom, Inc., a company with a health engagement solution that will further our purpose of operationalizing human understanding through tangible and actionable insights. $3.0 million of the total $5.0 million all-cash consideration was paid at closing. We paid the remaining $2.0 million in January 2022. All payments were made with cash on hand. The acquisition was accounted for as a business combination, using the acquisition method of accounting, which requires, among other things, certain assets acquired and liabilities assumed to be recognized at their fair values as of the acquisition date. The following table summarizes the fair value of assets acquired and liabilities assumed at the acquisition date.

 

Amount of Identified Assets Acquired and Liabilities Assumed

 
  

($ in thousands)

 

Current Assets

 $184 

Property and equipment

  10 

Customer related

  100 

Technology

  600 

Goodwill

  4,340 

Total assets acquired

 $5,234 

Current liabilities

  284 

Net assets acquired

 $4,950 

 

The identifiable intangible assets are being amortized over their estimated useful lives of 5 years. The goodwill and identifiable intangible assets are deductible for tax purposes. Goodwill related to the acquisition was primarily attributable to anticipated synergies and other intangibles that do not qualify for separate recognition.

 

The financial results associated with the PatientWisdom assets we acquired and liabilities we assumed are included in our consolidated financial statements from the date of acquisition, although the amounts are insignificant for 2021. Pro-forma information has not been presented because the amounts for 2021 are insignificant. Acquisition-related costs of $119,000 are included in selling, general and administrative expenses for the year ended December 31, 2021.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Contracts With Customers
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

(3)

Contracts with Customers

 

The following table disaggregates revenue for the years ended December 31, 2021, 2020 and 2019 based on timing of revenue recognition (In thousands):

 

  

2021

  

2020

  

2019

 

Subscription services recognized ratably over time

 $137,008  $122,499  $114,216 

Services recognized at a point in time

  3,216   2,932   4,992 

Fixed, non-subscription recognized over time

  3,065   2,907   3,248 

Unit price services recognized over time

  4,665   4,939   5,526 

Total revenue

 $147,954  $133,277  $127,982 

 

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):

 

  

December 31,

2021

  

December 31,

2020

 

Accounts receivables

 $13,728  $13,923 

Contract assets included in other current assets

 $99  $311 

Deferred revenue

 $(17,213

)

 $(15,585

)

 

Significant changes in contract assets and contract liabilities during the years ended December 31, 2021 and 2020 are as follows (in thousands):

 

  

2021

  

2020

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(15,631

)

 $-  $(16,083

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   16,694   -   15,338 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (311

)

  -   (103

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

  -   326   -   (24

)

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  99   -   311   - 

 

We have elected to apply the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at December 31, 2021 approximated $2.9 million of which $1.3 million, $1.1 million, and $587,000 is expected to be recognized during 2022, 2023, and 2024, respectively.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 4 - Equity Investments
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Investment [Text Block]

(4)

Equity Investments

 

We make equity investments to promote business and strategic objectives. For investments that do not have a readily determinable fair value, we apply either cost or equity method of accounting depending on the nature of our investment and our ability to exercise significant influence. Investments are periodically analyzed to determine whether or not there are any indicators of impairment and written down to fair value if the investment has incurred an other than temporary impairment. Our investment of $1.3 million in convertible preferred stock of PracticingExcellence.com, Inc., a privately-held Delaware corporation (“PX”) is included in non-current assets. It is not practicable for us to estimate fair value at each reporting date due to the cost and complexity of the calculations for this non-public entity. Therefore, it is carried at cost less impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, if any. We have a seat on PX's board of directors and our investment, which is not considered to be in-substance common stock, represents approximately 15.1% of the issued and outstanding equity interests in PX.

 

 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 5 - Property and Equipment
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

(5)

Property and Equipment

 

At December 31, 2021, and 2020, property and equipment consisted of the following:

 

  

2021

  

2020

 
  

(In thousands)

 

Furniture and equipment

 $4,901  $4,808 

Computer equipment

  2,672   2,638 

Computer software

  27,828   27,087 

Building

  9,271   7,515 

Leaseholds

  502   232 

Land

  425   425 

Property and equipment at cost

  45,599   42,705 

Less accumulated depreciation and amortization

  33,208   30,979 

Net property and equipment

 $12,391  $11,726 

 

Depreciation and amortization expense related to property and equipment, including assets under capital lease, for the years ended December 31, 2021, 2020, and 2019 was $5.7 million, $6.5 million, and $5.4 million, respectively. There were no significant impairments in property and equipment during 2021, 2020, and 2019. However, we did shorten the useful lives of certain assets to reflect our best estimate of when assets are expected to be disposed of or replaced.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

(6)

Goodwill and Intangible Assets

 

Goodwill and intangible assets consisted of the following at December 31, 2021:

 

  

Gross

  

Accumulated

Impairment

  

Net

 
  

(In thousands)

 

Goodwill

 $62,328  $(714

)

 $61,614 

 

  

Useful Life

  

Gross

  

Accumulated

Amortization

  

Net

 
  

(In years)

      

(In thousands)

     

Non-amortizing intangible assets:

                

Indefinite trade name

      1,191       1,191 

Amortizing intangible assets:

                

Customer related

  5-15   9,445   9,325   120 

Technology

  7   1,959   1,480   479 

Trade names

  5-10   1,572   1,572   -- 

Total amortizing intangible assets

      12,976   12,377   599 

Total intangible assets other than goodwill

     $14,167  $12,377  $1,790 

 

Goodwill and intangible assets consisted of the following at December 31, 2020:

 

  

Gross

  

Accumulated

Impairment

  

Net

 
  

(In thousands)

 

Goodwill

 $57,969  $(714

)

 $57,255 

 

  

Useful Life

  

Gross

  

Accumulated

Amortization

  

Net

 
  

(In years)

      

(In thousands)

     

Non-amortizing intangible assets:

                

Indefinite trade name

      1,191       1,191 

Amortizing intangible assets:

                

Customer related

  5-15   9,344   9,256   88 

Technology

  7   1,360   1,229   131 

Trade names

  5-10   1,572   1,572   -- 

Total amortizing intangible assets

      12,276   12,057   219 

Total intangible assets other than goodwill

     $13,467  $12,057  $1,410 

 

The following represents a summary of changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 (in thousands):

 

Balance as of December 31, 2019

 $57,935 

Impairment

  (714

)

Foreign currency translation

  34 

Balance as of December 31, 2020

 $57,255 

Goodwill acquired

  4,340 

Foreign currency translation

  19 

Balance at December 31, 2021

 $61,614 

 

As discussed in Note 1, we recorded an impairment of $714,000 to the Canada reporting unit’s goodwill in December 2020.

 

Aggregate amortization expense for customer related intangibles, trade names, and technology for the years ended December 31, 2021, 2020 and 2019 was $320,000, $318,000, and $374,000, respectively. Estimated future amortization expense for 2022, 2023, 2024 and 2025 is $180,000, $140,000, $140,000 and $139,000, respectively.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

(7)

Income Taxes

 

For the years ended December 31, 2021, 2020, and 2019, income before income taxes consists of the following:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

U.S. Operations

 $48,145  $41,357  $40,045 

Foreign Operations

  476   110   474 

Income before income taxes

 $48,621  $41,467  $40,519 

 

Income tax expense consisted of the following components:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Federal:

            

Current

 $9,092  $3,546  $5,574 

Deferred

  (224

)

  (308

)

  718 

Total

 $8,868  $3,238  $6,292 
             

Foreign:

            

Current

 $143  $225  $94 

Deferred

  (17

)

  (6

)

  33 

Total

 $126  $219  $127 
             

State:

            

Current

 $2,197  $578  $1,322 

Deferred

  (36

)

  172   372 

Total

 $2,161  $750  $1,694 
             

Total

 $11,155  $4,207  $8,113 

 

As a result of the Tax Cut and Jobs Act (the “Tax Act”), we determined that we would no longer indefinitely reinvest the earnings of our Canadian subsidiary. Our Canadian subsidiary declared a deemed dividend to the Company for $9.6 million in 2020. Additionally, a withholding tax of 5% was paid for the dividend distribution.

 

We received notice in December 2019, that we met qualification requirements for the Nebraska Advantage LB312 Act (“NAA”) related to certain investment and full-time equivalent employee thresholds in the year ended 2017. NAA provides direct refunds of sales tax on qualified property, as well as investment credits and employment credits that can be claimed through credits of Nebraska income tax, employment tax, and sales tax on non-qualified property. We expect to receive direct refunds of Nebraska sales tax on qualified property incurred from 2014 to 2023. Investment credits started to accumulate in 2014 and can be earned through 2023. These credits can be claimed against Nebraska income taxes or through sales tax on non-qualified property through 2028. The employment credits are earned from 2017 through 2023, and they can be claimed against Nebraska payroll taxes through 2028. In 2019, we recorded cumulative adjustments for direct refunds and credits earned through the year ending December 31, 2019, which reduced operating expenses by approximately $1.9 million. For the year ended December 31, 2021 and 2020, adjustments for credits reduced operating expenses by approximately $473,000 and $435,000, respectively. In addition, income tax credits of $10,000, $45,000 and $24,000 were recorded as a reduction to income tax expense for the years ended December 31, 2021, 2020 and 2019, respectively.

 

The differences between income taxes expected at the U.S. federal statutory income tax rate of 21 percent and the reported income tax (benefit) expense are summarized as follows:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Expected federal income taxes

 $10,210  $8,708  $8,509 

Foreign tax rate differential

  26   6   26 

State income taxes, net of federal benefit and state tax credits

  1,531   607   1,344 

Share-based compensation

  (660

)

  (5,713

)

  (1,579

)

Compensation limit for covered employees

  --   463   -- 

Federal tax credits

  (272

)

  (261

)

  (419

)

Uncertain tax positions

  254   157   34 

Nondeductible expenses (income) related to recapitalization

  --   --   (24

)

Goodwill Impairment

  --   184   -- 

Withholding tax on repatriation of foreign earnings

  8   18   107 

GILTI

  --   10   13 

Other

  58   28   102 
  $11,155  $4,207  $8,113 

 

Deferred tax assets and liabilities at December 31, 2021 and 2020, were comprised of the following:

 

  

2021

  

2020

 
  

(In thousands)

 

Deferred tax assets:

        

Allowance for doubtful accounts

 $24  $29 

Accrued expenses

  687   696 

Share-based compensation

  740   735 

Accrued bonuses

  267   145 

Employer payroll tax deferral

  200   323 

Uncertain tax positions

  161   104 

Other

  66   11 

Gross deferred tax assets

  2,145   2,043 

Less valuation allowance

  --   -- 

Deferred tax assets

  2,145   2,043 

Deferred tax liabilities:

        

Prepaid expenses

  89   93 

Deferred contract costs

  945   1,111 

Property and equipment

  1,579   1,725 

Intangible assets

  6,338   6,109 

Repatriation withholding

  182   174 

Other

  --   96 

Deferred tax liabilities

  9,133   9,308 

Net deferred tax liabilities

 $(6,988

)

 $(7,265

)

 

In March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we had deferred $1.3 million of employer social security tax payments as of December 31, 2020. In accordance with the CARES Act, we paid half of this liability in December 2021, and we expect to pay the remaining $656,000 in December 2022. We have had no other impacts to our consolidated financial statements or related disclosures from the CARES Act.

 

In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider projected future taxable income, carry-back opportunities, and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods which the deferred tax assets are deductible, we believe it is more likely than not that we will realize the benefits of these deductible differences excluding the foreign tax credit carryforward. In 2020, we wrote off the deferred tax asset for prior year foreign tax credit carryforwards of $535,000 and the related valuation allowance. We made the assessment that due to our Canadian subsidiary’s decreased projected future income and the lower US tax rate compared to the Canadian tax rate, it was unlikely we would realize this asset.

 

We had an unrecognized tax benefit at December 31, 2021 and 2020, of $1.1 million and $768,000, respectively, excluding interest of $19,000 and $15,000 at December 31, 2021 and 2020, respectively. Of these amounts, $918,000 and $668,000 at December 31, 2021 and 2020, respectively, represents the net unrecognized tax benefits that, if recognized, would favorably impact the effective income tax rate. The change in the unrecognized tax benefits for 2021 and 2020 was as follows:

 

  

(In thousands)

 

Balance of unrecognized tax benefits at December 31, 2019

 $592 

Reductions due to lapse of applicable statute of limitations

  (34

)

Reductions due to tax positions of prior years

  4 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  206 

Balance of unrecognized tax benefits at December 31, 2020

 $768 

Reductions due to lapse of applicable statute of limitations

  (38

)

Additions due to tax positions of prior years

  -- 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  345 

Balance of unrecognized tax benefits at December 31, 2021

 $1,075 

 

We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Canada federal and provincial jurisdictions. Tax years 2018 and forward remain subject to U.S. federal examination. Tax years 2015 and forward remain subject to state examination. Tax years 2017 and forward remain subject to Canadian federal and provincial examination.

 

 
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 8 - Notes Payable
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Debt Disclosure [Text Block]

(8)

Notes Payable

 

Our long-term debt consists of the following:  

 

  

2021

  

2020

 
  

(In thousands)

 

Term Loans

 $26,620  $30,713 

Less: current portion

  (4,278

)

  (4,061

)

Less: unamortized debt issuance costs

  (73

)

  (105

)

Notes payable, net of current portion

 $22,269  $26,547 

 

Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on May 28, 2020 and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-down term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan may be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The May 2020 amendment increased the Line of Credit from $15,000,000 to $30,000,000.

 

The Term Loan is payable in monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%. Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.35% at December 31, 2021). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. As of December 31, 2021, and December 31, 2020, the Line of Credit did not have a balance. We did not borrow on the Line of Credit during 2021. We have not borrowed on the Delayed Draw Term Loan since origination.

 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the term(s) of the Credit Facilities. As of December 31, 2021, we were in compliance with our financial covenants. 

 

Scheduled maturities of notes payable at December 31, 2021 are as follows:

 

2022

 $4,306 

2023

  4,529 

2024

  4,762 

2025

  13,023 

 
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Share-based Compensation
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

(9)

Share-Based Compensation

 

We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur.

 

Our 2004 Non-Employee Director Stock Plan, as amended (the “2004 Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock. The 2004 Director Plan provides for grants of nonqualified stock options to each of our directors who we do not employ. On the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately one year following the date of grant and option terms are generally the earlier of ten years following the date of grant, or three years from the termination of the outside director’s service. At December 31, 2021, there were 780,330 shares of Common Stock available for issuance pursuant to future grants under the 2004 Director Plan. We have accounted for grants of 2,219,670 shares of Common Stock under the 2004 Director Plan using the date of grant as the measurement date for financial accounting purposes.

 

Our 2006 Equity Incentive Plan (the “2006 Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of Common Stock. Stock options granted may be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally five to ten years following the date of grant. At December 31, 2021, there were 806,537 shares of Common Stock available for issuance pursuant to future grants under the 2006 Equity Incentive Plan. We have accounted for grants of 993,463 shares of Common Stock and restricted stock under the 2006 Equity Incentive Plan using the date of grant as the measurement date for financial accounting purposes.

 

During 2021, 2020 and 2019, we granted options to purchase 101,091, 70,471, and 100,615 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

 

  

2021

  

2020

  

2019

 

Expected dividend yield at date of grant

  2.15

%

  1.84

%

  2.60

%

Expected stock price volatility

  34.85

%

  33.62

%

  34.01

%

Risk-free interest rate

  0.91

%

  1.35

%

  2.38

%

Expected life of options (in years)

  7.01   7.39   7.46 

 

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.

 

The following table summarizes stock option activity under 2006 Equity Incentive Plan and the 2004 Director Plan for the year ended December 31, 2021:

 

  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Common Stock

                

Outstanding at December 31, 2020

  600,571  $25.31         

Granted

  101,091  $44.96         

Exercised

  (116,753

)

 $13.14      $3,535 

Expired

  (22,837

)

  9.74         

Forfeited

  (84,432

)

 $38.38         

Outstanding at December 31, 2021

  477,640  $30.88   5.97  $6,337 

Exercisable at December 31, 2021

  249,488  $23.99   4.82  $4,805 

 

The following table summarizes information related to stock options for the years ended December 31, 2021, 2020 and 2019:

 

  

2021

  

2020

  

2019

 

Weighted average grant date fair value of stock options granted

 $12.55  $18.67  $11.99 

Intrinsic value of stock options exercised (in thousands)

 $3,535  $25,912  $8,280 

Intrinsic value of stock options vested (in thousands)

 $4,805  $1,965  $1,891 

 

As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock option awards was approximately $1.1 million which was expected to be recognized over a weighted average period of 2.37 years.

 

There was $446,000 and $1.7 million in cash received from stock options exercised for the years ended December 31, 2021 and 2020, respectively and no cash received from options exercised in 2019. We recognized $607,000, $680,000, and $934,000 of non-cash compensation for the years ended December 31, 2021, 2020, and 2019, respectively, related to options, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from stock options exercised was $862,000, $6.3 million, and $1.9 million for the years ended December 31, 2021, 2020, and 2019, respectively.

 

During 2021 and 2019 we granted 12,698 and 6,005 non-vested shares of Common Stock, respectively, under the 2006 Equity Incentive Plan. No shares of non-vested Common Stock were granted during the year ended December 31, 2020. As of December 31, 2021, we had 12,698 non-vested shares of Common Stock outstanding under the 2006 Equity Incentive Plan. These shares vest over five years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or not vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized $17,000, $23,000, and $290,000 of non-cash compensation for the years ended December 31, 2021, 2020, and 2019, respectively, related to this non-vested stock, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from vesting of restricted stock was $235,000 for the year ended December 31, 2020. No restricted stock vested during the year end December 31, 2021 and 2019.

 

The following table summarizes information regarding non-vested stock granted to associates under the 2006 Equity Incentive Plans for the year ended December 31, 2021:

 

  

Common Stock

Outstanding

  

Common Stock

Weighted

Average Grant

Date Fair Value

Per Share

 

Outstanding at December 31, 2020

  6,005  $38.30 

Granted

  12,698  $42.92 

Vested

  --  $-- 

Forfeited

  (6,005

)

 $38.30 

Outstanding at December 31, 2021

  12,698  $42.92 

 

As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock awards was approximately $436,000 and is expected to be recognized over a weighted average period of 4.00 years.

 

 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Leases
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Leases Disclosure [Text Block]

(10)

Leases

 

We lease printing, computer, other equipment and office space in the United States and Canada. The leases remaining terms as of December 31, 2021 range from less than one year to 4.93 years.

 

Certain equipment and office lease agreements include provisions for periodic adjustments to rates and charges. The rates and charges are adjusted based on actual usage or actual costs for internet, common area maintenance, taxes or insurance, as determined by the lessor and are considered variable lease costs.

 

The components of lease expense for the years ended December 31, 2021, 2020 and 2019 included (in thousands):

 

  

2021

  

2020

  

2019

 

Operating leases

 $669  $600  $781 

Finance leases:

            

Asset amortization

  489   355   252 

Interest on lease liabilities

  34   37   39 

Variable lease cost

  99   62   86 

Short-term lease cost

  59   42   42 

Sublease income

  (81

)

  --   -- 

Total net lease cost

 $1,269  $1,096  $1,200 

 

In 2020, we adjusted the useful life of the operating right of use assts associated with our Atlanta, Georgia and Markham, Ontario office leases based on the expectation that we will vacate the office space before the end of the lease term.

 

Supplemental balance sheet information related to leases (in thousands):

  

  

December 31,

2021

  

December 31,

2020

 

Operating leases:

        

Operating ROU assets

 $975  $1,308 
         

Current operating lease liabilities

  493   461 

Noncurrent operating lease liabilities

  820   896 

Total operating lease liabilities

 $1,313  $1,357 

 

  

December 31,

2021

  

December 31,

2020

 

Finance leases:

        

Furniture and equipment

 $1,042  $1,014 

Computer Equipment

  659   662 

Computer Software

  207   207 

Property and equipment under finance lease, gross

  1,908   1,883 

Less accumulated amortization

  (1,074

)

  (605

)

Property and equipment under finance lease, net

 $834  $1,278 
         

Current obligations of finance leases

 $470  $493 

Noncurrent obligations of finance leases

  348   778 

Total finance lease liabilities

 $818  $1,271 
         

Weighted average remaining lease term (in years):

        

Operating leases

  2.80   3.68 

Finance leases

  1.93   2.69 
         

Weighted average discount rate:

        

Operating leases

  3.85

%

  4.40

%

Finance leases

  3.42

%

  3.38

%

 

Supplemental cash flow and other information related to leases were as follows (in thousands):

 

  

2021

  

2020

  

2019

 

Cash paid for amounts included in the measurement of lease liabilities:

            

Operating cash flows from operating leases

 $680  $596  $789 

Operating cash flows from finance leases

  34   36   38 

Financing cash flows from finance leases

  493   332   229 
             

ROU assets obtained in exchange for operating lease liabilities

  560   276   16 

ROU assets obtained in exchange for finance lease liabilities

  40   817   192 

 

Undiscounted payments under non-cancelable finance and operating leases at December 31, 2021 were as follows (in thousands):

 

  

Finance Leases

  

Operating Leases

 

2022

 $488  $531 

2023

  315   513 

2024

  23   227 

2025

  10   118 

2026

  10   -- 

Thereafter

  --   -- 

Total minimum lease payments

  846   1,389 

Less: Amount representing interest

  (28

)

  (76

)

Present value of minimum lease payments

  818   1,313 

Current portion

  (470

)

  (493

)

Lease obligations, net of current portion

 $348  $820 

 

Undiscounted cash receipts due under the sublease agreement at December 31, 2021 are as follows (in thousands):

 

  

Operating Lease

 

2022

 $118 

2023

  122 

2024

  127 

2025

  65 

Total minimum lease receipts

 $432 

 

 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 11 - Related Party
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

(11)

Related Party

 

A director who began serving on our board in May 2021, served as chief executive officer of Allina Health during 2021, a not-for-profit healthcare system. In connection with its routine business operations, Allina Health purchases certain of our products and services. Total revenue we earned from Allina Health in year ended December 31, 2021 approximated $1.7 million.

 

A director, who served on our board through October 2021, also served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) until January 2020 and continued to serve on the board of directors of Ameritas until October 2021. In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $278,000, $248,000, and $242,000 in 2021, 2020, and 2019 respectively.

 

A director, who served on our board through May 2020, also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during 2020 we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. Total payments for these services totaled $1.1 million in 2020.

 

During 2017, we acquired a cost method investment in convertible preferred stock of Practicing Excellence.com, Inc., a privately-held Delaware Corporation (“PX”), which is included in other non-current assets and is carried at cost, adjusted for changes resulting from observable price changes in orderly transactions of the same investment in PX, if any.  We also have an agreement with PX which commenced in 2016 under which we act as a reseller of PX services and PX receives a portion of the revenues. The total revenue earned from the PX reseller agreement in the years ended December 31, 2021, 2020, and 2019 was $35,000, $294,000, and $578,000, respectively. We no longer earn revenue under this agreement after June 30, 2021 due to termination of the reseller agreement.

 

 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 12 - Associate Benefits
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Compensation and Employee Benefit Plans [Text Block]

(12)

Associate Benefits

 

We sponsor a qualified 401(k) plan covering substantially all associates with no eligibility service requirement. Under the 401(k) plan, we match 25.0% of the first 6.0% of compensation contributed by each associate. Employer contributions, which are discretionary, vest to participants at a rate of 20% per year. We contributed $531,000, $521,000, and $447,000 in 2021, 2020, and 2019, respectively, as a matching percentage of associate 401(k) contributions.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

(13)

Segment Information

 

In March 2021, we changed our operating segments from six to one to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker.

 

The table below presents entity-wide information regarding our revenue and assets by geographic area (in thousands):

 

  

2021

  

2020

  

2019

 

Revenue:

            

United States

 $144,987  $130,305  $124,369 

Canada

  2,967   2,972   3,613 

Total

 $147,954  $133,277  $127,982 

Long-lived assets:

            

United States

 $83,722  $77,448  $78,906 

Canada

  111   1,863   2,622 

Total

 $83,833  $79,311  $81,528 

Total assets:

            

United States

 $153,879  $128,319  $95,668 

Canada

  3,661   5,104   15,017 

Total

 $157,540  $133,423  $110,685 

 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Foreign Currency Transactions and Translations Policy [Policy Text Block]

Translation of Foreign Currencies

 

Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.
Revenue [Policy Text Block]

Revenue Recognition

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 3 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

●

Identify the contract, or contracts, with a customer;

 

●

Identify the performance obligations in the contract;

 

●

Determine the transaction price;

 

●

Allocate the transaction price to the identified performance obligations; and

 

●

Recognize revenue when, or as, we satisfy the performance obligations.

 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve- month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch-up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.
Deferred Charges, Policy [Policy Text Block]

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. We deferred incremental costs of obtaining a contract of $1.9 million, $3.7 million and $3.6 million in the years ended December 31, 2021, 2020 and 2019, respectively. Deferred contract costs, net of accumulated amortization was $3.8 million and $4.6 million at December 31, 2021 and 2020, respectively. Total amortization by expense classification for the years ended December 31, 2021, 2020 and 2019 was as follows:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Direct expenses

 $157  $272  $34 

Selling, general and administrative expenses

 $2,494  $2,970  $2,874 

Total amortization

 $2,651  $3,242  $2,908 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $31,000, $63,000 and $22,000 for the years December 31, 2021, 2020 and 2019, respectively.
Accounts Receivable [Policy Text Block]

Trade Accounts Receivable

 

The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

The following table provides the activity in the allowance for doubtful accounts for the years ended December 31, 2021, 2020 and 2019 (in thousands):

 

  

Balance at

Beginning

of Year

  

Bad Debt

Expense

  

Write-offs,

net of

Recoveries

  

Balance

at End

of Year

 
                 

Year Ended December 31, 2019

 $175  $75  $106  $144 

Year Ended December 31, 2020

 $144  $46  $70  $120 

Year Ended December 31, 2021

 $120  $38  $64  $94 
Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.

 

We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.8 million and $2.7 million of costs incurred for the development of internal-use software for the years ended December 31, 2021 and 2020, respectively.

 

When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of three to ten years for furniture and equipment, three to five years for computer equipment, one to five years for capitalized software, and seven to forty years for our office building and related improvements. Software licenses are amortized over the term of the license.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets and Amortizing Intangible Assets

 

Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended December 31, 2021, 2020, or 2019.

 

Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result may trigger an impairment review:

 

 

●

Significant underperformance in comparison to historical or projected operating results;

 

●

Significant changes in the manner or use of acquired assets or our overall strategy;

 

●

Significant negative trends in our industry or the overall economy;

 

●

A significant decline in the market price for our common stock for a sustained period; and

 

●

Our market capitalization falling below the book value of our net assets.
Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and Intangible Assets

 

Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review intangible assets with indefinite lives for impairment annually as of October 1 and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.

 

When performing the impairment assessment, we will first assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did not recognize any impairments related to indefinite-lived intangibles during 2021, 2020 or 2019.

 

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. All of our goodwill is allocated to our reporting unit, which is the same as our operating segment. Goodwill is reviewed for impairment at least annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable.

 

We review goodwill for impairment by first assessing qualitative factors to determine whether any impairment may exist. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of October 1, 2021 and determined the fair value of our reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended December 31, 2021 or 2019. A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to September 2022, during December 2020 we chose not to enter into a new contract with this customer or otherwise extend the term of the contract beyond September 2022. We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at December 31, 2020. We recognized an impairment of $714,000 for the excess of the then Canada reporting unit’s carrying value over the fair value, using discounted cash flows.

 

In March 2021, we changed our operating segments from six to one to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker. In connection with this change, our previous reporting units were combined into one reporting unit. We performed an interim qualitative analysis immediately before and after the reorganization and concluded that the fair value of our reporting units likely exceeded the carrying values and no impairments were recorded. Following the reorganization, we considered the current and expected future economic and market conditions, including the impact of the COVID-19 pandemic, on our reporting unit. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has not occurred which would require an additional interim impairment test to be performed as it is not more likely than not that an impairment loss had been incurred at December 31, 2021.
Insurance Recoveries [Policy Text Block]

Insurance Recoveries

 

We record insurance recoveries when the realization of the claim is probable. In 2020 we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in February 2020 (the “February incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the February incident did not have a significant impact on our consolidated financial statements. In 2020, we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.
Income Tax, Policy [Policy Text Block]

Income Taxes

 

We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended December 31, 2021, 2020, and 2019, we recorded income tax benefits relating to these tax credits of $10,000, $45,000, and $24,000, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.

 

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

 

In 2021, we adopted ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The adoption of this standard had no material impact to our consolidated financial statements.
Share-based Payment Arrangement [Policy Text Block]

Share-Based Compensation

 

All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:

 

  

2021

  

2020

  

2019

 
  

(In thousands)

 

Amounts charged against income, before income tax benefit

 $623  $680  $1,224 

Amount of related income tax benefit

  (919

)

  (6,764

)

  (2,081

)

Net (benefit) expense to net income

 $(296

)

 $(6,084

)

 $(857

)

 

We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents were $6.3 million and $5.0 million as of December 31, 2021, and 2020, respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances may exceed federally insured limits.
Lessee, Leases [Policy Text Block]

Leases

 

We determine whether a lease is included in an agreement at inception. We recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for our operating leases under which we are lessee. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 

Due to remote working arrangements, we reassessed our office needs and subleased our Seattle location under an agreement considered to be an operating lease beginning in May 2021. We have not been legally released from our primary obligations under the original lease and therefore we continue to account for the original lease separately. We recorded an ROU asset impairment charge in 2021 of $324,000, which was the amount by which the carrying value of the Seattle office lease ROU asset exceeded the fair value. We estimated the fair value based on the discounted cash flows of estimated net rental income for the office space subleased. The ROU asset impairment charge is included in depreciation, amortization and impairment expenses. There were no ROU asset impairment charges in 2020 or 2019. Rent income from the sublessee are included in the statement of operations on a straight-line basis as an offset to rent expense associated with the original operating lease included in other expenses.
Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

The following details our financial assets within the fair value hierarchy at December 31, 2021 and 2020:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of December 31, 2021

                

Money Market Funds

 $6,306  $--  $--  $6,306 

Total Cash Equivalents

 $6,306  $--  $--  $6,306 
                 

As of December 31, 2020

                

Money Market Funds

 $5,015  $--  $--  $5,015 

Total Cash Equivalents

 $5,015  $--  $--  $5,015 

 

There were no transfers between levels during the years ended December 31, 2021 and 2020.

 

Our long-term debt described in Note 8 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.

 

The following are the carrying amount and estimated fair values of long-term debt:

 

  

December 31,

2021

  

December 31,

2020

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $26,620  $30,713 

Estimated fair value of long-term debt

 $27,708  $32,943 

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). We estimated the fair value of the Seattle office ROU using discounted cash flows of the sublease based on management’s most recent projections, which are considered level 3 inputs in the fair value hierarchy and recorded an ROU asset impairment charge of $324,000 during 2021. As of December 31, 2021 and 2020, there was no indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill in December 2020 as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level 3 inputs in the fair value hierarchy.
Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do not believe the final disposition of claims at December 31, 2021 will have a material adverse effect on our consolidated financial position, results of operations or liquidity.

 

We became self-insured for group medical and dental insurance on January 1, 2019.   We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance. We do not self-insure for any other types of losses, and therefore do not carry any additional excess loss insurance. In addition, we had aggregate claims loss coverage with a minimum aggregate deductible of $3.2 million and $2.8 million, in 2021 and 2020, respectively. We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but not reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a third-party actuarial IBNR analysis.  As of December 31, 2021 and 2020, our accrual related to self-insurance was $406,000 and $418,000, respectively.
Earnings Per Share, Policy [Policy Text Block]

Earnings Per Share

 

Basic net income per share was computed using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

We had 127,185, 65,127 and 16,221 options of Common Stock for the years ended December 31, 2021, 2020 and 2019, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.

 

  

2021

  

2020

  

2019

 
  

(In thousands, except per share data)

 

Numerator for net income per share - basic:

            

Net income

 $37,466  $37,260  $32,406 

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (18

)

  (57

)

  (109

)

Net income attributable to common shareholders

 $37,448  $37,203  $32,297 

Denominator for net income per share - basic:

            

Weighted average common shares outstanding – basic

  25,422   25,170   24,809 

Net income per share – basic

 $1.47  $1.48  $1.30 

Numerator for net income per share - diluted:

            

Net income attributable to common shareholders for basic computation

 $37,448  $37,203  $32,297 

Denominator for net income per share - diluted:

            

Weighted average common shares outstanding – basic

  25,422   25,170   24,809 

Weighted average effect of dilutive securities – stock options

  218   526   844 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,640   25,696   25,653 

Net income per share – diluted

 $1.46  $1.45  $1.26 
New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements Not Yet Adopted

 

In March 2020, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate. 

 

In October 2021, FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The amendment requires an acquirer in a business combination apply Topic 606 to recognize and measure contract assets in revenue contracts acquired in a business combination rather than fair value. The amendment is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the timing and the impact of adopting this new guidance on our consolidated financial statements.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Amortization of Capitalized Contract Cost [Table Text Block]
  

2021

  

2020

  

2019

 
  

(In thousands)

 

Direct expenses

 $157  $272  $34 

Selling, general and administrative expenses

 $2,494  $2,970  $2,874 

Total amortization

 $2,651  $3,242  $2,908 
Financing Receivable, Allowance for Credit Loss [Table Text Block]
  

Balance at

Beginning

of Year

  

Bad Debt

Expense

  

Write-offs,

net of

Recoveries

  

Balance

at End

of Year

 
                 

Year Ended December 31, 2019

 $175  $75  $106  $144 

Year Ended December 31, 2020

 $144  $46  $70  $120 

Year Ended December 31, 2021

 $120  $38  $64  $94 
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
  

2021

  

2020

  

2019

 
  

(In thousands)

 

Amounts charged against income, before income tax benefit

 $623  $680  $1,224 

Amount of related income tax benefit

  (919

)

  (6,764

)

  (2,081

)

Net (benefit) expense to net income

 $(296

)

 $(6,084

)

 $(857

)
Fair Value, by Balance Sheet Grouping [Table Text Block]
  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of December 31, 2021

                

Money Market Funds

 $6,306  $--  $--  $6,306 

Total Cash Equivalents

 $6,306  $--  $--  $6,306 
                 

As of December 31, 2020

                

Money Market Funds

 $5,015  $--  $--  $5,015 

Total Cash Equivalents

 $5,015  $--  $--  $5,015 
  

December 31,

2021

  

December 31,

2020

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $26,620  $30,713 

Estimated fair value of long-term debt

 $27,708  $32,943 
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

2021

  

2020

  

2019

 
  

(In thousands, except per share data)

 

Numerator for net income per share - basic:

            

Net income

 $37,466  $37,260  $32,406 

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (18

)

  (57

)

  (109

)

Net income attributable to common shareholders

 $37,448  $37,203  $32,297 

Denominator for net income per share - basic:

            

Weighted average common shares outstanding – basic

  25,422   25,170   24,809 

Net income per share – basic

 $1.47  $1.48  $1.30 

Numerator for net income per share - diluted:

            

Net income attributable to common shareholders for basic computation

 $37,448  $37,203  $32,297 

Denominator for net income per share - diluted:

            

Weighted average common shares outstanding – basic

  25,422   25,170   24,809 

Weighted average effect of dilutive securities – stock options

  218   526   844 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,640   25,696   25,653 

Net income per share – diluted

 $1.46  $1.45  $1.26 
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 2 - Acquisition (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Amount of Identified Assets Acquired and Liabilities Assumed

 
  

($ in thousands)

 

Current Assets

 $184 

Property and equipment

  10 

Customer related

  100 

Technology

  600 

Goodwill

  4,340 

Total assets acquired

 $5,234 

Current liabilities

  284 

Net assets acquired

 $4,950 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Contracts With Customers (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

2021

  

2020

  

2019

 

Subscription services recognized ratably over time

 $137,008  $122,499  $114,216 

Services recognized at a point in time

  3,216   2,932   4,992 

Fixed, non-subscription recognized over time

  3,065   2,907   3,248 

Unit price services recognized over time

  4,665   4,939   5,526 

Total revenue

 $147,954  $133,277  $127,982 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
  

December 31,

2021

  

December 31,

2020

 

Accounts receivables

 $13,728  $13,923 

Contract assets included in other current assets

 $99  $311 

Deferred revenue

 $(17,213

)

 $(15,585

)

  

2021

  

2020

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(15,631

)

 $-  $(16,083

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   16,694   -   15,338 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (311

)

  -   (103

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

  -   326   -   (24

)

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  99   -   311   - 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 5 - Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Property, Plant and Equipment [Table Text Block]
  

2021

  

2020

 
  

(In thousands)

 

Furniture and equipment

 $4,901  $4,808 

Computer equipment

  2,672   2,638 

Computer software

  27,828   27,087 

Building

  9,271   7,515 

Leaseholds

  502   232 

Land

  425   425 

Property and equipment at cost

  45,599   42,705 

Less accumulated depreciation and amortization

  33,208   30,979 

Net property and equipment

 $12,391  $11,726 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Intangible Assets and Goodwill [Table Text Block]
  

Gross

  

Accumulated

Impairment

  

Net

 
  

(In thousands)

 

Goodwill

 $62,328  $(714

)

 $61,614 
  

Useful Life

  

Gross

  

Accumulated

Amortization

  

Net

 
  

(In years)

      

(In thousands)

     

Non-amortizing intangible assets:

                

Indefinite trade name

      1,191       1,191 

Amortizing intangible assets:

                

Customer related

  5-15   9,445   9,325   120 

Technology

  7   1,959   1,480   479 

Trade names

  5-10   1,572   1,572   -- 

Total amortizing intangible assets

      12,976   12,377   599 

Total intangible assets other than goodwill

     $14,167  $12,377  $1,790 
  

Gross

  

Accumulated

Impairment

  

Net

 
  

(In thousands)

 

Goodwill

 $57,969  $(714

)

 $57,255 
  

Useful Life

  

Gross

  

Accumulated

Amortization

  

Net

 
  

(In years)

      

(In thousands)

     

Non-amortizing intangible assets:

                

Indefinite trade name

      1,191       1,191 

Amortizing intangible assets:

                

Customer related

  5-15   9,344   9,256   88 

Technology

  7   1,360   1,229   131 

Trade names

  5-10   1,572   1,572   -- 

Total amortizing intangible assets

      12,276   12,057   219 

Total intangible assets other than goodwill

     $13,467  $12,057  $1,410 
Schedule of Goodwill [Table Text Block]

Balance as of December 31, 2019

 $57,935 

Impairment

  (714

)

Foreign currency translation

  34 

Balance as of December 31, 2020

 $57,255 

Goodwill acquired

  4,340 

Foreign currency translation

  19 

Balance at December 31, 2021

 $61,614 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
  

2021

  

2020

  

2019

 
  

(In thousands)

 

U.S. Operations

 $48,145  $41,357  $40,045 

Foreign Operations

  476   110   474 

Income before income taxes

 $48,621  $41,467  $40,519 
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

2021

  

2020

  

2019

 
  

(In thousands)

 

Federal:

            

Current

 $9,092  $3,546  $5,574 

Deferred

  (224

)

  (308

)

  718 

Total

 $8,868  $3,238  $6,292 
             

Foreign:

            

Current

 $143  $225  $94 

Deferred

  (17

)

  (6

)

  33 

Total

 $126  $219  $127 
             

State:

            

Current

 $2,197  $578  $1,322 

Deferred

  (36

)

  172   372 

Total

 $2,161  $750  $1,694 
             

Total

 $11,155  $4,207  $8,113 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

2021

  

2020

  

2019

 
  

(In thousands)

 

Expected federal income taxes

 $10,210  $8,708  $8,509 

Foreign tax rate differential

  26   6   26 

State income taxes, net of federal benefit and state tax credits

  1,531   607   1,344 

Share-based compensation

  (660

)

  (5,713

)

  (1,579

)

Compensation limit for covered employees

  --   463   -- 

Federal tax credits

  (272

)

  (261

)

  (419

)

Uncertain tax positions

  254   157   34 

Nondeductible expenses (income) related to recapitalization

  --   --   (24

)

Goodwill Impairment

  --   184   -- 

Withholding tax on repatriation of foreign earnings

  8   18   107 

GILTI

  --   10   13 

Other

  58   28   102 
  $11,155  $4,207  $8,113 
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

2021

  

2020

 
  

(In thousands)

 

Deferred tax assets:

        

Allowance for doubtful accounts

 $24  $29 

Accrued expenses

  687   696 

Share-based compensation

  740   735 

Accrued bonuses

  267   145 

Employer payroll tax deferral

  200   323 

Uncertain tax positions

  161   104 

Other

  66   11 

Gross deferred tax assets

  2,145   2,043 

Less valuation allowance

  --   -- 

Deferred tax assets

  2,145   2,043 

Deferred tax liabilities:

        

Prepaid expenses

  89   93 

Deferred contract costs

  945   1,111 

Property and equipment

  1,579   1,725 

Intangible assets

  6,338   6,109 

Repatriation withholding

  182   174 

Other

  --   96 

Deferred tax liabilities

  9,133   9,308 

Net deferred tax liabilities

 $(6,988

)

 $(7,265

)
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
  

(In thousands)

 

Balance of unrecognized tax benefits at December 31, 2019

 $592 

Reductions due to lapse of applicable statute of limitations

  (34

)

Reductions due to tax positions of prior years

  4 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  206 

Balance of unrecognized tax benefits at December 31, 2020

 $768 

Reductions due to lapse of applicable statute of limitations

  (38

)

Additions due to tax positions of prior years

  -- 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  345 

Balance of unrecognized tax benefits at December 31, 2021

 $1,075 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 8 - Notes Payable (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Debt [Table Text Block]
  

2021

  

2020

 
  

(In thousands)

 

Term Loans

 $26,620  $30,713 

Less: current portion

  (4,278

)

  (4,061

)

Less: unamortized debt issuance costs

  (73

)

  (105

)

Notes payable, net of current portion

 $22,269  $26,547 
Schedule of Maturities of Long-term Debt [Table Text Block]

2022

 $4,306 

2023

  4,529 

2024

  4,762 

2025

  13,023 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Share-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

2021

  

2020

  

2019

 

Expected dividend yield at date of grant

  2.15

%

  1.84

%

  2.60

%

Expected stock price volatility

  34.85

%

  33.62

%

  34.01

%

Risk-free interest rate

  0.91

%

  1.35

%

  2.38

%

Expected life of options (in years)

  7.01   7.39   7.46 
Share-based Payment Arrangement, Activity [Table Text Block]
  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Common Stock

                

Outstanding at December 31, 2020

  600,571  $25.31         

Granted

  101,091  $44.96         

Exercised

  (116,753

)

 $13.14      $3,535 

Expired

  (22,837

)

  9.74         

Forfeited

  (84,432

)

 $38.38         

Outstanding at December 31, 2021

  477,640  $30.88   5.97  $6,337 

Exercisable at December 31, 2021

  249,488  $23.99   4.82  $4,805 
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value, Intrinsic Value of Exercised and Vested in Period, and Fair Value of Vested in Period [Table Text Block]
  

2021

  

2020

  

2019

 

Weighted average grant date fair value of stock options granted

 $12.55  $18.67  $11.99 

Intrinsic value of stock options exercised (in thousands)

 $3,535  $25,912  $8,280 

Intrinsic value of stock options vested (in thousands)

 $4,805  $1,965  $1,891 
Schedule of Nonvested Share Activity [Table Text Block]
  

Common Stock

Outstanding

  

Common Stock

Weighted

Average Grant

Date Fair Value

Per Share

 

Outstanding at December 31, 2020

  6,005  $38.30 

Granted

  12,698  $42.92 

Vested

  --  $-- 

Forfeited

  (6,005

)

 $38.30 

Outstanding at December 31, 2021

  12,698  $42.92 
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Leases (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Lease, Cost [Table Text Block]
  

2021

  

2020

  

2019

 

Operating leases

 $669  $600  $781 

Finance leases:

            

Asset amortization

  489   355   252 

Interest on lease liabilities

  34   37   39 

Variable lease cost

  99   62   86 

Short-term lease cost

  59   42   42 

Sublease income

  (81

)

  --   -- 

Total net lease cost

 $1,269  $1,096  $1,200 
Lessee, Lease, Balance Sheet Information [Table Text Block]
  

December 31,

2021

  

December 31,

2020

 

Operating leases:

        

Operating ROU assets

 $975  $1,308 
         

Current operating lease liabilities

  493   461 

Noncurrent operating lease liabilities

  820   896 

Total operating lease liabilities

 $1,313  $1,357 
  

December 31,

2021

  

December 31,

2020

 

Finance leases:

        

Furniture and equipment

 $1,042  $1,014 

Computer Equipment

  659   662 

Computer Software

  207   207 

Property and equipment under finance lease, gross

  1,908   1,883 

Less accumulated amortization

  (1,074

)

  (605

)

Property and equipment under finance lease, net

 $834  $1,278 
         

Current obligations of finance leases

 $470  $493 

Noncurrent obligations of finance leases

  348   778 

Total finance lease liabilities

 $818  $1,271 
         

Weighted average remaining lease term (in years):

        

Operating leases

  2.80   3.68 

Finance leases

  1.93   2.69 
         

Weighted average discount rate:

        

Operating leases

  3.85

%

  4.40

%

Finance leases

  3.42

%

  3.38

%
Lease, Cash flow [Table Text Block]
  

2021

  

2020

  

2019

 

Cash paid for amounts included in the measurement of lease liabilities:

            

Operating cash flows from operating leases

 $680  $596  $789 

Operating cash flows from finance leases

  34   36   38 

Financing cash flows from finance leases

  493   332   229 
             

ROU assets obtained in exchange for operating lease liabilities

  560   276   16 

ROU assets obtained in exchange for finance lease liabilities

  40   817   192 
Lessee, Operating and Finance Lease, Liability, Maturity [Table Text Block]
  

Finance Leases

  

Operating Leases

 

2022

 $488  $531 

2023

  315   513 

2024

  23   227 

2025

  10   118 

2026

  10   -- 

Thereafter

  --   -- 

Total minimum lease payments

  846   1,389 

Less: Amount representing interest

  (28

)

  (76

)

Present value of minimum lease payments

  818   1,313 

Current portion

  (470

)

  (493

)

Lease obligations, net of current portion

 $348  $820 
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]
  

Operating Lease

 

2022

 $118 

2023

  122 

2024

  127 

2025

  65 

Total minimum lease receipts

 $432 
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
  

2021

  

2020

  

2019

 

Revenue:

            

United States

 $144,987  $130,305  $124,369 

Canada

  2,967   2,972   3,613 

Total

 $147,954  $133,277  $127,982 

Long-lived assets:

            

United States

 $83,722  $77,448  $78,906 

Canada

  111   1,863   2,622 

Total

 $83,833  $79,311  $81,528 

Total assets:

            

United States

 $153,879  $128,319  $95,668 

Canada

  3,661   5,104   15,017 

Total

 $157,540  $133,423  $110,685 
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Significant Accounting Policies (Details Textual)
 12 Months Ended
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Incremental Costs of Obtaining a Contract, Deferred During Period $ 1,900,000 $ 3,700,000 $ 3,600,000
Capitalized Contract Cost, Net, Noncurrent 3,772,000 4,555,000  
Capitalized Contract Cost, Impairment Loss 31,000 63,000 22,000
Capitalized Computer Software, Additions 2,800,000 2,700,000  
Asset Impairment Charges, Total 0 0 0
Impairment of Intangible Assets (Excluding Goodwill), Total 0 0 0
Goodwill, Impairment Loss $ 0 714,000  
Number of Operating Segments 1    
Number of Reporting Units 1    
Income Tax Credits and Adjustments $ 10,000 45,000 $ 24,000
Cash Equivalents, at Carrying Value, Total 6,300,000 5,000,000.0  
Operating Lease, Impairment Loss 324,000    
Excess Loss Coverage Per Person 150,000    
Claims Loss Coverage, Minimum Aggregate Deductible 3,200,000 2,800,000  
Self Insurance Reserve, Current $ 406,000 $ 418,000  
Common Class A [Member]      
Stock Options Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 127,185 65,127 16,221
Cyber Attack [Member] | Recoveries Received Direct by the Company [Member]      
Proceeds from Insurance Settlement, Operating Activities   $ 3,300,000  
Cyber Attack [Member] | Recoveries Paid Directly by Insurer to Outside Vendor [Member]      
Proceeds from Insurance Settlement, Operating Activities   447,000  
Cyber Attack [Member] | Reimbursement for Lost Revenue [Member]      
Insurance Recoveries   533,000  
Property Damage Excluding Cyber Attack [Member] | Other Income [Member]      
Insurance Recoveries   260,000  
Canadian Subsidiary [Member]      
Goodwill, Impairment Loss $ 714,000 $ 714,000  
Number of Customers 1    
Minimum [Member]      
Capitalized Contract Cost, Amortization Period (Year) 3 years    
Minimum [Member] | Furniture and Fixtures [Member]      
Property, Plant and Equipment, Useful Life (Year) 3 years    
Minimum [Member] | Computer Equipment [Member]      
Property, Plant and Equipment, Useful Life (Year) 3 years    
Minimum [Member] | Software and Software Development Costs [Member]      
Property, Plant and Equipment, Useful Life (Year) 1 year    
Minimum [Member] | Building and Building Improvements [Member]      
Property, Plant and Equipment, Useful Life (Year) 7 years    
Maximum [Member]      
Capitalized Contract Cost, Amortization Period (Year) 5 years    
Maximum [Member] | Furniture and Fixtures [Member]      
Property, Plant and Equipment, Useful Life (Year) 10 years    
Maximum [Member] | Computer Equipment [Member]      
Property, Plant and Equipment, Useful Life (Year) 5 years    
Maximum [Member] | Software and Software Development Costs [Member]      
Property, Plant and Equipment, Useful Life (Year) 5 years    
Maximum [Member] | Building and Building Improvements [Member]      
Property, Plant and Equipment, Useful Life (Year) 40 years    
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Capitalized contract cost $ 2,651 $ 3,242 $ 2,908
Direct Expenses [Member]      
Capitalized contract cost 157 272 34
Selling, General and Administrative Expenses [Member]      
Capitalized contract cost $ 2,494 $ 2,970 $ 2,874
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Balance $ 120 $ 144 $ 175
Bad debt expense 38 46 75
Write-offs, net of recoveries 64 70 106
Balance $ 94 $ 120 $ 144
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Non-cash share-based compensation expense $ 623 $ 680 $ 1,224
Amount of related income tax benefit (919) (6,764) (2,081)
Net (benefit) expense to net income $ (296) $ (6,084) $ (857)
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Total carrying amount of long-term debt $ 26,620 $ 30,713
Estimated fair value of long-term debt 27,708 32,943
Fair Value, Recurring [Member]    
Assets, fair value 6,306 5,015
Money Market Funds [Member] | Fair Value, Recurring [Member]    
Assets, fair value 6,306 5,015
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]    
Assets, fair value 6,306 5,015
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | Fair Value, Recurring [Member]    
Assets, fair value $ 6,306 $ 5,015
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Numerator for net income per share - basic:      
Net income $ 37,466 $ 37,260 $ 32,406
Denominator for net income per share - basic:      
Weighted average common shares outstanding – basic (in shares) 25,422 25,170 24,809
Net income per share – basic (in dollars per share) $ 1.47 $ 1.48 $ 1.30
Numerator for net income per share - diluted:      
Weighted average common shares outstanding – basic (in shares) 25,422 25,170 24,809
Denominator for diluted earnings per share – adjusted weighted average shares (in shares) 25,640 25,696 25,653
Net income per share – diluted (in dollars per share) $ 1.46 $ 1.45 $ 1.26
Common Stock [Member]      
Numerator for net income per share - basic:      
Net income $ 37,466 $ 37,260 $ 32,406
Allocation of distributed and undistributed income to unvested restricted stock shareholders (18) (57) (109)
Net income attributable to common shareholders $ 37,448 $ 37,203 $ 32,297
Denominator for net income per share - basic:      
Weighted average common shares outstanding – basic (in shares) 25,422 25,170 24,809
Net income per share – basic (in dollars per share) $ 1.47 $ 1.48 $ 1.30
Numerator for net income per share - diluted:      
Net income attributable to common shareholders $ 37,448 $ 37,203 $ 32,297
Weighted average common shares outstanding – basic (in shares) 25,422 25,170 24,809
Weighted average effect of dilutive securities – stock options (in shares) 218 526 844
Denominator for diluted earnings per share – adjusted weighted average shares (in shares) 25,640 25,696 25,653
Net income per share – diluted (in dollars per share) $ 1.46 $ 1.45 $ 1.26
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 2 - Acquisition (Details Textual) - USD ($)
 12 Months Ended
Jan. 04, 2021
Dec. 31, 2021
Payments to Acquire Businesses, Gross   $ 3,000,000
Selling, General and Administrative Expenses [Member]    
Business Combination, Acquisition Related Costs   $ 119,000
PatientWisdom, Inc. [Member]    
Payments to Acquire Businesses, Gross $ 3,000,000.0  
Business Combination, Consideration Transferred, Total 5,000,000.0  
Business Combination, Consideration Transferred, Liabilities Incurred $ 2,000,000.0  
Finite-Lived Intangible Asset, Useful Life (Year) 5 years  
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 2 - Acquisition - Fair Value of Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Jan. 04, 2021
Dec. 31, 2020
Dec. 31, 2019
Goodwill $ 61,614   $ 57,255 $ 57,935
PatientWisdom, Inc. [Member]        
Current Assets   $ 184    
Property and equipment   10    
Goodwill   4,340    
Total assets acquired   5,234    
Current liabilities   284    
Net assets acquired   4,950    
PatientWisdom, Inc. [Member] | Customer Relationships [Member]        
Intangible assets   100    
PatientWisdom, Inc. [Member] | Technology-Based Intangible Assets [Member]        
Intangible assets   $ 600    
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Contracts With Customers 1 (Details Textual)
$ in Millions
Dec. 31, 2021
USD ($)
Long-term Contract with Customer [Member]  
Revenue, Remaining Performance Obligation, Amount $ 2.9
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Contracts With Customers 2 (Details Textual) - Long-term Contract with Customer [Member]
Dec. 31, 2021
USD ($)
Revenue, Remaining Performance Obligation, Amount $ 2,900,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 1 year
Revenue, Remaining Performance Obligation, Amount $ 1,300,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 1 year
Revenue, Remaining Performance Obligation, Amount $ 1,100,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 1 year
Revenue, Remaining Performance Obligation, Amount $ 587,000
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue $ 147,954 $ 133,277 $ 127,982
Transferred over Time [Member] | Subscription Services [Member]      
Revenue 137,008 122,499 114,216
Transferred over Time [Member] | Fixed, Non-subscription Services [Member]      
Revenue 3,065 2,907 3,248
Transferred over Time [Member] | Unit Price Services [Member]      
Revenue 4,665 4,939 5,526
Transferred at Point in Time [Member] | Service [Member]      
Revenue $ 3,216 $ 2,932 $ 4,992
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Accounts receivables $ 13,728 $ 13,923
Deferred revenue (17,213) (15,585)
Revenue recognized that was included in deferred revenue at beginning of year due to completion of services (15,631) (16,083)
Increases due to invoicing of client, net of amounts recognized as revenue 16,694 15,338
Decreases due to completion of services (or portion of services) and transferred to accounts receivable (311) (103)
Change due to cumulative catch-up adjustments arising from changes in expected contract consideration 326 (24)
Increases due to revenue recognized in the period with additional performance obligations before invoicing 99 311
Other Current Assets [Member]    
Contract assets included in other current assets $ 99 $ 311
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 4 - Equity Investments (Details Textual)
$ in Millions
Dec. 31, 2021
USD ($)
Equity Securities without Readily Determinable Fair Value, Amount $ 1.3
Cost Method Investment, Ownership Percentage 15.10%
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 5 - Property and Equipment (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Impairment, Long-Lived Asset, Held-for-Use, Total $ 0 $ 0 $ 0
Including Assets Held under Capital Lease [Member]      
Depreciation, Depletion and Amortization, Nonproduction, Total $ 5,700 $ 6,500 $ 5,400
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property and equipment at cost $ 45,599 $ 42,705
Less accumulated depreciation and amortization 33,208 30,979
Net property and equipment 12,391 11,726
Furniture and Fixtures [Member]    
Property and equipment at cost 4,901 4,808
Computer Equipment [Member]    
Property and equipment at cost 2,672 2,638
Software and Software Development Costs [Member]    
Property and equipment at cost 27,828 27,087
Building and Building Improvements [Member]    
Property and equipment at cost 9,271 7,515
Leasehold Improvements [Member]    
Property and equipment at cost 502 232
Land [Member]    
Property and equipment at cost $ 425 $ 425
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Goodwill, Impairment Loss $ 0 $ 714,000  
Amortization of Intangible Assets, Total 320,000 318,000 $ 374,000
Finite-Lived Intangible Asset, Expected Amortization, Year One 180,000    
Finite-Lived Intangible Asset, Expected Amortization, Year Two 140,000    
Finite-Lived Intangible Asset, Expected Amortization, Year Three 140,000    
Finite-Lived Intangible Asset, Expected Amortization, Year Four 139,000    
Canadian Subsidiary [Member]      
Goodwill, Impairment Loss $ 714,000 $ 714,000  
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Goodwill, gross $ 62,328 $ 57,969  
Goodwill, accumulated impairment (714) (714)  
Goodwill, net 61,614 57,255 $ 57,935
Finite-lived intangible assets, gross 12,976 12,276  
Finite-lived intangible assets, accumulated amortization 12,377 12,057  
Finite-lived intangible assets, net 599 219  
Total intangible assets other than goodwill 14,167 13,467  
Total intangible assets other than goodwill 1,790 1,410  
Customer Relationships [Member]      
Finite-lived intangible assets, gross 9,445 9,344  
Finite-lived intangible assets, accumulated amortization 9,325 9,256  
Finite-lived intangible assets, net $ 120 $ 88  
Customer Relationships [Member] | Minimum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 5 years 5 years  
Customer Relationships [Member] | Maximum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 15 years 15 years  
Technology-Based Intangible Assets [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 7 years 7 years  
Finite-lived intangible assets, gross $ 1,959 $ 1,360  
Finite-lived intangible assets, accumulated amortization 1,480 1,229  
Finite-lived intangible assets, net 479 131  
Trade Names [Member]      
Finite-lived intangible assets, gross 1,572 1,572  
Finite-lived intangible assets, accumulated amortization $ 1,572 $ 1,572  
Trade Names [Member] | Minimum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 5 years 5 years  
Trade Names [Member] | Maximum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 10 years 10 years  
Trade Names 1 [Member]      
Indefinite trade name $ 1,191 $ 1,191  
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Goodwill $ 57,255 $ 57,935
Impairment 0 (714)
Foreign currency translation 19 34
Goodwill acquired 4,340  
Goodwill $ 61,614 $ 57,255
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Deemed Dividend Paid by Foreign Subsidiary   $ 9,600,000  
Cumulative Tax Incentives $ 473,000 435,000 $ 1,900,000
Income Tax Credits and Adjustments 10,000 45,000 24,000
Social Security Tax Payable, Current 656,000 1,300,000  
Deferred Tax Asset, Prior Year Foreign Tax Credit Carryforwards, Write Off   535,000  
Unrecognized Tax Benefits, Ending Balance 1,075,000 768,000 $ 592,000
Unrecognized Tax Benefits, Interest on Income Taxes Accrued 19,000 15,000  
Unrecognized Tax Benefits that Would Impact Effective Tax Rate $ 918,000 $ 668,000  
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Income Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
U.S. Operations $ 48,145 $ 41,357 $ 40,045
Foreign Operations 476 110 474
Income before income taxes $ 48,621 $ 41,467 $ 40,519
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Current $ 9,092 $ 3,546 $ 5,574
Deferred (224) (308) 718
Total 8,868 3,238 6,292
Current 143 225 94
Deferred (17) (6) 33
Total 126 219 127
Current 2,197 578 1,322
Deferred (36) 172 372
Total 2,161 750 1,694
Income Tax Expense (Benefit), Total $ 11,155 $ 4,207 $ 8,113
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Expected federal income taxes $ 10,210 $ 8,708 $ 8,509
Foreign tax rate differential 26 6 26
State income taxes, net of federal benefit and state tax credits 1,531 607 1,344
Share-based compensation (660) (5,713) (1,579)
Compensation limit for covered employees   463  
Federal tax credits (272) (261) (419)
Uncertain tax positions 254 157 34
Nondeductible expenses (income) related to recapitalization     (24)
Goodwill Impairment   184  
Withholding tax on repatriation of foreign earnings 8 18 107
GILTI   10 13
Other 58 28 102
Income Tax Expense (Benefit), Total $ 11,155 $ 4,207 $ 8,113
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Allowance for doubtful accounts $ 24 $ 29
Accrued expenses 687 696
Share-based compensation 740 735
Accrued bonuses 267 145
Employer payroll tax deferral 200 323
Uncertain tax positions 161 104
Other 66 11
Gross deferred tax assets 2,145 2,043
Deferred tax assets 2,145 2,043
Deferred tax liabilities:    
Prepaid expenses 89 93
Deferred contract costs 945 1,111
Property and equipment 1,579 1,725
Intangible assets 6,338 6,109
Repatriation withholding 182 174
Other   96
Deferred tax liabilities 9,133 9,308
Net deferred tax liabilities $ (6,988) $ (7,265)
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Balance of unrecognized tax benefits $ 768,000 $ 592,000
Reductions due to lapse of applicable statute of limitations (38,000) (34,000)
Reductions due to tax positions of prior years   4,000
Additions based on tax positions related to the current year 345,000 206,000
Balance of unrecognized tax benefits $ 1,075,000 $ 768,000
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 8 - Notes Payable (Details Textual) - Credit Agreement [Member] - First National Bank of Omaha [Member]
 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
May 28, 2020
USD ($)
Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio 1.10    
Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold $ 5,500,000    
Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio 3.00    
London Interbank Offered Rate (LIBOR) [Member]      
Debt Instrument, Basis Spread on Variable Rate 2.25%    
Term Loan [Member]      
Debt Instrument, Face Amount     $ 33,002,069
Debt Instrument, Periodic Payment, Total $ 462,988    
Debt Instrument, Interest Rate, Stated Percentage 5.00%    
Delayed Draw Term Loan [Member]      
Line of Credit Facility, Maximum Borrowing Capacity $ 15,000,000   15,000,000
Revolving Credit Facility [Member]      
Line of Credit Facility, Maximum Borrowing Capacity $ 30,000,000   $ 30,000,000
Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate 2.35%    
Long-term Line of Credit, Total $ 0 $ 0  
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.20%    
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 8 - Notes Payable - Summary of Notes Payable (Details) - Term Loan [Member] - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Term Loans $ 26,620 $ 30,713
Less: current portion (4,278) (4,061)
Less: unamortized debt issuance costs (73) (105)
Notes payable, net of current portion $ 22,269 $ 26,547
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
2022 $ 4,306
2023 4,529
2024 4,762
2025 $ 13,023
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Share-based Compensation (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Proceeds from Stock Options Exercised $ 446,000 $ 1,734,000 $ 0
Share-based Payment Arrangement, Exercise of Option, Tax Benefit $ 862,000 $ 6,300,000 $ 1,900,000
Common Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) 101,091 70,471 100,615
Share-based Payment Arrangement, Option [Member]      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 1,100,000    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) 2 years 4 months 13 days    
Share-based Payment Arrangement, Option [Member] | Direct, Selling, General and Administrative Expenses [Member]      
Share-based Payment Arrangement, Expense $ 607,000 $ 680,000 $ 934,000
Nonvested [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 5 years    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 436,000    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) 4 years    
Nonvested [Member] | Direct, Selling, General and Administrative Expenses [Member]      
Share-based Payment Arrangement, Expense $ 17,000 23,000 290,000
Restricted Stock [Member]      
Tax Benefit Realized Restricted Stock Vested $ 0 235,000 $ 0
Director Plan 2004 [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 780,330    
Share-based Compensation Arrangement by Share-based Payment Award, Options Grants Cumulative (in shares) 2,219,670    
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Director [Member]      
Share Based Compensation, Arrangement By Share Based Payment Award, Options Grant, Amount $ 100,000 $ 100,000  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 1 year    
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Director [Member] | Maximum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years    
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Director [Member] | Minimum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 3 years    
Director Plan 2004 [Member] | Common Stock [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 3,000,000    
The 2006 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 806,537    
Share-based Compensation Arrangement by Share-based Payment Award, Options Grants Cumulative (in shares) 993,463    
The 2006 Equity Incentive Plan [Member] | Maximum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years    
The 2006 Equity Incentive Plan [Member] | Minimum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 5 years    
The 2006 Equity Incentive Plan [Member] | Nonvested [Member]      
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) 12,698 0 6,005
Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares) 12,698    
The 2006 Equity Incentive Plan [Member] | Common Stock [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 1,800,000    
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) - Common Stock [Member]
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Expected dividend yield at date of grant 2.15% 1.84% 2.60%
Expected stock price volatility 34.85% 33.62% 34.01%
Risk-free interest rate 0.91% 1.35% 2.38%
Expected life of options (in years) (Year) 7 years 3 days 7 years 4 months 20 days 7 years 5 months 15 days
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Exercised, number of options (in shares) (116,753) (630,373) (227,902)
Common Stock Options [Member]      
Beginning balance, outstanding, number of options (in shares) 600,571    
Beginning balance, outstanding, weighted average exercise price (in dollars per share) $ 25.31    
Granted, number of options (in shares) 101,091 70,471 100,615
Granted, weighted average exercise price (in dollars per share) $ 44.96    
Exercised, number of options (in shares) (116,753)    
Exercised, weighted average exercise price (in dollars per share) $ 13.14    
Intrinsic value of stock options exercised (in thousands) $ 3,535    
Expired, number of options (in shares) (22,837)    
Expired, weighted average exercise price (in dollars per share) $ 9.74    
Forfeited, number of options (in shares) (84,432)    
Forfeited, weighted average exercise price (in dollars per share) $ 38.38    
Ending balance, outstanding, number of options (in shares) 477,640 600,571  
Ending balance, outstanding, weighted average exercise price (in dollars per share) $ 30.88 $ 25.31  
Outstanding, weighted average remaining contractual term (Year) 5 years 11 months 19 days    
Outstanding, aggregate intrinsic value $ 6,337    
Exercisable, number of options (in shares) 249,488    
Weighted average exercise price (in dollars per share) $ 23.99    
Exercisable, weighted average remaining contractual term (Year) 4 years 9 months 25 days    
Exercisable, aggregate intrinsic value $ 4,805    
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Share-based compensation - Stock Option Activity (Details) - Common Stock [Member] - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Weighted average grant date fair value of stock options granted (in dollars per share) $ 12.55 $ 18.67 $ 11.99
Intrinsic value of stock options exercised (in thousands) $ 3,535 $ 25,912 $ 8,280
Intrinsic value of stock options vested (in thousands) $ 4,805 $ 1,965 $ 1,891
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Share-based Compensation - Non-vested Stock (Details) - Common Stock [Member]
 12 Months Ended
Dec. 31, 2021
$ / shares
shares
Outstanding (in shares) | shares 6,005
Outstanding (in dollars per share) | $ / shares $ 38.30
Granted (in shares) | shares 12,698
Granted (in dollars per share) | $ / shares $ 42.92
Forfeited (in shares) | shares (6,005)
Forfeited (in dollars per share) | $ / shares $ 38.30
Outstanding (in shares) | shares 12,698
Outstanding (in dollars per share) | $ / shares $ 42.92
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Leases (Details Textual)
Dec. 31, 2021
Minimum [Member]  
Lessee, Operating Lease, Remaining Lease Term (Year) 1 year
Maximum [Member]  
Lessee, Operating Lease, Remaining Lease Term (Year) 4 years 11 months 4 days
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Leases - Lease Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating leases $ 669 $ 600 $ 781
Asset amortization 489 355 252
Interest on lease liabilities 34 37 39
Variable lease cost 99 62 86
Short-term lease cost 59 42 42
Sublease income (81)    
Total net lease cost $ 1,269 $ 1,096 $ 1,200
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Operating lease right-of-use assets $ 975 $ 1,308
Property and equipment at cost 45,599 42,705
Less accumulated amortization (33,208) (30,979)
Property and equipment under finance lease, net 12,391 11,726
Current obligations of finance leases 470 493
Noncurrent obligations of finance leases 348 778
Total finance lease liabilities $ 818 $ 1,271
Operating leases (Year) 2 years 9 months 18 days 3 years 8 months 4 days
Finance leases (Year) 1 year 11 months 4 days 2 years 8 months 8 days
Operating leases 3.85% 4.40%
Finance leases 3.42% 3.38%
Other Current Liabilities [Member]    
Current operating lease liabilities $ 493 $ 461
Other Noncurrent Liabilities [Member]    
Operating lease obligations, net of current portion 820 896
Other Current Liabilities and Other Noncurrent Liabilities [Member]    
Total operating lease liabilities 1,313 1,357
Furniture and Equipment Held under Finance Leases [Member]    
Property and equipment at cost 1,042 1,014
Computer Equipment Held under Finance Leases [Member]    
Property and equipment at cost 659 662
Computer Software Held under Finance Leases [Member]    
Property and equipment at cost 207 207
Assets Held under Finance Leases [Member]    
Property and equipment at cost 1,908 1,883
Less accumulated amortization (1,074) (605)
Property and equipment under finance lease, net $ 834 $ 1,278
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating cash flows from operating leases $ 680 $ 596 $ 789
Operating cash flows from finance leases 34 36 38
Financing cash flows from finance leases 493 332 229
ROU assets obtained in exchange for operating lease liabilities 560 276 16
ROU assets obtained in exchange for finance lease liabilities $ 40 $ 817 $ 192
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
2022, finance leases $ 488  
2022, operating leases 531  
2023, finance leases 315  
2023, operating leases 513  
2024, finance leases 23  
2024, operating leases 227  
2025, finance leases 10  
2025, operating leases 118  
2026, finance leases 10  
Finance leases, total minimum lease payments 846  
Operating leases, total minimum lease payments 1,389  
Finance leases, less: Amount representing interest (28)  
Operating leases, less: Amount representing interest (76)  
Present value of minimum finance lease payments 818 $ 1,271
Current portion, finance leases (470) (493)
Finance leases obligations, net of current portion 348 778
Other Current Liabilities and Other Noncurrent Liabilities [Member]    
Present value of minimum operating lease payments 1,313 1,357
Other Current Liabilities [Member]    
Current portion, operating leases (493) (461)
Other Noncurrent Liabilities [Member]    
Operating lease obligations, net of current portion $ 820 $ 896
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Leases - Undiscounted Payments Under Sublease (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
2022 $ 118
2023 122
2024 127
2025 65
Total minimum lease receipts $ 432
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 11 - Related Party (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Allina Health [Member]      
Revenue from Related Parties $ 1,700,000    
Ameritas Life Insurance Corp [Member]      
Related Party Transaction, Amounts of Transaction 278,000 $ 248,000 $ 242,000
IMA Financial Group [Member] | Purchasing Directors and Officers and Employment Practices Liability Insurance [Member]      
Related Party Transaction, Amounts of Transaction   1,100,000  
PracticingExcellence.com [Member]      
Revenue from Related Parties $ 35,000 $ 294,000 $ 578,000
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 12 - Associate Benefits (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay 25.00%    
Defined Contribution Plan, Maximum Percentage of Annual Contribution Employee Subject to Match 6.00%    
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage 20.00%    
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 531,000 $ 521,000 $ 447,000
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information (Details Textual)
 12 Months Ended
Dec. 31, 2021
Number of Operating Segments 1
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information - Assets by Geographic Area (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue $ 147,954 $ 133,277 $ 127,982
Long-lived assets 83,833 79,311 81,528
Total assets 157,540 133,423 110,685
UNITED STATES      
Revenue 144,987 130,305 124,369
Long-lived assets 83,722 77,448 78,906
Total assets 153,879 128,319 95,668
CANADA      
Revenue 2,967 2,972 3,613
Long-lived assets 111 1,863 2,622
Total assets $ 3,661 $ 5,104 $ 15,017
XML 88 nrc20211231_10k_htm.xml IDEA: XBRL DOCUMENT 0000070487 2021-01-01 2021-12-31 0000070487 2021-06-30 0000070487 2022-02-25 0000070487 2021-12-31 0000070487 2020-12-31 0000070487 2020-01-01 2020-12-31 0000070487 2019-01-01 2019-12-31 0000070487 us-gaap:CommonStockMember 2018-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000070487 us-gaap:RetainedEarningsMember 2018-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000070487 us-gaap:TreasuryStockMember 2018-12-31 0000070487 2018-12-31 0000070487 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000070487 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000070487 us-gaap:CommonStockMember 2019-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000070487 us-gaap:RetainedEarningsMember 2019-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000070487 us-gaap:TreasuryStockMember 2019-12-31 0000070487 2019-12-31 0000070487 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000070487 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonStockMember 2020-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000070487 us-gaap:RetainedEarningsMember 2020-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000070487 us-gaap:TreasuryStockMember 2020-12-31 0000070487 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000070487 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000070487 us-gaap:CommonStockMember 2021-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000070487 us-gaap:RetainedEarningsMember 2021-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000070487 us-gaap:TreasuryStockMember 2021-12-31 0000070487 srt:MinimumMember 2021-12-31 0000070487 srt:MaximumMember 2021-12-31 0000070487 nrc:DirectExpensesMember 2021-01-01 2021-12-31 0000070487 nrc:DirectExpensesMember 2020-01-01 2020-12-31 0000070487 nrc:DirectExpensesMember 2019-01-01 2019-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000070487 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0000070487 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0000070487 srt:MinimumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-12-31 0000070487 srt:MaximumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-12-31 0000070487 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-12-31 0000070487 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-12-31 0000070487 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0000070487 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0000070487 nrc:CanadianSubsidiaryMember 2021-12-31 0000070487 nrc:CanadianSubsidiaryMember 2021-01-01 2021-12-31 0000070487 nrc:CyberAttackMember nrc:RecoveriesReceivedDirectByTheCompanyMember 2020-01-01 2020-12-31 0000070487 nrc:CyberAttackMember nrc:RecoveriesPaidDirectlyByInsurerToOutsideVendorMember 2020-01-01 2020-12-31 0000070487 nrc:CyberAttackMember nrc:ReimbursementForLostRevenueMember 2020-01-01 2020-12-31 0000070487 us-gaap:OtherIncomeMember nrc:PropertyDamageExcludingCyberAttackMember 2020-01-01 2020-12-31 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000070487 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000070487 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000070487 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000070487 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000070487 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0000070487 us-gaap:CommonClassAMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonClassAMember 2019-01-01 2019-12-31 0000070487 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000070487 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000070487 nrc:PatientWisdomIncMember 2021-01-04 2021-01-04 0000070487 nrc:PatientWisdomIncMember 2021-01-04 0000070487 nrc:PatientWisdomIncMember us-gaap:CustomerRelationshipsMember 2021-01-04 0000070487 nrc:PatientWisdomIncMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-04 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0000070487 us-gaap:OtherCurrentAssetsMember 2021-12-31 0000070487 us-gaap:OtherCurrentAssetsMember 2020-12-31 0000070487 us-gaap:LongTermContractWithCustomerMember 2022-01-01 2021-12-31 0000070487 us-gaap:LongTermContractWithCustomerMember 2023-01-01 2021-12-31 0000070487 us-gaap:LongTermContractWithCustomerMember 2024-01-01 2021-12-31 0000070487 us-gaap:LongTermContractWithCustomerMember 2021-12-31 0000070487 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000070487 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000070487 us-gaap:ComputerEquipmentMember 2021-12-31 0000070487 us-gaap:ComputerEquipmentMember 2020-12-31 0000070487 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0000070487 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0000070487 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0000070487 us-gaap:BuildingAndBuildingImprovementsMember 2020-12-31 0000070487 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000070487 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000070487 us-gaap:LandMember 2021-12-31 0000070487 us-gaap:LandMember 2020-12-31 0000070487 nrc:IncludingAssetsHeldUnderCapitalLeaseMember 2021-01-01 2021-12-31 0000070487 nrc:IncludingAssetsHeldUnderCapitalLeaseMember 2020-01-01 2020-12-31 0000070487 nrc:IncludingAssetsHeldUnderCapitalLeaseMember 2019-01-01 2019-12-31 0000070487 nrc:TradeNames1Member 2021-12-31 0000070487 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000070487 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000070487 us-gaap:CustomerRelationshipsMember 2021-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-01 2021-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0000070487 srt:MinimumMember us-gaap:TradeNamesMember 2021-01-01 2021-12-31 0000070487 srt:MaximumMember us-gaap:TradeNamesMember 2021-01-01 2021-12-31 0000070487 us-gaap:TradeNamesMember 2021-12-31 0000070487 nrc:TradeNames1Member 2020-12-31 0000070487 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0000070487 us-gaap:CustomerRelationshipsMember 2020-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-01-01 2020-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0000070487 srt:MinimumMember us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000070487 us-gaap:TradeNamesMember 2020-12-31 0000070487 nrc:CanadianSubsidiaryMember 2020-01-01 2020-12-31 0000070487 nrc:TermLoanMember 2021-12-31 0000070487 nrc:TermLoanMember 2020-12-31 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2021-12-31 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-05-28 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2020-05-28 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:DelayedDrawTermLoanMember 2021-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:DelayedDrawTermLoanMember 2020-05-28 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2021-01-01 2021-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2021-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-12-31 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-12-31 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2021-01-01 2021-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2021-01-01 2021-12-31 0000070487 nrc:DirectorPlan2004Member us-gaap:CommonStockMember 2021-12-31 0000070487 srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2021-01-01 2021-12-31 0000070487 srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2020-01-01 2020-12-31 0000070487 srt:MaximumMember srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2021-01-01 2021-12-31 0000070487 srt:MinimumMember srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2021-01-01 2021-12-31 0000070487 nrc:DirectorPlan2004Member 2021-12-31 0000070487 nrc:The2006EquityIncentivePlanMember us-gaap:CommonStockMember 2021-12-31 0000070487 srt:MinimumMember nrc:The2006EquityIncentivePlanMember 2021-01-01 2021-12-31 0000070487 srt:MaximumMember nrc:The2006EquityIncentivePlanMember 2021-01-01 2021-12-31 0000070487 nrc:The2006EquityIncentivePlanMember 2021-12-31 0000070487 nrc:CommonStockOptionsMember 2021-01-01 2021-12-31 0000070487 nrc:CommonStockOptionsMember 2020-01-01 2020-12-31 0000070487 nrc:CommonStockOptionsMember 2019-01-01 2019-12-31 0000070487 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000070487 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000070487 nrc:CommonStockOptionsMember 2020-12-31 0000070487 nrc:CommonStockOptionsMember 2021-12-31 0000070487 us-gaap:EmployeeStockOptionMember 2021-12-31 0000070487 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2021-01-01 2021-12-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2019-01-01 2019-12-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2020-01-01 2020-12-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2021-12-31 0000070487 nrc:NonvestedMember 2021-01-01 2021-12-31 0000070487 nrc:NonvestedMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000070487 nrc:NonvestedMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000070487 nrc:NonvestedMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000070487 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000070487 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000070487 us-gaap:CommonStockMember 2020-12-31 0000070487 us-gaap:CommonStockMember 2021-12-31 0000070487 nrc:NonvestedMember 2021-12-31 0000070487 us-gaap:OtherCurrentLiabilitiesMember 2021-12-31 0000070487 us-gaap:OtherCurrentLiabilitiesMember 2020-12-31 0000070487 us-gaap:OtherNoncurrentLiabilitiesMember 2021-12-31 0000070487 us-gaap:OtherNoncurrentLiabilitiesMember 2020-12-31 0000070487 nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember 2021-12-31 0000070487 nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember 2020-12-31 0000070487 nrc:FurnitureAndEquipmentHeldUnderFinanceLeasesMember 2021-12-31 0000070487 nrc:FurnitureAndEquipmentHeldUnderFinanceLeasesMember 2020-12-31 0000070487 nrc:ComputerEquipmentHeldUnderFinanceLeasesMember 2021-12-31 0000070487 nrc:ComputerEquipmentHeldUnderFinanceLeasesMember 2020-12-31 0000070487 nrc:ComputerSoftwareHeldUnderFinanceLeasesMember 2021-12-31 0000070487 nrc:ComputerSoftwareHeldUnderFinanceLeasesMember 2020-12-31 0000070487 nrc:AssetsHeldUnderFinanceLeasesMember 2021-12-31 0000070487 nrc:AssetsHeldUnderFinanceLeasesMember 2020-12-31 0000070487 nrc:AllinaHealthMember 2021-01-01 2021-12-31 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2021-01-01 2021-12-31 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2020-01-01 2020-12-31 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2019-01-01 2019-12-31 0000070487 nrc:PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember nrc:IMAFinancialGroupMember 2020-01-01 2020-12-31 0000070487 nrc:PracticingExcellencecomMember 2021-01-01 2021-12-31 0000070487 nrc:PracticingExcellencecomMember 2020-01-01 2020-12-31 0000070487 nrc:PracticingExcellencecomMember 2019-01-01 2019-12-31 0000070487 country:US 2021-01-01 2021-12-31 0000070487 country:US 2020-01-01 2020-12-31 0000070487 country:US 2019-01-01 2019-12-31 0000070487 country:CA 2021-01-01 2021-12-31 0000070487 country:CA 2020-01-01 2020-12-31 0000070487 country:CA 2019-01-01 2019-12-31 0000070487 country:US 2021-12-31 0000070487 country:US 2020-12-31 0000070487 country:US 2019-12-31 0000070487 country:CA 2021-12-31 0000070487 country:CA 2020-12-31 0000070487 country:CA 2019-12-31 iso4217:USD shares thunderdome:item iso4217:USD shares utr:Y pure 0000070487 National Research Corporation false --12-31 FY 2021 94000 120000 0.01 0.01 2000000 2000000 0 0 0 0 0.001 0.001 110000000 60000000 30898600 30775154 25361409 25390968 5537191 5384186 87203 227902 6005 0.78 180112 630373 6793 0.21 153005 116753 0.48 P3Y P5Y P3Y P10Y P3Y P5Y P1Y P5Y P7Y P40Y 0 0 0 0 0 1 1 0 0 P1Y P1Y P1Y 0 0 30000000 15000000 0 0 1.10 3.00 100000 P1Y P10Y P3Y P5Y P10Y 0 P5Y 0 P1Y 1 10-K true 2021-12-31 false 001-35929 DE 47-0634000 1245 Q Street Lincoln NE 68508 402 475-2525 Common Stock, $.001 par value NRC NASDAQ No No Yes Yes Accelerated Filer false false true false 533334729 25194447 KPMG LLP Lincoln, Nebraska 54361000 34690000 13728000 13923000 3884000 2645000 752000 1235000 982000 1619000 73707000 54112000 12391000 11726000 1790000 1410000 61614000 57255000 975000 1308000 3772000 4555000 14000 3277000 3057000 157540000 133423000 4278000 4061000 1943000 1095000 7139000 6460000 5450000 3184000 3044000 17213000 15585000 1321000 1296000 40388000 31681000 22269000 26547000 7002000 7265000 2544000 3615000 72203000 69108000 31000 31000 173942000 171785000 -36112000 -61375000 -2375000 -2399000 50149000 43727000 85337000 64315000 157540000 133423000 147954000 133277000 127982000 533000 52350000 49187000 46435000 38960000 34441000 32973000 6374000 7505000 5539000 97684000 91133000 84947000 50270000 42677000 43035000 14000 18000 37000 1667000 1813000 2091000 4000 585000 -462000 -1649000 -1210000 -2516000 48621000 41467000 40519000 11155000 4207000 8113000 37466000 37260000 32406000 1.47 1.48 1.30 1.46 1.45 1.26 25422000 25170000 24809000 25640000 25696000 25653000 37466000 37260000 32406000 24000 -190000 707000 24000 -190000 707000 37490000 37070000 33113000 30000 157312000 -106339000 -2916000 -29004000 19083000 4722000 4722000 3618000 3618000 1224000 1224000 19424000 19424000 707000 707000 32406000 32406000 30000 162154000 -93357000 -2209000 -33726000 32892000 10001000 10001000 1000 8951000 8952000 680000 680000 5278000 5278000 -190000 -190000 37260000 37260000 31000 171785000 -61375000 -2399000 -43727000 64315000 6422000 6422000 1534000 1534000 623000 623000 12203000 12203000 24000 24000 37466000 37466000 31000 173942000 -36112000 -2375000 -50149000 85337000 37466000 37260000 32406000 6374000 7505000 5539000 -277000 -134000 1099000 310000 185000 39000 260000 -7000 -12000 6000 623000 680000 1224000 -343000 2271000 -311000 842000 827000 529000 34000 -16000 8000 -783000 351000 719000 4000 -247000 647000 -285000 1370000 806000 484000 -1529000 11000 1388000 -773000 97000 46344000 40636000 40917000 5514000 3984000 4656000 3000000 260000 -8514000 -3724000 -4656000 21000000 21000000 4093000 3568000 3715000 36000 493000 332000 229000 446000 1734000 721000 2784000 1103000 4142000 9159000 10517000 31299000 -18162000 -15503000 -36346000 3000 -236000 611000 19671000 21173000 526000 34690000 13517000 12991000 54361000 34690000 13517000 1554000 1735000 2014000 10644000 5217000 6946000 40000 817000 192000 1088000 7217000 3618000 1950000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">1</em>)</b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Summary of Significant Accounting Policies</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Description of Business and Basis of Presentation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our purpose is to enable human understanding. Our solutions enable health care organizations to understand what matters most to each person they serve. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 11pt;text-indent:-5pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 11pt;text-indent:-5pt;"><b>Principles of Consolidation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Translation of Foreign Currencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Revenue Recognition</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or <em style="font: inherit;">no</em> notice without penalty. See Note <em style="font: inherit;">3</em> for further information about our contracts with customers. We account for revenue using the following steps:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify the contract, or contracts, with a customer;</p> </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify the performance obligations in the contract;</p> </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Determine the transaction price;</p> </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Allocate the transaction price to the identified performance obligations; and</p> </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognize revenue when, or as, we satisfy the performance obligations.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Our revenue arrangements with a client <em style="font: inherit;"> may </em>include combinations of more than <em style="font: inherit;">one</em> service offering which <em style="font: inherit;"> may </em>be executed at the same time, or within close proximity of <em style="font: inherit;">one</em> another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together. For contracts that contain more than <em style="font: inherit;">one</em> separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do <em style="font: inherit;">not</em> contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Our arrangements with customers consist principally of <em style="font: inherit;">four</em> different types of arrangements: <em style="font: inherit;">1</em>) subscription-based service agreements; <em style="font: inherit;">2</em>) <em style="font: inherit;">one</em>-time specified services performed at a single point in time; <em style="font: inherit;">3</em>) fixed, non-subscription service agreements; and <em style="font: inherit;">4</em>) unit-priced service agreements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Subscription-based services - </i>Services that are provided under subscription-based service agreements are usually for a <em style="font: inherit;">twelve</em>- month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but <em style="font: inherit;"> may </em>also be billed on a quarterly and monthly basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>One-time services </i>–<i> </i>These agreements typically require us to perform a specific <em style="font: inherit;">one</em>-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Fixed, non-subscription services </i>–<i> </i>These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch-up adjustment which could impact the amount and timing of revenue for any period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Unit-price services </i>–<i> </i>These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but <em style="font: inherit;">not</em> invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;"><b>Deferred Contract Costs </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from <span style="-sec-ix-hidden:c81336539">three</span> to <span style="-sec-ix-hidden:c81336540">five</span> years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of <em style="font: inherit;">one</em> year or less. We deferred incremental costs of obtaining a contract of $1.9 million, $3.7 million and $3.6 million in the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively. Deferred contract costs, net of accumulated amortization was $3.8 million and $4.6 million at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively. Total amortization by expense classification for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">157</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $31,000, $63,000 and $22,000 for the years <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Trade Accounts Receivable</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following table provides the activity in the allowance for doubtful accounts for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bad Debt</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expense</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Write-offs,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">net of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Recoveries</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">at End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <div> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"/></tr> </tbody></table> </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Property and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.8 million and $2.7 million of costs incurred for the development of internal-use software for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is <em style="font: inherit;">not</em> included or we do <em style="font: inherit;">not</em> have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective <em style="font: inherit;"> January 1, 2020, </em>we prospectively adopted ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> Intangibles-Goodwill and Other-Internal Use Software (Subtopic <em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of <span style="-sec-ix-hidden:c81336570">three</span> to <span style="-sec-ix-hidden:c81336571">ten</span> years for furniture and equipment, <span style="-sec-ix-hidden:c81336572">three</span> to <span style="-sec-ix-hidden:c81336573">five</span> years for computer equipment, <span style="-sec-ix-hidden:c81336574">one</span> to <span style="-sec-ix-hidden:c81336575">five</span> years for capitalized software, and <span style="-sec-ix-hidden:c81336576">seven</span> to <span style="-sec-ix-hidden:c81336577">forty</span> years for our office building and related improvements. Software licenses are amortized over the term of the license.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Impairment of Long-Lived Assets and Amortizing Intangible Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we <em style="font: inherit;">first</em> compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is <em style="font: inherit;">not</em> recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and <em style="font: inherit;">third</em>-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> or <em style="font: inherit;">2019.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result <em style="font: inherit;"> may </em>trigger an impairment review:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant underperformance in comparison to historical or projected operating results;</p> </td></tr> <tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant changes in the manner or use of acquired assets or our overall strategy;</p> </td></tr> <tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant negative trends in our industry or the overall economy;</p> </td></tr> <tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A significant decline in the market price for our common stock for a sustained period; and</p> </td></tr> <tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our market capitalization falling below the book value of our net assets.</p></td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:43.1%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Goodwill and Intangible Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. We review intangible assets with indefinite lives for impairment annually as of <em style="font: inherit;"> October 1 </em>and whenever events or changes in circumstances indicate that the carrying value of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">When performing the impairment assessment, we will <em style="font: inherit;">first</em> assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than <em style="font: inherit;">not</em> that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did <span style="-sec-ix-hidden:c81336592"><span style="-sec-ix-hidden:c81336593"><span style="-sec-ix-hidden:c81336594">not</span></span></span> recognize any impairments related to indefinite-lived intangibles during <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020</em> or <em style="font: inherit;">2019.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are <em style="font: inherit;">not</em> individually identified and separately recognized. All of our goodwill is allocated to our reporting unit, which is the same as our operating segment. Goodwill is reviewed for impairment at least annually, as of <em style="font: inherit;"> October 1, </em>and whenever events or changes in circumstances indicate that the carrying value of goodwill <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We review goodwill for impairment by <em style="font: inherit;">first</em> assessing qualitative factors to determine whether any impairment <em style="font: inherit;"> may </em>exist. If we believe, as a result of the qualitative assessment, that it is more likely than <em style="font: inherit;">not</em> that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of <em style="font: inherit;"> October 1, 2021 </em>and determined the fair value of our reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended <em style="font: inherit;"> December 31, 2021 </em>or <em style="font: inherit;">2019.</em> A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to <em style="font: inherit;"> September 2022, </em>during <em style="font: inherit;"> December 2020 </em>we chose <em style="font: inherit;">not</em> to enter into a new contract with this customer or otherwise extend the term of the contract beyond <em style="font: inherit;"> September 2022. </em>We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at <em style="font: inherit;"> December 31, 2020. </em>We recognized an impairment of $714,000 for the excess of the then Canada reporting unit’s carrying value over the fair value, using discounted cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In <em style="font: inherit;"> March 2021, </em>we changed our operating segments from <em style="font: inherit;">six</em> to <span style="-sec-ix-hidden:c81336609">one</span> to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker. In connection with this change, our previous reporting units were combined into <span style="-sec-ix-hidden:c81336610">one</span> reporting unit. We performed an interim qualitative analysis immediately before and after the reorganization and concluded that the fair value of our reporting units likely exceeded the carrying values and <em style="font: inherit;">no</em> impairments were recorded. Following the reorganization, we considered the current and expected future economic and market conditions, including the impact of the COVID-<em style="font: inherit;">19</em> pandemic, on our reporting unit. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has <em style="font: inherit;">not</em> occurred which would require an additional interim impairment test to be performed as it is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that an impairment loss had been incurred at <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><em style="font: inherit;"/></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Insurance Recoveries</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We record insurance recoveries when the realization of the claim is probable. In <em style="font: inherit;">2020</em> we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in <em style="font: inherit;"> February 2020 (</em>the <em style="font: inherit;"> “February </em>incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the <em style="font: inherit;"> February </em>incident did <em style="font: inherit;">not</em> have a significant impact on our consolidated financial statements. In <em style="font: inherit;">2020,</em> we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than <em style="font: inherit;">not</em> to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> we recorded income tax benefits relating to these tax credits of $10,000, $45,000, and $24,000, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We recognize the effect of income tax positions only if those positions are more likely than <em style="font: inherit;">not</em> of being sustained. Recognized income tax positions are measured at the largest amount that is greater than <em style="font: inherit;">50%</em> likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In <em style="font: inherit;">2021,</em> we adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Simplifying the Accounting for Income Taxes (Topic <em style="font: inherit;">740</em>). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The adoption of this standard had <em style="font: inherit;">no</em> material impact to our consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Share-Based Compensation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amounts charged against income, before income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amount of related income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net (benefit) expense to net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,084</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Cash and Cash Equivalents</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We consider all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Cash equivalents were $6.3 million and $5.0 million as of <em style="font: inherit;"> December 31, 2021, </em>and <em style="font: inherit;">2020,</em> respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances <em style="font: inherit;"> may </em>exceed federally insured limits.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Leases</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We determine whether a lease is included in an agreement at inception. We recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for our operating leases under which we are lessee. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements <em style="font: inherit;"> may </em>include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do <em style="font: inherit;">not</em> contain any residual value guarantees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is <em style="font: inherit;">not</em> readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Due to remote working arrangements, we reassessed our office needs and subleased our Seattle location under an agreement considered to be an operating lease beginning in <em style="font: inherit;"> May 2021. </em>We have <em style="font: inherit;">not</em> been legally released from our primary obligations under the original lease and therefore we continue to account for the original lease separately. We recorded an ROU asset impairment charge in <em style="font: inherit;">2021</em> of $324,000, which was the amount by which the carrying value of the Seattle office lease ROU asset exceeded the fair value. We estimated the fair value based on the discounted cash flows of estimated net rental income for the office space subleased. The ROU asset impairment charge is included in depreciation, amortization and impairment expenses. There were <em style="font: inherit;">no</em> ROU asset impairment charges in <em style="font: inherit;">2020</em> or <em style="font: inherit;">2019.</em> Rent income from the sublessee are included in the statement of operations on a straight-line basis as an offset to rent expense associated with the original operating lease included in other expenses.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Fair Value Measurements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (<em style="font: inherit;">1</em>) Level <em style="font: inherit;">1</em> Inputs—quoted prices in active markets for identical assets and liabilities; (<em style="font: inherit;">2</em>) Level <em style="font: inherit;">2</em> Inputs—observable market-based inputs other than Level <em style="font: inherit;">1</em> inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data; (<em style="font: inherit;">3</em>) Level <em style="font: inherit;">3</em> Inputs—unobservable inputs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following details our financial assets within the fair value hierarchy at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 1</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 2</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 3</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2021</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2020</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">There were <em style="font: inherit;">no</em> transfers between levels during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our long-term debt described in Note <em style="font: inherit;">8</em> is recorded at historical cost. The fair value of long-term debt is classified in Level <em style="font: inherit;">2</em> of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following are the carrying amount and estimated fair values of long-term debt:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26,620</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,943</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are <em style="font: inherit;">not</em> recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). We estimated the fair value of the Seattle office ROU using discounted cash flows of the sublease based on management’s most recent projections, which are considered level <em style="font: inherit;">3</em> inputs in the fair value hierarchy and recorded an ROU asset impairment charge of $324,000 during <em style="font: inherit;">2021.</em> As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> there was <span style="-sec-ix-hidden:c81336668">no</span> indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill in <em style="font: inherit;"> December 2020 </em>as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level <em style="font: inherit;">3</em> inputs in the fair value hierarchy.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Commitments and Contingencies</b><br/> <br/> From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do <span style="-sec-ix-hidden:c81336671">not</span> believe the final disposition of claims at <em style="font: inherit;"> December 31, 2021 </em>will have a material adverse effect on our consolidated financial position, results of operations or liquidity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We became self-insured for group medical and dental insurance on <em style="font: inherit;"> January 1, 2019.   </em>We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance. We do <em style="font: inherit;">not</em> self-insure for any other types of losses, and therefore do <em style="font: inherit;">not</em> carry any additional excess loss insurance. In addition, we had aggregate claims loss coverage with a minimum aggregate deductible of $3.2 million and $2.8 million, in <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but <em style="font: inherit;">not</em> reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a <em style="font: inherit;">third</em>-party actuarial IBNR analysis.  As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> our accrual related to self-insurance was $406,000 and $418,000, respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Earnings Per Share</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Basic net income per share was computed using the weighted-average number of common shares outstanding during the period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We had 127,185, 65,127 and 16,221 options of Common Stock for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except per share data)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,466</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Allocation of distributed and undistributed income to unvested restricted stock shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income attributable to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,422</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income attributable to common shareholders for basic computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common <b>s</b>hares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,422</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average effect of dilutive securities – stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">844</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for diluted earnings per share – adjusted weighted average shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share – diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <div> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"/></tr> </tbody></table> </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">In <em style="font: inherit;"> March 2020, </em>the Financial Accounting Standards Board (the “FASB”) issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> "Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of <em style="font: inherit;"> March 12, 2020 </em>through <em style="font: inherit;"> December 31, 2022. </em>We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In <em style="font: inherit;"> October 2021, </em>FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2021</em>-<em style="font: inherit;">08,</em> “Business Combinations (Topic <em style="font: inherit;">805</em>): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The amendment requires an acquirer in a business combination apply Topic <em style="font: inherit;">606</em> to recognize and measure contract assets in revenue contracts acquired in a business combination rather than fair value. The amendment is effective for public business entities for fiscal years beginning after <em style="font: inherit;"> December 15, 2022, </em>including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the timing and the impact of adopting this new guidance on our consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 11pt;text-indent:-5pt;"><b>Principles of Consolidation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Translation of Foreign Currencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Revenue Recognition</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or <em style="font: inherit;">no</em> notice without penalty. See Note <em style="font: inherit;">3</em> for further information about our contracts with customers. We account for revenue using the following steps:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify the contract, or contracts, with a customer;</p> </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify the performance obligations in the contract;</p> </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Determine the transaction price;</p> </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Allocate the transaction price to the identified performance obligations; and</p> </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognize revenue when, or as, we satisfy the performance obligations.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Our revenue arrangements with a client <em style="font: inherit;"> may </em>include combinations of more than <em style="font: inherit;">one</em> service offering which <em style="font: inherit;"> may </em>be executed at the same time, or within close proximity of <em style="font: inherit;">one</em> another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together. For contracts that contain more than <em style="font: inherit;">one</em> separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do <em style="font: inherit;">not</em> contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Our arrangements with customers consist principally of <em style="font: inherit;">four</em> different types of arrangements: <em style="font: inherit;">1</em>) subscription-based service agreements; <em style="font: inherit;">2</em>) <em style="font: inherit;">one</em>-time specified services performed at a single point in time; <em style="font: inherit;">3</em>) fixed, non-subscription service agreements; and <em style="font: inherit;">4</em>) unit-priced service agreements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Subscription-based services - </i>Services that are provided under subscription-based service agreements are usually for a <em style="font: inherit;">twelve</em>- month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but <em style="font: inherit;"> may </em>also be billed on a quarterly and monthly basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>One-time services </i>–<i> </i>These agreements typically require us to perform a specific <em style="font: inherit;">one</em>-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Fixed, non-subscription services </i>–<i> </i>These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch-up adjustment which could impact the amount and timing of revenue for any period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Unit-price services </i>–<i> </i>These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but <em style="font: inherit;">not</em> invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;"><b>Deferred Contract Costs </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from <span style="-sec-ix-hidden:c81336539">three</span> to <span style="-sec-ix-hidden:c81336540">five</span> years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of <em style="font: inherit;">one</em> year or less. We deferred incremental costs of obtaining a contract of $1.9 million, $3.7 million and $3.6 million in the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively. Deferred contract costs, net of accumulated amortization was $3.8 million and $4.6 million at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively. Total amortization by expense classification for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">157</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $31,000, $63,000 and $22,000 for the years <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively.</p> 1900000 3700000 3600000 3800000 4600000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">157</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 157000 272000 34000 2494000 2970000 2874000 2651000 3242000 2908000 31000 63000 22000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Trade Accounts Receivable</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following table provides the activity in the allowance for doubtful accounts for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bad Debt</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expense</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Write-offs,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">net of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Recoveries</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">at End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bad Debt</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expense</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Write-offs,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">net of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Recoveries</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">at End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 175000 75000 106000 144000 144000 46000 70000 120000 120000 38000 64000 94000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Property and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.8 million and $2.7 million of costs incurred for the development of internal-use software for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is <em style="font: inherit;">not</em> included or we do <em style="font: inherit;">not</em> have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective <em style="font: inherit;"> January 1, 2020, </em>we prospectively adopted ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> Intangibles-Goodwill and Other-Internal Use Software (Subtopic <em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of <span style="-sec-ix-hidden:c81336570">three</span> to <span style="-sec-ix-hidden:c81336571">ten</span> years for furniture and equipment, <span style="-sec-ix-hidden:c81336572">three</span> to <span style="-sec-ix-hidden:c81336573">five</span> years for computer equipment, <span style="-sec-ix-hidden:c81336574">one</span> to <span style="-sec-ix-hidden:c81336575">five</span> years for capitalized software, and <span style="-sec-ix-hidden:c81336576">seven</span> to <span style="-sec-ix-hidden:c81336577">forty</span> years for our office building and related improvements. Software licenses are amortized over the term of the license.</p> 2800000 2700000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Impairment of Long-Lived Assets and Amortizing Intangible Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we <em style="font: inherit;">first</em> compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is <em style="font: inherit;">not</em> recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and <em style="font: inherit;">third</em>-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> or <em style="font: inherit;">2019.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result <em style="font: inherit;"> may </em>trigger an impairment review:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant underperformance in comparison to historical or projected operating results;</p> </td></tr> <tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant changes in the manner or use of acquired assets or our overall strategy;</p> </td></tr> <tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant negative trends in our industry or the overall economy;</p> </td></tr> <tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A significant decline in the market price for our common stock for a sustained period; and</p> </td></tr> <tr><td style="vertical-align:top;width:0.9%;"> </td><td style="vertical-align:top;width:2.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our market capitalization falling below the book value of our net assets.</p></td></tr> </tbody></table> 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Goodwill and Intangible Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. We review intangible assets with indefinite lives for impairment annually as of <em style="font: inherit;"> October 1 </em>and whenever events or changes in circumstances indicate that the carrying value of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">When performing the impairment assessment, we will <em style="font: inherit;">first</em> assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than <em style="font: inherit;">not</em> that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did <span style="-sec-ix-hidden:c81336592"><span style="-sec-ix-hidden:c81336593"><span style="-sec-ix-hidden:c81336594">not</span></span></span> recognize any impairments related to indefinite-lived intangibles during <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020</em> or <em style="font: inherit;">2019.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are <em style="font: inherit;">not</em> individually identified and separately recognized. All of our goodwill is allocated to our reporting unit, which is the same as our operating segment. Goodwill is reviewed for impairment at least annually, as of <em style="font: inherit;"> October 1, </em>and whenever events or changes in circumstances indicate that the carrying value of goodwill <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We review goodwill for impairment by <em style="font: inherit;">first</em> assessing qualitative factors to determine whether any impairment <em style="font: inherit;"> may </em>exist. If we believe, as a result of the qualitative assessment, that it is more likely than <em style="font: inherit;">not</em> that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of <em style="font: inherit;"> October 1, 2021 </em>and determined the fair value of our reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended <em style="font: inherit;"> December 31, 2021 </em>or <em style="font: inherit;">2019.</em> A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to <em style="font: inherit;"> September 2022, </em>during <em style="font: inherit;"> December 2020 </em>we chose <em style="font: inherit;">not</em> to enter into a new contract with this customer or otherwise extend the term of the contract beyond <em style="font: inherit;"> September 2022. </em>We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at <em style="font: inherit;"> December 31, 2020. </em>We recognized an impairment of $714,000 for the excess of the then Canada reporting unit’s carrying value over the fair value, using discounted cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In <em style="font: inherit;"> March 2021, </em>we changed our operating segments from <em style="font: inherit;">six</em> to <span style="-sec-ix-hidden:c81336609">one</span> to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker. In connection with this change, our previous reporting units were combined into <span style="-sec-ix-hidden:c81336610">one</span> reporting unit. We performed an interim qualitative analysis immediately before and after the reorganization and concluded that the fair value of our reporting units likely exceeded the carrying values and <em style="font: inherit;">no</em> impairments were recorded. Following the reorganization, we considered the current and expected future economic and market conditions, including the impact of the COVID-<em style="font: inherit;">19</em> pandemic, on our reporting unit. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has <em style="font: inherit;">not</em> occurred which would require an additional interim impairment test to be performed as it is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that an impairment loss had been incurred at <em style="font: inherit;"> December 31, 2021.</em></p> 0 1 714000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Insurance Recoveries</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We record insurance recoveries when the realization of the claim is probable. In <em style="font: inherit;">2020</em> we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in <em style="font: inherit;"> February 2020 (</em>the <em style="font: inherit;"> “February </em>incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the <em style="font: inherit;"> February </em>incident did <em style="font: inherit;">not</em> have a significant impact on our consolidated financial statements. In <em style="font: inherit;">2020,</em> we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.</p> 3300000 447000 533000 260000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than <em style="font: inherit;">not</em> to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> we recorded income tax benefits relating to these tax credits of $10,000, $45,000, and $24,000, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We recognize the effect of income tax positions only if those positions are more likely than <em style="font: inherit;">not</em> of being sustained. Recognized income tax positions are measured at the largest amount that is greater than <em style="font: inherit;">50%</em> likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In <em style="font: inherit;">2021,</em> we adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Simplifying the Accounting for Income Taxes (Topic <em style="font: inherit;">740</em>). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The adoption of this standard had <em style="font: inherit;">no</em> material impact to our consolidated financial statements.</p> 10000 45000 24000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Share-Based Compensation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amounts charged against income, before income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amount of related income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net (benefit) expense to net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,084</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amounts charged against income, before income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amount of related income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net (benefit) expense to net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,084</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> 623000 680000 1224000 919000 6764000 2081000 -296000 -6084000 -857000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Cash and Cash Equivalents</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We consider all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Cash equivalents were $6.3 million and $5.0 million as of <em style="font: inherit;"> December 31, 2021, </em>and <em style="font: inherit;">2020,</em> respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances <em style="font: inherit;"> may </em>exceed federally insured limits.</p> 6300000 5000000.0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Leases</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We determine whether a lease is included in an agreement at inception. We recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for our operating leases under which we are lessee. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements <em style="font: inherit;"> may </em>include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do <em style="font: inherit;">not</em> contain any residual value guarantees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is <em style="font: inherit;">not</em> readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Due to remote working arrangements, we reassessed our office needs and subleased our Seattle location under an agreement considered to be an operating lease beginning in <em style="font: inherit;"> May 2021. </em>We have <em style="font: inherit;">not</em> been legally released from our primary obligations under the original lease and therefore we continue to account for the original lease separately. We recorded an ROU asset impairment charge in <em style="font: inherit;">2021</em> of $324,000, which was the amount by which the carrying value of the Seattle office lease ROU asset exceeded the fair value. We estimated the fair value based on the discounted cash flows of estimated net rental income for the office space subleased. The ROU asset impairment charge is included in depreciation, amortization and impairment expenses. There were <em style="font: inherit;">no</em> ROU asset impairment charges in <em style="font: inherit;">2020</em> or <em style="font: inherit;">2019.</em> Rent income from the sublessee are included in the statement of operations on a straight-line basis as an offset to rent expense associated with the original operating lease included in other expenses.</p> 324000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Fair Value Measurements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (<em style="font: inherit;">1</em>) Level <em style="font: inherit;">1</em> Inputs—quoted prices in active markets for identical assets and liabilities; (<em style="font: inherit;">2</em>) Level <em style="font: inherit;">2</em> Inputs—observable market-based inputs other than Level <em style="font: inherit;">1</em> inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data; (<em style="font: inherit;">3</em>) Level <em style="font: inherit;">3</em> Inputs—unobservable inputs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following details our financial assets within the fair value hierarchy at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 1</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 2</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 3</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2021</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2020</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">There were <em style="font: inherit;">no</em> transfers between levels during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our long-term debt described in Note <em style="font: inherit;">8</em> is recorded at historical cost. The fair value of long-term debt is classified in Level <em style="font: inherit;">2</em> of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following are the carrying amount and estimated fair values of long-term debt:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26,620</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,943</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are <em style="font: inherit;">not</em> recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). We estimated the fair value of the Seattle office ROU using discounted cash flows of the sublease based on management’s most recent projections, which are considered level <em style="font: inherit;">3</em> inputs in the fair value hierarchy and recorded an ROU asset impairment charge of $324,000 during <em style="font: inherit;">2021.</em> As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> there was <span style="-sec-ix-hidden:c81336668">no</span> indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill in <em style="font: inherit;"> December 2020 </em>as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level <em style="font: inherit;">3</em> inputs in the fair value hierarchy.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 1</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 2</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 3</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2021</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2020</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26,620</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,943</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 6306000 6306000 6306000 6306000 5015000 5015000 5015000 5015000 26620000 30713000 27708000 32943000 324000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Commitments and Contingencies</b><br/> <br/> From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do <span style="-sec-ix-hidden:c81336671">not</span> believe the final disposition of claims at <em style="font: inherit;"> December 31, 2021 </em>will have a material adverse effect on our consolidated financial position, results of operations or liquidity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We became self-insured for group medical and dental insurance on <em style="font: inherit;"> January 1, 2019.   </em>We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance. We do <em style="font: inherit;">not</em> self-insure for any other types of losses, and therefore do <em style="font: inherit;">not</em> carry any additional excess loss insurance. In addition, we had aggregate claims loss coverage with a minimum aggregate deductible of $3.2 million and $2.8 million, in <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but <em style="font: inherit;">not</em> reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a <em style="font: inherit;">third</em>-party actuarial IBNR analysis.  As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> our accrual related to self-insurance was $406,000 and $418,000, respectively.</p> 150000 3200000 2800000 406000 418000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Earnings Per Share</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Basic net income per share was computed using the weighted-average number of common shares outstanding during the period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We had 127,185, 65,127 and 16,221 options of Common Stock for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except per share data)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,466</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Allocation of distributed and undistributed income to unvested restricted stock shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income attributable to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,422</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income attributable to common shareholders for basic computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common <b>s</b>hares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,422</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average effect of dilutive securities – stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">844</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for diluted earnings per share – adjusted weighted average shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share – diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 127185 65127 16221 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except per share data)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,466</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Allocation of distributed and undistributed income to unvested restricted stock shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income attributable to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,422</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income attributable to common shareholders for basic computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common <b>s</b>hares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,422</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average effect of dilutive securities – stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">844</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for diluted earnings per share – adjusted weighted average shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share – diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 37466000 37260000 32406000 18000 57000 109000 37448000 37203000 32297000 25422000 25170000 24809000 1.47 1.48 1.30 37448000 37203000 32297000 25422000 25170000 24809000 218000 526000 844000 25640000 25696000 25653000 1.46 1.45 1.26 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">In <em style="font: inherit;"> March 2020, </em>the Financial Accounting Standards Board (the “FASB”) issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> "Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of <em style="font: inherit;"> March 12, 2020 </em>through <em style="font: inherit;"> December 31, 2022. </em>We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In <em style="font: inherit;"> October 2021, </em>FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2021</em>-<em style="font: inherit;">08,</em> “Business Combinations (Topic <em style="font: inherit;">805</em>): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The amendment requires an acquirer in a business combination apply Topic <em style="font: inherit;">606</em> to recognize and measure contract assets in revenue contracts acquired in a business combination rather than fair value. The amendment is effective for public business entities for fiscal years beginning after <em style="font: inherit;"> December 15, 2022, </em>including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the timing and the impact of adopting this new guidance on our consolidated financial statements.</p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">2</em>)</b> </p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">ACQUISITION</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">On <em style="font: inherit;"> January 4, 2021, </em>we acquired substantially all assets and assumed certain liabilities of PatientWisdom, Inc., a company with a health engagement solution that will further our purpose of operationalizing human understanding through tangible and actionable insights. $3.0 million of the total $5.0 million all-cash consideration was paid at closing. We paid the remaining $2.0 million in <em style="font: inherit;"> January 2022. </em>All payments were made with cash on hand. The acquisition was accounted for as a business combination, using the acquisition method of accounting, which requires, among other things, certain assets acquired and liabilities assumed to be recognized at their fair values as of the acquisition date. The following table summarizes the fair value of assets acquired and liabilities assumed at the acquisition date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td colspan="4" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="text-decoration: underline; ">Amount of Identified Assets Acquired and Liabilities Assumed</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">($ in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current Assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,340</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,234</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,950</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">The identifiable intangible assets are being amortized over their estimated useful lives of 5 years. The goodwill and identifiable intangible assets are deductible for tax purposes. Goodwill related to the acquisition was primarily attributable to anticipated synergies and other intangibles that do <em style="font: inherit;">not</em> qualify for separate recognition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">The financial results associated with the PatientWisdom assets we acquired and liabilities we assumed are included in our consolidated financial statements from the date of acquisition, although the amounts are insignificant for <em style="font: inherit;">2021.</em> Pro-forma information has <em style="font: inherit;">not</em> been presented because the amounts for <em style="font: inherit;">2021</em> are insignificant. Acquisition-related costs of $119,000 are included in selling, general and administrative expenses for the year ended <em style="font: inherit;"> December 31, 2021.</em></p> 3000000.0 5000000.0 2000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td colspan="4" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="text-decoration: underline; ">Amount of Identified Assets Acquired and Liabilities Assumed</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">($ in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current Assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,340</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,234</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,950</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 184000 10000 100000 600000 4340000 5234000 284000 4950000 P5Y 119000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">3</em>) </b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Contracts with Customers</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following table disaggregates revenue for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> based on timing of revenue recognition (In thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 5%; margin-right: 5%;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Subscription services recognized ratably over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">137,008</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">122,499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">114,216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services recognized at a point in time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,992</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed, non-subscription recognized over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,907</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unit price services recognized over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,665</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,526</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,277</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,982</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivables</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,728</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,923</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contract assets included in other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(17,213</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Significant changes in contract assets and contract liabilities during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contract</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Asset</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deferred</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contract</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Asset</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deferred</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Increase (Decrease)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Revenue recognized that was included in deferred revenue at beginning of year due to completion of services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(16,083</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to invoicing of client, net of amounts recognized as revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,694</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Decreases due to completion of services (or portion of services) and transferred to accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change due to cumulative catch-up adjustments arising from changes in expected contract consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">326</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to revenue recognized in the period with additional performance obligations before invoicing</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We have elected to apply the practical expedient to <em style="font: inherit;">not</em> disclose the value of unsatisfied performance obligations for contracts with an original expected length of <em style="font: inherit;">one</em> year or less. Total remaining contract revenue for contracts with original duration of greater than <em style="font: inherit;"><span style="-sec-ix-hidden:c81336831"><span style="-sec-ix-hidden:c81336832"><span style="-sec-ix-hidden:c81336833">one</span></span></span></em> year expected to be recognized in the future related to performance obligations that are unsatisfied at <em style="font: inherit;"> December 31, 2021 </em>approximated $2.9 million of which $1.3 million, $1.1 million, and $587,000 is expected to be recognized during <em style="font: inherit;">2022,</em> <em style="font: inherit;">2023,</em> and <em style="font: inherit;">2024,</em> respectively.</p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 5%; margin-right: 5%;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Subscription services recognized ratably over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">137,008</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">122,499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">114,216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services recognized at a point in time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,992</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed, non-subscription recognized over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,907</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unit price services recognized over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,665</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,526</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,277</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,982</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 137008000 122499000 114216000 3216000 2932000 4992000 3065000 2907000 3248000 4665000 4939000 5526000 147954000 133277000 127982000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivables</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,728</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,923</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contract assets included in other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(17,213</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contract</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Asset</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deferred</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contract</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Asset</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deferred</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Increase (Decrease)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Revenue recognized that was included in deferred revenue at beginning of year due to completion of services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(16,083</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to invoicing of client, net of amounts recognized as revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,694</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Decreases due to completion of services (or portion of services) and transferred to accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change due to cumulative catch-up adjustments arising from changes in expected contract consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">326</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to revenue recognized in the period with additional performance obligations before invoicing</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 13728000 13923000 99000 311000 17213000 15585000 15631000 16083000 16694000 15338000 311000 103000 -326000 24000 99000 311000 2900000 1300000 1100000 587000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">4</em>) </b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Equity Investments</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We make equity investments to promote business and strategic objectives. For investments that do <em style="font: inherit;">not</em> have a readily determinable fair value, we apply either cost or equity method of accounting depending on the nature of our investment and our ability to exercise significant influence. Investments are periodically analyzed to determine whether or <em style="font: inherit;">not</em> there are any indicators of impairment and written down to fair value if the investment has incurred an other than temporary impairment. Our investment of $1.3 million in convertible preferred stock of PracticingExcellence.com, Inc., a privately-held Delaware corporation (“PX”) is included in non-current assets. It is <em style="font: inherit;">not</em> practicable for us to estimate fair value at each reporting date due to the cost and complexity of the calculations for this non-public entity. Therefore, it is carried at cost less impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, if any. We have a seat on PX's board of directors and our investment, which is <em style="font: inherit;">not</em> considered to be in-substance common stock, represents approximately 15.1% of the issued and outstanding equity interests in PX.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1300000 0.151 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">5</em>)</b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Property and Equipment</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">At <em style="font: inherit;"> December 31, 2021, </em>and <em style="font: inherit;">2020,</em> property and equipment consisted of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,901</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,672</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,828</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Building</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,515</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leaseholds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">502</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">232</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment at cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">45,599</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,208</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,979</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,391</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,726</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Depreciation and amortization expense related to property and equipment, including assets under capital lease, for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> was $5.7 million, $6.5 million, and $5.4 million, respectively. There were no significant impairments in property and equipment during <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019.</em> However, we did shorten the useful lives of certain assets to reflect our best estimate of when assets are expected to be disposed of or replaced.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,901</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,672</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,828</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Building</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,515</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leaseholds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">502</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">232</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment at cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">45,599</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,208</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,979</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,391</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,726</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 4901000 4808000 2672000 2638000 27828000 27087000 9271000 7515000 502000 232000 425000 425000 45599000 42705000 33208000 30979000 12391000 11726000 5700000 6500000 5400000 0 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">6</em>) </b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Goodwill and Intangible Assets </span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Goodwill and intangible assets consisted of the following at <em style="font: inherit;"> December 31, 2021:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Impairment</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(714</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">61,614</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Useful Life</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amortization</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="font-family: Times New Roman; font-size: 10pt; width: 7%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="font-family: Times New Roman; font-size: 10pt; width: 7%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,445</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,325</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="3" style="width: 7%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">7</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,959</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,480</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">479</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,976</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">599</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total intangible assets other than goodwill</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Goodwill and intangible assets consisted of the following at <em style="font: inherit;"> December 31, 2020:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Impairment</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,969</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(714</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,255</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Useful Life</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amortization</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="font-family: Times New Roman; font-size: 10pt; width: 7%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="font-family: Times New Roman; font-size: 10pt; width: 7%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="3" style="width: 7%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">7</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,229</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">131</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">219</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total intangible assets other than goodwill</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,467</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,410</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">The following represents a summary of changes in the carrying amount of goodwill for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,935</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Impairment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(714</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,255</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,340</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">61,614</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">As discussed in Note <em style="font: inherit;">1,</em> we recorded an impairment of $714,000 to the Canada reporting unit’s goodwill in <em style="font: inherit;"> December 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Aggregate amortization expense for customer related intangibles, trade names, and technology for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $320,000, $318,000, and $374,000, respectively. Estimated future amortization expense for <em style="font: inherit;">2022,</em> <em style="font: inherit;">2023,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2025</em> is $180,000, $140,000, $140,000 and $139,000, respectively.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Impairment</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(714</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">61,614</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Useful Life</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amortization</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="font-family: Times New Roman; font-size: 10pt; width: 7%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="font-family: Times New Roman; font-size: 10pt; width: 7%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,445</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,325</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="3" style="width: 7%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">7</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,959</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,480</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">479</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,976</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">599</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total intangible assets other than goodwill</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Impairment</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,969</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(714</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,255</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Useful Life</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amortization</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="font-family: Times New Roman; font-size: 10pt; width: 7%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="font-family: Times New Roman; font-size: 10pt; width: 7%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="3" style="width: 7%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">7</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,229</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">131</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">219</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total intangible assets other than goodwill</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"> </em></em></em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,467</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,410</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 62328000 714000 61614000 1191000 1191000 P5Y P15Y 9445000 9325000 120000 P7Y 1959000 1480000 479000 P5Y P10Y 1572000 1572000 12976000 12377000 599000 14167000 12377000 1790000 57969000 714000 57255000 1191000 1191000 P5Y P15Y 9344000 9256000 88000 P7Y 1360000 1229000 131000 P5Y P10Y 1572000 1572000 12276000 12057000 219000 13467000 12057000 1410000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,935</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Impairment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(714</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,255</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,340</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">61,614</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 57935000 714000 34000 57255000 4340000 19000 61614000 714000 320000 318000 374000 180000 140000 140000 139000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">7</em>) </b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Income Taxes </span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">For the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> income before income taxes consists of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 45pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign Operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">476</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">474</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,621</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,467</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Income tax expense consisted of the following components:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 45pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Federal:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,092</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,546</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,574</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">718</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,238</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,292</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Foreign</span>:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">219</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">State</span>:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,197</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">578</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">372</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,161</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,694</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,155</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,113</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">As a result of the Tax Cut and Jobs Act (the “Tax Act”), we determined that we would <em style="font: inherit;">no</em> longer indefinitely reinvest the earnings of our Canadian subsidiary. Our Canadian subsidiary declared a deemed dividend to the Company for $9.6 million in <em style="font: inherit;">2020.</em> Additionally, a withholding tax of <em style="font: inherit;">5%</em> was paid for the dividend distribution.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We received notice in <em style="font: inherit;"> December 2019, </em>that we met qualification requirements for the Nebraska Advantage <em style="font: inherit;">LB312</em> Act (“NAA”) related to certain investment and full-time equivalent employee thresholds in the year ended <em style="font: inherit;">2017.</em> NAA provides direct refunds of sales tax on qualified property, as well as investment credits and employment credits that can be claimed through credits of Nebraska income tax, employment tax, and sales tax on non-qualified property. We expect to receive direct refunds of Nebraska sales tax on qualified property incurred from <em style="font: inherit;">2014</em> to <em style="font: inherit;">2023.</em> Investment credits started to accumulate in <em style="font: inherit;">2014</em> and can be earned through <em style="font: inherit;">2023.</em> These credits can be claimed against Nebraska income taxes or through sales tax on non-qualified property through <em style="font: inherit;">2028.</em> The employment credits are earned from <em style="font: inherit;">2017</em> through <em style="font: inherit;">2023,</em> and they can be claimed against Nebraska payroll taxes through <em style="font: inherit;">2028.</em> In <em style="font: inherit;">2019,</em> we recorded cumulative adjustments for direct refunds and credits earned through the year ending <em style="font: inherit;"> December 31, 2019, </em>which reduced operating expenses by approximately $1.9 million. For the year ended <em style="font: inherit;"> December 31, 2021 </em>and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2020,</em> adjustments for credits reduced operating expenses by approximately $473,000 and $435,000, respectively. In addition, income tax credits of $10,000, $45,000 and $24,000 were recorded as a reduction to income tax expense for the years ended <em style="font: inherit;"> December 31, 2021, </em><em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2020</em> and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The differences between income taxes expected at the U.S. federal statutory income tax rate of <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">21</em> percent and the reported income tax (benefit) expense are summarized as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 45pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected federal income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal benefit and state tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,531</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(660</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,579</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation limit for covered employees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(261</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">254</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">157</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nondeductible expenses (income) related to recapitalization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill Impairment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Withholding tax on repatriation of foreign earnings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">107</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">GILTI</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">102</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,155</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,113</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Deferred tax assets and liabilities at <em style="font: inherit;"> December 31, 2021 </em>and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2020,</em> were comprised of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">687</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued bonuses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">267</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Employer payroll tax deferral</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">161</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">104</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,043</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,043</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred contract costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">945</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,579</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Repatriation withholding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">182</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,265</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In <em style="font: inherit;"> March 27, 2020, </em>the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we had deferred $1.3 million of employer social security tax payments as of <em style="font: inherit;"> December 31, 2020. </em>In accordance with the CARES Act, we paid half of this liability in <em style="font: inherit;"> December 2021, </em>and we expect to pay the remaining $656,000 in <em style="font: inherit;"> December 2022. </em>We have had <em style="font: inherit;">no</em> other impacts to our consolidated financial statements or related disclosures from the CARES Act.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">In assessing the realizability of deferred tax assets, we consider whether it is more likely than <em style="font: inherit;">not</em> that some portion, or all, of the deferred tax assets will <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">not</em> be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider projected future taxable income, carry-back opportunities, and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods which the deferred tax assets are deductible, we believe it is more likely than <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">not</em> that we will realize the benefits of these deductible differences excluding the foreign tax credit carryforward. In <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2020,</em> we wrote off the deferred tax asset for prior year foreign tax credit carryforwards of $535,000 and the related valuation allowance. We made the assessment that due to our Canadian subsidiary’s decreased projected future income and the lower US tax rate compared to the Canadian tax rate, it was unlikely we would realize this asset.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We had an unrecognized tax benefit at <em style="font: inherit;"> December 31, 2021 </em>and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2020,</em> of $1.1 million and $768,000, respectively, excluding interest of $19,000 and $15,000 at <em style="font: inherit;"> December 31, 2021 </em>and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2020,</em> respectively. Of these amounts, $918,000 and $668,000 at <em style="font: inherit;"> December 31, 2021 </em>and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2020,</em> respectively, represents the net unrecognized tax benefits that, if recognized, would favorably impact the effective income tax rate. The change in the unrecognized tax benefits for <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2021</em> and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2020</em> was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">592</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to lapse of applicable statute of limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to settlement with taxing authorities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to lapse of applicable statute of limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions due to tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to settlement with taxing authorities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">345</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,075</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Canada federal and provincial jurisdictions. Tax years <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2018</em> and forward remain subject to U.S. federal examination. Tax years <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2015</em> and forward remain subject to state examination. Tax years <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2017</em> and forward remain subject to Canadian federal and provincial examination.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 45pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign Operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">476</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">474</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,621</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,467</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 48145000 41357000 40045000 476000 110000 474000 48621000 41467000 40519000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 45pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Federal:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,092</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,546</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,574</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">718</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,238</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,292</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Foreign</span>:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">219</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">State</span>:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,197</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">578</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">372</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,161</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,694</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,155</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,113</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 9092000 3546000 5574000 -224000 -308000 718000 8868000 3238000 6292000 143000 225000 94000 -17000 -6000 33000 126000 219000 127000 2197000 578000 1322000 -36000 172000 372000 2161000 750000 1694000 11155000 4207000 8113000 9600000 1900000 473000 435000 10000 45000 24000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 45pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected federal income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal benefit and state tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,531</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(660</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,579</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation limit for covered employees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(261</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">254</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">157</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nondeductible expenses (income) related to recapitalization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill Impairment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Withholding tax on repatriation of foreign earnings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">107</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">GILTI</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">102</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,155</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,113</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 10210000 8708000 8509000 26000 6000 26000 1531000 607000 1344000 -660000 -5713000 -1579000 463000 272000 261000 419000 254000 157000 34000 -24000 184000 8000 18000 107000 10000 13000 58000 28000 102000 11155000 4207000 8113000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">687</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued bonuses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">267</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Employer payroll tax deferral</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">161</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">104</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,043</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,043</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred contract costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">945</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,579</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Repatriation withholding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">182</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,265</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> 24000 29000 687000 696000 740000 735000 267000 145000 200000 323000 161000 104000 66000 11000 2145000 2043000 2145000 2043000 89000 93000 945000 1111000 1579000 1725000 6338000 6109000 182000 174000 96000 9133000 9308000 6988000 7265000 1300000 656000 535000 1100000 768000 19000 15000 918000 668000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">592</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to lapse of applicable statute of limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to settlement with taxing authorities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to lapse of applicable statute of limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions due to tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to settlement with taxing authorities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">345</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,075</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 592000 34000 4000 206000 768000 38000 345000 1075000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">8</em>) </b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Notes Payable</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our long-term debt consists of the following:  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Term Loans</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26,620</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,061</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: unamortized debt issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,269</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,547</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on <em style="font: inherit;"> May 28, 2020 </em>and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-down term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan <em style="font: inherit;"> may </em>be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The <em style="font: inherit;"> May 2020 </em>amendment increased the Line of Credit from <em style="font: inherit;">$15,000,000</em> to <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">$30,000,000.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">The Term Loan is payable in monthly installments of $462,988 through <em style="font: inherit;"> May 2025, </em>with a balloon payment due at maturity in <em style="font: inherit;"> May 2025. </em>The Term Loan bears interest at a fixed rate per annum of 5%. Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the <em style="font: inherit;">30</em>-day London Interbank Offered Rate plus 225 basis points (2.35% at <em style="font: inherit;"> December 31, 2021). </em>Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in <em style="font: inherit;"> May 2023. </em>As of <em style="font: inherit;"> December 31, 2021, </em>and <em style="font: inherit;"> December 31, 2020, </em>the Line of Credit did <span style="-sec-ix-hidden:c81337236"><span style="-sec-ix-hidden:c81337245">not</span></span> have a balance. We did <em style="font: inherit;">not</em> borrow on the Line of Credit during <em style="font: inherit;">2021.</em> We have <em style="font: inherit;">not</em> borrowed on the Delayed Draw Term Loan since origination.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of <span style="-sec-ix-hidden:c81337242">1.10x</span> for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of <span style="-sec-ix-hidden:c81337244">3.00x</span> or less for all testing periods throughout the term(s) of the Credit Facilities. As of <em style="font: inherit;"> December 31, 2021, </em>we were in compliance with our financial covenants. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Scheduled maturities of notes payable at <em style="font: inherit;"> December 31, 2021 </em>are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,529</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,762</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Term Loans</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26,620</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,061</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: unamortized debt issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,269</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,547</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 26620000 30713000 4278000 4061000 73000 105000 22269000 26547000 30000000 33002069 15000000 462988 0.05 0.0225 0.0235 0.0020 5500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,529</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,762</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 4306000 4529000 4762000 13023000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">9</em>)</b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Share-Based Compensation</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our <em style="font: inherit;">2004</em> Non-Employee Director Stock Plan, as amended (the <em style="font: inherit;">“2004</em> Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock. The <em style="font: inherit;">2004</em> Director Plan provides for grants of nonqualified stock options to each of our directors who we do <em style="font: inherit;">not</em> employ. On the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately <span style="-sec-ix-hidden:c81337276">one</span> year following the date of grant and option terms are generally the earlier of <span style="-sec-ix-hidden:c81337277">ten</span> years following the date of grant, or <span style="-sec-ix-hidden:c81337278">three</span> years from the termination of the outside director’s service. At <em style="font: inherit;"> December 31, 2021, </em>there were 780,330 shares of Common Stock available for issuance pursuant to future grants under the <em style="font: inherit;">2004</em> Director Plan. We have accounted for grants of 2,219,670 shares of Common Stock under the <em style="font: inherit;">2004</em> Director Plan using the date of grant as the measurement date for financial accounting purposes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Our <em style="font: inherit;">2006</em> Equity Incentive Plan (the <em style="font: inherit;">“2006</em> Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of Common Stock. Stock options granted <em style="font: inherit;"> may </em>be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally <span style="-sec-ix-hidden:c81337286">five</span> to <span style="-sec-ix-hidden:c81337287">ten</span> years following the date of grant. At <em style="font: inherit;"> December 31, 2021, </em>there were 806,537 shares of Common Stock available for issuance pursuant to future grants under the <em style="font: inherit;">2006</em> Equity Incentive Plan. We have accounted for grants of 993,463 shares of Common Stock and restricted stock under the <em style="font: inherit;">2006</em> Equity Incentive Plan using the date of grant as the measurement date for financial accounting purposes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">During <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> we granted options to purchase 101,091, 70,471, and 100,615 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield at date of grant</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.91</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following table summarizes stock option activity under <em style="font: inherit;">2006</em> Equity Incentive Plan and the <em style="font: inherit;">2004</em> Director Plan for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of<br/> Options</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Terms</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Common Stock</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600,571</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">101,091</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44.96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(116,753</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(22,837</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.74</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(84,432</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">477,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30.88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.97</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">249,488</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23.99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,805</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following table summarizes information related to stock options for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average grant date fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.55</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.67</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intrinsic value of stock options exercised (in thousands)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,280</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intrinsic value of stock options vested (in thousands)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,805</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,965</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,891</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">As of <em style="font: inherit;"> December 31, 2021, </em>the total unrecognized compensation cost related to non-vested stock option awards was approximately $1.1 million which was expected to be recognized over a weighted average period of 2.37 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">There was $446,000 and $1.7 million in cash received from stock options exercised for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively and no cash received from options exercised in <em style="font: inherit;">2019.</em> We recognized $607,000, $680,000, and $934,000 of non-cash compensation for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> respectively, related to options, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from stock options exercised was $862,000, $6.3 million, and $1.9 million for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">During <em style="font: inherit;">2021</em> and <em style="font: inherit;">2019</em> we granted 12,698 and 6,005 non-vested shares of Common Stock, respectively, under the <em style="font: inherit;">2006</em> Equity Incentive Plan. <span style="-sec-ix-hidden:c81337328">No</span> shares of non-vested Common Stock were granted during the year ended <em style="font: inherit;"> December 31, 2020. </em>As of <em style="font: inherit;"> December 31, 2021, </em>we had 12,698 non-vested shares of Common Stock outstanding under the <em style="font: inherit;">2006</em> Equity Incentive Plan. These shares vest over <span style="-sec-ix-hidden:c81337331">five</span> years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or <em style="font: inherit;">not</em> vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized $17,000, $23,000, and $290,000 of non-cash compensation for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> respectively, related to this non-vested stock, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from vesting of restricted stock was $235,000 for the year ended <em style="font: inherit;"> December 31, 2020. </em>No restricted stock vested during the year end <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2019.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The following table summarizes information regarding non-vested stock granted to associates under the <em style="font: inherit;">2006</em> Equity Incentive Plans for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Outstanding</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average Grant</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date Fair Value</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Per Share</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,698</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42.92</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42.92</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">As of <em style="font: inherit;"> December 31, 2021, </em>the total unrecognized compensation cost related to non-vested stock awards was approximately $436,000 and is expected to be recognized over a weighted average period of 4.00 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 3000000 100000 780330 2219670 1800000 806537 993463 101091 70471 100615 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield at date of grant</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.91</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 0.0215 0.0184 0.0260 0.3485 0.3362 0.3401 0.0091 0.0135 0.0238 P7Y3D P7Y4M20D P7Y5M15D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of<br/> Options</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Terms</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Common Stock</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600,571</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">101,091</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44.96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(116,753</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(22,837</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.74</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(84,432</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">477,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30.88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.97</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">249,488</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23.99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,805</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 600571 25.31 101091 44.96 116753 13.14 3535000 22837 9.74 84432 38.38 477640 30.88 P5Y11M19D 6337000 249488 23.99 P4Y9M25D 4805000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average grant date fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.55</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.67</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intrinsic value of stock options exercised (in thousands)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,280</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intrinsic value of stock options vested (in thousands)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,805</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,965</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,891</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 12.55 18.67 11.99 3535000 25912000 8280000 4805000 1965000 1891000 1100000 P2Y4M13D 446000 1700000 0 607000 680000 934000 862000 6300000 1900000 12698 6005 12698 17000 23000 290000 235000 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Outstanding</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average Grant</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date Fair Value</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Per Share</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,698</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42.92</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42.92</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 6005 38.30 12698 42.92 6005 38.30 12698 42.92 436000 P4Y <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">10</em>) </b></p> </td><td style="vertical-align:top;width:44.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Leases</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We lease printing, computer, other equipment and office space in the United States and Canada. The leases remaining terms as of <em style="font: inherit;"> December 31, 2021 </em>range from less than <span style="-sec-ix-hidden:c81337419">one</span> year to 4.93 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Certain equipment and office lease agreements include provisions for periodic adjustments to rates and charges. The rates and charges are adjusted based on actual usage or actual costs for internet, common area maintenance, taxes or insurance, as determined by the lessor and are considered variable lease costs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The components of lease expense for the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> included (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">669</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance leases:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asset amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;">489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">355</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">252</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Variable lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,269</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">In <em style="font: inherit;">2020,</em> we adjusted the useful life of the operating right of use assts associated with our Atlanta, Georgia and Markham, Ontario office leases based on the expectation that we will vacate the office space before the end of the lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Supplemental balance sheet information related to leases (in thousands):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">  </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Operating leases:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating ROU assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">975</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Noncurrent operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,313</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Finance leases:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,014</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Computer Equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">659</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Computer Software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment under finance lease, gross</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,883</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,074</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment under finance lease, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current obligations of finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Noncurrent obligations of finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total finance lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average remaining lease term (in years):</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.68</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average discount rate:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Supplemental cash flow and other information related to leases were as follows (in thousands):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">596</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">789</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">560</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for finance lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">817</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">192</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Undiscounted payments under non-cancelable finance and operating leases at <em style="font: inherit;"> December 31, 2021 </em>were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Finance Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Operating Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">488</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">531</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">513</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total minimum lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">846</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,389</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less: Amount representing interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Present value of minimum lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,313</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease obligations, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Undiscounted cash receipts due under the sublease agreement at <em style="font: inherit;"> December 31, 2021 </em>are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Operating Lease</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">122</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total minimum lease receipts</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">432</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> P4Y11M4D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">669</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance leases:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asset amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;">489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">355</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">252</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Variable lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,269</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 669000 600000 781000 489000 355000 252000 34000 37000 39000 99000 62000 86000 59000 42000 42000 81000 1269000 1096000 1200000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Operating leases:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating ROU assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">975</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Noncurrent operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,313</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Finance leases:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,014</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Computer Equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">659</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Computer Software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment under finance lease, gross</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,883</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,074</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment under finance lease, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current obligations of finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Noncurrent obligations of finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total finance lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average remaining lease term (in years):</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.68</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average discount rate:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> 975000 1308000 493000 461000 820000 896000 1313000 1357000 1042000 1014000 659000 662000 207000 207000 1908000 1883000 1074000 605000 834000 1278000 470000 493000 348000 778000 818000 1271000 P2Y9M18D P3Y8M4D P1Y11M4D P2Y8M8D 0.0385 0.0440 0.0342 0.0338 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">596</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">789</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">560</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for finance lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">817</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">192</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 680000 596000 789000 34000 36000 38000 493000 332000 229000 560000 276000 16000 40000 817000 192000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Finance Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Operating Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">488</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">531</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">513</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total minimum lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">846</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,389</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less: Amount representing interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Present value of minimum lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,313</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease obligations, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 488000 531000 315000 513000 23000 227000 10000 118000 10000 846000 1389000 28000 76000 818000 1313000 470000 493000 348000 820000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Operating Lease</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">122</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total minimum lease receipts</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">432</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 118000 122000 127000 65000 432000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">11</em>) </b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Related Party</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">A director who began serving on our board in <em style="font: inherit;"> May 2021, </em>served as chief executive officer of Allina Health during <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2021,</em> a <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">not</em>-for-profit healthcare system. In connection with its routine business operations, Allina Health purchases certain of our products and services. Total revenue we earned from Allina Health in year ended <em style="font: inherit;"> December 31, 2021 </em>approximated $1.7 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">A director, who served on our board through <em style="font: inherit;"> October 2021, </em>also served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) until <em style="font: inherit;"> January 2020 </em>and continued to serve on the board of directors of Ameritas until <em style="font: inherit;"> October 2021. </em>In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $278,000, $248,000, and $242,000 in <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2019</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">A director, who served on our board through <em style="font: inherit;"> May 2020, </em>also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during <em style="font: inherit;">2020</em> we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. Total payments for these services totaled $1.1 million in <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">During <em style="font: inherit;">2017,</em> we acquired a cost method investment in convertible preferred stock of Practicing Excellence.com, Inc., a privately-held Delaware Corporation (“PX”), which is included in other non-current assets and is carried at cost, adjusted for changes resulting from observable price changes in orderly transactions of the same investment in PX, if any.  We also have an agreement with PX which commenced in <em style="font: inherit;">2016</em> under which we act as a reseller of PX services and PX receives a portion of the revenues. The total revenue earned from the PX reseller agreement in the years ended <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">2019</em> was $35,000, $294,000, and $578,000, respectively. We <em style="font: inherit;">no</em> longer earn revenue under this agreement after <em style="font: inherit;"> June 30, 2021 </em>due to termination of the reseller agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1700000 278000 248000 242000 1100000 35000 294000 578000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">12</em>) </b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Associate Benefits</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">We sponsor a qualified <em style="font: inherit;">401</em>(k) plan covering substantially all associates with <em style="font: inherit;">no</em> eligibility service requirement. Under the <em style="font: inherit;">401</em>(k) plan, we match 25.0% of the <em style="font: inherit;">first</em> 6.0% of compensation contributed by each associate. Employer contributions, which are discretionary, vest to participants at a rate of 20% per year. We contributed $531,000, $521,000, and $447,000 in <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> respectively, as a matching percentage of associate <em style="font: inherit;">401</em>(k) contributions.</p> 0.250 0.060 0.20 531000 521000 447000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">13</em>) </b></p> </td><td style="vertical-align:top;width:44.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Segment Information</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In <em style="font: inherit;"> March 2021, </em>we changed our operating segments from <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">six</em> to <span style="-sec-ix-hidden:c81337569">one</span> to reflect a change in corporate reporting structure to the Company’s Chief Executive Officer and chief operating decision maker.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">The table below presents entity-wide information regarding our revenue and assets by geographic area (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenue:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144,987</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,305</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124,369</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,972</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,954</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,982</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83,722</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78,906</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,863</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,622</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">83,833</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,528</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">153,879</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">128,319</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,661</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,104</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">157,540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">110,685</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenue:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144,987</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,305</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124,369</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,972</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,954</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,982</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83,722</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78,906</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,863</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,622</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">83,833</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,528</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">153,879</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">128,319</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,661</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,104</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">157,540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">110,685</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 144987000 130305000 124369000 2967000 2972000 3613000 147954000 133277000 127982000 83722000 77448000 78906000 111000 1863000 2622000 83833000 79311000 81528000 153879000 128319000 95668000 3661000 5104000 15017000 157540000 133423000 110685000 185 EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

8E QWC!; H#?2GI%JGCH/D,''S MX21TOQ^KCS^KC7Z]>RYG5.F/TD],K?X_IR73B('8S&7=4U* 0=_"*[Q MLV"78FK9E7W6>"%[.BYN<.D$9KFHID*W M"8%@(YJ3,48W1&%*8Y+TT,1A>V2')73:Q3#";@])U!Y!)#,,*1$# SV!3+M MIKV!O%UP+?:IZA;LAC_A,D!%TIK7VEOE*K/*8:QEM(/CARD. M[Q"#,$O\,D,MV.L)Y*0+Y*0_([G4[ LO&S+]J8/RK>L[?M6J65)BO"U8O9*V M!.N]N![UNA*[1%4P)RG :IKPMA,(E&[,I863GXS@@/]X2'S8238!)2 M+1GA3DA&?:4DZQ"8]9<2M+-%4SIY5UQ3(3;L!F:Z&A, DD;FKHQ@VEU-G.7D!0%O;694;A?U[86@+YN!W M3DMTJ?F=5V*ARD)H](A11B6(R@?6X6%;AEH^W'K.SL%@BLT*:CSCX#5/LE;S M<.0UCP\G@&BMT'^\T1M?76=.9N$BQ4/CF30D76.-A<6$Y9]_RN(H^L53LG@< M)'%,4X1K,$Z"#'9\W"3K.1VJ]D$R\5/FIE'XMO@5'GI'_]97Q-++QM\ESK8= MUO_U8*?/5A]N=M*KXV(VHR[3X0PLJ6ZMLJQL0JDU_'@A=_-PZH#R^5:0,/E=,D=!-N/IK&H_[PKJ2ZR*9^C6ZYP"M=:#J _S.%ITW[00*Z=__I/U!+ P04 M" #1:&14AK>J89<" "?!0 &0 'AL+W=O(%2!UY:,H8:BNUL >D@2I@VXMI+]SDDE@X=K ="OOT M.SMIUFE037N3^.R[G_]WR=UTH_2]J1 M/-5"FEE06=N\1R%<""2\= S@^%*%[B[WM(_^-PIES4S M>*[$-Y[;:A:947S++Y5*L-:.=--+?PJ?IH$L>E^RBW5M,IIS@[OU86 M(8$WL,@>6FZX+]7A'5L+-$?3T-(5SC',>MRRPR6OX.($KI2TE8'W,L?\3T!( MV@:!R5;@,ME+O,#L&,;Q")(HB??PQD/"8\\;[TG80)?@'EPZX%*/2U_!W5*7 MY*U 4 7<8*9*R7]B#I5O3_G>O M">[PR<)2J.S^QTOEWZO&=?"9:5B&LX!:U*!^Q& .BUJUTCJ%_R'K\ "X!%NI MUI"+.8+S5FNB; $'$)^FL-(T)K1]]A@D9%,[GS@B=_D MHW>3"%[ZT.%.TY"^TH\& YFK5=<_P^XP?19=T_UV[T;7%=,EEP8$%A0:';^= M!*"[<= 95C6^!=?*4C'\LJ()BMHYT'FAZ*_L#7?!,)/GOP!02P,$% @ MT6AD5+= IQ!"! ^PD !D !X;"]W;W)K&UL MC5;;;MLX$/V5@9 '!Y!CW7P+; -)NL46:!=!DFX?%OM 4V.+&XG4DI2=[-?O MD+)E)W7=ODC#RYR9,Q>2LZW2SZ9 M/!2E=+,@\+:^GHP,+S BIDK5:.DE972 M%;,TU.N!J36RW"M5Y2")HM&@8D(&BYF?N]>+F6IL*23>:S!-53']>HNEVLZ# M.-A//(AU8=W$8#&KV1H?T7ZM[S6-!AU*+BJ41B@)&E?SX":^OAVZ_7[#GP*W MYD@&QV2IU+,;?,KG0>0&O)DU10C ]^$+>#.FT9MH/?$EB6:R]G DCVG-> [[-L6._D!=IS M%T(M#/PF<\S? @S(T<[;9._M;7(6\0/R*TCC$)(HB<_@I1W[U..E9]@;: F> M@@33^&Q61JN1>T=<'L$)X8:N5I+\1_FH*E*EN4K MJ UJL-1?< %Q.@ZC:.*D) FSZ=1)<18F\0@>3V P"PQJ):0%(5N0U&].PFF: M0!9.IPE\%"^8AR"5[)MCIXYP#CZD830:.O5H[*"R"7R5PD*MR?1)&@?5+!R1 M*ME,IS ,A\D(GI1E)6UN0T]4LG$X'6:>*(&/QYXHS4T2.)/U89?UX=FL[SN' M.O>H<<*NH^#&&+1'X\^"+44I[&L(3.94(QS%QM?'KY7)67=.EPDU#E9+"MF^ M>>#]3 0WG*M&6A_FG4/&QRP<)Y-6F";I@09SM Q5 "\;:F]7"LH6A,@;K5%V M&R[ %U0:.Z,KI+7\*#F]>$RED\*EERF!DR')AZI^&\4#PKZS?K;^27*ZK Q" MCQA[Z;);.ZHG6U!1;]E;.OE[=VG/$M="2B'7KKU?D6G(:<$JX*JJ2]PW?E>S M%W2VMLQ&:>Q9MN-1&$TAKA=-YUT? M"'4TS9PP#--T GO*YB=.]I2F?M;OYR]]?5)XI=D%@B#8]V4"/9?<2[+;BZ/4 M"W<%DVOLS#954S)W_P)GEA?]I@:6_T.M0O<[03$MC&.\TJH"[E5=)@!?:KJ] MR2[?9YD$(W+4[0G;AY3ZG=BS+<^'0Z,R@:?_. MD73JJ&4IVH/<4-)I&H]20Q7=]Q7=/WF"#(XN9#H+UO[98< 'KKV;N]GN97/3 M7NB'[>VSZ O35' &2ER1:G0UIN[7[5.C'5A5^^M]J2P=/%XLZ'6&VFV@]96B M2VXW< :Z]][B?U!+ P04 " #1:&14.>9V!L(" #(!0 &0 'AL+W=O M+4MQW5<) &:=L4* M=$/0[O(P[$&UF5BH;'F2W+3[^E%RXJ5 FP?K2AX>TCJ<;95^,#6BA:=&MF8> MU-9V9U%DRAH;;DY4ARW=K)5NN*6MWD2FT\@K[]3(B,7Q:=1PT0:+F3];Z<5, M]5:*%E<:3-\T7#\O4:KM/$B"_<&MV-36'42+6<(?V>[?2M(M&E$HTV!JA M6M"XG@?GR=ERXNR]P0^!6W.P!I?)O5(/;G-=S8/8$4*)I74(G*9'O$ I'1#1 M^+/##,:0SO%PO4>_\KE3+O?^EO57;S[C+)W-XI9+& MC[ =;"=% &5OK&IVSL2@$>TP\Z=='0XN;,]UR8XB7F)Y M FD2 HM9<@0O'7-//5YZ)'<#0X)'X"8CW,3#3=Z VU5?"CX(FQ!XH[05?X>#- T9I97&89$7 M\)4Z6_=ZM'>0L# M7"62),S9*;SV#*(#=36H-[Z'&.+9MW80VG@ZMJGS09W_ MS8<>]X7KC6@-2%R3:WR29P'HH6\,&ZLZK]5[94GY?EE3JT7M#.A^K>C-[C8N MP-B\%_\ 4$L#!!0 ( -%H9%1BDY:!H , .4) 9 >&PO=V]R:W-H M965T*I'B^\_%<.=LI_60JQBP\UT*: MN5=9N[WR?5-4K*;F4FV9Q#]KI6MJ<:DWOMEJ1LM6J!8^"8+4KRF7WF+6[MWI MQ4PU5G#)[C28IJZI?EDQH79S+_3V&Q_YIK)NPU_,MG3#[IG]M+W3N/('E)+7 M3!JN)&BVGGO+\&J5N//M@<^<[+G&[MF M0C@@I/&UQ_0&E4[P>+Y'_ZV].][ED1IVK<077MIJ[DT]*-F:-L)^5+O?67^? MEF"AA&E'V'5G4^)!T1BKZEX8&=1<=E_ZW-OA2& :O"% >@'2\NX4M2S?44L7 M,ZUVH-UI1'.3]JJM-)+CTCGEWFK\RU'.+FZ599#"!;Q7JMQQ(8#*$FZDI7+# M'P6#I3',&CA[H+@RYS/?HE8GZQ>]AE6G@;RA(23P04E;&?A5EJS\-X"/= ?. M9,]Y1481W['B$J)P B0@X0A>--@@:O&B$1L8Z"XX ALV<9C&LM&Q2S#"PP3R21R[,2() MA"1 PQ>55$)M7B!#X#S)<8RG <19#@^#9M/)!_@SR4@_7ES @[(4$V:$"FJ9 MY%GJ/E&609+GO=#KD\I62-A65,+FX(TPGH1IYB8= DXF61Z<<, /.SC))GF: M'SL8=TB2_#\<',4QCB1)83K]WK]1ZEQ("'HY"O\S_Y+.OT&2 0E_VK_1)-[[ MUR$X_\;(9*0.)4,=2GZX#OUDQ1D%/EUQ8$4%E86[KE.(-9K5CWCAKDZ'>1]X M47(G@H@*=\XA^U7HS'3?O ,%"H1MJN"P^[PQMFV;7NP_'N ?2!Z@V7 M!@1;HVAPF:$7=/>HZ!96;=M&_J@L!G\[K? =QK0[@/_7"AM9OW *AI?=XA]0 M2P,$% @ T6AD5/MA7()N!@ ,A$ !D !X;"]W;W)K&ULQ5A=3^0X%OTK5FD>"BE-)3>X_MQ[K53IUMMOK<;*2U[K,JZ/9MM MK&U.%HLVW\A*M,>ZD37>K+6IA,6M>5BTC9&B<$I5N>"^GRPJH>K9^:E[=F/. M3W5G2U7+&\/:KJJ$>;J4I=Z>S8+9[L&M>MA8>K X/VW$@[R3]EMS8W"W&%$* M5> .1N7),7I?(?^J_,=OJQ$*Z]T^8B*^VMWOY# M#O[$A)?KLG57MNUE4PCG76MU-2C#@DK5_2@>ASA,%#+_#04^*'!G=[^0L_*C ML.+\U.@M,R0--)HX5YTVC%,U)>7.&KQ5T+/G7[65+&4?V'6=ZTJR>_$H6S:_ M%ZM2MD>G"XLU2'*1#WB7/1Y_ R_@[#==VTW+/M6%+%X"+&#<:"'?67C)]R)^ ME/DQ"P./<9\'>_#"T>/0X85[/&Y9[^ >N&B$BQQ<] ;<':/6D;D:'G)V[4-'%QR58LOEUS>Q&=RU6;X_8M^.[8_9[(XV@PFC9+RS*O""* M:1)X89S2Q/=\/-F9.I&.TH0%@8\Q>N6PZN^LHY #36"& XV2 32&.7NB'H]1 MCP^.^I6N&EW+VK:3'"#J[-,C6ES$"^E&N)20*-N<\8D=L'OH9AC3(V+VVHH1@YF5) MYA1Y2&/B<0#M$O6\0!"%N').:5U.D8.4@!-4J84,)#)A"Y]"J>('JNQS2,PN^56 M?6&XKM0Z<8+,D5.%:@J\. Q8@OP@WU'$[C;"R ^T!Q8,H%1(3IV(O M11(Q@6:ZQ.1J*E6J"DNA4T#YAR3>R*HI]9.$JQ\^L"@):1A*Y84A% MJA^<*>ZTT@AK!G)1O(>$26%JB+4L@S*RF[+/UU_NKQV8SQ"[W^U&&A9GC--K M_JY*2<=*20^NE+&4J4(NVE8BZD2*+TJL4"56(6R'%-?]KD;RJC]$LBJMP M9IVPBQ(G28'L.RX5NEO9=5?B?)?KCC8!=)Z(+DMVD>>F(Y[M,I]D*4N6R=M, M3B.?I6$\:JYTW9$BQ_Y%.^2GGK&&->+)Z+*G:>&LI,KS?1;R\$UJ4C\,_&C( MAI^I,XO5!_\;Y\SND) MNR&JJDF(LB5;3A30)JW!T1F3%J!+0(*0L/O&X,/ V"='$_EGIQI7%GWE!UZ* M?>>ZMJ)^<+4WV)1X(?:LQ O0Q&ZG-;*=U%"0<>PENRC!.R3L+0>PC0;8Q98> M[9-?T=R*MP1_09?REAGMIIBF'D]B=K2GBK*QBK*#J^A;C3:B'VKUUU!)P\&C M9;?$%;3MK3#%@86T=]DW"NE5^5R*TI$$IG53TR@VJYUIPB*ZN:Q6"'9_S':' M@!B'BMN^>1)UBTY2FRQ%TSH\T32ERIT?M'%TUCUU+7XX)\Y#:IW_"?&R)*#4 M&(4Z?D)OQ.'R)PI@CBVE8Q?1A "()J*#IZ9/+DAR410#9%_6^G7Q39H]B(5O MJ_YH0^O"Y^2]P>*T/:UWC+7U_M/VO'I^(/ 1?\=_"S>_YKPFS /"HZ4<@U5_SC%H=[T M7^C]C=6-^RI>:8MO;#?=2(&S!PG@_5KC.W&XH07>G._P902P,$% @ MT6AD5(4?(+BW @ ) 8 !D !X;"]W;W)K&UL ME57!;MLP#/T5PN@A!;S:EA,G#9( 3;MA!=HA:+OM,.R@V$QLU)8\26[:??TH MV?6RH0FVBT5*Y.,C)=*SG52/.D*M*!'R8H*A2ZD (6;N7<139Z$EA"6FQB)P6I[P$LO2 A&-'QVFUX>TCOOR*_H'ESOELN8: M+V7YMPZ30PZL+"+/IT%AH)8TR#M )!;6M.-4U3W'N4:]I5$_H+5P! M[">$P;4 D\M&RWW+3J,(4Q(6T&RFV[XRM MR']&ULE5?;;N,V$/V5@=$"":#( MNE\"QX"3[+9YV#1(MED411\8:VP3D427I.WX[SND9-G9)(K[(DHDY_#,S)DQ M/=H(^:P6B!I>JK)6%X.%ULOSX5!-%U@QY8HEUK0R$[)BFC[E?*B6$EEAC:IR M&'A>,JP8KP?CD9V[D^.16.F2UW@G0:VJBLGM)99BSY?:#,Q'(^6 M;(X/J/]IV6\W/'+I[L?D=6W]B@S<5I;)/V+1[O0%,5TJ+JC4F!A6OFY&]M'$XQB!H M#0++NSG(LKQFFHU'4FQ FMV$9EZLJ]::R/':).5!2UKE9*?'MT(CY' &#PLF M\Q&NX/?@A9WWH<4+>[Q7T#C8 Q=U<)&%BSZ M>Z"2*58E@IB]BN<=VY*.-4PV3!8./&@Q?88_EB:\RH%'5JZ:4$\4U48S#7]; M5O =7S11FQBH,W20P8^1Z/HWW7#V?S20B\%HCD=,@S6F>F_OVD#"VAX39X2$E MGUE"H@W2":]ABTRJ4T@-;NJ&.3VB!'JR&7?9C/NS^5X&)85BCN;=@8GI*,;) MXW+5>]H'N;I=54\HC4Z<^O +!+$;^O";T0]1\SW?\7(S'T5NGG0N M%'#B^XF3QB&/$-N4$^RR(G" MP)J&F5',)P1]B-+422+/&'ANED'LYBE])$Y(![2L;$K?M0ZBW(G(BMP+W3P' MDGA@?'(R+^X37M()+SE:>*]:\8'ZX&G;UV*ZYF)#KZC(X XE%[3T1BAV"UP; M%7QE7#8"<-XH@C2XSQ<%%QZI:.GU -K,[B&,Q<][CBR5WO@F<^U:RKS5*LDP<./8C)F;&'7XODGV/BP? .!>U/Q5#>T$;:K" MR7TCF*(F9,GS9A1=?4H,.T4F![]0W8KZO9\J[?_V_5Z M#_H@E1]VFU<+QPG9"*]E_GG?!6X>["1]=D8S]#CH M0XWY:0?P:1OZ"?F]Q T/KG85RKF]P"J8BE6MFUM>-]O=D2?-U7"_O;E@?V-R M3C*#$F=DZKDI_2#)YM+:?&BQM!?%)Z'IVFE?%W3/1VDVT/I,T'6I_3 '=/\< MQO\!4$L#!!0 ( -%H9%3'[M.)A 4 #T/ 9 >&PO=V]R:W-H965T MLVY@<:%DR4H]FE[;M5LTM9 MFUR4_%:!KHN"J:=KGLO-U<@=;3ONQ&IMJ&,ZNZS8BM]S\[6Z5=B:=B@+4?!2 M"UF"XLNKT6OWXCJA\7; -\$WNO<.%,E+^X&CGD$,]Y9@B!X>.!W_ \ M)R!TXV>+.>JF),/^^Q;]G8T=8YDSS6]D_ETLS/IJE(Q@P9>LSLV=W/S%VWA" MPLMDKNTO;-JQS@BR6AM9M,;H02'*YLD>VW4XQL!K#3SK=S.1]?(-,VQVJ>0& M%(U&-'JQH5IK=$Z4E)1[H_"K0#LS^R0-!]>!<_C ,3@-IU_8/.?Z[')J$)X& M3;,6ZKJ!\@Y N1Y\E*59:WA;+OAB%V"*?G7.>5OGKKU!Q#<\FX#OCL%S/'< MS^^"]2V>/Q"LAB; ;B@@PLL7' SJ[8&&ZD-O"/184O_-' =2ZS'_^^M("# M>+3_+G3%,GXUP@VFN7K@HYF-G7X<_'%3^%QQQ8PH5Y W"3N!*$KIUW'P-TY< M>"=*5F:\'7 !K[7&W)!'@#OV;%CNV$FCIHT!#F0M[+(6_B9KN!R8MC9[ MURRWBW5O)?!]V>@\F'/5]GKO/7X%14BG[ M:1S:Y?&=!&YJI7B)F=PUWDEHD/H01"Y\DF5VQ/ $?4DP TV:AD9:)UR_>8;Q M45'N4_5=K4IA:L6!E0O@/VM1%>2AY0$2R3[= /=<4=5(-WC;#8F0;1&RL?MT M+Y=FPQ#*)#\0;+")97=0Y M,WRQNZ%.T:\X0%*?1DZ(CS^9B[A_ @GN-$OSN)?'>2Y6=@(-Q+3G M*:/]; X:^4$",4[1Y'/GXUXV$S=I'7+ANZUN%/0#$F#%L1Y3Q?]%!+OU3T4) M3YPI?7;Q7*>\2>* /XF2O:2#.T'_O0GN]F>S+(3.9(TQ(11_ =.?)"&\@F 2 M./C8P_4G2)A7^/ 3>#4@'%$G'-%189Y?Y;2_OIEVR T+)4L]O>UK2H)<2NTXALG MZ8#Q,X:!'X&_S?,1%D1@W_? \]*^MLFY08XU ?+';,U*I 2MP) *A1$N6AR! M&QT%=7@#(*42-P8W]8:J3MR1)SZJZOQ:11*&+6-;:GUHIW\:PT>&*HAO1Y)L M0EJ+>2:IM=_A@>4U)^8?FL!-V@JUE=>*!)S$FW04X8B'9TWX?15M M%!J!LSV[$ZNF)[9&#G DZ3B2_)8C4HWW,S&&VR8$,!+F'.ZPBN)-9C'&#.H, M%_1OE-P_)VFZ^WNAJ^;*]&OX&PO=V]R:W-H965T[0W3P//3*SJ.=<_OK.+;-#@=IK_0>%>ULM!FDHZG9 MQG9O4+8!-/2Q2)(B'F2GHL4LK-V9Q4P?7-\IO#-@#\,@S;1].X\2+PA[;)QGD/1YPEOL>T]$,OZ9.*-S2 ]\:9_8?P^Y4RYK:?%6 M]Y^[UNWF415!BQMYZ-V]/OZ)4SZYYVMT;\,(Q\DWB: Y6*>'"4P*ADZ-7_D\ MU>%G &("B*![#!14OI5.+F9&'\%X;V+S1D@UH$EPPBT5V\%[-1ZUK]FO#W+=H_UM%CN*Y1%Q,_$N1U[Q"B\7\%$KM[/P3K78 M_I<@)I%GI>*D="DN,K[%Y@I2SD D@E_@2\^9IX$OO9"YA3'!"W39F2X+=-DK M="MJE_;0(^@-W.,3J@/"QN@!WCT[-$KVZD2W<6(O. M,EA_@S]0;XW<[[J& #?491:^!(GP@,\.EKUN'K_^Z#0NBO.=?6WWLL%Y1*UK MT3QAM B%]$-" Z]/JJ_AD^HBM-6)KDWA(92XL:;J62 MK03!ZJ+T8RD@905=J ?M* 4/+EF=9P&<,E$&&D%KE1AKT(<:R%"#_\>N4E8* M0499LBRKO%&Q.BE.@3GGP%E5I!2\(,=36,)5:>K=:Y:2#ZUPEHMJ;.$E]]3S4N69\F4:B9\>,X35E0Y_.B& MQ2_:EN[%-CQ.%AI]4&[LX//J^?V[&=O^N_OX>'Z49MLI"SUN")ISL:J7C+,JK> MB!W+X9.UD!G5<"LW([63C":V49:.R'@\&664YX.;*_OL3MY+@>X,'AP5>^V6KS8'1SM:,;MF3Z^^Y.PMVH\I+PC.6*BQQ)MKX> MS/#;130V#:S%#\X>U-$U,JFLA/AI;CXDUX.QB8BE+-;&!85_]VS.TM1X@CA^ MWSL=5'V:AL?7!^_O;?*0S(HJ-A?IOWBBM]>#BP%*V)H6J?XJ'O[)]@E%QE\L M4F7_HH>][7B XD)ID>T;0P09S\O_]'$/Q%$#,FUI0/8-2-\&P;Y!T+=!N&\0 M6F3*5"P."ZKIS944#T@::_!F+BR8MC6DSW,S[DLMX5,.[?3-9Z$9PNA7M"P' M'HDU6O)-SM<\IKE&LS@61:YYOD%W(N4Q9PJ]6C!->:K0-_:H"YJ^OAII",4X M',7[;F_+;DE+MYB@3R+76X7>Y0E+3AV,(((C(F.#O MRP5Z]7R=)!]7H!=9YV.+\0QY+!JM0TQ3- MA=+*#-^7%8Q.;D:,PL-<2UA;0[1@:R8E2]"BD'8TF>0B:1JYLLO(=FEHX_X& M7X[-S]7H_AC#NETP;;!;--A-3NU.<@^KW$-O[G.ZXY W_P-R.J1I01BBS\S\ M$7E<0,:Y;DJR]#TY"7Y*ZDG6[<(HBEJ#CZK@H[\:_(=L1[DT@XH^"M4TXVZC M>O"X'GK=:A+41Z=N14AK>I,JO.BRN/"3PTN ^"$#T 1^8:O4H9L@D#B[Q[CM$@,%?Q#B.2!I^EK3XX7G3EV M6BQ\%B:]%$@#N'0!Q 9 NJ1(9 M0]_H(YJ##$'/B.8)4,%_89/3#@6IBU$#%^S-3FFZSG4-WHAG@)T*8[\,SZG: MHG>_%_R>IB:3(:+ &U3*)P/S#YH6S+.T]LYK1%W/LFX8C3V4AYV48K^6NGGY MD<$FNM=ZP@T2ZD/322/V:R,0$U/*]@OB<0^1;9C9KIA?)?+&6.HJAB,/,$[' M<(>0I91G9[$,T2?87F5%AF:;C60;"COH!4L*J&" 7QO#JVM50!I'N%O\3A-Q MJH;]LK9DJ5$!54B:QPQ(0#%Y#ZG,V[=(>X_'JR4<3QJ";K##%^TQ.P7#?@F# MG4,&I2&, : _0[]]8H;#_N/9-V.G'-@O'4LMXI_ QW8;@DHMA,W*6HILOV.A MMBX%PGQ'I=E-*SL'E]MR!Y.9J@B]XCDJ-_.OT?]0:XEPB^O2@LD47T3G4-;M M)A%8GO-8@[L)(2T<39Q0$;]0S9^,1LRTIH#- 6Y(["N+S=PWM1]<,BC4H8S@ M$DIWM'I">LLL9#1_ZC-&Q&D6\6O6G10Q8XDJ1\5-WB73.K5ES_!(46?F! &V ME2T%'ZY7(8%G91$G;,0O;#U NZ/\ %CZ9""SN4 K+="70BN>,/2#Y8F0O0!T MND3\NO2L -;%)PRG[?@Y[2$==5PK?CQ;%5+9.-$:L $6UO#XGN4%ZP64DQSB MEYQC8CR,6B,(=9V)@J =!*H-1KUG(Q+.B'.^3#MZG.4TXS=&R6,':X.98JD^&COS),]8-I%XX MG)4%>S@Z[4Z/>!PK!WW+A[D]#X1=4..Q3>^J(7 ,'/@9^+#1Z8%^X @SZ"#, M]K,/D%4H3?XHI;<\H4*O_LVH;#QB[.@G0$_0TGO,=G3.YF?2/YIKU0LJQXV!GQL/M#!$=ZDYC34]F3IC5W+W=\7618H^\C7SP>3O MHP=,CD<#/X\VP%0=_U1Q]X+(,6?0CSG_'D3^/GI Y-@U\+-K T2'@S$;>W6S M *%+18E8>;;;!S='LH&?9)\'-W\?V.+F"]=1=N"G[ ;8;@N>6HDTH5*/1!+'0\'/IY^%D0Z^ACVCG30D?>80=YT\>^Y!TZ\@Y?B+P[^HFZ@7#D M'7:0]QD0?XN\PZ/O)UZ O#OZP.-NG!Q[AQWL7&ULK55=;]HP%/TK5M2'5NJ:#P(I%2 !Z3X>.J&R;@_3'DQR(58= MF]FF=/WUNW9"1OE2)_4%;.>=0%@R'/)A>Y[A3'+&]_760$E MU5=R"0*OS*4JJ<&M6OAZJ8#FCE1R/PJ"CE]2)KQ!SYU-U* G5X8S 1-%]*HL MJ?HS B[7?2_T-@?W;%$8>^ />DNZ@"F8A^5$X&X4V: M6+P#?&>PUEMK8IW,I'RTFR]YWPML0< A,U:!XM\3C(%S*X1E_*XUO>:6EKB] MWJA_=-[1RXQJ&$O^@^6FZ'O7'LEA3E?)KEVOV1=8P./9"MM M9%F3L8*2B>J?/M.YX_,4#&5<7R#^89J2 M\[,+*&C\=GIP@)Z^F1YV3[AI-4^SY?3B(WICNF2& M-JVOP]J17'T&I0>4.H&UPWH ME96XL1*?M)(RA:UA\W)I\O,.RAFH7R=2:C?2[?=+J9+J;'D+V\E.2/N8*-G- M:!_3B@\GU&EL=$[:F&*SQ._RDGP" 8IR@M\4&>;8))A&3[:?_E=\27/?Y/WB M2_9?C;@;[^1W -1-@IT #X"ND]T(_:U.6():N(FBB>MA55-H3INA-72]>N=\ MA,.LFCW_9*I)>$?5@@E-.,Q1,KA*L"1539=J8^32]=N9--B]W;+ @0S* O#Z M7&+/K3?V!LV('_P%4$L#!!0 ( -%H9%0UI3M(O ( *L' 9 >&PO M=V]R:W-H965TI8G%.\!/!CM],";6R4K*9SOYEH^]P H"#IFQ$2B^7F .G-M M*.-7$]-K?VF)A^-]]"_..WI940USR9]8;LJQ=^.1' JZY>9![KY"XV=HXV62 M:_"3;:B.KAHP**B;J-WUM\G! "),3A*@A1,>$^ 1AT! &'R7$#2%V MF:FMN#RDU-#)2,D=41:-T>S )=.QT3X3=MN71N%7ACPS^2X-D)!-TEFM-#JA-(S(O12FU.2S MR"%_&\!'VZWW:.]]%KT;,87LB@S""Q(%4=@C:/YQ>M!#3S],#V_?<3-H=W+@ MXL4GXLTHMSO2E]B:.'1$6P=>,)FH^.70:P\FCM]BTA[,];#%O%$=MZKC?ZC. M\9JN#(%7K&2Z5WX=(3GX[>#F2'T7$B='XKN04]J'K?;AN]J?%#-P*8M"7Q"! M%1JOCH),OH#"6])G9-B1D!RE>-Z%7!_M5-J%A$'2[R1IG23_>W:2SI[?'FON M0CK'*^W!'!RO6K1_4,8J4&O7#C1Q-:6^U>UJVW&FKM >K<^P$]6-XV^8NHW= M4[5F0A,.!88,KJY1D:I;0STQ&ULC55=;]HP%/TK5]$>6FDT'X245H#$QZKMH1,JZ_9LDAMB MU;&9;4JW7S_;"5F@ ?4E\<]]7:8$E M43=BB]SLY$*61)NIW/AJ*Y%DCE0R/PJ"Q"\)Y=YDY-:6;N49N8W*ADMD2LJ.$C,Q]XTO%\, M+-X!?E+X$-"!FFVBH0\WK%.3)FA4P8OVM-K_FD);;' M!_4'Y]UX61.%<\%^T4P78V_H088YV3'])/9?L?;C DP%4^X)^QH;>)#NE!9E M3381E)17;_)6YZ%%"),SA*@F1*>$^ RA7Q/Z'R7$-2%VF:FLN#PLB":3D11[ MD!9MU.S )=.QC7W*;=E76II=:GAZ\EUHA!!ZL*KJ#B*'%=UPFM.4< W3-!4[ MKBG?P%(PFE)4%EP0B3V;[PSFHC1G4!%7QFEIT0J>,!5&Y*_9IQP>*"<\I83! M2A.-YM08R-4"-:%,71N]Y]4"KCY=PR>+_E&(G2(\4R-?&X8WD __ Q1$(4= 2XDJ0+4*F+8+B&]VC%VIKZ0'3MIVD]=)$O5'_FL[ M&QV887",6;S'A%$4-Z C8W%C++YHK#IW]O!*9.:(V6-G?"%H\@9KY)A3W>6I M4DU:L?3N;*:/3'6 DMLD/K'5@8J"8=CM:]#X&EPNF&G\5W7\UX?B@!; S49E ML]%=[W @ L D !D M !X;"]W;W)K&ULM59=3]LP%/TK5Q$/( 'Y:M,6 MM96@'1H23!4%]C#MP4UO6@O'[FRG!6D_?G820J ?JZ;N);&3K' MQ4B:GEM5F=(4N:*"@\2DYUSZ%P,_)^2()XHK56N#M3(1XMEV;J8]Q[.*D&&L M;0EB;DL<(&.VDM'QJRSJ5&-:8KW]5OTZ-V_,3(C"@6#?Z53/>T[;@2DF)&/Z M7JR^8FFH:>O%@JG\"JL2ZSD09TJ+M"0;!2GEQ9V\E$'4"'YC"R$H"<&^A+ D MA+G10EEN:T@TZ7>E6(&T:%/--O)LQ#:^(^)E*\V*Y+: MU&PX3/#9F4:9FL4UT9M\%H6;>6'[U2W[01194%0:>Q172C$MW8*?I]\9W" M/<:9E#;Q'W>83E#^W#&7S6J YLX!BE5\6LMD4P+--6]1Z$6? E@'-3V_N=E_ M5,F+=LJ[$QQ?X8[(9_.7O\[,UU.9A]_PS^FTJN%;!TBGM4\ZZZ#MZ;0K>>V] M5\<-7V16ZBTND9F_W"%BZE0Z.@>(J;-/3.N@[3'YWON/WSM$4/]IM?FU#;N)#>@-D3IUK93>Y8QYF>4*V"8&)IWWC)\61P/BHX6BWR'G0AM]NN\ M.3='*I068-XGPNRR9<=NVM4AK?\'4$L#!!0 ( -%H9%0.3[U; 04 "<7 M 9 >&PO=V]R:W-H965TY=-1: M,AH:HSARB.OVG)CRI#,>F;%'.1Z)C8YXPAXE4ILXIO*?>Q:)W6T'=_8#G_AR MI=,!9SQ:TR6;,?VT?I3PYA1>0AZS1'&1(,D6MYT[?#,E?FI@$%\XVZG*,TJI MS(5X3E\^A+<=-YT1BUB@4Q<4_K9LPJ(H]03S^#MWVBEBIH;5Y[WWWPQY(#.G MBDU$])6'>G7;&710R!9T$^E/8O<[RPF9"08B4N87[7*LVT'!1FD1Y\8P@Y@G MV3_]EB>B8H![#08D-R!U Z_!H)L;=,\U\'(#SV0FHV+R,*6:CD=2[)!,T> M M?3#)--9 GR?INL^TA*\<[/3XH] ,8?0>S;*%1V*!9GR9\ 4/:*+171"(3:)Y MLD2/(N(!9PK 'V%#?D@"$3/TR"2:K:AD:"+B]493LYR74Z8IC]05@)]F4W1Y M<84ND(-4BE2()^@IX5J]JPQ\7HF-HDD(@Q<'[R-' ]%TNDZ0D[K/2)$&4IB@ M!Y'HE4*_)B$+#QTXD*$B362?IGO2ZG'*@FO4Q>\0<0FV3&AROKEK,9^>;8Z' M+6RZQ:)WC;]NTZ)O8B:I%A+!P8$26$R>+>8:%M.L""P;5!,/;EJB>44TST3S MFJ(5_FTKF=GZQC8]I+;C;M_K]4;.MII>&XKTW$/4U((BGEOZ.IB^7TS?;TW6 ME"4""N_%Z>H5\7JMZ?IJCBH6(KJ%15HR!*%B**F\4N#L5AK*(JW(GW\:$(Q_ MR6*C2[X'7=D2G47M59)#?(^06J)M*-RO)]J"\@;NT)[H?D&\?^8^J23VF&(H MHHA*56*L;+-0_-:6LJ&.MY0%U;REL%O*F]M*O5Z]>581HS(!OLJRU6CX%^@N8';UM.7Y M.I&5?$:'A'M>C?#$#AO63KZI'>8W[$!5*7LXW;=KQ0D MU1EU.H\,Z^IQW4:Q9UOXNJ!-K##B=NLT+3!"AOT&GJ7*X_ZK]%.X5%L\>!/Y MR\.>TC\K[%@ ;; 6!2RU'[>+_P]MJ_)8)_HJ.ZK>6%E1#;I&2L$G[JOT5J14 M4G*VDGYGX>8!3A6N%790TY*/L.TMYWO$$SG<_H5#-MAQTUTW984S--RF:&M#V M=G/N^V:YQH29NMJ@I)U8Z819FNJ5;S8:692!$N&'0=#Q$\:E-QID:S,]&JC4 M"BYQIL&D2<+T\P2%V@Z]AO>R<,M7:^L6_-%@PU8X1WN_F6F:^865B"S %XY;JNU'W.MI.WM+)4SV M#]O\;#?P8)D:JY(]F!@D7.9?MMO'X0#0:!T!A'M ^%9 _DBYX5EL3R[0,BX, MW.'.IDR'=9?[CU,<@_A$0^?F*Q#T*I!&(2-$OBT&GZ! MRSHT&V5PG[06@L-"<)C9:QVQ-V//5(36@%6Y9HTP20V=,@9-#3YH94P9S=QL M.S/K[L;3J!EDOX'_5,*G6?!I5O*94P5SN2+'*%$S 4Q&,(XHU=Q8S5R1P_L= M75IB!]]N,%F@_EX1AU;AMU7I]T4S3%6RX)*YQ-=^J8);%,QB1 >,+8U(ZU5$ M&HW^T8"T"V+MWR3(12FIP)2G_;]#=*98/+NFBQ.1?\ODBB\$PICR:VMP;S!.!9&, M$4Z^(M.E+:W:11N>"6C*JM$_:,7N&;QA>L6E 8$QF0KJ7=*K\Z ]F-%'7H_<0V_>-]'/P%02P,$% @ T6AD5#C^X,XI M P 8PH !D !X;"]W;W)K&ULG5;;3N,P$/T5 M*]H'D*"Y]X+:2M#"+JL%(:X/JWUPFVECX=C!=BA(^_%KIR$MRF4C7A([F3-G MYMB>\7C#Q;., 11Z2RB3$RM6*CVQ;;F,(<&RQU-@^L^*BP0K/15K6Z8"<)2# M$FI[CM.W$TR8-1WGWV[$=,PS10F#&X%DEB18O)\!Y9N)Y5H?'V[).E;F@ST= MIW@-=Z >TANA9W;I)2(),$DX0P)6$^O4/3EW?0/(+1X);.3>&)E4%IP_F\EE M-+$<$Q%06"KC NO7*\R 4N-)Q_%2.+5*3@/<'W]XO\B3U\DLL(09IT\D4O'$ M&EHH@A7.J+KEFQ]0)!0:?TM.9?Y$F\+6L= RDXHG!5A'D!"V?>.W0H@]@!LT M +P"X'4%^ 7 [PH("D#0%1 6@#QU>YM[+MP<*SP="[Y!PEAK;V:0JY^CM5Z$ MF8URIX3^2S1.3:^Y N2A8W2Z?,F()/GJ':,+3 1ZQ#0#Q%?H5$I0$F$6H5\$ M+PC59B#1P1P4)E0>:L##W1P=?#M$WQ!AZ#[FF=36+R& M>.:P["'?/4*>X[DU\%D[_"=F/>0$C?!Y=W:G!G[>&>Z./L-MO2[EXGCEXGBY MOZ#!WW?.HPVAM$[&+3+,D:8:O$[[;M\-QO;K?KI5JW#@A>%GJ_,ZJY&_L_H4 MO%\&[[<&?X/U)F'JBK-LI M024K=QC4YQ26I&%[3D)7:*'>\Z, ^L"DNF:J.O*MG_X^N5//W2^Y^U_=#+-^ MA2WP@P:^0AA23[LM+IT5V[JJ(<5 M:J]IB4[_V1_#\N8<_U9W/]NL)B39A$%%8:Y?0&&BZV M-YKM1/$T;]D+KO2"Y\-8WP)!& /]?\5UVRXFYA90WBNG_P!02P,$% @ MT6AD5(]80W - @ "P0 !D !X;"]W;W)K&UL M?5-=;]LP#/PKA-&'%DCCQ%F[M7 ,- FBV(%G7AV$/BL/80O7A272<_?M) MLFMXP-H76Y1X=SQ*3!MMGFV)2'"60MEY5!)5]W%L\Q(ELV-=H7(G1VTD(Q>: M(K:5078(("GB9#*YC27C*LK2L+")7QN^.,^HE/7"X?F'_&+P[+WMF<:G%$S]0 M.8\^1'# (ZL%;77S"3L_-YXOU\*&+S1M[JU+SFM+6G9@5X'DJOVS<]>' 2"9 MO@)(.D 2ZFZ%0I4K1BQ+C6[ ^&S'YA?!:D"[XKCRE[(CXTZYPU'V51/"#*YA MJ149UR,+3YQ*6 9I-!:F<+E"8EQ8^(YGJIFX@@O@"M9<"-=8F\;D"O%T<=Z) M+EK1Y!71%>9CF$U'D$R2Z>-N!9<75_^RQ,Y&[R7IO22!]MTKM%^T*JX)C>S- MN&8.O,#/-I:T7_ZU(K<11?X%]3/?_874$L#!!0 ( -%H9%2Z MM*5NK0( !L* 9 >&PO=V]R:W-H965TE&63#U<8"%7/2_T'E^, M^'1F[ L_B>=LBF,TU_.AHIE?9\EXB4)S*4!AWO/.P[.+T EBL)F(XU>5U*MK6N'V^#'[)]<\-3-A&ONR MN.&9F?6\K@<9YFQ1F)%E,\DT: MA 8<0U\*HVB/--QP,X.^*XU*0P0' S2,%QJN<&T6K#BD\*]23(\-JK(6$OB6 M#FXOL9R@NHM]0YBVF)]62!<;I.@%I &F)] (CR *HO!Z/("##X=_9_&IR;K3 MJ.XTK[F^.[,;&1T'(7UW[&.S9FW^-U82Z-2LG??CC=TH>[W1K7OJOKXWND^]$>[P MQFG-=OK&WFCN]488_#EJ@O?CCCTL>^T1;IV@X>L;I*JQ[9!6M_/4(/[646^O M39=,3;G04&!.PN"D0QG4YB:RF1@Y=Z?_1!HZF-UP1K&ULI59=;]HP%/TK5K2'5FJ;Q$D(J0"IA57;0RM4VO5A MVH-)+L1J8C/;0"?MQ\]QTA1"0(R^@#_.N3[WV,YU;\W%JTP!%'K+,R;[5JK4 MXMJV99Q"3N057P#3,S,N0RSXGX*3S5!4#]J"W('.8@'I>C(7NV764A.; ).4, M"9CUK1OW>N0:@D'\H+"6&VU4I#+E_+7H?$_ZEE,H@@QB580@^F\%0\BR(I+6 M\;L*:M5K%L3-]GOT.Y.\3F9*) QY]D(3E?:MKH42F)%EIA[Y^AM4"05%O)AG MTORB=85U+!0OI>)Y1=8*IZ,T-F7<_0% M48:>4KZ4A"6R9RNMLEC+CBM%MZ4BO$>1B]&]UI)*])4ED&P'L'5Z=8[X/<=; M?##B".(KY+D7"#O8;1$T/)[NM-!'1]/=Z$ V7KUCGHGG[XE7>=]F;$D,#+&X M\*N!ZX=1X/?LU6:Z+3#/PV&X#1NUP' 8=7$-VY+OU_+]@_*?!&%R!D) @O@* M!'K2GQ'T\Q[R*8A?Z"^:+*R M]YQ.T'!R%X0CIWD06R)AO]ON8K<6WOVC8CA'6T>T1YPR9;[YS8M&ULE5;?;^,V#/Y7A. >6J"M?R5. MVO'R4[3FH[V?:26!1)?1])B9SM MI?JN4P!#WO),Z/D@-:;XZ'F:I9!3?2<+$+BSD2JG!I=JZ^E" 4V<49YYH>_' M7DZY&"QF3O:L%C-9FHP+>%9$EWE.U8][R.1^/@@&!\$+WZ;&"KS%K*!;> 7S MM7A6N/(:+PG/06@N!5&PF0^6P<=5X RY/YGJ F-K#\F,^U^R;[6]0>$E=K(O#9&!#D7U3]]JP-Q8A#$9PS"VB!L M&PS/&$2U0>2(5L@[(>+C;-&-ES8-+X:A;L<[[5WBR :AY.9 MMSO%WJ!'B VQ *4@0X@Y$"7WP*@_QR<&WP3@,HA:^/K71 M:#+J!SAJ (XN GRI<-D0RJW@?R-4DU)#]E1C^;&LQ,JQ=9BTB!#46<.6"\'% MEL@-^0%4D00WC"1,YD4&[L[@C@:UXZP_-:,^4G$4M+CWJ<7^Y$QRXH9[?)'[ MHV#X^FN\G#5N+G:2LYH0RS@(1**E)(U99?NU<,'RJAZZ2C"]J];'VLQ]U,14$[ MG3U*@7\FF9.&\^0BYU5*Q18:PF5>9M1V2<*H8>EM61":_(GO+;9A)$$5US;/ M&_LJ,V=JZYW 6X$]%AFSPQN.'YHGH%P+Z&,\Z9")PKA%N*MS&P[[^4X;OM/_ M5[RJ>Y.1D$F!%*"X3+"Y8LNA2<(M$YI9L>MM@@&1ZXQO'46-UQK%<+P,?:2G M'4+3:8MS5^6T$-YQ#OQCQ_8OLOZ,?!3V3:Q*<6BZY/@_KC04H*3F2"X M7$>'Q-/*^>DC*-WIK#Z]4NCMRT&GEW3"TZ/3C8]W,MS@G+!U,Y\F[B96;;N1 M-G/ETDU3+?F]G3?=T'1T4PVK3U3A*ZY)!AMTZ=^-$9&JYK]J863A1JBU-#BL MN,\49V905@'W-Q+'J'IA#VBF\,4_4$L#!!0 ( -%H9%3D4EU%(@( $X$ M 9 >&PO=V]R:W-H965T(22"Q MIDF!;2B-!'1H?.A6T<$^N^FUL7#L8%^:]M]S=D+5284OB<^^>_?>Y3E9:^R+ M*Q$)MI72;AR51/5U'+NBQ$JX@:E1\\G*V$H0AW8=N]JB6(:B2L7I<'@55T+J M*,_"WLSFF6E(28TS"ZZI*F%WMZA,.XZ2Z'WC4:Y+\AMQGM5BC7.DIWIF.8KW M*$M9H7;2:+"X&D'A&>)K3M8@U>R,.;%!P_+<33TA%!A01Y!\&N# M=ZB4!V(:KSUFM&_I"P_7[^CW03MK60B'=T;]DTLJQ]'W"):X$HVB1]/^PE[/ MI<W450=$X,E5?S PJJ;NWV/9S."A(DP\*TKX@#;R[1H'E1)#( M,VM:L#Z;T?PB2 W53$YJ_U'F9/E40[C6D ?;B ]B>^AR+QDJ2Z'B&5+(#X9%M*M4.6 A:GIY8 M*(1[(2T\"]7@.=Q4IM%T3$G7\D=HZ9V]R9/!*(LW1WB.]CQ'G_*\,XY@BDQM M>3#G<_C3:K2NE#7,T!:\Q;?A&*7/T9/+03+\[N 3!T)UB?P^,R&/;]W%0/^ZJT@DN<:C!EGC/].D:A5H.@ M$[Q-W/+%TKJ)<-@OV +OT#X44TU1V+!D/$=IN)*@<3X(1IVS)';Y/N$'QY59 M&X-3,E/JT067V2!HNPVAP-0Z!D:O9YR@$(Z(MO%4OP&4R6,?\*JRCV- TA+8U5>@VD'.9?5 MF[W4?5@#=$YV *(:$&T">CL W1K0_2R@5P-ZOC.5%-^'A%DV[&NU NVRB$N@8,OA_ %N(3[I2H-84P_M+0?QQJF=>UQ53O:4;L3P;62=FG@ M7&:8O2<(24BC)GI3,X[V,B:8'D.WTX*H'76V;&CR>7A["SSY-+SS;8^:;G,V M7<_7V\%WF1>,:W<,+;A2=<5,TWELT03+&E#/G-RV@2&!E/?3!CW*E+?]3K]TH66B5 ME6D5[NQM_*$O\6E[L[T?DT[BS:1D"U.OO=GD<.V:YZ@7WBX-I*J4MKHCS6SC MR"-O1!OS8W+JREC_T50V?\WT@DL# N=$V3YVQJ@KZZP"JPIO)C-ER9K\<$E_ M&]0N@=;GB@RE#ER!YO\U_ M02P,$% @ T6AD5 0Q)=6 P $ P !D M !X;"]W;W)K&ULK9=1CYLX$,>_BH7ZT$J]!9L0 M0I5$NDVZNDK;:M5.5MCBC>NJ^,M9%S?R )RO+.6*N,&IVKCZD(!3RJG+'69 MYXW=C(O_HM]5XE',(]>PD.D7D9CMS)DX M)($U+U/S4>[_@D908./%,M75+]DWMIY#XE(;F37.2)")O+[RIR81'0J$;D]C6NC,*[ OW,_(,T M0 +R!WE0N#64^4%XGI"WWTM1X,LR>&-5OV BU^=L7B[!<)'J5VC]:;4D+U^\ M(B^(R,G?6UEJM-53UR"K?:(;-URW-1<[P[6$^(;X]#5A'J,][HO+W;UC=Q9 M-SF![['RHC#JAQ^U\*-!^ ]8NHK>;/>!CIXA4.9'] 2TQXJ&;-P/&K2@P2#H M7:ER84H%%>6=>+)C3?YY#]DCJ*\#FV[@QFG3>[1%J MV**&@Z@+F16E =6I"A)Z#/RSR0B:E&C0=257)L] M;S9%.UG"#C^8-?4"D2_:)M0[U'#OROEI AYI#R?L](3WFGF3L#]'M//1H8/ MMZ5($Y%O*N!V\B[#@[\#RWY9@@[5FUZ[?#I1ZK,*!GRC<]U&_Z M7P4<&Y.M3)/?3\FAS-+A.OL_4O*\C ;>Z9GJ,6(^.Y.00ZFEP[7VWD)>(O]0 M6NFU:VL3\/A;'9S*'S:J8=U.NV9[Y?=<;42N20IK]/)N0G17=?M93XPLJ@[N M41KL!ZOA%EMV4-8 [Z\E=G'-Q#:%[9^ ^;]02P,$% @ T6AD5/.AT(S] M @ NPD !D !X;"]W;W)K&ULM59K3]LP%/TK M5K0/(!7R[ NUE?J #0DV1&'3-.V#V]PV%H[=V2XM^_6SG304DG1,&E\:/^XY M/L>N?6]OP\6#3 4VJ:4R;Z3*+4Z6;ON,[NX%;LDR4&7 ' MO15>PA34_>I&Z)Y;L,0D!28)9TC HN\,_;.)[QF C?A*8"/WVLA8F7'^8#J7 M<=_QC"*@,%>& NO/(XR!4L.D=?S*29UB30/<;^_8+ZQY;6:&)8PY_49BE?2= MCH-B6. U5;=\\PER0TW#-^=4VE^TR6);.GB^EHJG.5@K2 G+OGB;;\0>P&_5 M ((<$+P&1#6 , >$;P5$.2"R.Y-9L?LPP0H/>H)OD##1FLTT[&9:M+9/F#GW MJ1)ZEFB<&GSF"E +G:"/G,<;0BG"+$:73&&V)#,*:"@E*(F.)J PH1+=P5:M M,3W6D/OI!!U]..ZY2@LQ=.X\7W24+1K4+.H'Z)HSE4ATSF*(7Q*XVD%A(]C9 M& 4'&2

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end XML 90 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 218 516 1 false 72 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://nrchealth.com/20211231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Income Sheet http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income Consolidated Statements of Income Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Income Sheet http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals) Sheet http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals Consolidated Statements of Shareholders' Equity (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Consolidated Statements of Cash Flows Sheet http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Summary of Significant Accounting Policies Sheet http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies Note 1 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Acquisition Sheet http://nrchealth.com/20211231/role/statement-note-2-acquisition Note 2 - Acquisition Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Contracts With Customers Sheet http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers Note 3 - Contracts With Customers Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Equity Investments Sheet http://nrchealth.com/20211231/role/statement-note-4-equity-investments Note 4 - Equity Investments Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Property and Equipment Sheet http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment Note 5 - Property and Equipment Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Goodwill and Intangible Assets Sheet http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets Note 6 - Goodwill and Intangible Assets Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Income Taxes Sheet http://nrchealth.com/20211231/role/statement-note-7-income-taxes Note 7 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Notes Payable Notes http://nrchealth.com/20211231/role/statement-note-8-notes-payable Note 8 - Notes Payable Notes 16 false false R17.htm 016 - Disclosure - Note 9 - Share-based Compensation Sheet http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation Note 9 - Share-based Compensation Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Leases Sheet http://nrchealth.com/20211231/role/statement-note-10-leases Note 10 - Leases Notes 18 false false R19.htm 018 - Disclosure - Note 11 - Related Party Sheet http://nrchealth.com/20211231/role/statement-note-11-related-party Note 11 - Related Party Notes 19 false false R20.htm 019 - Disclosure - Note 12 - Associate Benefits Sheet http://nrchealth.com/20211231/role/statement-note-12-associate-benefits Note 12 - Associate Benefits Notes 20 false false R21.htm 020 - Disclosure - Note 13 - Segment Information Sheet http://nrchealth.com/20211231/role/statement-note-13-segment-information Note 13 - Segment Information Notes 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies 22 false false R23.htm 022 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables Note 1 - Summary of Significant Accounting Policies (Tables) Tables http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies 23 false false R24.htm 023 - Disclosure - Note 2 - Acquisition (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables Note 2 - Acquisition (Tables) Tables http://nrchealth.com/20211231/role/statement-note-2-acquisition 24 false false R25.htm 024 - Disclosure - Note 3 - Contracts With Customers (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables Note 3 - Contracts With Customers (Tables) Tables http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers 25 false false R26.htm 025 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables Note 5 - Property and Equipment (Tables) Tables http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment 26 false false R27.htm 026 - Disclosure - Note 6 - Goodwill and Intangible Assets (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables Note 6 - Goodwill and Intangible Assets (Tables) Tables http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets 27 false false R28.htm 027 - Disclosure - Note 7 - Income Taxes (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables Note 7 - Income Taxes (Tables) Tables http://nrchealth.com/20211231/role/statement-note-7-income-taxes 28 false false R29.htm 028 - Disclosure - Note 8 - Notes Payable (Tables) Notes http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables Note 8 - Notes Payable (Tables) Tables http://nrchealth.com/20211231/role/statement-note-8-notes-payable 29 false false R30.htm 029 - Disclosure - Note 9 - Share-based Compensation (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables Note 9 - Share-based Compensation (Tables) Tables http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation 30 false false R31.htm 030 - Disclosure - Note 10 - Leases (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-10-leases-tables Note 10 - Leases (Tables) Tables http://nrchealth.com/20211231/role/statement-note-10-leases 31 false false R32.htm 031 - Disclosure - Note 13 - Segment Information (Tables) Sheet http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables Note 13 - Segment Information (Tables) Tables http://nrchealth.com/20211231/role/statement-note-13-segment-information 32 false false R33.htm 032 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual Note 1 - Summary of Significant Accounting Policies (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables 33 false false R34.htm 033 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Sheet http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Details 34 false false R35.htm 034 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Sheet http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Details 35 false false R36.htm 035 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) Sheet http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) Details 36 false false R37.htm 036 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) Sheet http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) Details 37 false false R38.htm 037 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) Sheet http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) Details 38 false false R39.htm 038 - Disclosure - Note 2 - Acquisition (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual Note 2 - Acquisition (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables 39 false false R40.htm 039 - Disclosure - Note 2 - Acquisition - Fair Value of Assets and Liabilities (Details) Sheet http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details Note 2 - Acquisition - Fair Value of Assets and Liabilities (Details) Details 40 false false R41.htm 040 - Disclosure - Note 3 - Contracts With Customers 1 (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual Note 3 - Contracts With Customers 1 (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables 41 false false R42.htm 041 - Disclosure - Note 3 - Contracts With Customers 2 (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual Note 3 - Contracts With Customers 2 (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables 42 false false R43.htm 042 - Disclosure - Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) Sheet http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) Details 43 false false R44.htm 043 - Disclosure - Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Sheet http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Details 44 false false R45.htm 044 - Disclosure - Note 4 - Equity Investments (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-4-equity-investments-details-textual Note 4 - Equity Investments (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-4-equity-investments 45 false false R46.htm 045 - Disclosure - Note 5 - Property and Equipment (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual Note 5 - Property and Equipment (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables 46 false false R47.htm 046 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Details 47 false false R48.htm 047 - Disclosure - Note 6 - Goodwill and Intangible Assets (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual Note 6 - Goodwill and Intangible Assets (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables 48 false false R49.htm 048 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Sheet http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Details 49 false false R50.htm 049 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) Sheet http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) Details 50 false false R51.htm 050 - Disclosure - Note 7 - Income Taxes (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual Note 7 - Income Taxes (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables 51 false false R52.htm 051 - Disclosure - Note 7 - Income Taxes - Income Before Income Taxes (Details) Sheet http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details Note 7 - Income Taxes - Income Before Income Taxes (Details) Details 52 false false R53.htm 052 - Disclosure - Note 7 - Income Taxes - Income Tax Expense (Details) Sheet http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details Note 7 - Income Taxes - Income Tax Expense (Details) Details 53 false false R54.htm 053 - Disclosure - Note 7 - Income Taxes - Income Tax Reconciliation (Details) Sheet http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details Note 7 - Income Taxes - Income Tax Reconciliation (Details) Details 54 false false R55.htm 054 - Disclosure - Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 55 false false R56.htm 055 - Disclosure - Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) Sheet http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) Details 56 false false R57.htm 056 - Disclosure - Note 8 - Notes Payable (Details Textual) Notes http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual Note 8 - Notes Payable (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables 57 false false R58.htm 057 - Disclosure - Note 8 - Notes Payable - Summary of Notes Payable (Details) Notes http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details Note 8 - Notes Payable - Summary of Notes Payable (Details) Details 58 false false R59.htm 058 - Disclosure - Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details) Notes http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details) Details 59 false false R60.htm 059 - Disclosure - Note 9 - Share-based Compensation (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual Note 9 - Share-based Compensation (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables 60 false false R61.htm 060 - Disclosure - Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Sheet http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Details 61 false false R62.htm 061 - Disclosure - Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Sheet http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Details 62 false false R63.htm 062 - Disclosure - Note 9 - Share-based compensation - Stock Option Activity (Details) Sheet http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details Note 9 - Share-based compensation - Stock Option Activity (Details) Details 63 false false R64.htm 063 - Disclosure - Note 9 - Share-based Compensation - Non-vested Stock (Details) Sheet http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details Note 9 - Share-based Compensation - Non-vested Stock (Details) Details 64 false false R65.htm 064 - Disclosure - Note 10 - Leases (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual Note 10 - Leases (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-10-leases-tables 65 false false R66.htm 065 - Disclosure - Note 10 - Leases - Lease Expense (Details) Sheet http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details Note 10 - Leases - Lease Expense (Details) Details 66 false false R67.htm 066 - Disclosure - Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) Sheet http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) Details 67 false false R68.htm 067 - Disclosure - Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) Sheet http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) Details 68 false false R69.htm 068 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) Sheet http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) Details 69 false false R70.htm 069 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Sublease (Details) Sheet http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details Note 10 - Leases - Undiscounted Payments Under Sublease (Details) Details 70 false false R71.htm 070 - Disclosure - Note 11 - Related Party (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual Note 11 - Related Party (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-11-related-party 71 false false R72.htm 071 - Disclosure - Note 12 - Associate Benefits (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual Note 12 - Associate Benefits (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-12-associate-benefits 72 false false R73.htm 072 - Disclosure - Note 13 - Segment Information (Details Textual) Sheet http://nrchealth.com/20211231/role/statement-note-13-segment-information-details-textual Note 13 - Segment Information (Details Textual) Details http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables 73 false false R74.htm 073 - Disclosure - Note 13 - Segment Information - Assets by Geographic Area (Details) Sheet http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details Note 13 - Segment Information - Assets by Geographic Area (Details) Details 74 false false All Reports Book All Reports nrc20211231_10k.htm ex_335795.htm ex_335796.htm ex_335797.htm ex_335798.htm ex_335803.htm ex_337775.htm nrc-20211231.xsd nrc-20211231_cal.xml nrc-20211231_def.xml nrc-20211231_lab.xml nrc-20211231_pre.xml graph6.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 95 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nrc20211231_10k.htm": { "axisCustom": 0, "axisStandard": 31, "contextCount": 218, "dts": { "calculationLink": { "local": [ "nrc-20211231_cal.xml" ] }, "definitionLink": { "local": [ "nrc-20211231_def.xml" ] }, "inline": { "local": [ "nrc20211231_10k.htm" ] }, "labelLink": { "local": [ "nrc-20211231_lab.xml" ] }, "presentationLink": { "local": [ "nrc-20211231_pre.xml" ] }, "schema": { "local": [ "nrc-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 636, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 68, "http://nrchealth.com/20211231": 4, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 78 }, "keyCustom": 48, "keyStandard": 468, "memberCustom": 33, "memberStandard": 37, "nsprefix": "nrc", "nsuri": "http://nrchealth.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://nrchealth.com/20211231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 2 - Acquisition", "role": "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "shortName": "Note 2 - Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 3 - Contracts With Customers", "role": "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "shortName": "Note 3 - Contracts With Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 4 - Equity Investments", "role": "http://nrchealth.com/20211231/role/statement-note-4-equity-investments", "shortName": "Note 4 - Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 5 - Property and Equipment", "role": "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "shortName": "Note 5 - Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 6 - Goodwill and Intangible Assets", "role": "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "shortName": "Note 6 - Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 7 - Income Taxes", "role": "http://nrchealth.com/20211231/role/statement-note-7-income-taxes", "shortName": "Note 7 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 8 - Notes Payable", "role": "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "shortName": "Note 8 - Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 9 - Share-based Compensation", "role": "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "shortName": "Note 9 - Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:LeasesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 10 - Leases", "role": "http://nrchealth.com/20211231/role/statement-note-10-leases", "shortName": "Note 10 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:LeasesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 11 - Related Party", "role": "http://nrchealth.com/20211231/role/statement-note-11-related-party", "shortName": "Note 11 - Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 12 - Associate Benefits", "role": "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits", "shortName": "Note 12 - Associate Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 13 - Segment Information", "role": "http://nrchealth.com/20211231/role/statement-note-13-segment-information", "shortName": "Note 13 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "shortName": "Note 1 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 2 - Acquisition (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables", "shortName": "Note 2 - Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 3 - Contracts With Customers (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables", "shortName": "Note 3 - Contracts With Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 5 - Property and Equipment (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables", "shortName": "Note 5 - Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 6 - Goodwill and Intangible Assets (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables", "shortName": "Note 6 - Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 7 - Income Taxes (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables", "shortName": "Note 7 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 8 - Notes Payable (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables", "shortName": "Note 8 - Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 9 - Share-based Compensation (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables", "shortName": "Note 9 - Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 10 - Leases (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-10-leases-tables", "shortName": "Note 10 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 13 - Segment Information (Tables)", "role": "http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables", "shortName": "Note 13 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "nrc:IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "nrc:IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalizedContractCostAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalizedContractCostAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2018-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 2 - Acquisition (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "shortName": "Note 2 - Acquisition (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember", "decimals": "INF", "lang": null, "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Income", "role": "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "lang": null, "name": "nrc:InsuranceRecoveries1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 2 - Acquisition - Fair Value of Assets and Liabilities (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "shortName": "Note 2 - Acquisition - Fair Value of Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-01-04_BusinessAcquisitionAxis-PatientWisdomIncMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 3 - Contracts With Customers 1 (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "shortName": "Note 3 - Contracts With Customers 1 (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 3 - Contracts With Customers 2 (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual", "shortName": "Note 3 - Contracts With Customers 2 (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2022-01-01", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 3 - Contracts With Customers - Disaggregation of Revenue (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "shortName": "Note 3 - Contracts With Customers - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_ProductOrServiceAxis-SubscriptionServicesMember_TimingOfTransferOfGoodOrServiceAxis-TransferredOverTimeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "shortName": "Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "nrc:ContractWithCustomerLiabilityRevenueRecognizedFromDeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 4 - Equity Investments (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-4-equity-investments-details-textual", "shortName": "Note 4 - Equity Investments (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 5 - Property and Equipment (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual", "shortName": "Note 5 - Property and Equipment (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "shortName": "Note 5 - Property and Equipment - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 6 - Goodwill and Intangible Assets (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "shortName": "Note 6 - Goodwill and Intangible Assets (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "shortName": "Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "shortName": "Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "first": true, "lang": null, "name": "nrc:DeemedDividendPaidByForeignSubsidiary", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 7 - Income Taxes (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual", "shortName": "Note 7 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "first": true, "lang": null, "name": "nrc:DeemedDividendPaidByForeignSubsidiary", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 7 - Income Taxes - Income Before Income Taxes (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "shortName": "Note 7 - Income Taxes - Income Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 7 - Income Taxes - Income Tax Expense (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details", "shortName": "Note 7 - Income Taxes - Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 7 - Income Taxes - Income Tax Reconciliation (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "shortName": "Note 7 - Income Taxes - Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "shortName": "Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "shortName": "Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-FirstNationalBankOfOmahaMember", "decimals": "INF", "first": true, "lang": null, "name": "nrc:DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 8 - Notes Payable (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual", "shortName": "Note 8 - Notes Payable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-FirstNationalBankOfOmahaMember", "decimals": "INF", "first": true, "lang": null, "name": "nrc:DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31_LongtermDebtTypeAxis-TermLoanMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:SecuredDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 8 - Notes Payable - Summary of Notes Payable (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "shortName": "Note 8 - Notes Payable - Summary of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31_LongtermDebtTypeAxis-TermLoanMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:SecuredDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "shortName": "Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 9 - Share-based Compensation (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "shortName": "Note 9 - Share-based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "shortName": "Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-CommonStockOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "shortName": "Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-CommonStockOptionsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 9 - Share-based compensation - Stock Option Activity (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "shortName": "Note 9 - Share-based compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2020-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 9 - Share-based Compensation - Non-vested Stock (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "shortName": "Note 9 - Share-based Compensation - Non-vested Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2020-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31_RangeAxis-MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 10 - Leases (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "shortName": "Note 10 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31_RangeAxis-MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 10 - Leases - Lease Expense (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details", "shortName": "Note 10 - Leases - Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "shortName": "Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:LeaseCashFlowTableTextBlock", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "shortName": "Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:LeaseCashFlowTableTextBlock", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "shortName": "Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)", "role": "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "shortName": "Consolidated Statements of Shareholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Sublease (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details", "shortName": "Note 10 - Leases - Undiscounted Payments Under Sublease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nrc:LeasesDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_RelatedPartyTransactionsByRelatedPartyAxis-AllinaHealthMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 11 - Related Party (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual", "shortName": "Note 11 - Related Party (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_RelatedPartyTransactionsByRelatedPartyAxis-AllinaHealthMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 12 - Associate Benefits (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual", "shortName": "Note 12 - Associate Benefits (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R73": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note 13 - Segment Information (Details Textual)", "role": "http://nrchealth.com/20211231/role/statement-note-13-segment-information-details-textual", "shortName": "Note 13 - Segment Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R74": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note 13 - Segment Information - Assets by Geographic Area (Details)", "role": "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "shortName": "Note 13 - Segment Information - Assets by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Consolidated Statements of Cash Flows", "role": "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 1 - Summary of Significant Accounting Policies", "role": "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "shortName": "Note 1 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 72, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-document-and-entity-information", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details", "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables", "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-document-and-entity-information", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details", "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables", "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrchealth.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "nrc_AllinaHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to Allina Health, a not-for-profit healthcare system.", "label": "Allina Health [Member]" } } }, "localname": "AllinaHealthMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_AmeritasLifeInsuranceCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about related party.", "label": "Ameritas Life Insurance Corp [Member]" } } }, "localname": "AmeritasLifeInsuranceCorpMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_AmortizationOfCapitalizedContractCostTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Amortization of Capitalized Contract Cost [Table Text Block]" } } }, "localname": "AmortizationOfCapitalizedContractCostTableTextBlock", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "nrc_ApicSharebasedPaymentArrangementIncreaseDecreaseForCostRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Non-cash stock compensation expense" } } }, "localname": "ApicSharebasedPaymentArrangementIncreaseDecreaseForCostRecognition", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "nrc_AssetsHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived property, plant or equipment assets held by a lessee through a finance lease arrangement.", "label": "Assets Held under Finance Leases [Member]" } } }, "localname": "AssetsHeldUnderFinanceLeasesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "domainItemType" }, "nrc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, including goodwill, acquired at the acquisition date.", "label": "nrc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_CanadianSubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Canadian Subsidiary.", "label": "Canadian Subsidiary [Member]" } } }, "localname": "CanadianSubsidiaryMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ClaimsLossCoverageMinimumAggregateDeductible": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of minimum aggregate deductible for claims loss coverage.", "label": "nrc_ClaimsLossCoverageMinimumAggregateDeductible", "terseLabel": "Claims Loss Coverage, Minimum Aggregate Deductible" } } }, "localname": "ClaimsLossCoverageMinimumAggregateDeductible", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to common stock options.", "label": "Common Stock Options [Member]" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "domainItemType" }, "nrc_ComputerEquipmentHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment held by a lessee through a finance lease arrangement.", "label": "Computer Equipment Held under Finance Leases [Member]" } } }, "localname": "ComputerEquipmentHeldUnderFinanceLeasesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "domainItemType" }, "nrc_ComputerSoftwareHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer software held by a lessee through a finance lease arrangement.", "label": "Computer Software Held under Finance Leases [Member]" } } }, "localname": "ComputerSoftwareHeldUnderFinanceLeasesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "domainItemType" }, "nrc_ContractWithCustomerAssetIncreaseRevenueRecognizedConditionalConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right to consideration in exchange for good or service transferred to customer with right conditioned on satisfaction of other performance obligations.", "label": "Increases due to revenue recognized in the period with additional performance obligations before invoicing" } } }, "localname": "ContractWithCustomerAssetIncreaseRevenueRecognizedConditionalConsideration", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "nrc_ContractWithCustomerLiabilityBillings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in obligation to transfer good or service to customer due to billings to customer in excess of revenue", "label": "Increases due to invoicing of client, net of amounts recognized as revenue" } } }, "localname": "ContractWithCustomerLiabilityBillings", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "nrc_ContractWithCustomerLiabilityRevenueRecognizedFromDeferredRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of revenue recognized that was previously included in the balance of deferred revenue under contract with customer liabilities.", "label": "nrc_ContractWithCustomerLiabilityRevenueRecognizedFromDeferredRevenue", "negatedLabel": "Revenue recognized that was included in deferred revenue at beginning of year due to completion of services" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognizedFromDeferredRevenue", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "nrc_CostMethodInvestmentOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the cost method of accounting.", "label": "nrc_CostMethodInvestmentOwnershipPercentage", "terseLabel": "Cost Method Investment, Ownership Percentage" } } }, "localname": "CostMethodInvestmentOwnershipPercentage", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-4-equity-investments-details-textual" ], "xbrltype": "percentItemType" }, "nrc_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a credit agreement, providing a revolving credit facility, term loan facility, and delayed draw-down term facility.", "label": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_CumulativeTaxIncentives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cumulative state tax incentives that reduced the operating expenses.", "label": "nrc_CumulativeTaxIncentives", "terseLabel": "Cumulative Tax Incentives" } } }, "localname": "CumulativeTaxIncentives", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_CyberAttackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents cyber attack.", "label": "Cyber Attack [Member]" } } }, "localname": "CyberAttackMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The maximum amount of quarterly dividends included in the fixed charge coverage calculation unless liquidity falls below a specified threshold.", "label": "nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "terseLabel": "Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold" } } }, "localname": "DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum cash flow leverage ratio the borrower is allowable to maintain under a debt instrument agreement.", "label": "nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio", "terseLabel": "Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio" } } }, "localname": "DebtInstrumentCovenantMaximumCashFlowLeverageRatio", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "pureItemType" }, "nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum fixed charge coverage ratio the borrower is required to maintain under a debt instrument agreement.", "label": "nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "terseLabel": "Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio" } } }, "localname": "DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "pureItemType" }, "nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of debt instrument borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate", "terseLabel": "Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate" } } }, "localname": "DebtInstrumentPercentageBearingVariableInterestPercentageRate", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "nrc_DeemedDividendPaidByForeignSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deemed dividend paid by foreign subsidiary.", "label": "nrc_DeemedDividendPaidByForeignSubsidiary", "terseLabel": "Deemed Dividend Paid by Foreign Subsidiary" } } }, "localname": "DeemedDividendPaidByForeignSubsidiary", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredAcquisitionConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of consideration for a current period business acquisition that did not result in cash payments in the period but will be paid in a future period.", "label": "nrc_DeferredAcquisitionConsideration", "terseLabel": "Deferred acquisition consideration" } } }, "localname": "DeferredAcquisitionConsideration", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxAssetPriorYearForeignTaxCreditCarryforwardsWriteOff": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of prior year foreign tax credit carryforwards deferred tax assets and valuation allowance written off.", "label": "nrc_DeferredTaxAssetPriorYearForeignTaxCreditCarryforwardsWriteOff", "terseLabel": "Deferred Tax Asset, Prior Year Foreign Tax Credit Carryforwards, Write Off" } } }, "localname": "DeferredTaxAssetPriorYearForeignTaxCreditCarryforwardsWriteOff", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxAssetsEmployerPayrollTaxDeferral": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to employer payroll tax deferral.", "label": "nrc_DeferredTaxAssetsEmployerPayrollTaxDeferral", "terseLabel": "Employer payroll tax deferral" } } }, "localname": "DeferredTaxAssetsEmployerPayrollTaxDeferral", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxAssetsUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from uncertain tax positions.", "label": "nrc_DeferredTaxAssetsUncertainTaxPositions", "terseLabel": "Uncertain tax positions" } } }, "localname": "DeferredTaxAssetsUncertainTaxPositions", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxLiabilitiesContractCosts": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to contract costs.", "label": "nrc_DeferredTaxLiabilitiesContractCosts", "terseLabel": "Deferred contract costs" } } }, "localname": "DeferredTaxLiabilitiesContractCosts", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxLiabilitiesRepatriationWithholding": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences attributable to repatriation withholding.", "label": "nrc_DeferredTaxLiabilitiesRepatriationWithholding", "terseLabel": "Repatriation withholding" } } }, "localname": "DeferredTaxLiabilitiesRepatriationWithholding", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_DefinedContributionPlanMaximumPercentageOfAnnualContributionEmployeeSubjectToMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay, by the terms of the plan, that the employer may apply a percentage match contribution to a defined contribution plan.", "label": "nrc_DefinedContributionPlanMaximumPercentageOfAnnualContributionEmployeeSubjectToMatch", "terseLabel": "Defined Contribution Plan, Maximum Percentage of Annual Contribution Employee Subject to Match" } } }, "localname": "DefinedContributionPlanMaximumPercentageOfAnnualContributionEmployeeSubjectToMatch", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual" ], "xbrltype": "percentItemType" }, "nrc_DelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a delayed draw term loan.", "label": "Delayed Draw Term Loan [Member]" } } }, "localname": "DelayedDrawTermLoanMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DepreciationAmortizationAndImpairment": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and the total loss recognized during the period from impairments.", "label": "Depreciation, amortization and impairment" } } }, "localname": "DepreciationAmortizationAndImpairment", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "nrc_DirectExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to direct expenses.", "label": "Direct Expenses [Member]" } } }, "localname": "DirectExpensesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "domainItemType" }, "nrc_DirectSellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to direct, selling, general and administrative expenses.", "label": "Direct, Selling, General and Administrative Expenses [Member]" } } }, "localname": "DirectSellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DirectorPlan2004Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2004 director plan.", "label": "Director Plan 2004 [Member]" } } }, "localname": "DirectorPlan2004Member", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_EffectiveIncomeTaxRateReconciliationNondeductibleRecapitalizationExpenseAmount": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to recapitalization.", "label": "Nondeductible expenses (income) related to recapitalization" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleRecapitalizationExpenseAmount", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_ExcessLossCoveragePerPerson": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess loss coverage per covered person related to self-insurance group medical and dental insurance.", "label": "nrc_ExcessLossCoveragePerPerson", "terseLabel": "Excess Loss Coverage Per Person" } } }, "localname": "ExcessLossCoveragePerPerson", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_FirstNationalBankOfOmahaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity First National Bank of Omaha.", "label": "First National Bank of Omaha [Member]" } } }, "localname": "FirstNationalBankOfOmahaMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_FixedNonSubscriptionServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to fixed, non-subscription services.", "label": "Fixed, Non-subscription Services [Member]" } } }, "localname": "FixedNonSubscriptionServicesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_FurnitureAndEquipmentHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Furniture and equipment held by a lessee through a finance lease arrangement.", "label": "Furniture and Equipment Held under Finance Leases [Member]" } } }, "localname": "FurnitureAndEquipmentHeldUnderFinanceLeasesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "domainItemType" }, "nrc_GainOnPropertyInsuranceRecoveries": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount by which an insurance settlement exceeds net book value of property damaged from an event, such as a natural catastrophe, explosion or fire.", "label": "nrc_GainOnPropertyInsuranceRecoveries", "negatedLabel": "Gain on insurance recoveries for damaged property" } } }, "localname": "GainOnPropertyInsuranceRecoveries", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_IMAFinancialGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to IMA Financial Group.", "label": "IMA Financial Group [Member]" } } }, "localname": "IMAFinancialGroupMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_IncludingAssetsHeldUnderCapitalLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, including long lived property, plant or equipment assets held by a lessee through a capital lease arrangement.", "label": "Including Assets Held under Capital Lease [Member]" } } }, "localname": "IncludingAssetsHeldUnderCapitalLeaseMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual" ], "xbrltype": "domainItemType" }, "nrc_IncomeTaxReconciliationCompensationLimitForCoveredEmployees": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation limits for covered employees.", "label": "Compensation limit for covered employees" } } }, "localname": "IncomeTaxReconciliationCompensationLimitForCoveredEmployees", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_IncomeTaxReconciliationUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the differences between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable uncertain tax positions.", "label": "Uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationUncertainTaxPositions", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_IncreaseDecreaseInAccruedExpensesWagesBonusesAndProfitSharing": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net change during the reporting period in the aggregate amount of expenses and accrued compensation incurred but not yet paid.", "label": "Accrued expenses, wages and bonuses" } } }, "localname": "IncreaseDecreaseInAccruedExpensesWagesBonusesAndProfitSharing", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease assets after deduction of operating lease liabilities.", "label": "nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet", "negatedLabel": "Operating lease assets and liability, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of incremental costs of obtaining a contract deferred during the period.", "label": "nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "terseLabel": "Incremental Costs of Obtaining a Contract, Deferred During Period" } } }, "localname": "IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_InsuranceRecoveries1": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount recovered from insurance for lost revenues that are reported as a separate line item.", "label": "Insurance recoveries" } } }, "localname": "InsuranceRecoveries1", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "nrc_InsuranceRecoveriesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure for accounting policies related to insurance recoveries.", "label": "Insurance Recoveries [Policy Text Block]" } } }, "localname": "InsuranceRecoveriesPolicyTextBlock", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "nrc_LeaseCashFlowTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow and other information related to leases.", "label": "Lease, Cash flow [Table Text Block]" } } }, "localname": "LeaseCashFlowTableTextBlock", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "nrc_LeasesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for leases.", "label": "Leases Disclosure [Text Block]" } } }, "localname": "LeasesDisclosureTextBlock", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases" ], "xbrltype": "textBlockItemType" }, "nrc_LesseeLeaseBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of balance sheet information related lessee's lease .", "label": "Lessee, Lease, Balance Sheet Information [Table Text Block]" } } }, "localname": "LesseeLeaseBalanceSheetInformationTableTextBlock", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "nrc_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating and finance lease liability.", "label": "Lessee, Operating and Finance Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "nrc_NonqualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents nonqualified stock options.", "label": "Nonqualified Stock Options [Member]" } } }, "localname": "NonqualifiedStockOptionsMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_NonvestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to nonvested shares.", "label": "Nonvested [Member]" } } }, "localname": "NonvestedMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customers accounting for a substantial portion of one reporting unit's revenue.", "label": "nrc_NumberOfCustomers", "terseLabel": "Number of Customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "nrc_OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities and other noncurrent liabilities.", "label": "Other Current Liabilities and Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "domainItemType" }, "nrc_PatientWisdomIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to PatientWisdom, Inc.", "label": "PatientWisdom, Inc. [Member]" } } }, "localname": "PatientWisdomIncMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "nrc_PracticingExcellencecomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity PracticingExcellence.com.", "label": "PracticingExcellence.com [Member]" } } }, "localname": "PracticingExcellencecomMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_PropertyDamageExcludingCyberAttackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to property damage excluding cyber attack.", "label": "Property Damage Excluding Cyber Attack [Member]" } } }, "localname": "PropertyDamageExcludingCyberAttackMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ProvisionalTaxExpenseBenefitForGlobalIntangibleLowTaxedIncome": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) from the December 22, 2017 Tax Cut and Jobs Act related to the GILTI tax.", "label": "GILTI" } } }, "localname": "ProvisionalTaxExpenseBenefitForGlobalIntangibleLowTaxedIncome", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about purchasing directors and officers and employment practices liability insurance in a related party transaction.", "label": "Purchasing Directors and Officers and Employment Practices Liability Insurance [Member]" } } }, "localname": "PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_RecoveriesPaidDirectlyByInsurerToOutsideVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to recoveries paid directly by insurer to outside vendor.", "label": "Recoveries Paid Directly by Insurer to Outside Vendor [Member]" } } }, "localname": "RecoveriesPaidDirectlyByInsurerToOutsideVendorMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_RecoveriesReceivedDirectByTheCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to recoveries received direct by the company.", "label": "Recoveries Received Direct by the Company [Member]" } } }, "localname": "RecoveriesReceivedDirectByTheCompanyMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ReimbursementForLostRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to reimbursement for lost revenue.", "label": "Reimbursement for Lost Revenue [Member]" } } }, "localname": "ReimbursementForLostRevenueMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ReserveForUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings to reserve for uncertain tax positions.", "label": "Reserve for uncertain tax positions" } } }, "localname": "ReserveForUncertainTaxPositions", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the fair value granted for share based compensation arrangement to each non-employee director at the annual meeting or when joining the board", "label": "nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantAmount", "terseLabel": "Share Based Compensation, Arrangement By Share Based Payment Award, Options Grant, Amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantAmount", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of nonvested restricted shares outstanding.", "label": "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsCumulative": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted for plan to date.", "label": "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsCumulative", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options Grants Cumulative (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsCumulative", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value, aggregate intrinsic value of equity options exercised and intrinsic value and fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value, Intrinsic Value of Exercised and Vested in Period, and Fair Value of Vested in Period [Table Text Block]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently vested.", "label": "Intrinsic value of stock options vested (in thousands)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedIntrinsicValue", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "nrc_SocialSecurityTaxPayableCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Balance social security tax payable and outstanding that was deferred as a result of the CARES Act.", "label": "nrc_SocialSecurityTaxPayableCurrent", "terseLabel": "Social Security Tax Payable, Current" } } }, "localname": "SocialSecurityTaxPayableCurrent", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_StockOptionsExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because the exercise price exceeds the fair market value.", "label": "nrc_StockOptionsExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Stock Options Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "StockOptionsExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "nrc_StockTenderedCashlessExerciseOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock tendered to the company for cashless exercise of stock options in connection with equity incentive plans.", "label": "Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans" } } }, "localname": "StockTenderedCashlessExerciseOfStockOptions", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_SubscriptionServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to subscription services.", "label": "Subscription Services [Member]" } } }, "localname": "SubscriptionServicesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_TaxBenefitRealizedRestrictedStockVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The tax benefit realized from the vesting of restricted stock during the period.", "label": "nrc_TaxBenefitRealizedRestrictedStockVested", "terseLabel": "Tax Benefit Realized Restricted Stock Vested" } } }, "localname": "TaxBenefitRealizedRestrictedStockVested", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a term loan.", "label": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "domainItemType" }, "nrc_The2006EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2006 Equity Incentive plan.", "label": "The 2006 Equity Incentive Plan [Member]" } } }, "localname": "The2006EquityIncentivePlanMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_TradeNames1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names 1 [Member]" } } }, "localname": "TradeNames1Member", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "nrc_UnitPriceServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to unit price services.", "label": "Unit Price Services [Member]" } } }, "localname": "UnitPriceServicesMember", "nsuri": "http://nrchealth.com/20211231", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-lease-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Lease Expense (Details)" } } }, "localname": "statement-statement-note-10-leases-lease-expense-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details)" } } }, "localname": "statement-statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)" } } }, "localname": "statement-statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases" } } }, "localname": "statement-statement-note-10-leases-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details)" } } }, "localname": "statement-statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-undiscounted-payments-under-sublease-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Undiscounted Payments Under Sublease (Details)" } } }, "localname": "statement-statement-note-10-leases-undiscounted-payments-under-sublease-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-13-segment-information-assets-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information - Assets by Geographic Area (Details)" } } }, "localname": "statement-statement-note-13-segment-information-assets-by-geographic-area-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-13-segment-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information" } } }, "localname": "statement-statement-note-13-segment-information-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Acquisition - Fair Value of Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-2-acquisition-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Acquisition" } } }, "localname": "statement-statement-note-2-acquisition-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-3-contracts-with-customers-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Contracts With Customers - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)" } } }, "localname": "statement-statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-3-contracts-with-customers-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Contracts With Customers" } } }, "localname": "statement-statement-note-3-contracts-with-customers-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-5-property-and-equipment-summary-of-property-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment - Summary of Property and Equipment (Details)" } } }, "localname": "statement-statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-5-property-and-equipment-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment" } } }, "localname": "statement-statement-note-5-property-and-equipment-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)" } } }, "localname": "statement-statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)" } } }, "localname": "statement-statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-intangible-assets-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets" } } }, "localname": "statement-statement-note-6-goodwill-and-intangible-assets-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-income-before-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Income Before Income Taxes (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-income-before-income-taxes-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-income-tax-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Income Tax Expense (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-income-tax-expense-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-income-tax-reconciliation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Income Tax Reconciliation (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-income-tax-reconciliation-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes" } } }, "localname": "statement-statement-note-7-income-taxes-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details)" } } }, "localname": "statement-statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-8-notes-payable-summary-of-notes-payable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Notes Payable - Summary of Notes Payable (Details)" } } }, "localname": "statement-statement-note-8-notes-payable-summary-of-notes-payable-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-8-notes-payable-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Notes Payable" } } }, "localname": "statement-statement-note-8-notes-payable-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-nonvested-stock-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based Compensation - Non-vested Stock (Details)" } } }, "localname": "statement-statement-note-9-sharebased-compensation-nonvested-stock-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based compensation - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-9-sharebased-compensation-stock-option-activity-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)" } } }, "localname": "statement-statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details)" } } }, "localname": "statement-statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based Compensation" } } }, "localname": "statement-statement-note-9-sharebased-compensation-tables", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "nrc_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://nrchealth.com/20211231", "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r113", "r256", "r261", "r267", "r454", "r455", "r461", "r462", "r526", "r609" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r113", "r256", "r261", "r267", "r454", "r455", "r461", "r462", "r526", "r609" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r272", "r304", "r348", "r350", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r585", "r588", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r272", "r304", "r348", "r350", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r585", "r588", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r180", "r327", "r330", "r541", "r584", "r586" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r180", "r327", "r330", "r541", "r584", "r586" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r272", "r304", "r337", "r348", "r350", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r585", "r588", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r272", "r304", "r337", "r348", "r350", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r585", "r588", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r181", "r182", "r327", "r331", "r587", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r181", "r182", "r327", "r331", "r587", "r595", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r186", "r522" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34", "r529" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r22", "r187", "r188" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade accounts receivable, less allowance for doubtful accounts of $94 and $120, respectively", "terseLabel": "Accounts receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r246" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedTerseLabel": "Less accumulated amortization", "terseLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r48", "r50", "r51", "r52", "r480" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated other comprehensive loss, foreign currency translation adjustment" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r49", "r52", "r60", "r61", "r62", "r115", "r116", "r117", "r460", "r589", "r590", "r622" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r23" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r115", "r116", "r117", "r386", "r387", "r388", "r469" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r353", "r382", "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "totalLabel": "Net (benefit) expense to net income" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "auth_ref": [ "r191", "r210" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]" } } }, "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r194", "r205", "r206", "r209" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r28", "r194", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Write-offs, net of recoveries" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r93", "r228", "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r93", "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "us-gaap_AssetImpairmentCharges", "terseLabel": "Asset Impairment Charges, Total" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r108", "r166", "r170", "r176", "r201", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r454", "r461", "r482", "r527", "r529", "r558", "r573" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r47", "r108", "r201", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r454", "r461", "r482", "r527", "r529" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r354", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r347", "r349" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r347", "r349", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r435" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r445", "r446", "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r444", "r445", "r446", "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r439" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details": { "order": 1.0, "parentTag": "nrc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "terseLabel": "Current Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r439" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r438", "r439" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details": { "order": 2.0, "parentTag": "nrc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r438", "r439" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details": { "order": 0.0, "parentTag": "nrc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r439" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r98", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Finance lease obligations originated for property and equipment" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "auth_ref": [ "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions made to capitalized computer software costs during the period.", "label": "us-gaap_CapitalizedComputerSoftwareAdditions", "terseLabel": "Capitalized Computer Software, Additions" } } }, "localname": "CapitalizedComputerSoftwareAdditions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized contract cost" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_CapitalizedContractCostAmortizationPeriod", "terseLabel": "Capitalized Contract Cost, Amortization Period (Year)" } } }, "localname": "CapitalizedContractCostAmortizationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_CapitalizedContractCostAxis": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.", "label": "Capitalized Contract Cost [Axis]" } } }, "localname": "CapitalizedContractCostAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizedContractCostDomain": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.", "label": "Capitalized Contract Cost [Domain]" } } }, "localname": "CapitalizedContractCostDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedContractCostImpairmentLoss": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "us-gaap_CapitalizedContractCostImpairmentLoss", "terseLabel": "Capitalized Contract Cost, Impairment Loss" } } }, "localname": "CapitalizedContractCostImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "auth_ref": [ "r214" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.", "label": "Deferred contract costs, net", "terseLabel": "Capitalized Contract Cost, Net, Noncurrent" } } }, "localname": "CapitalizedContractCostNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r29", "r95" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Assets, fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r89", "r95", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r89", "r483" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "us-gaap_CashEquivalentsAtCarryingValue", "terseLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r106", "r108", "r131", "r135", "r136", "r139", "r141", "r147", "r148", "r149", "r201", "r256", "r261", "r262", "r263", "r267", "r268", "r302", "r303", "r305", "r306", "r482", "r619" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r253", "r596" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Dividends declared per common share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r115", "r116", "r469" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r529" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; authorized 110,000,000 shares in 2021 and 60,000,000 shares in 2020, issued 30,898,600 in 2021 and 30,775,154 in 2020, outstanding 25,361,409 in 2021 and 25,390,968 in 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r335", "r336", "r351", "r393" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r55", "r57", "r58", "r65", "r565", "r580" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r102", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r311", "r313", "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract assets included in other current assets" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.", "label": "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable", "negatedLabel": "Decreases due to completion of services (or portion of services) and transferred to accounts receivable" } } }, "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerDurationAxis": { "auth_ref": [ "r327", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Axis]" } } }, "localname": "ContractWithCustomerDurationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerDurationDomain": { "auth_ref": [ "r327", "r332" ], "lang": { "en-us": { "role": { "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Domain]" } } }, "localname": "ContractWithCustomerDurationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "negatedLabel": "Change due to cumulative catch-up adjustments arising from changes in expected contract consideration" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r311", "r312", "r328" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue", "negatedTerseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r68" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r109", "r418", "r426" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentFederalTaxExpenseBenefit", "terseLabel": "Current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r109", "r418" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Current" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r109", "r418", "r426" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit", "terseLabel": "Current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r105", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r286", "r293", "r294", "r295", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r107", "r113", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r297", "r298", "r299", "r300", "r494", "r559", "r561", "r572" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r269", "r297", "r298", "r492", "r494", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r40", "r270" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41", "r107", "r113", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r297", "r298", "r299", "r300", "r494" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r41", "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "us-gaap_DebtInstrumentPeriodicPayment", "terseLabel": "Debt Instrument, Periodic Payment, Total" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r419", "r426" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r33", "r282", "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "us-gaap_DeferredFinanceCostsNet", "negatedLabel": "Less: unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r419", "r426" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Deferred" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r397", "r398" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "us-gaap_DeferredIncomeTaxAssetsNet", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r93", "r109", "r419", "r426", "r427", "r428" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r17", "r18", "r411", "r560", "r571" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "totalLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r397", "r398" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r419", "r426" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "Deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r412" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r413" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "us-gaap_DeferredTaxAssetsOther", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses", "terseLabel": "Accrued bonuses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "terseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r398", "r413" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "us-gaap_DeferredTaxLiabilitiesOther", "terseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses", "terseLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "terseLabel": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r93", "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "us-gaap_DepreciationAndAmortization", "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectOperatingCosts": { "auth_ref": [ "r71" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate direct operating costs incurred during the reporting period.", "label": "Direct" } } }, "localname": "DirectOperatingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20211231/role/statement-note-13-segment-information", "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "us-gaap_DividendsCommonStockCash", "negatedLabel": "Dividends declared common share" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r10", "r38" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share of common stock:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r66", "r120", "r121", "r122", "r123", "r124", "r128", "r131", "r139", "r140", "r141", "r144", "r145", "r470", "r471", "r566", "r581" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic earnings per share (in dollars per share)", "terseLabel": "Net income per share \u2013 basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator for net income per share - basic:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r66", "r120", "r121", "r122", "r123", "r124", "r131", "r139", "r140", "r141", "r144", "r145", "r470", "r471", "r566", "r581" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted earnings per share (in dollars per share)", "terseLabel": "Net income per share \u2013 diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator for net income per share - diluted:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r483" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r392", "r400" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued wages and bonuses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r382" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details": { "order": 0.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "negatedLabel": "Amount of related income tax benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r385" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "terseLabel": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r60", "r61", "r62", "r115", "r116", "r117", "r119", "r125", "r127", "r146", "r204", "r307", "r308", "r386", "r387", "r388", "r422", "r423", "r469", "r484", "r485", "r486", "r487", "r488", "r489", "r589", "r590", "r591", "r622" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-4-equity-investments-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r472", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r472", "r481" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r284", "r297", "r298", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r346", "r473", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r472", "r473", "r474", "r475", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r284", "r338", "r339", "r344", "r346", "r473", "r530" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r284", "r297", "r298", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r346", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r477", "r479" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r109", "r399" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "totalLabel": "Total" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r499", "r505", "r516" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r501", "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r498", "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "us-gaap_FinanceLeaseLiability", "terseLabel": "Present value of minimum finance lease payments", "totalLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r498" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Current obligations of finance leases", "negatedTerseLabel": "Current portion, finance leases" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r498" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Noncurrent obligations of finance leases", "terseLabel": "Finance leases obligations, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "totalLabel": "Finance leases, total minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2022, finance leases" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive", "terseLabel": "2026, finance leases" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2025, finance leases" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2024, finance leases" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2023, finance leases" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Finance leases, less: Amount representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r500", "r510" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Financing cash flows from finance leases", "negatedLabel": "Payments on finance lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r499", "r505", "r516" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Asset amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r513", "r516" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r512", "r516" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1", "verboseLabel": "Finance leases (Year)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r235" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "terseLabel": "Finite-lived intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r229", "r231", "r235", "r239", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r235", "r543" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Finite-lived intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r229", "r234" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r235", "r542" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "terseLabel": "Finite-lived intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r109" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "totalLabel": "Total" } } }, "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r93" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "us-gaap_GainLossOnDispositionOfAssets1", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r216", "r218", "r529", "r557" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details": { "order": 3.0, "parentTag": "nrc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill", "periodStartLabel": "Goodwill", "terseLabel": "Goodwill, net" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill acquired" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r224", "r232" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r219", "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillGross", "terseLabel": "Goodwill, gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r219", "r223" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss", "negatedTerseLabel": "Goodwill, accumulated impairment" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r93", "r217", "r221", "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillImpairmentLoss", "negatedLabel": "Impairment", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r93", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill", "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r93", "r243", "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r242", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r110", "r429" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "terseLabel": "U.S. Operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r64", "r166", "r169", "r172", "r175", "r178", "r556", "r564", "r568", "r582" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r110", "r429" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "terseLabel": "Foreign Operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r249", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxCreditsAndAdjustments": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.", "label": "us-gaap_IncomeTaxCreditsAndAdjustments", "terseLabel": "Income Tax Credits and Adjustments" } } }, "localname": "IncomeTaxCreditsAndAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r111", "r401", "r409", "r415", "r424", "r430", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r112", "r126", "r127", "r165", "r399", "r425", "r431", "r583" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r59", "r395", "r396", "r409", "r410", "r414", "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r400" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Foreign tax rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r400" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Expected federal income taxes" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r400" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.", "label": "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "verboseLabel": "Goodwill Impairment" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r400" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "us-gaap_IncomeTaxReconciliationOtherReconcilingItems", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r400" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Withholding tax on repatriation of foreign earnings" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r400" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State income taxes, net of federal benefit and state tax credits" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r400" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "us-gaap_IncomeTaxReconciliationTaxCredits", "negatedLabel": "Federal tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r45", "r563", "r579" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income taxes receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r92" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r92" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r92", "r540" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCharges": { "auth_ref": [ "r92" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.", "label": "us-gaap_IncreaseDecreaseInDeferredCharges", "negatedTerseLabel": "Deferred contract costs, net" } } }, "localname": "IncreaseDecreaseInDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "auth_ref": [ "r92" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.", "label": "us-gaap_IncreaseDecreaseInIncomeTaxes", "terseLabel": "Income taxes receivable and payable" } } }, "localname": "IncreaseDecreaseInIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r92" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current and long-term assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r132", "r133", "r134", "r141" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "terseLabel": "Weighted average effect of dilutive securities \u2013 stock options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r230", "r238" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill", "terseLabel": "Indefinite trade name" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r230", "r238" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_InsuranceRecoveries": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.", "label": "us-gaap_InsuranceRecoveries", "terseLabel": "Insurance Recoveries" } } }, "localname": "InsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "terseLabel": "Total intangible assets other than goodwill" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r227", "r233" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net", "terseLabel": "Total intangible assets other than goodwill" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r63", "r164", "r491", "r493", "r567" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r86", "r90", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest expense, net of capitalized amounts" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r74", "r163" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r198", "r200", "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-4-equity-investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r514", "r516" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Operating leases, total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2022, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2025, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2024, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r515" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2023, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Operating leases, less: Amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm", "terseLabel": "Lessee, Operating Lease, Remaining Lease Term (Year)" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r517" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "totalLabel": "Total minimum lease receipts" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r517" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r517" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r517" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r517" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details": { "order": 0.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r108", "r171", "r201", "r256", "r257", "r258", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r455", "r461", "r462", "r482", "r527", "r528" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r108", "r201", "r482", "r529", "r562", "r577" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r108", "r201", "r256", "r257", "r258", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r455", "r461", "r462", "r482", "r527", "r528", "r529" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r16", "r561", "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "us-gaap_LineOfCredit", "terseLabel": "Long-term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r35", "r107" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r35", "r107" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermContractWithCustomerMember": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which duration is classified as long-term.", "label": "Long-term Contract with Customer [Member]" } } }, "localname": "LongTermContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r16", "r283", "r296", "r297", "r298", "r561", "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Total carrying amount of long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Estimated fair value of long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r113", "r254", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r113", "r254", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r113", "r254", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r113", "r254", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebtNoncurrent", "terseLabel": "Notes payable, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r41" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes payable, net of current portion and unamortized debt issuance costs" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r41", "r255" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r89", "r91", "r94" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r120", "r121", "r122", "r123", "r128", "r129", "r138", "r141", "r166", "r169", "r172", "r175", "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "terseLabel": "Net income attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator for net income per share - basic:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncatastrophicEventAxis": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Information by type of noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Axis]" } } }, "localname": "NoncatastrophicEventAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_NoncatastrophicEventDomain": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Domain]" } } }, "localname": "NoncatastrophicEventDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "us-gaap_NoncurrentAssets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of notes payable, net of unamortized debt issuance costs" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "us-gaap_NumberOfReportingUnits", "terseLabel": "Number of Reporting Units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r166", "r169", "r172", "r175", "r178" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r506", "r516" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "us-gaap_OperatingLeaseCost", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "us-gaap_OperatingLeaseImpairmentLoss", "terseLabel": "Operating Lease, Impairment Loss" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total operating lease liabilities", "terseLabel": "Present value of minimum operating lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current operating lease liabilities", "negatedLabel": "Current portion, operating leases" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease obligations, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r502", "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r497" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r513", "r516" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r512", "r516" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "verboseLabel": "Operating leases (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r46", "r529" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r452", "r453", "r459" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other comprehensive income, foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r54", "r57", "r452", "r453", "r459" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r465", "r468" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeMember": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other revenue.", "label": "Other Income [Member]" } } }, "localname": "OtherIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r38", "r529" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "auth_ref": [ "r137", "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "negatedTerseLabel": "Allocation of distributed and undistributed income to unvested restricted stock shareholders" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r82" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchase of shares for treasury" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r84" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r82" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Payment of dividends on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r82" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Payment of payroll tax withholdings on share-based awards exercised" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r78", "r448" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "us-gaap_PaymentsToAcquireBusinessesGross", "negatedLabel": "Acquisition consideration", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r354", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r20", "r302" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20", "r302" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r20", "r529" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r211", "r212" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "auth_ref": [ "r77", "r88" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.", "label": "Insurance proceeds for damaged property" } } }, "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": { "auth_ref": [ "r85", "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.", "label": "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities", "terseLabel": "Proceeds from Insurance Settlement, Operating Activities" } } }, "localname": "ProceedsFromInsuranceSettlementOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r81", "r107" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Borrowings on line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r80", "r385" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from the exercise of stock options", "terseLabel": "Proceeds from Stock Options Exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r53", "r56", "r62", "r87", "r108", "r118", "r126", "r127", "r166", "r169", "r172", "r175", "r178", "r201", "r256", "r257", "r258", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r452", "r457", "r458", "r463", "r464", "r471", "r482", "r568" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r32", "r247" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r251", "r597", "r598", "r599" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r245" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "terseLabel": "Property and equipment at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r247", "r529", "r569", "r578" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Net property and equipment", "terseLabel": "Property and equipment under finance lease, net", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r30", "r247", "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r245" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r67", "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r345", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r520", "r523" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r345", "r520", "r521", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r345", "r520", "r523", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r518", "r519", "r521", "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r83", "r107" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "us-gaap_RepaymentsOfLinesOfCredit", "negatedLabel": "Payments on line of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r83" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "us-gaap_RepaymentsOfNotesPayable", "negatedLabel": "Payments on notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r308", "r389", "r529", "r576", "r592", "r593" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r115", "r116", "r117", "r119", "r125", "r127", "r204", "r386", "r387", "r388", "r422", "r423", "r469", "r589", "r591" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r161", "r162", "r168", "r173", "r174", "r180", "r181", "r184", "r326", "r327", "r541" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r325", "r329", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r69", "r259", "r261", "r262", "r266", "r267", "r268", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "us-gaap_RevenueFromRelatedParties", "terseLabel": "Revenue from Related Parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "us-gaap_RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r511", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "ROU assets obtained in exchange for finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r511", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "ROU assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r353", "r381", "r391" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r224", "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r70", "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r366", "r370", "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r408", "r421" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r16", "r561", "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "us-gaap_SecuredDebt", "terseLabel": "Term Loans" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r14", "r559", "r574" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "us-gaap_SecuredDebtCurrent", "negatedTerseLabel": "Less: current portion" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r157", "r159", "r160", "r166", "r167", "r172", "r176", "r177", "r178", "r179", "r180", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-13-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "us-gaap_SelfInsuranceReserveCurrent", "terseLabel": "Self Insurance Reserve, Current" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Non-cash share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Outstanding (in dollars per share)", "periodStartLabel": "Outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield at date of grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Intrinsic value of stock options exercised (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Expired, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, number of options (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average grant date fair value of stock options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r361", "r384" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Ending balance, outstanding, number of options (in shares)", "periodStartLabel": "Beginning balance, outstanding, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Ending balance, outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Beginning balance, outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r352", "r358" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r354", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r376", "r390" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life of options (in years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r507", "r516" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r101", "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r109", "r399", "r425" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.", "label": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "totalLabel": "Total" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r19", "r20", "r21", "r106", "r108", "r131", "r135", "r136", "r139", "r141", "r147", "r148", "r149", "r201", "r256", "r261", "r262", "r263", "r267", "r268", "r302", "r303", "r305", "r306", "r307", "r482", "r619" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r44", "r60", "r61", "r62", "r115", "r116", "r117", "r119", "r125", "r127", "r146", "r204", "r307", "r308", "r386", "r387", "r388", "r422", "r423", "r469", "r484", "r485", "r486", "r487", "r488", "r489", "r589", "r590", "r591", "r622" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details", "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables", "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r115", "r116", "r117", "r146", "r541" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases", "http://nrchealth.com/20211231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20211231/role/statement-note-10-leases-undiscounted-payments-under-sublease-details", "http://nrchealth.com/20211231/role/statement-note-11-related-party", "http://nrchealth.com/20211231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20211231/role/statement-note-12-associate-benefits-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-details-textual", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20211231/role/statement-note-2-acquisition", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-details-textual", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-2-details-textual", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments", "http://nrchealth.com/20211231/role/statement-note-4-equity-investments-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables", "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r20", "r21", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Issuance of restricted common shares, net of forfeitures (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r307", "r308", "r363" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Shares of common stock for the exercise of stock options (in shares)", "negatedTerseLabel": "Exercised, number of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r44", "r307", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Issuance of common shares for the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r25", "r26", "r108", "r196", "r201", "r482", "r529" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r509", "r516" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "us-gaap_SubleaseIncome", "negatedLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash paid for:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20211231/role/statement-note-10-leases-tables", "http://nrchealth.com/20211231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20211231/role/statement-note-2-acquisition-tables", "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20211231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20211231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-2-acquisition-fair-value-of-assets-and-liabilities-details", "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r327", "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r327", "r333" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r189", "r190", "r192", "r193", "r195", "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred over Time [Member]" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r43", "r309" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r43", "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r21", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Purchase of shares of treasury stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r43", "r309", "r310" ], "calculation": { "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 5,537,191 Common shares in 2021 and 5,384,186 Common shares in 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r307", "r308", "r309" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Purchase of shares of treasury stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r394", "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Balance of unrecognized tax benefits", "periodStartLabel": "Balance of unrecognized tax benefits", "terseLabel": "Unrecognized Tax Benefits, Ending Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "terseLabel": "Reductions due to tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "auth_ref": [ "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense accrued for an underpayment of income taxes.", "label": "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "terseLabel": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued" } } }, "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "negatedTerseLabel": "Reductions due to lapse of applicable statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r150", "r151", "r152", "r153", "r154", "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r508", "r516" ], "calculation": { "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-note-8-notes-payable", "http://nrchealth.com/20211231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r130", "r141" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "terseLabel": "Denominator for diluted earnings per share \u2013 adjusted weighted average shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares and share equivalents outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r128", "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding \u2013 basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrchealth.com/20211231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20211231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131251-203054" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r393": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r434": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r525": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r612": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r613": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r614": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r615": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r616": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r617": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r618": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r619": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r620": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r621": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080549-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" } }, "version": "2.1" } ZIP 96 0001437749-22-005273-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-005273-xbrl.zip M4$L#!!0 ( -%H9%19QRS;J 0 !4= - 97A?,S,U-SDU+FAT;>U9 M;4_C.!#^#+]BU!4L2.E+"NQ"6RKURLNM.%@$[ ]P$J>QSK&SMON2^_4W=M)" MRQ98!%PY@8JL9.R9R3//C)U))S$I[W822J+N^EK',,-IMU,OQO5.O1!T AGE M.&2@3<[I8266PE1CDC*>MS[?L)1JN*!CN)(I$9_;3JK9/[3E-S)37(Z(8D28 MEI J);R=$C5@HF7%E>ZF"'36[M2S[OH2&PLFGF+!T(FI$LX&HJ78(#%W3,+T MO[GC['>"[O$D80$SL-/LU(/N0ZZ\Q>.^A0W8_#F4IKU@J;C9AEM[X S"G$4H M3<(=D"&DPE#5AM(/:$RQ[5-E6,Q"8I@4<#E4>HA*P$CP]^%'[;K6K\$U#9W4 MW]EKN @$RM*N2S3T(ID9<MG$X_:'P!&8-)*%P3%1!!=?7[A-,<>J&QDF:C ML1(1?1&TYY'])B"40I1(C)E)' XD#&6:$9$S,8">$$/"X8IF4B$> DY0%=JH MGEEP+EQ$G%Q3HL($^E+AS")06U;;YJ?]9K/1[A#!=[\$W#\Y9F!#*X:@&?Y)<>]!/&(WA>$+#H6$C M"M]C) TJ) *#KZAF$3)L&N[2(\])4=L9'3$!5S4X(XK,E)TP043(\!%+91[2 MU+(QA^Q1'J)N#:1D7_9<]GD0$(T*<'Z:P]]"CCF-!M3#9<2TWI"7A@2<0B!5 M1-5AI5%!)#C/2!0A46;7.B/A]+IT:;ONWE.^.OT6KY!P-.@\K<=3-;" M;S9RATEF&*_ISR!1-,0;:LNR6LUMD&S S_;VM M:'O&3$PGQ8S5<#S!C!,#.J6G?["S6Y \=3GY23YC:-UP2673H4?54YC MTW+<*F^XXW5KQK8BOQ8YN9!G-LT*U-!S/G&>\CN9&/]-SMD7G,.,=UJ+9LI:#: MQU?%0R683@HC"WT_*Y_U_OHR39G6=IU4P(RV3Q+',,SPCGT4JDWM#2,:L1&$ MG&A]6/FK=WU3O>R='E?_N#KNG6&.WY5>GI[<7"W<2^*JDN/[-VV1A%\S,S4W.38N:'1M[5OM;MLV%/V]/@6185T*V''L)%MKNP&R+BV* MKEV1=@] 291%E")5DK+C/?W.)>6OQ&F=K"F2Q@526^+7)7G//>=2\K#PI3H> M%H)GQX]^&GKIE3@>=N+GHV$G%@P3DTWQ43'GITH\W\F-]NV&9+._WD$8?Y@'73W>L-. M&LU,SEX44N3LI=1.4F&_MBK?S^+WM74UFC%OV%FM!.L> M\';W<)<_8<:R[E'67-0Z$Y;Y0K /(JVM]!*6G9ZG!=_XY0]3[!/B;'8D><[^SLP1*F* M9YG4H_FUJW@ZN[Y^#)C(S!?XNO]+8T=;B=SW>>W-[$:( _'.#J+=HY\0\"R^ MT&LU]".U3_5D%J9<6Z>V&UJ/^.SS:VZ_!H[_!V M#7O-"CX6S,*9Q$1D\![IV(G6-:+#F:B,!9(T>XF6\,[V&X+5NQ!.0KD3W*8% M>V$L:H;;@XOSQ"?M _@F.,K6*^^05_;NJE?^P1U\$8Y73MDG;29*9"/1BLYI MHU=F!B-HXUF*SC@B(==3T(*WM8!%W(L2'$/NRA$Z039$=SDG8K#,E#(P3*AW MJ8(6J7".VRE5*?DG$7AFWJ?#O0S&8$A%VTMC4(54VK0N44VC>4-0DT("'JZF M_Q;M)\**IA.:0"F=@A2#([*)] 4FZ"J1!@.IWPJFF0S3Q'Y@49+I\C)LX7:/ MX'9P[^ F6#[7B@L';@%KJ(YBNU0N=4Y=!ZDI=:KJ#'T")$O>V@+ I%535L'' M"9X$6Z46^&M3K:-=\20T#=D67<5+22F;CFBD_AD1TA)( M(VC(EHT'RE<&RC$0S?,B=%&#-&I_"\=O#N[K@&N1U$QY[39O0IHO$0!/,U)4D::VZ !T-98ND"!J"1WZH61_ M09_+%&R%X@&-C8Q<(*K5T#,52E I;'%&R8S[8&CB9":A?E$M2MT@"33U4SN2 MGR%TN:!5 V$:)V".#V)Y3"J8L)"Q:!%%\;*6Q[=$4$50,=J+ M;$N]#P/KR?W ^L;4=PGRFY/FQLA'M!C+C #-G='!0;E#,*"\DU#.;3;#'&* MY(E4TD])$Z\;EN)/@&= WOR@>)WLCR+DO)E05=L*R'=!PZ7I787XZYJH.O$<8$'F.Y%..X;UN M31(YU^X;\'B\7)]7!E2C(3C8Q>PU,;6_VH)-E :?UQ:4FN=?/SEBR2SI#X%* MQ)6@$USJ? O,!P',[*X"\\_H\Y>Q0Z>\33H92M8"]!JL2_K9I&EM"2%+^#U,$CXSAYXG2BD M?Q@TO$($UZ0SW50* *A1N/.#IXG@GTBRQG0PB-:0R(:'K;/'-->"97-*%,_! MUS =S]#0B3G170GA)OU%$^ 0/MR*NME!-+NZQ'RQ'F$RC6$"R[49V_#ZUR'+=;;[_5N!(/N MK;^K,+VDBY8-B_O<3HSWINR'YQJL6YVSG_?#O\'5AO]VNW9W7">ZY>I[FS=: MY*,8:E;#9P.O&_G5#0)QL]$W:7G+*[U=X%M>X"O?(O_&*_V]F2*38Y8J[MSS MG;]./GQLOS]Y==K^X^STY U6<[GT_:N7'\\NW"ORMC63RS>)7=C[5^_^>;L8 M#37H!QAK/F!%)_P@8]@)O][X#U!+ P04 " #1:&14V O7 U<' 3,@ M#0 &5X7S,S-3['= %F;=L76 M+LBZ'T!)E$64$E62LN/]^CUWDE_CK$Z6%,GB%JTM\<@[DO?>?*QOZ'W6NO/B@QN+"YK*H;_8%2WK]M^J)[GX9FALCZ;0L M0D\4UN72]$4NW5 7/<$B05V&MC1ZB!M.#[, Y<^+R)?]0:<\>7:-'2L&].>: M6?&2WD;M@J):3V,&Y,7TW\%A2?H'T#9_Y*N:!3'MT$T$*RXJHT3W4+:[1[ORA;!.=(^3YJ(J$N5$R)3X$W-Q M.FA8=G899[(8*G$:!YIM]^?#H__-AB\OU;N6>*\Q6V7$ZSWQJYSX%A:5=GN" M59&A]Q7G'&2$C8JLPY:\W-G?@2'&E#))=#&<7?M2QM/KFP>!L4Y"AJ_[WS5V MM(U*0X\#7'.# T%O&O(0&Q$O';[09S)5.:(EBJ5I_##8LAEZ?^_G[[@?Q.\J M2BVM6'>/5XO&[X1D8[N.CO>.[M>P=R*3B 1.C;0:JP3>H[TX+8I*&G&A2NL MI4*\04^X9_LWPM4'CB?<[I5T<29>60=)OMU?G2<^:1^0JMA1ME[Y@+SRX*%Z MY2_2PQ?A>/E$?"KLV*ADJ%JU<[K:*Q,+#84-(L9@4A="%A/DA> J!8MD4#F2 M#+FK1.Q$MM%PV%129G#"YII3#,M=$2A4K+R7;D(BN?RD.-',QO2XE\ 8J#2T MO:2#!&+MXBJ'6('N388:9XC2PE?TW[S_6#G5#$(3R+4W8'%P1#'6(<,$?:EB M-I#&+6&:33!-[ <6)9HL+L,6;H\(;H>/#FY*I+J 0Q,VY@[< M8@CF:WT*Z+ ME(9FKJF+V%0)Q@1(%KRU!8!I9R:BA(\3/ FVQLSQU[B^7U$-B">:!FZ11&4@ M -!9((/5>;8GECX3J;%C/T6D4T/M@R,^*>EF;3>L;"T RT^-N6+M%EN/"%M' M#Q5;'Y<<\?FW/QUT?^S[!CT-9Z?0;^M:C%WTG9!.,1C@W)IV'TXKE"=/T#XC M<1++D?8H]=%UHGULK*_0CQ*BLZ9&1>ELK!+<]F(7($@44%5[^E*Y1,66KZNM MXUWU@KMRN457]:6FFJVHT4CC"TI("R"M04.V;*PH75*40A'-7\[)!_M'=^O9:^5ATKX-/.Y+P.N150SEI7?O MQOD@! M/(VFFD7:RF$ I*N1]IP$(:4*'H>*_7GZ7$S!3AG):&QHY!Q1K28]4Z-&*H4M MWAJ=R,"&1EXG&NP78C7594I0T#B5)_K)H!]8W3GU7(+]YTMP8^8@6 M(YT0H*6W!3NH] @&5'<2RJ5+IIA##- RTD:'"7'B=6HI_C \&7FSD^)UM+\F M(9?-A,K*E4"^9PX?QX (&\ 5[% 5H.8& 0 MJJ2X0B*HSFN0(_[H$CQ@"_.G M ?/XH<+\;"1-Q7F/,*#2%,6G'L%[_9HB7ZNI)1C8[(P;ZN7B-; MA>LMV(1IR)FTHM(\_?+)D8BF13\'*E6O!)W@TN!;8#X)8"8/%9BO:Y^_BATZ MY6W*26Y9"] ;9%WBSS:.*T<(6:"K:T;-K0^X3P\O,9;'PHC/%=@NAMZ]IDL* MJ",?KD@WAL< (!]0T]DU/W"I[7I16Y5)/V/VE$DY-*B$*0:O1Y/^)\+H3\HT MI]4K\JW_O$3;@U+]PA,B"AU-[HF$?#[(+X"(E>TKY^*12?1IMU.=* MPWR.+%41\Z'VB^V!U]-(P@_VP.O4H/R#4GZ'"*Y)9[JQ5@!0PW!G!T]C)3\1 M9:W+02:M7,CRP];I8YH;P;(Y):K/P==D.IF@HU>S1'@OJE#"FH!'(JS)N#%;Q T.&S5 MS%$7(VM&BNAC(8?-BQ"N2;0J+XV=*+2.,UMG5[F$>,^O#K5HYUBTC<[/1M>M[S M4F]7^+Y7^)H7R9E'G3M0OP0YY\[7_6MGCD2/1&RD]R]W?C_]\V/[_/3M6?N7 MB[/3W^A7%0NMYV_??+Q8N9>E;6?'5V]2MA'G;S_\]7ZN#1*06_U6W6_:,!!_7O^*$P_M)I'F"TH#:23:%325(D29]NPD#O'FV)EM:.E? M/^>#$=A6]:FMJCV SW?G^_WN?#G93U5& S_%* Z./OB**(H#WZS6(]^L#'[( MXXU>"8Q;*?.";>7#T#XP#B.<@*/R@#$3)DO4%6::J 0G; MG^.6^'X87#^D)"2%QC?#X"DJ+Y$N'/]<<34X0*J4 ]CA00D(>XA00T*C !!A MIK 80,T#K&W>5YQ);0.>P!<6XQSK/[V=XR61^@2.8;8**8E@&$5\Q11A2Q@1 MD;W+*GU?2462S6&9%BF&2XY$7%3I,Q$X4ES(M\!LBA3A#%%]7Q(C$:5PQ47. M1:GNOXO[V4_X&X:H[EC%0>F+(2S:I0SA!@1.=-^RJ#"5'J+LY=I!*J1PIL]+ M^#@B%,.4R],J%==U#=NQNJ[5AE)V>[TSMR%[M=QS+:]7R^>>[7H[N6,U9+N2 M'Q?I/6.03XHQ1EE;8X0"R1_H+9#:&Q@O>!,Q M64-$D907K%\S,S4X,#,N:'1MS59=;]HP%'TNO^(J4^G+(,!4%24A$NL84KU Z:^?$TCY6*G6=D-]B&Y\;\PY/CZ^.$A,RL,@882&M;/ MH.$L#-QUK 7NNA!$DJYLR$";%6<]9R:%:D2@GW4Z+F*+RB[(1U$>G,#]PLK!W!.(#X&P3#[DR# M<)P+3^$\,3N04#W=$CZ(PL%=@A&:P(TJ,E'8:1?#IUB=8N50_Y5+XQ\@K9,^ M;/&@!(0]1-A PHX6$#-AF/)APP-:E0:W>:21(E$KD#,8$8-2$ X3IAE1<0+7 M4F7-MR#)Z\SP,]<&9ZO'['!5$GA\Y5*5Z?J[;J=]Y6O06[6(+@3[Q&*61DS! MA_9[Z+0Z;4 -'+5A%"+&Y=([H6Z&1)Q!)!5EJN>T'+OKG&>$4A3SA['.2%R- MGR_S$JE)[&OK?,.CP=G,>"0WLDJ4YVZ=<6QWJ9W9!J/L2Q%I!;E@RF!,^&9[ M4J24L\VO=RZ;E^?E7#OE7WEA3S7K^R#?L7[@YN&#QPM4U]!G,6XUNZ=@?),K MU!3CPI.%^Z2:$X'WI4>/K<'&4OT7;D)EL)<)LC_[E53^G[I/'GZX)H)0LG/2 MWJ1#O@MCJ_+(]ML_];([G*H545Q S(G6/>=K_W;:&/>'@\;'R:#_Q6JP6QT/ M/T\G![EDUE!R^6>R:%\P'HY^?-NBV2^*&\LCP;)PRQN,O<\4UYW?4$L#!!0 M ( -%H9%31%8$?/Q( #E( - 97A?,S,W-S5<^W/<-I+^ M^?)7H+RW6:=J)$NR\UA)4=5$EA\5Q_9)X[O[%4-B9A"3Q(0@-9K]Z^_K;H $ MYR%Y4[N7JBA5CCDD"#0:_?CZ09\OFK*X.%\8G5]\]1_GC6T*<_%F\LL[=97; MQM7GS^06GI6FT2I;Z-J;YL6NR3>F/NNGXIGXYZVNK:Z:TXKV5)PUYJXYT(6=5Z>UG2^:LU+7G#];7GSU;R$E V]-?2\M+Z]N+J_??IR\ M_?!>?7BE)F^NU/75Z[FLR44U.KY\ZSA;JTM5+5_-M];19&$7B>')T M=NG*I:[6(_YY?!9OK\SFG=;'&ZZ.]UQ;AYO?J(4&,9516:$]D^5-UM:VL>!( M;>;6XWQ-KEILH%8W8K=(NC"2R+GI1U_=P?9502C5:M;7;1&_>?AT=&Q>MKOGT;=T*CX_N%CDZ,) M^.G;$B^LXWG,365J"!!.K03GJUPM:W=K/4[-QS$I[W#<#5Q%W2S4U!1NI7*' M+52N4_0ACH*=WYK<4>9A:'/%U#;&:0F2HS M]#0L2,(:+*E7EZ;&3FVF,1]H>EMEB933=#^M"[V"*S,:*H 1JX7%!9:UW=#- MI2!G1MR*C\N.JZIE7>)]8.I7X#FJE;< 9EL?'Z X^P.KIGA]9X =;0$*('D:8!>KX^&1T='1$?Y0' MSB2T%YX#V&'$J7IJO\&PHXUA]'*J]0.[>L2&=0GSSH-'+-A/+2;:7(VF^<@J M1RYAYTS)1(=*_-PK,ZU;,E$GW[*?.QG1U?'?7XQ>O/A>3F,WE6H%W8;6^Q:K M$5&N;7R#"VQ6J*Q<0ADYCV5'G7]HAD>@9"DS'Z-BC6=P@TH7AI= 9/F6MRC2L+[YYX*7BD/[?P[Q %X$V#I^ K^^B\ M@[3LI.%[Q:"8;EC'?D)2MA*XL8?=S&"(P[)#1&N.PG<*"%!N5:QYW84K0,*V MW8-P06:Q>BHAMP[P@R21WC1%0.(#.GI\1W!+#%[%\N]PO\:>&NS&'ZHW>Q8F ML4W7I,"@6Y?!&,O]UGL+4S!_L$H9EPR+$;_A$K!C0,;2-HW,K&5>BC=HQL") M0W63_!(%A8U/M!=OD:OC' .\GP##TF@@+E:\#;8&-4WW9.Y,G5G@N])A)WBI M4M\>_37R+LR_="NR'!C &D.O$<>%ES*R9[L@9!Y@\D>G66.P9(__WA0G,J8V MLTL"TH9"!D@%3%4._%+;:=LP<,:-PO[6VCR@\232(+8O:PM9E/.G!4G0M[R^ M2(5H<.KR]PI^E#3,9,HE2UI8@FWSU&<@4-2 ?$&+T)Q"A"'X& "W0X7HC.2G M%A%VU2T6)I6-LNMM]9ED;=96['Q /Z^-(4DK\NI*V)ZX_WUY6',NTQD5.5G9%+F!")8CG80,"[A-3(=[TSB M6U_KQ&N/$84>S'MO8M)F.'3$)S3_9$@.8.B$)I M/DY62)S9K$>,6F ]8!9J1@=:$(6X\8%;'M'2'$6I=DG7NP+#32,,.T[P 9+. MCC;@(4Z:.#6S=^)$C0=3F'2LPEZ7_N[2.OP#J+@P<[JFMVL3H$#O31AANV7( MY6!%0F(6E\&&QTQ-R%)E<;W" I#(#S' Y(+L\]8G6F7H\ATD1&8%$22 M0YB8W9CIEBPS%_ H+XV%J3A7NP[P9<'PDD3KSY0?+(EG]!AF (:=XT,6]MS. M(&8@$?1V2<9B+=I)M'%_D3'X M<[-;4L"(# XFT"0'(557+*#,FO_&M*[UZN,@F]YETBEK3L+[X0%?F.3J__2P M(>#9+^,&&S8-_YQA//V=A!N)\=YIAV NQ16R](KC[:RGF!4Q*B3R:TE:Z0QV MF,:F%K7U[*)\6C09A6H6I\&Y'#5B,\;FUF[:5D;1T"U''13D[64=\H\N7F,9 M3H8) \(A_=HI?82N<4YC;)B*G-_2/0[7-[\3(P3UT6'&8R2R;D@\^@X< 9&?#@H3I_9B]( M/3]Q1/40OAU4!_4\*(;$NAA(#O;KEAN[I985.3X?JI#SC&H%X&(V\B!&&WNV$B7!IS9HN"X M%(X\P'/X<\L%RUO39=(T%.57!O?;.2I"XZ0W9J1(596=J0*AOT!)#:#DZK:D M_,@*C^L1/6>L0&0VX56U0A 14WVZFSQFON1N0!?SVB%4H P<>;QF8M]A=)&!0%G\<*G_= M(^*H_8F&/^BAMK6DEXT0 3'FCL60*-#3MA'!HC/,=.O-O5K2**KO-^J[[PY. MGCW?G?D-]_"GVI-A$]0V?'>GT,MNHE2D6AD2QV%/0^7KJ&Q6[@" LLX[.+K# M4BR+5KIXNJEYMYA?)D^T=;0AWQN,C=%AQ\9MH[+)*#+#NWDTK&1O%3,DQ*X> MAV[MK@ M?"%"QBX9&:YJ*NU4P(7@8.X#-MM$X#]=>_0CPJJ9?/TII>)_Y1V@\Y MC(L=585WT0OL,W4,WPB$UX:=!H4OLGXG)F&I<$9^D,*CU_&*=Z61]!\%'4,I M]9OZL2N)DRVLF5$M,6O9NX@OXNK0;L)'G%\%B=RUYEW1BH)+FH;Y10JS3;\* MOI!+_E+]"J6P-*;!4M/6VXHP'1F$ELNB/,$VBV/\)^E.F3DW.B_H_5&O^T$3 M)*#+H.$&DK)1D9I28,?[BLM/S8ST6 @%<>&L'/F?8PA)R\U\=X;,R>,$?O)&_5!R&F16=N0198M M8KF&5<[_O_8+(K02Q/SCDX^O?_KY25QR9?-F09\:'/WU3,GK!X69-:>*/SX( M=SC5R+?HXX/!7*\FU]UDB0U2H<5<)0MLO+N8'=1NM7TS,_!^'U^___1+OP>, MH*\KTK^^.E_4<>&/X]=7!S]=7XU_/AB_FEQ=GT)A5GJ-D'4*TV_J4ZJ:F@$Q M9Y )V=7)\NX,NE4X#/O+$?^']W3VF<2KR@^&C[88\.;E;@80%W_W]B7)D%ZY.0WM_*'NZT=N5[Q8V/J4V>G197V^R(5%^UIC]HF MT@E-3HR* MVZ) , +T0YE7ZY>A;NKMB=(8 MOONF@>?$P\*M=8'+X:F8GPH!&24WR08P9TK*2E?87R. YG/E5J2"M]85G;! :7E-++KQ.<_W+[KO M%7!VZJE@<([8!OS88GM;85+(0]\>.TNZ6-,!8K1BYY0?-CSY;QB(/;6W/;]3 M=,MQ8RRN)5D.;,+>4$)_<=!F7)NW6$R"]5 M5?Y&R[NXOT&X$(.QV'=JMTW0T$1PO!#,$/_H6=5Z24G4=9+8"_HS>"_>0X#> MUEPIC\N'(]U:=M2]"T4NE]!!$PH.W&^%".Y_Z.7"FEO3]8GZ[>VD?7=TL WW#K MW2 CUF6.HYTZ.7H^L%,X+OGBBZ!(AU M:@5D)@:K;PFDC[B#M4T^D33Q.\:8QN*""O='Q7Q1DN]*IQZ)53/57'/\S&7* MT#[8Q=)9SZS83BC=_%4<:GOF)'U_+Z=L$MNEYB//JRB:G1:*OK7KR=&==**9FQ!S="( M,D*4)+848S4\;=I<4#\VIYSEH?[#OOWQB+F M#N1Y'VNZ-!^)BU3MYM3.$>1FCW]**GJ0D\RD 4''L(%4#GK0[W_LN697 M/VO]J7JJUZKGKK7N=54]_'C8!I"\4-50!:"AH0&L_OP #VL )0 &.OI?SY^& M^>?!PL'"PL3$PL/&?H1#@$= @(^'CT](1$9"2$1*A(]/0D5"2DY!24E)0$Q- M0T5!0T9!2?'7)&@8?][!Q,+%PL*E(,0GI/A?;@\# %(G%..S/&P9@'*)O/2-P\:BH:6CI.!]S M<3_A>2HF+O%,4DI)645535WCQ>LW^@:&1L8F-K9V]@Z.0"&1T;GYC\.K^P MN+2\\F,5#('N[.[M'QP>'<-__KJ\NKY!W/[^RR\T ;:?V__KE^D?_Q"Q\3$ MP,3^RR\T=+^_!I!B8K$*/R)3U,6V]B!G$PG'H7B>7MPXB,LNJ@>C?.LYAT?% M\13""?_+M7]X]L\Y%O$O>?9_.?9O?H$!!!AH?SX>!BE 'G#_\H[!\1_: M*9 ;G;AQ]'YK.?4?NK(DC.6_2+8Y55EKPH MTS5F1G M5 'X,MLDWO77_3<=4-=_I@BK.!E5&M;<2>876_!AC&_, DN8QF*.DZX#B ;( M/K\R9;#O#K*D/33FH> 57CG.+FHX*7/!O!(:MT3._ "S\ M?26^/64&UT $XUMK7-FUX/N97E5FFXQRW* QK14%,JLI@,QWXLG\S:6W*]N(\XT E0UPQ*"?7A'K-QDQ)B[%4!!'+]@*(N3M3^H8/7<760WCY?E"_^)3BN*%L840XAYV\L?2./E&&94=0D&- M)?21GZ;K6I%X$VLV0'6HT/2 @*HC1N??C9Z1,;Q31SZ%RYO0=K! [LZV(;7S_J[?\_]0Z]@0 7!S)#^*!!K$:+2&!Z35XGPLUB[_UC] MS@4?=V)Q#]RM$U*.1=$8K9Q7Q,8QY9W_[IS M+9K '_-FXD2!\0'P]_5H" L1])>&9FY61K>>!+_5%$O1F"?Y.E>;U]/&&B9M MZFQU^4R,<7PL%<,$\3TX#?#9 M^AOJ/ J)^R01V-"*8B\;B#S%#V?#91CG8O:L)%F<&803;X LMIE(]CB4%F0' M4QO>L)]2AU/'US[MU8,3?%F=>FPG'(&65C7Y!NL]M0OWC G@1&Z<^B;4Y+_I M7XA0QYF8'(LGS;"-_B3OM7S/ZQ\6X%6%?;6"]6(/'E=,$5?,PP,<=?O$=_67EV%-?N73HL?WW7:I[<:OI&-(5:>'H-5._=E*-KIBB.I M* N!INPI@PCG&ORX957-#R4AY V M:X43I>^WL%U_RX[K.,:P^13TVH4T =*3],/H2;-![[L="86QDR_ M+?+L3HMA*IK%UO@[-+* 6ZV50X32SX[EVP\:UR>^J]^T%^?W4Z?<@69XO MK@ .E.*1=_H@3KAJ=3&PRS#ELN;DS%>)*H= 8+3!B+'RZVW(.V*]9S221<3: M?[=TJC44W X1B.1.U86/Y3NP]@9+&EBS\'M'/8H"]71,W*K)K&A7(JU@;M7; M01J$QW.+%;'[XQ&)#@L\ C1/YBP_'LD&H^2!Z9&H^3@Z(+,U4[M04C6,R?-?BG,57J MM"Y;BB*W$MJZSJ.9O^^/_N'0Q (B1&_%AA,3 1RK,J[6U>[GXXYFSG2.,=_= M\(ES:4-9Z PX".(0#E*K.J1[ "1[;P@:+>AH!@ EWUW#TW#2468\5JD?X!<* M3)E_-SC?/_,Z&V$#8?1DI->'9Q>Z?M9R:4\#U]\R&=$J\54WOMH=Q'XWL?_9 M>:O5<,B2H#5N2<:OW#CQL"AW-?]'[92(>]03_(CO_4(695X)@*N_IZR>'D%RTNLP2[0/ 63O*X$#+ M6,:KLN;8\:?1>)/Y#4^2_C?G9OZ6ZN_8-$7$^O^W$)=SG8:PFH(X,$G.)5EP MN^;R;0&9S'^YK;5)W)6W>[1+SC@M,]/TT+D@U7SN>]WXD=*>;;FU2?5892/1 M.%N"9ND+LHJ'CA@U_T5R^;_3C](6 M>A\K^- /Q0/+B?+1;%M^VBORJ+,CO#*>C'XD/ 0(JB#,+VJ*F6!T+K@OEWE2 M#5+N1P#AY$,HG"6N6:3HCJ:6C=G"V(=9)[JZ'N<6<_X:K&PE7"ZGKEB6C%(: MKLT^&B0(-CYRACWRNX=,HV05X?>F8_ZBT( 7H"V(9;_^2J::-'TI?L^([NAI M?WP!R8I@G5A;O3>VA1C;V]]*4'&R[FDB:K/(XT*(592?D7$2:T-&,<6 M@HA)>#M4;"7JZBXT=I.C<HO895QHLYHAA!&C%;ZIW-\VX"!0?*":IY9W5[Q4.UGDHT MV!FZ80SB\FI01#Q$8^6-/U*K=*+K32)1T50H*96GJ.N;G/W[-2I,P ^.)'W3 MAD0+[,99UZNI5%K_D"WECJRB6+V<-^&NY6D.W$W48".K78P"0@#(7&(0/S79 MLL5A[*Z?C)C2L0 MV$8)3B%^!)F*^1H8=GF")?[P2*)A2U#/?>B(KH;QHH>7 MI0'2&G%;@62!96="5[V[&TC]]S)4GV+5&PQ.3\]HU:OO5[JT&>JLB_)QA@1/=8QS\0&V0_UU ML ?=BY8 (XI=4/@E_WZ%BR^-<>OTV]J6!VDU;S M/C$M'X#E/6:$U)T\UN2.-@-J=LZYCQ@1Z5KF7S,J)5=>M_7Q3YY?[8U_;ZYTQZULF.IC;X4L9%FIX 1-J4>NQJY]FI(EXOVNP<$.)!"Z1B.V3;FD MBL]F,TR.Q!V -.CK1GCMR),")3;Y9I'D\$?0:^C^BH(X746[#6M;'7'^AS ((2[O!15)41#X!F]U9FA.8E\^D=5;+;^0.@9?MG MW;(5/68FY=AZUNFD\%D MDT"209$7Y4V)$[=Y&.D*S/C^0=M;?] "QM\>"P\.AIXQ:1,AG\4._\Y)\#:7 M O*'K',F6#:+32E/V-CIX<D M!D"/S?);!SL3I(1PK@*]N$^NEQV'WPMD/N6_P M,BD[DV5OW&B*?CJWL;3P[][)B9+AA4P;OHXU:EJIK_6.]VF9]\Z;L._I:E46 MW%=A0C:E$=&?WRUOA:-8'$-)6G!\S.EU6[I3OR:?LT;L2UK,@<5">&0YXM@01A4C>*\V=(/R@QF:8K5IE)7S^D^Q ,-LV88)=F41,VC?;E M2XS&DFHVC/:W'.H30ZC!4J\_(03EHWRF-B1TO_3UP.J^1Q9;3EOSK?B.L*L@>3N4Q$F.8$F,M>('(GO#VK]":@[D%Q3;6#M SO//?B$\;+#Q2OQ!%UDL^.6]+?>XLZ%Q^E!GIW1W)GL63P M6JU1I*#I&+X;"UJAOU,"R<+MBXL1O+JPB]BK210K@FE>FP*HJU;Y'=XR#WWJST.HJ;DFL5?:X2=B1\#U::^#2-OMZ$ MR4H03]?H0E**">W>"M/Z#$:2(MPKMA#N(V#]FP@0NVQV ]9YLA=Y8B3Z\\;G MY:+29$D#(S16!&GJE)=U,Z."CXR/J'+KQA-;:)YVCP#Y&\H6(4:/]:V2)O;: MOA!\+8L<9/&KCSC1:6U>V.OKZ(S!YWXK.NG%'IW,CN'A.1Y6Y%7PH8@X,=1& M,([N8K!_M0:R%2FF';LI(K592(GLZB%#^%[)C>/1[NO4OL7GR&#F)R7)T/R5 M9" X>,\\+H__A_Y)"U(Z;3(LBC$3(W7F;DXR@5*<=RJ56WP5F@%NR,7[.=9< M_B)K]&H60;%+R^A0Y]38$!&X3TQZY3&LHK *:*/7M.)6SQ;S]3 O$GMUQ_Z= MB>OPN'".GAAG#PK/YQ4RW:+H0OU" M#&E8'E)J0S/TIB%#6U@^%\0(32/+A'[\5B/!XCF!T\=M/1^UACFGOQCJO)#1 MJR%#P^1J;*B6AU36\2.U=_KQ+?TM=1>0AI \\<6B!:Z.,($&IRK&LK:3\EI%__AZ[ %.2:$U\#OROBG>1MREA26:T;WV1(I-M8')"7 ?%/W M][7P)W9<'W7^\*?"4)<++$3,K^<(VDK@M=SCKD4^I+5KW0E=8;\ZX J5\(8:GQ9=EP8;P:/!URD*+ND)J;Z MJ$"HMZVML;=19TZ-XL[7;&(DN=$M@W+&[&N/3[6,*_QC"S-=962/-*3F 4#K M7^RB6NEC9R,CQ%E>_3;NIZ;HYQ@_ [Q(CC.; =HB8AQ8[])-M+RK=O(F7R>L M,-Y-1I(KYBG"Q3Y6L(V^V[ MB\AV2W*.GMRI8?%W6F('X&)>#Z?99HXODR239#756OE^[T33]4'L\#R=91]> MZ>#0@<"+R#IWOK+%MXL^7.%GI=&41O&;DC1*C^FEF9O:9?XDGK5K+KA#G!PM M4G!>ACYHVY)*K<&I3Z@_PZY_UIV_J+DQ-X#S[F6FC"( _.C1Z;F5L!GUF0;L M!BJ?] NL>W;Q+.^ZS6VL+,RZ.6/8&BR=(C'J.\DWX5P953M\:0T*Q2'\X^ MG54.PXU*:&7$BDJDL9S@K&JZ9)I*52AP\#I //B^R0WL>S.XTZO)/)**JP$, M\BYX,F>Q/#HO79VC$U7>W2?.E]R-9\H.V)&$ALFQP_4TH:&IA3BM9]C##P#2 M$$:$IBK,%@RZJ/ WN9M>*/M58MOH=46[#\\*7.:@@2'!-3\L4^M?@B!P4 M$\PA?FT*/E98;PZ\!G,.KQN#32^(^>!C46//FZQ-]UFVB8CD*C.AL9'6\]YG M!MI4AQY'@>_[5+).G'3BW,HFZ=F"U\R;<(8R_$O-$/%%1_AU [E].1XU1^+) M 5X5XJ4$KY7#;&DEOOQM[)OF?^&%"YQIW"5=3*D#-4&]\9 M[)991P7'ZDOE7*=[<^-4LBI@.N6_**F7(E4D^6Q[Y4>@]G@JFM.*!4>;)>41 MB1:DDRW6\-=%B?KI;KJBO@-_>PW6=X]N]JI1KM&91"5(:,0I4@-8,@/-,\V; MTGR:JMT5(7-?\2:!BY =B\="F1:[>$91@9G=7Q!B&2LG@*1$^,!*1PKQD2HP MY"!1J7,5N#XY: _X.P?+_6VWG1UK.2%;IZ?0FL9H(/6PY6JE&:(7IFT&,QQO M]/"I-T9$9_GDBXV(; T2MK;HK)=%D\TWJ6I: MSIJH+>[IQQDY](]E1KGK,K]\8GI6KS8U8J>L* /^G#$+CM._Z'S?HFLH1&@V9!Z3SQJU$!GRF.6Y1[>\I-W:_6F2 M@]CB+)H*AB M;!<3;KAC4=N^"%K:,\!/+TMK705F,J>MQH9D,7? VF%.H'N4>X-W,M76\')3 MZ[<:IAJ*P"B)Y\>[-/2V"6E9.!C(%;+\@7:+#4[@X)O5K#.E/&KE#V&!CR$M(NV;V)=$"8"?VB2.*%:X1!B*.=3* MW_>K6&MGQI5R,P5&IA,$I&:F-OSYF]3:4-M0"@TH,;%3"'O3;(\QA0&O V?=6*6' M;9=+^C&9N=([*C#W3E=PTQ-0F>ENG-!:9HK#R%:3]J@\A?/O:%1EA3^7'EE? M0>-S0<+>6@WGS[(_2 ;:;%69)+B51-OV??F4WO8=-/#!5\XH(1>Q#U2<9FLQZ=[8OT**?USY3KXNQT6)OX-@XS'JTA&2_Q1D:WZ+03ZGLA%E(+MF . M?^UL8A!;?D17GUEFK/@H,?#GK:>)R0>.KQ_8 <+2X0SPB1H4\WT#B!(:3.6\ MILD8B%^1JITQ_K)G 5E3I^@>&?Q^(/J+WVEHCR$:[C,+9XQAR]9'S0YWW,>A ME$@ER*]JIVP)B=F^G+(Q:XRO/1F;0LIU60/ZZY[:>M@O ',(:5@[5&VH >/P M3Z6\W3$['OW4(G^)5PN/%Y"=@>)(G1:+; MUB9HX87?]O8E<_/%F>3.3%R?3*QZ9^>"C$&V\Q_J.*1D4^DX#_QUY(PY0_DI MO:>Y:3VX:&38Z5VEI'5*L-SX]1!,%I5(59&=NZAC!J0"3W<4++&+CLI.MJD/ M M'C,4N!!&\((C_I8&/ I:\]$-%P#.ANX.=12)XV@1KG_//L7P%D'(92#JNT M94FFY$\G=M/.6!X]U<=KC0ZXXP4]7\K][K,@PU5J;N3OK+00ZE.E*>(D8>*Z M_8EOVY3U9[ENL[RP&1'QBQOUOW@,7KX%>"A(UFFB+XNIV4]V*5YYH6[SB=VC M0[<-4GS\W:RU3P2[T Z:4!=>YKC7_E+:L5"NEAZX?GULC5K-<]!23!#P<8+Z M2[?7^9$)$*#(()_;;:U"<2-^!:.NPHBSN#R)%4_IZ5^8! ;_![836Z MH2U[Z:67VNQMY/S2D*#"DC[R=>XIEG=47Z"N5L9F5 M:G#$T]Y.F*>HGF,! O+'3X/@3WH$WR=\X4 M@M/>?R4@P94\=_[11XJ:Z6J("!%V9N)=NC1G^@D]?P#H],>.X-=::/A1^-DQ M@/'M=4G ]5IS!]MM-\S?=K,N3-S9F)M:8/GUU)1%> T=LSQB6G)J7-DG&NT MXNP$<*28#_ ,.<1A_?"#W%KP?D$(PA=&+(3@?K&U/4J,L3]ZK(NFH5I,TMS& M3&,4'TD4>:G8#(2GR-W1WJV-"4+/5P- MJQ8]OTR_\I.M+ML*"_S84^8YQ(]H8CHF-$34W$G[-T"O8N-KQ605+_,PVK6>R'(9;(B8@ [I2JQJVB$Z &SKY=.#*3 "8*OV\M0[Q: M&_65 @D;(W*TE^J+^V8;!GT*SC?MHI[.=;FXL[:A*QIP>!E<$4<_ *BU5D83 M"06FAI:S-R6[];6U;O5L\Z=Z:W_9T_H>ZK/ M9WI$N/6QXZ'$(;Q(*\3K&G]+2W<"A.]1[5L5<6IR"Z4J\W$^S\C'AW/%X4DJ M+PA/E6/W=["W#O]DRZN958?1KOZDNAX+D!@$K6K#*;>@W*>"_I9 _'$P/Y_- M3[,UQM/O?5YMB[MHOTAS?U[$6Z*#%&%Y$.<9*#.AOWY=WSB$D&X9_#7 S4!S M#7]V_NL$O^IBAD36QUL>C%UQYTO5! #B^M>U#MP[TSFWM[4]1M!T-#MW*1\5 M&^#%M?HT/ 3>X@569Y5>Q;3J>,+TTQ-OY_V?MJFM&W*;G6[?:N5E2"+FG=Z1/[G$*>[/_3KEGZDL.DFR>=,\W5O MH?;L^=G!"I_8ROP#H,W-5>]2X$.;!-6\%L&+HY;S+ [Z2"9:P.->_/%"')"2 M!PQ["(4'*X@O_F%^E)-K^P!8/:O69BRO-6@7GMD;YU5A[R?%Q H[*?C1X/>' MA(GD7&O#-XNAKGK'_!+#JNGJX&YB:V+PDY4S'8&&*=3?V1>G<4HFO3?=!GZ1""S/.7 MO&ES56]5G<]><&/L)C:L5HY)62;(D$+E\1&6@UT<3NTG=#NO&">RG+?\Y+/Y_)A;8#HGRF''X2L<0=&YL4@0M$>!]BNF\([J M:%G001[)%<*6\0!XU39OM>"&S!,+$E]HQS<&D$"^3W*H$N%]\4I/(_0!:Y_. ME!QM8?ALQ4C0[3=7'X%'T<'5.+$UV4&[M=644416T4K>*AR-M&J5[C9:]=&1!!F%0U_PHP0 M3!X?-6D00F))N 'L$U\I6KF4[EY]NTQ&KY(-!9]KBT._>Y.<9I +V)K5[[IW MJ>C.AMHP"@Y'6#OOA)+*.)E]2@\: MG@^Z+0;O"YNU-I93(8QR)U#YN/.5(7!TZW4>W_*URGM%^+*!SMF@SV;]J0E4Q470=>37TR;,$0M+PW>X M9F$;GFBUG0\ ^\4NV'F6#5>R6-65*Y\V5DJK,V$M^1I8"V^8OXEMA!U''\-M MK4/^&[W8Z:4.=JK:G9#_VP7+^?-:=S%\1J+9HY]:$,0&8?GZ,C?9O ;^$U 1 M;AH-MG#%MH>))6$(FN,?(GGUZ[.IDTE*Y;6SQ()WGO.^$E.._?Q'$YRV*CY\ MU]M/S:[*9MN&E7,*3.35(5/NU?X)#P##!T!T>/W03B,)]P MU3?:U;T2=-S)M4^[N0?V]S&7,;#!.5;X0?PIM+,Q6%"W8-V$+V>YXJR^-/D! MX!7MN)=A7A]NZI*$*V-SE,"-,5X7ZO#QTC24],*%6&<^^=+JRX+UWOAK8SW-<_54 MK.[EYY/^9]=5UO3DWW7C^5:K0IB@L8\BFS,!BZ^,&-C:E7 -YHWC,"[ZB)D^$8BUS;ECO M6QP\Q1\I$:0I'"T&F-^<&GK4",;J/0"@C[O]L[O,?H=4,FR^YA\,$FM[3QH$D*I4@=ZZD=1G!XCAD&U8?W+%( $4'#0"# M? JT:9!L-#]2"J9<\LRZKS?EV4H)S_I72K4B $ N:WY%>EO[%MTL](?JW0/@ M17E]PC]Y.^+_!^$IJ*LU+;6 M-'RN[3KBZT']$I-$^*??)6SJ13?#N$JJU>J OU0Y4E!+.Z+!GT2^E07TKW\/ MN6DWZ59@N B7W\7U> !8TU_<\V1W\1R 8C-#(?B M-=YO]-"_:O7-SU63--4)[2HN8]Y4FD6_&9M)IMK"<;ED(=?L7KQ*5I65PW?5 M?D-%6F6;_JT699;<$N /(>;C_8!POS-%"(Z"@Q$K8EJ"PUUU*<5RA?Q=%KTC M!#96,B,?2U)Y!B*_1O!6A*[60**7<_A3BK?KN$Q3@ 8!%=OIU!CMB?[Y, ] MVB*E[SP=B%RG&W$U'=_"TW"UMD7$0_0YVHIMW,@-FU^-J9/O=F)T*U/^SD]6 M8&I5L?-WȀ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

QLO.HP PED; R*ZG%D[H*;3#5VZK!VTGFQ3Z'(-[6;!4F\!HAWO#B,[M#;& M.GG$9Q=L6DW"*NTZKV7+K8&Q:$$7R?0[J, 3S9G)!$T7^W MI#0K*N])DL$A@,#N+KS/DI-&>:*LOJ_.<*F:Q*&48L[B),]H!'K-'4=SB[_* M4[^C_#%6;ZKVLO2DH*[8QI4-5>YB"3)FY3W+%C,TS/-\W,5QQEU MI_]KII$ M;(()E@])\"$)/B3AZ$,2-"R ]21>H_/:Z_'V+U&C\^LW@Q])BD+GZV^>F78J M!SHWO]42:*]JC&J,^QB0\,\\%L7PK:QMIA'&,:_%7M:[!KYGS9>1 M\GW.XVU PTPM.GG(R5V]+82OC/1"Y"MKRT2O3_':MM>VO;;MM6VO;7MM^SUH MVZ,SB$.'FX<>=V2'"^\>^'=2E#:&MA^ MEVOKM%I:Q>X_V/0;D#35820W]7')8L'E>]A:E8JT"A!2J[Y>P? *AEG'8%VEW 4DC0*ZS;=KI2@!!QM'3;(BQBM) M7DFR$O:TB:JMZV=Y-<&K"5Y-\&J"5Q.\FO"NU03;$W)4>?FG8%$5*RBDRGA7 MKD!=BTRS=@X&RT''D9];$>7E:"]'MXP4VA8!@4?]:'LXQ?&Z@HGD8#M"[:*: MK$?R&H/7&+S&X#4&KS%XC>$]:0R=C\P)NAG 8M"HZM'/4D]0A;ZDDC' M*K.B]H3.&=]3+CD*%5F1]5>5>;96GSN,ZG0^OJ9\%X$M::ZVL+AE22*)?B+< M-C^J[8#>H. -"MZ@X T*WJ#@#0KOU:#068B8M'&AHVH!Q(ZT#DE':1H('E.I MD5[T*2!NG)5'NHG*HQK;?BG^$<&:;!1)K:QMYC'&,;=!:/#V-F]O:VUG>K U MJ.F[.$7RF60Y+]AO>3W,/>6K%NCLAO$V &\#\#8 ;P/P-@!O WB?-H"FLW'2 M"GX;86!4+>?70*@*D ^J &@0'E0 ;:7O0$<;1_.QH\;K0.]%!ZJ]MN1NMU1> MU,'EG*2+8DV=;/9-;LA&?353!HOR_CGQ23;,Q&5:ULC]G<:+94:CV2/E9$&+ M'\_DXMP5FRTO8^2Q/ /#XHOK^?FS/.-C491_^HT*V7L[FK*$;CM>SU_^9I0T MCP^84PWQ"TL?"QJ+"9LIZR6T6$^[09RBU52&;H>ZS6!(T!_NB;M,TE=M#+5J M2Q2J0%OY7>M9Z?X0;TGPE@1O2?"6!&])\):$]VE)Z/\TG;3MH;W(-:&X@F/5 M<"8=W6"OXHQJ\_KP?9 4%XJWN\!7TWL*A*"T>-+AY4J7Z9SQ57,.1IJ+]6LK+1%UZK3AY<4]82>D;C4 OLM]!O@0PUDJT'3HHW_+P7PT_O@0[5/1'B0C*+<[F,>$J2[UD\XFR!2?K91R29,8EC[ ,>ACJ@5Z9]LJT5Z:],NV5::], MOR=E>JR3=5R)/A#Y:D7X)F#S0,2+-)Y+(N6O) Q9GBKU)%BS) YC*N22S4B< MB$ MKISLU@90X._A22/I [U1ZM6%]Z(NU'HV3TE*HIBD=_F#B.4'OOG\@@,= M."V;FG:G)2'Q2EPQ(4Y9&7'S6>Z85;Z:59?9T3/)W<(L?BNJMNW>G>:-G(%9 MEI'P#_W$Z=IT?OKYIR#GE]^PZSR3/ MH+_)HX9Q+=U=AND1P]:V61)PLKE?4A5-2%(];[3OW .]\>HAYZ+8(A>,RWV= M55*?@4Q@G^XY= >AMN4"I)&21=5 ML#;L'@3H*^/$%Y:2_3?W\I.0LIYB_K5X.H[R7O!B>,_*V'0II:&8*QI/Y3&] MH#I'B;FQ ^I/\CB)RE" [4=)'I>"7_$*C._*JJ\#;*=D'4M%2Q5C+(4J*42Q M>?:DY*@H*LQ6NO=DT]4ULE)K5.JDE YY%O]5R(ZU*FCK_G@P[C>/4OKM\-7W MQ8/M"\TDPPMSJ?V_41G:='6"3"S5G:N/)"E8>'8J^?=&&TJ$9PGDI^NV)I0=K,>/SH&[JANC@E=O<--Y%N:NV _HN< MIW&6V>2T$;4L'="O1E&1$9)RI:(SS1U6B0+_5FYHC06#<&,T= MIHT"P=[>^BEW$?UW9<"5=EDUM7>(X9:NE>Z=+KY*J:H)0'UC!]2_S*4 25V0 M+BZ09$O*2[YO%'NU[1S0?,-92&E4Q,/M^/T=S;(R '&?YE-6*-$?%NT'NH41I_E@ M.P#9*?9J=!5P&L)?P6P;SCOOF> M1!Q8AA(:M@W4CYE-.C,J'MV/H: 3'^YI;_8H9L "(- L4@NMD('2QU&MT'[U MXTXKM:=JBCVN5("5&-TR;:O7LVYYT2@7]5#&D(D(QKTMA;;)_>BDY\XS8I6- MCVY!P(^P=@4I@(!_1,?HP>'7Z-@]S"5Q +4AQ@LE'^_33=.)=_^$;N4"@QW0 MK5N#M_"EC<:8!85RM7;TFG9:H#^C6:"^T*;U)GLXLD*;XPDV,$@M$\/12;%F MM/U58D-G_>WTF@U)Y.,:*(8&:DH[&%="'P8IJ&+%N )=;T"MHZ;'E0MZPPDI M%0.$]@LR:!V2E(&(?T6&&))K#A49L%3Q!Y0*A4+")@8!,P6A\+#(/39YA%!L MV$2;KKEL4-S8))W&A&\H,&R"C4TR/A0C-IG&I@ 2%",V>0:>^ M%B$6LL:I# M#@6'18+I5H4>:AC (M-8IS)" 6*1<'JM/+T'/\*5*1\#$DH6*8KAN]V) AJJ MA#CTI2<6I/A;3=[UK28W,#;4^8=XN_%(=[;)6WE0OM= M+K-MQ/)9SIN\#-!NR!"9K_X#=SPN5 C<#U%26L&&7]9&8[+UQTQLWD9E&6HA?6*PB'P>SBFA'=FX5::#,6T6\ M5<1;1;Q5Q%M%O%7$/385CQ%F-+J/5[+)]?Q.?BOF90G1LJ"2+CFA[^&G.$-2 M?N/9F10,#'QXF(=X*YNWLGDKF[>R>2L;-I.,M[)9+.\A#T*U8MBBIP/=]KS8"G-4'487).9%K;J79:)>J<&=Q_-6"6^50&^5\)*ZE]2/3U+O MB7=/3#1O?4Z/*IC_&*RKHO@!2:-"@BTJXG<3SFU''4= ;T>5%]+?M9!^F5:7 M"I1W#/R3)M%7N1QX=6E&49%86T_1OK,#@>^,KCD-X]+ZFT:'%_9HI#] #Q?U MI@ZNAE!F^B(S<3_Q%XQ_%3IYUJJOB[I3NIM+3C;WDAJ#C]>B)R90-MP*@H7$AF.M\$S,1M5!_1G52O53L*ANP2LL-_&NW$Q "B*[6:O:CCZ. MU:H;==YZ]:ZM5ZZ6/CQ9^S!(W&-V(M;D;,!PF1>-T1?X M/IB-"H+*_-?/PO266V^Y]9;;(2R;$,EHHD9;&Q46"!%;E?4^]5;@%$RGRCI8 M;P$BQU9VO1=]%8C]I\EC?VNJ&-5#\W,0%]?+!!EYIAW],;"QQO&^V-#B?2WO MV]>2K_*DN$GJGCQ?IBJV7WY^30&@96=*SJAD#@ZV5PP3N/% M@6I50Y=5OQZH+.]'D7-0<+8;'C->LK+BD?+[4_ESG)T2SC=SQI\(C\3O7#+& MZ_F\EOP^!NR,ZXZ%,4FJ=)>-?.@-V2AY^E1=_?(FP=&BAXN8ZH+Y[29.%)>F M_3NOLILU%C)8)V^5=&N5'(C:KRFG(5ND\5_%1CRAJ3R.M4NEH34>^J441CD5 MV76Z6]U4S,)02HFZ:^([C(0']_V29+^S/(F4 AUFY_,Y#:N#ZU:N.#OHP,&\ M+=V;\KPISYORTKUGH(5D.C&K'E@OF*@IST8HG)BISEJ$GYA!KF_=:J(V.9"L M"L3V\S2PP655(.Y?IH';2E =U<[Z2_&/"-8E>^EF: 4.-HZEU8H8;VI]WZ;6 MXJB9+3@M%I ^IMW4K@<#YD-VF0K)P=3@I^R1IB3-SI]#NE9[XB)^IM'IDO % M5;]QLJ"WRFNSE6*5MTHL6?+:?C#$T -A_4R>XU6^.B5B>9&PIRMZ0 L8%620 MH>B7[$L^6C>=< BP<7I&L2\@="(%L3A=_";_JWCG]MC>-ZBQU?0V7@^H$K*1 MVATG3ZJT]A4CJ79'-[;M3,U%S$7VI7"ODN2$I']"A.K6^[JCH;FA $8ZFCP,LRG9R/2\/#0WI=4T<4PJ0/)J: M(T%PI8PBSE@:<32XNA_*-2[N90!(B4"7%V>7-\V73$) M[^L&VT+57U8G4$,E25-3!)2;>8JQ\32I1\ ';^DC2QX5IWK)QTP[ M3'!P<> M97#@H5YKX#2Z9HXI-NY1?<-I46W#57PP7F<@ ,,6LU7<,>(SJ%K,QK"*$9M1 M,&)V0@A&?%IVS.#L#R.N1B, :ZMF3R[<%VI?1U-8 LP1&3@2 %5$P>P=RB@7;9^,M=,2QG.!,M3EC6[Q&D4RUDJM1[EFVPNHG59H M3V'Z?3+91C,?NC7:(%BSYO@8E$NRFUZ!X>SO[=T!P[[&31SI<=.9+5[H-IQ! MVWNY+FU]'RCW83O]M]/^ZRGUQR>"^D30XTD$[>XZ'U=MZ/'Z$4AU8,!!<:UPH$BR4IM.?L"2!Z;&FC5]K@/R @;/F@=4=+ MB_ D(/I?D:#O*;$)*DZ,IZ>TA=TUT0XZ$U@DJSZ2\_:81TB#_C40\J70!R(G M+9"M51G,PF#>+2':>MAQ4J-;DN63I-]WDK0\J5AZE['PC^N"F0E]GG1#T^XI MGC&G879'$]EP\8FFDHDD1068E=PEDN<416^J:K9Z,CN,TA,"QM7]JQ^___[O M#43J&G:FXPM+_Y0[/9['- *]6UB'/NAZE$(NC4R$U+7H7F]3\<83Q1M/#UCC MC'.2+@HF>K+9-ZGTRIDJ3U--Q">N;M2MRVL;:/1^$#\TT_3PFJ;=*[B5_^5Q MF&V71)[)(R=55RQ_R36O;[R'NIN?PWY:XFI_'XNV4J_4TU;W^TBTW:HMK+ER],UO8]*DG:V:7['1U7^R"HB^ M^SA+J+H<)5(*NQ2#-._5V,X5K;_'V?*6)L7)(I;Q^IX9U)P.(QPK/@0)4K.D M>)P\0&O%R$I7>06U76<7Z)1 TY U6-O&19&4A AQ/2\$&7.)%&W#:5&-8/4? MF!6,*8':=@YH/E^M$[:A]([RQSBD]5MOI](4JUO/65:J H2S!NW?DJ&+R!^AP#%@2GMC*G MJ!0BP\*J:^*04N-TUS>:!K485@-G(:614&S]D)EO6;Q.K@'W+X7(:726\YT@6![4KX3I8HT;C[A.@_G258,"J?>'LP:7-"8$<%[% MX/XAC AAL W=_6!K&T8T=:['-F8 B#&::DUVC&8H0P3GN9X#=9#.,2XB'LL M):"WS:(K(Z!9<0P>2(TJ^;S=1L-0IZ/'Y0>4^]&M1<.Q?GCXFR,54"['CM+- MD17@,L0CH5N3@\HIS#X]!.7R=B+M'4G-+V#H*YJ-T46J8\TA^:C6]U!B;J>E MBZ=REB$:']5RK3.$L,8$#'0K$6+HP2#)=G@;^I03-!!@BI-=EA0Z<&-(/;"$ MYW&%7 138QG^")P?/,7LK ,CT1PE=J99UE.^/*IC: AC-@8Y'L&^;TS/'U<\ M1# C%N%_P+GIJ7*9+^GI2WH>7TG/@6,H\0ERC>6X!JL[@N]P&W:%- 8EXSO; MX!/2?U#9N#*]^^5A%4D\[E'?'Q\9K% -<$*PU2T=/'0:."_8RI^.E(P,G!TL MY5$'GQU 1C%4KL-26[5E&A@4)C;YM4VI#BA6+%*IU3:PSP>'3@4V4[2A=7BL_>4L4XMG^IF_E>P6C7V:<&NDT- M],EQ[R(YSD?AX8K[\E%XB&(BO9_=^]F/S\_>1@X;UQ[Q(> J=)U&P9KP;-/1 M+ $<;23KA!4UWDCQ7HP4M;=CS%30)OEGL;2T]V'H&W5__HKR."/B*I[3RU3D MG*0A/65\K2<&UJ,S99>?9Q<2=1K&)/G$6:ZGJ*%E9TIN. FS.)2L4UT8F"14 M I9<0$L/J'UWJG+)DHB03]GF.HE9&EW/YW%(BX^E T?QI8H@*M\9>2@NN]R] M.#V( 89W4@.RX,0WBA$;:U[I&TZ+:@0FI$.B[N4R$&IY2'FIB%(3U_.#[P"P M@",@PJFOE@7H@0<'>.%I^QP#%KS[29QL#G^Q7W:& 9R@?*1I3E4O#QQ\W*'#27=V\D2T, M=^.R*>^E]%[*X_-2 C5X=!(!%%U+&^:XCMB/ 1&"2=%%_O%0!K%W#1*W&7(D MEZP]2=XO^Z[]LF=J^:FI%&KREIEW-*-/(WEXB(+>CV?I6FN94_G#OZ4D><\^DRQ52WU=RJ/9 NVEI\P3O-_!^ _1^ M Z\1>HWP^#3"O@ZYB:F,8\B"Z,QQO:R(]N<[<#ZPI.(/(1"/:VCX(:CX9!"G M<\9711V!CI8&JS%',C6TH,G;&MZ+K:$GR7M;S6R7X7%7+CF=VM#8WNL\7N?Q M.H_7>;S.,[I$!^3-HPIK/P4+QJ*G.$D"DD92D,E(NHCEC"LW"LU$(/+52DJ8 M 9L'X5*E^0K9*,B6- @)YQN)(B"%Q*E:[,:JA" [(6\<6L81#L?$XH5*+U1: MB3:?JN6D$6I>_^R0PEGX9Q[SEX7X&J@V=7&(Y()Q&B_2TYQSFH9EG$!YH]FVP_@$.7E:DUB7IR$S8CJ&WL%Q2LH7D'Q"HI74$974.H/_HFY6&Q. MF8FZ2MJ*!!/UA, ENU%5YU^*?T2P)AO% 0(A>T9Y0J-@13))HHIO5'C6.XMLCJ5ZO]7JME41\Q=*%*G=U1A^RS[O5=DO79;%R<3V_D9PCC-6_^\$U4=- ']+*1,T$/4BI M8]D/).L3+(FCHG3L[NM"+PZ)6 ;SA#W!3016HPUN!6A!C5?TWXNBK\O I)S3 MJ+#OB6()GLI%%$>TO-7V%2DV77J@;Z_2&,RG-'M0H4;=//E+^MK*>59_N]7W3D*M*Y&>T_//-^PWR[75R2,+69+EV0;SEW!?[\N8SLO)4R\/E\ M3K6[T0T1CF;[0LK_7R2_D1\OBWMC%3-)HZJNWB%C48M%:I8YIPW#:#.$ :;FR:'%Z M[ P+U;7(.FB@/B["-ZMPD>NT9-B%\'8]+V7.#QHPL$X.T.QV!14W)([>RMO- M#=U0_5:K*2J(W91!$GH0L'ZH,$F9D\I-W ;6VZXHD!4YV/(P^3W.EJ=2N)8K MB^_*AH)!@D9!@7=[!IU*O7JAK=T/[H<"TP%# ..IZ8,"RTY3J]2%#O5:^6[]8P &J4[=XM8" \J&M,?W9H#0.@1MGNW>*T ME&Z5S0O&;^FZK(1/K^>G;+5B:6$'UZ"$=W2(ZGJNG/^70N3EQ1-">_@#>KC% M$:O%E$8"_F;,G1RBJ>ICWS,I)"N]9LD299F4*TGYY.B)7$B1I%@)6W7^WKZ& M<;O:):5L8IP*:?]0(Y17ZGU)MF[5(.T5NC&]HXQ'+IUM\Y>G2\0 MW,\-IGEL2JA_V\ !E8>!=I#5T]C>,88O*D'-;'IM:NXBF<#F1$5W7OH$CA&H MS=?K\O0AR=9Q6L7@-VDZ-EU]:HI/3?&I*3XUY16DKL:2=H^QRI$"MTV&V,U685NHTN'&V.&+%,DT.7- MC;77;"+!@)/TX]%-$D391K?+8,=]V]@1=(=X"R#&:6@*64-W.O<] ?81->B. MXG93TF]*%SJ^T/9C= =FGQNB=>(F<%9^0CXK^M[:L%(@ M\I\GB]PB!!HX%[],9"[:QDVA8Y"=;('@H#ATXF,'0(>VP)81$NB$R8&FPQ@, M@TY\[&D2.L:1H!,@^YF6MD'$Z&2J3@P3'"$^%88) :39'%?Z2)*I\$=+], X MFJDPQ@[H]2$X4V%_M@L?&L2,3D#L![]%.C4ZCM\_ZP.$+:+3FOO=!]TBP]$I MUOU.#C1Q YU.W3NO;,R2 $[!KQ.;@K;IE%#!:6IR8_M"(] 9F9HLZ;(0$71. MIR:ANBNDA>ZT!T8]6D<9H]-KK2"\,(8;\GPYG5=R%TC>5^DFY"*@D>N^Y M[%+.W3"LR[KNC63!"KS7%OZ=K>.PT-X?E/9>:7$SSI4H6;H^7LJ;4LU5!C 5 MR+K(]ICT+&6NCMKY8E?9K$7GNV8UDXMI:$TYH\ 4"M,GU*L6$1N>$IU+^$T9F:&[L,LG[ MU883-9>E6/7Q:?;'F6:OSD#EDGUY7_5O),FI36&2UN.XPESI >T&ZTE4^TVS)=(O*IJNK0@X]U#]HP8?1F=W, MLBD#JP\C S.7>K![,:R5M(O.7 A^DQ:*+#K+'Q@D1,!#%[8%?X7M;"SHXK3 M@!N/QI&WH[$*4+_LIU\^ZPO0#.Q=;A ]T7%4&"Q[B0X=<[5X?^WU(70!7^_=VY,&=Q'W3*F_%OQ=7PM^$3_3 MZ(OD]/F#"'E<'.MWE#_&(:WW'=AUZDR?%5TCT/-5;N$;'JN\T 9B&EIVMV4* MGAW8,>5?KVV8\BO%P:,\S*YY147-\FIJ-BZEJB3%=L9JMRJH[91H1N!'OBU/ M")7@5%<8XORY"I!6Q73D_R(I^FA=BJU'U]&?Q!@30*B,Q**L,$K0W[9IUXX[CH>_3O6Y]PZ+S\=F^+ M63,@9]XWD_=_R)6-(2:@AQ4.4X#1+&<8JV5V)A%4:[?S@8-A88[$D!I%.S2H MP>L6H'FC<2!;;49;NRD:[[$52I#A<]P7Z*]Y\M<\'5^436=;*Q8W;IS.&5^5 M_DKRP/(LX+M:_F+7+2!%*?> I-'^NV1?T#U0JXJI M;V^H@J)L&@<)YAV?/BT3<^)'>DJR07?/JTJ%1XF9Z++%ZIJI#S M@\C;PH!@,4L#/1G?O-IN$EU79]4J2C+*:[F,;M^FYCX&QVT,CO>L]^9^;A2? MF+V8,EE',TR61...LW@O;W)1FI@;*IMROXL5@XO.NP6\6^#XW )PBP(:+ZH= M0&M=$(T?M3M.LS@_P<3;GLU]$\N[;6FRG6@";D?SQD23:$"1)7D5P"Y&O MJF];62)Z?>0X1HD!2/;V"6^?L SQFMYE5?ZJ)[>ALT5QVA/%M4X/F-9!A=J3 MS;[)MG[M$^'1!8EY6:MXS\?.G]=4782\+?>JKHO6&9S&>NZQS.EO3/ES"N_E MR+-:_^2IS^MM+/ZXX)1NKVT>:U9-SW4UIP_-V!YL5LP]Y:L/ILD<]('^@C'O MY>C+R^&MEKT%(V.\L&-TZVR+S8\N(GGD6ZW&C4(^GENMO"_!^Q*.SY%AF3T'N@;3HMJ M! Z/*3K)6HLIK^Y3%)=I%5K ,I(8=YN+1T]P9C_)AMD.V^\T7BPE@YD]4DX6 MM/CQ3)ZU.SEHH$EN285+,^TA;X 8R77MO8'<&\B/S4"N7>L,+A%,WS)NWO'H MK.*&%W(L)O%VZ]+;PKTMW-O"45DO^Q ;WYMEO+4^,S'3^#AF%B2FWI2ECP6M ME:FS9R-OP_"NS;L@\KQA][T8=MV;!Z=)M3=JCFMZ*R-N+E,A#TCUI2B*'MXO M25H=/Q>,SVE2G=CS[_]8\_XAG& MMP4FY!88; Z^;&7<+[GA7!S]^<*>8*>:<81L>* M=XIYIYAWBAVC4ZR;*/_>W&=X3Y-:1,.:$$G\D#.)M8BOP[-V,#YPO; M=0$8;VY\I^ /JM9H.V\W\#!QO%U6Q'C/=O>LVUE+;J(4W7K MV)5:6MLDS_-RA6E,1X >CG'<*C9U/?\J:'$OQFS%>!;_57>C>#O 5I)TR MH;O/],WO#FB\7A<7BZ2+)F+U#9WX$.0+5IF[353K&WK;]%'>VW"7/R0EEU-7 ML^BHK6WD@-K?"(_5A#4M8VT[;_WWQD=O?/3&QU>0F@[KB5H)6XE\$S7D@47V MB=K>&HZTR=K S/+F5$U5!H$)" G;M96-+VA4 UB>1K$H[C6F4; N;7W%MY2K M](A0L8)$;9=MAXXVLJ[/&]N,U@^]WM+V7BQMM<6!"C-Y=;7)]H;:F(I9&A6_ M?)'KZ,V/M6D,_0SF0-\\(8G:*7=+2K,K]6#%H_4!?DW-D2 PYLDT=Y@V"@19 M/X>BZN[F9X#5]DU;++2_NGP> J'VOGKW2/9LR ;,VUY8\%1N4'&FC>&&=D.( MZ(N43^Z?:/)(/[,T6^JXK\.:1"S%;J+QN436,X\;H*0>E+"ZC%^6'; M'3%"X'G2=3C$,]# ?=L.@QRQB1NW'@<[9BUW;CD*-KR6W+K36,[C4)JTR(;6 M>.@W:Y*P3GC0-&J3X'XN,-4;[(QU2D!]7&&!VRMMN_G8*)^WBSYR!Y:WVVC" M9O:FXLE%*-G9\]%E[P+>"^O7*8,J8JO?I8PAX[>W=][BG$87^M0"*=)U[&,I M?2SE\<52=G.WH&,WT.BH/FR"1Q!Z";84330,LY-U;*)!FBT]4A.-W>QH\9UH M>&<[QRH0["_(P';S8P!!_XH,=+O@ *@0,IYVVP_:=BBQR5KMG*]0M-B$K X> M=2AD;*)5#VXI*'1LDA8@\A$*#9M !7+'0<%ADY_@X9Y0A-AD)1LW)!0C-A') M*LX5"A*;2&3I?D68ZR2J1+,A\YMTS\"4TV2FT>) NPR'> 8*NU8?K_WM0)A1 M/[%>,+\:QD<'^>@@]-%!WA?M?=''YXONYXB>L$^Z_7DU45]T5\%DPF[I#F+X M1!W3[?2LLD'M6B1SFY!]S8X?4EUQ&T?2%9C ,IBYND$@^'AT$QS;",+=W@R%?Y8EB M4F5T,UNM.5TJ%>"QJL-VQ80J]4_C15K2&V[N.4E%4H:&1__.1:8XGGPGU_-[ M\JQ'/]237,Q;%!5G!$EN2!Q=IJ=D'621)$KFG66GA/.-%(5-M[9:]76!;<]!C# TS9Q07*Z0W^-L>2I9NSP! M.#"EV::K V1G=$XE#5%YK,F3JMSB^#&.I*H% M$YP;6CN@_USJJFQ#I6Y=2%%@N1/ ON*]-<_.Z!PMX[I@?ZA M(=?8U@GM&4D7L21BQT_.G\,DC^1YU3#S-EU=."?WBUCG=WS;PBV=4G@HCMTE M2R+*17F]6C/QQFYN$9G9#BH^\Y:8!J&\N8,+%"Q=J++O7UA&M^>2CGY#4P>4 M'Y)A7C:&ELY+U+RZ#4*# -3'53D7B!*M;^B6ZN;"0*:VKF@',\R&U@CHA[T M8P<'*&YXI9(T*L>&EF[H7I,XJJYC,:\=8ULGM#/)!;/-34+DR9D6E\FN*]NM M%D)S%P=(;E5H=$JC<\)3R=/%@1U;JKIQ&.OPP#OZ4+?CO"00*NVCDN_?$M,@ M*3=W<(#BGDO9*^>;1I:O;^B#(WUPI ^.],&1KR !O'7C;C, ,C/-!^!:.+G0 MO48P6'A8";I05C!&@%Z +F05# Y@;D<7F H&UV2$01=\"M]WG4&-E[QOL=&@ MVBL0XWCI^Q;[S=8G!,0Z7AH_&&LG/.-E[,/9"=PH#3W145VX&S3(A%N11NXMK%!Z.1SR[<[=.XO.MG>;GZ:@E#0 M2?)V\)KBF] )\7;P[)(U]F#'*(<;B'RU(GP3L'D@Y-Z*)7,A\E=2&GHD[PG6 M+)$,AXH@I5D0%YLQ6*OBL$O":2#_7.=9L0E;5LL=DH21BND.#\$7@?%%8*P" M'$\3(L3UO. VM7/9W'!:5/>V%GI)L3=>@*QMYR)IN)(P;RB_4ZSHA(@XU-!M M;(N%]H9H9% ?!%C.XB3/M*6P&UKCH=_R;6AZN4GKYL41OU,R%7UBEF4\?I!' M]4-"[]EV!=&HJH\WXU(G613]= D3_0WL(DV39GMU;/8HY922W@..5HFV)C[2 M!M6>\?17*1I$9Y)L75=1 ;=T3#GA1IS%HMRM1W:3OC:/,T6)#MZ;!B[3H0ZEI1K)%=S>)Z(=92+:[U2%^\D=]T@Y6= O MN9))K^?585R>3]=Y)K7>5(5R:N"T' 4/WC/+V>Q%,4/' M2+NB8LWJ#+KWW2?FOC54="$8/4Y6)Y,.NHF!<0T+4S(ZW@"CG?6B[Z!C$M;@ M 8X/A %';=:PT0"/;I]"J7^9$]ZK^1W=>V\Q)YTL-^A"SUI, ,B=-FI@SL_; M&)%,52]06D41NJK^#$B1%AC(EQ$D^]"B=M$WW9\S3HA-7W3Z.)KW$D?S9N7+ M+W;Y&+MDZ"K;CTL^+Y==(K\OFY#7=:];]NZ?XJ]I2+F*#I;?W#!1;+#74VC? ML4\Z#[,I#I+L&XALZC40A;=4*G@\+D+O5.J^CA:]T=V+8/&F0'IXA#) M;@E_XGJ/J[DQ&NH;0@1@G3"@:;[A ]DU)3MRBA0#*.TO&F.@?G?(T%W5+K92 M_Y:)$&ET0E,I>>T.)WK"TEPT;OW>QI_4'.T5O<,&ZMSI?;J:'X5SYFZIH/RQ M2%THB@601+PM&M!^MJR&G\X,)0E[4C>Z7C!^QO*';)XGV]H9_Y.^"3V] )#9IM_3*YEEZ7;;,""!@'#6;@P:_K@0;'RZ*==N]+TQ<1 M-DV=1$N4#:/X2$:WD8P^VLT'V_A@FW<9;&-CXD#G-P<2;X+;LUR/;A6,-D4- M:B(Z;_4@$]/1VH#.?3WF)!DM6.C\VO"9Z>2K0E:* MKHQ*#S!KG#Q F./51.P!9MM:@=A")FV,9)AE/Q/QC7"-)AC,XEP#ZE8.?70+ MN;^W##)!81; .N$'&X8Q"UJM5SPH+ 2SJ-7IW;<7/IS(6)98FZ-D,$M:G5ZL M#N:P$;&AE-A9$D>J/F2P^UJH:FME5.B6K,:85_!(@T>U6E+BXU;?>=SJFM.P M/$YF*\:S^*^M,>-R)85)7N,AL^[7F*9<,XT,-4:9F3JJV M2:%4"6AF=ZJNF0O/:2Q?:K:[L:LNN!;2%$&5,,OR8 BB*8ZI7M[4:LP=5(*6 MTHU2*N,TER16RUN>J"=TSC@]N/?S_%DN&"ENQ2GAF\(LH6XE4.HH2R2!"ZF: M4$ZUX7XC/-'9/$IJ*UY6V<.-)E!Q1!>STTPWLS&6H]N*5OC: M* +H-B$(<4O?%[K-:?5ZS1XJ=&$V5M@:33_HX $KS]H9%]'Q5SC]+VKP00S< MZ'AM2ZP&+P0ZYMH*HHU-$QV';86X7[#C\:26*W@D'RBZ<,@.T]7@+D47#=D* M:L>JX&/>MMRF%NY$CN!&L@XMF/EA2I23WA6;7 M1@FEN)O^CVZH 3!]9' MQS)8%1=0?0A$OEH1OE%V&R'W23R/0R)_)655QCA=!&N6Q*&Z>HH*_5.'.?=&LP_@UG1D/WA,1KK=KPJ(''ARU6\^JSS%@Z8VW#)TH M5\\..HWA#5S>P(7>P&4&8L-Y62OV-CESGO5AA,Z0 'L[#"H,H3)?#K%@.]DX MQS-<@%]K#X?:N."]$=X;X8_/"&^MG2$V;FVO)@GFC$M!HKR<9-NTY3WT0U* MT:C5!H$W:+T7@U9/JI;I$J%;&M+XT:""V75&B^YW'F?T>C[7Z<8M1W$3=?,8 M*S$"?J!(! 6(KD-))CL"K M[ F5,_2@[A$LDE6VE^@IKWRAJ' :,CF"5&L#.8V2:#D%,4D.\UR&UP?[)Q*A MRC@42*]5>JW26N\*R3:?\,T=HY4EN2'IJ-T@+FKF5W>$WE'^&(>TGEQ)8I7F M7Y9(> -$,PO]#NY")ZJE6*<;&1M[/=3KH5X/]7JHUT-'UUT@C'FB>N<0)^R$ M-=2V(M>H"NI'J?_\F"1)3I661(H+1 .21D&ROY:PG8[9_3GC MJ(E]T>DUO?>BZ=4&Q)_D0K('(>2F?XC38L_?[FP&EY%<;O$\)KM+>F=JS7$: MS=+H\,I0(?)5<05J6;QY>\OO*QRC/:_SK-Q(PB0IO\=",EKY&&VB@+FA SU@ M.[^S/7.HYI :0[C!_8X)$X+0]#H:]>D/#:T=TM_'?BZ33+.7UX%K9F"PYQW' M'-;-O'YN^&J?FBVN4F(W&=I="[;K@_U\P%G ML_'9TYG;K7Q3BU/J9OW.)O1I+I+3JFM";FE9=4 LX[4Y;0O0PP&."Z4'TJOX M\7#3EV_A9/.9_)OQ4Y7+;) $6HR "^>>QB]D99;C6H[R7O BD&(U"I_N9^_5 M.VB&V,(8DV!Z7;FL)&MUR;LMZ6 LU">4J'Y=U8]@' MXZR*%D+9N!$!/O+&1]X<7^3-2#Z.B0;O.+ 13S2V9Q3?!'!NL%VQ66^2 H+! MRR\\)K;>TF- M(=C#HB6RX$ 33W+%Y]D2*DV+[ M\8P^TH05I*H"D0V5RFW[^W ].'QK*Z3<Y_4"X4+^7 M:@@F5SFT&RY$OK[#$=5W,%"L#XN =?+5*@P4FMA";1N'M%ZNUJ2(F]^?+^57 MA06B&0>XOP.,EVFEFWO-E#0';W92(- % MA:QX%YZJ5097+)H5KI/56*.'&]4ZAACX5 Z%'EHF^LMU(TV!4 M;\<-:/31U#Z:^OBBJ0U>.G0,Q0Z1I;]NHM'1G2JA82MZU\T?ARYY" ;:/N0+ M"!1;G3N[."$@2&R5ZKH&M@%A_S(=V(8T#2/$7Y%!;.-,A0H%XYESVF%M=JZ. MFGOSOAQ\F3XQY+XDQO05IJ"6E M).;RHGE)4YI+1G M]>'2GGM2K+VRW;U:>7).J<2"8? MIX1O"F[[A:5*F97[.E$% *1:RR6N_N;)]HG3F,<+^6>\T$=V=1W0!PCY"E/H M0U*\ =(;((_/ -F;+#!1CB3@(%%3Y1\"II#2,D[*B1Y_Z:?/H M+M53*'5>.WTOVFEMV8;S^9R&6?RXW^^W SKCWU+R@1-4'E$\CY=9XR5/$H2.7[UID]H M*MFCFJM/"7L@R=XV>L6>U($4E;36@.AE/ =:'F23W"T)IT5PRN&R.G\.J1"R M0X6R=A\._1AG-HTW+]EHL-"V=DG_R]FO),T7[^/FDLC-"TQVL]+M&7CFZL6I66%Y&7#QYJSJ<40\\W"=+56H M<_655$<,MKTV0^!!>DO7).,5R?-J=Y\3GDJ2+1&#AL*#O-!MU:URDI;D0#6U M ]TT"AZ\\HM3*27&F27"M_V\I=U;VKVEW5O:O:7=D:EU$/ESTK;WCGK*I WO M+662B<87#VMPF%C\<:^&PHF&)%N*K1.+2>YF1YU8)/+0QOW)1BWW9%J9;BAS M5X,#%#D6>:]GSP,4_D2$.X!M#8H8K4AGCCQ$%TH\['0;SK.(A[RE=7C*3ZNRMJ&SBP4YY1J1=+8?DB3HD4*HMK M_/0UEQM:.Z#_BJ4+-9EG]"%3<60YYU3KL38W=D1]5A%TOS%>TFYJBH!R8^U6 M<^-I4H^@N.P=E2M8W3'VH%OP-2WU1_X:".7>?5#NW2 \\'(&(F/A'P%;%W\0Y422["_(4SFO M ?TS5W_$\O6DRKL4K!.2BN(RVBCF-)32;O%5.ROFN#2-8_MT@4QRRZ9UGA(.>QU*/"WTB2#SRYH$=/;M@?$[C3*H\0\^;X4D3G+=/LF&V V*ZH'3 )TUPWJ[S3 KQ:506T!B> M[34^;]IS.*ADHWW.M.?,@61C^72,\RMT$/?Z0AK=2+6Y\8;4(1_E9\[V41CB M UK#TLFV0VSQ08B8YFR_$8#=S'AK9#8N:U1!ADZW@0\K]6&E/JQT MD##,87T74PU.=>&'F&C$Z^!^UXE&RSJS3 'G"TOAHKX4("!L;#6+7/I#@%.& MI0"2NQ MX$1A*9XT6@@6<%ZP55%RZQ.#2HK82B\-'I@&G9C)R="#.OR@LX92 MQG9IBX=.W+$)W,!0/>CT3$[N[I9G )T6=.*UBZ0!Z&2A%,I=^F>A$X=2-!\A M;F#4--,/WP<)E02+0.3K=6F#)$GP0!*5XAN():59$*=SQE=E5B2GB1P@"C*V M[=@JE;3_YXZ3+CH4W3XE]%VGA,Z$H)GX)TVBKRJ_N,JPORH6C#8Y%-ZICY35 M=9Y1?OYG'J_5FK/X977,:EK5\ MY>>$%O)"&LU6C&=5&>\;SM:49QOE$\X.7]>K^1AJ> E7?JJ%1W-Q1D MZW/)FYHC06!,NFCN,&T4"!) #KG:EA]L-$",;;'0;BX?">F"!4ECK5I@+\=X M7FF[9[$(U=T+ZMZ&&ZG9P>#!!\&%=J?;%S^:XK_;#>( [;4\&24/JZAIXAD- MK?'0;^8;L$YXT#3R#G _YYANU5ZXGG\5M%#<0'@T?9QC:H6K5D&SZN,*"US?M.WF )%6ESO9-)3CLNB)"9>I(@JL$R8T^ILF(%TP M(6F\1<"BY['A0J )^]0X%+E51Y_ MQ>;^WSSX\LWMW#= MH..R;1":O8?HN&@GB,UW DTJ@1ODS09BPY8-8N,: $+$EL,Q3!0@<#*PY67 MW2= @-A2G>&Q7D" V'*6K>*_H,(!MA1C0- A%!INP<)R&\9HD%86Z"TD0PGZLFQD!G)UES7!/-#T'%J%^8 M$4@1KQ$\;((%90M.ULLX# BGI*4IIN-31C*Y]$)E!]-*8;KCFU+6K/XHYK68 MT^J+?YW.7@F5;W_H;+B 4?+U3D/)_@<\QAU\%+T?YR-B*G1"QG::3^4>D3>[( M_59X)TXV1??31.Y'8[&HH1_G9[#MXQ#4Z-I!.Z3.4,&OL;U;#+N/_XPIE\++ M<7G/Z9TS2LX^@M>KK$56P544SU!V-)3$ /ESCJ MYAC&5II['ALN3)SO@$KQE@58(VTS$OE$:!2A.NR#JN#(IZE1!VE8+$;1>')N\B[Z)QJ_>;>]73<+3:H=*A_G MR$P1@T=^F)5O,B7A7>Q#,7-F)U=BWQ+NCL=.&P9/A)':XFGHY0Y/P;+E8:HN3[!]2["^#K"=T3F5%$;5 M,KHL>!P4G%UGE^C*1=42':BS0W0O%E<[C#9#N'"&&Q>8BMV/TUSJTE61#I9J M8XI:#^0"M7'AV:!N/9 #U'8+&-]:A6PEBW?7=3COO/?.>_3.>V]\\\:W(S2^ MV6AH$S6YM5$!)FJ,ZRH[ F%C*XYGI9<#,6(K@-=&U0-"Q7;E45== @;V^5& M+>PP0*38;CEJK](# 6.[]:@?#0DJ8V"[#LGRS>J<1-7WZC\/1%#YS?\#4$L# M!!0 ( -%H9%39//&8)90 "\-" 4 ;G)C+3(P,C$Q,C,Q7VQA8BYX M;6SLO?USY+B1*/CS7<3]#SA[8WZ&66K.*U]-2M-3CYYNX M<+!(E$0/BRB3+*G+?_TA ?"C2@0))O%!S5Z$/:VJ(I&)1&8BD:)%F;+\/W_SYG=?_X;0/&9)FC_\YV\^W9V=WUU<7_^&E%64)U'&___,W MW]W^2#[=7Y!OOO[FF[.OOSW[^O=G9__C/[(T_^7/\)]U5%+"DD:E[H/OS=5_+'YM$7 M0S]_*YY]\_WWWW\E?FT>+=.^!_F@;[[ZWS^^OXL?Z38Z2W.@2 RXE.F?2_'E M>Q9'E2#CZ!2(]@GX=%8_=@9?G;WYYNS;-[_[7":_X50G1)*N8!G]2#<$_OWT M\5H+\_NOX(FO"SHIO^]K"B.7@,\O@<\WOP!\/AMWVC5 M8<=YHTRWNXS^YJO9F-[2(F7)N]PRROW#.L']KHJ*R@7V+P>VC/\]JZ+,+N8O MA[2-,U=AU#+.+X:TC/,':ID_3@>TAR\"T>HEDH;89?#4>_Z7>A &'%"J IY2 MX9V!Z>>*\OU(:?"-U[&_Y%W^[9/%^2_/J/.>JHDJK MPW6^8<56:/<:B$!2O&_TN,0I@RV"%6JV1_.=-NQ9UJ6D$8%>DKZ@)=L7L=Q0 M.638\FE^]NGN-_^CADTX<"*ADP[X__BJ1?;E5,Z+FL91$8_@II[X*F9\-]U5 MQ_/:%&P[@<1L*MTD&3@*IPMRPB2 ?5F;&)NH7 O\]^790Q3MO@+V^8IF55E_ M(QCJ[.LW:MO^K?KZ;W>/44'?\GT]N6#;'<=C;G,7Z9/:<(9_2-7 ">\Z1WN1";WAI]K M::EADD0!)8>49@F)*I)P\(1MR .?3.55;/RO/@NVI)X%^>V^3'-:EGQNZS07 M4_M(8_:0I_^DR35'L4HW:;3.8!*T*L_C?^S3@B9<(;WG7Z=96J6T%!/DC^?\ M(/&0\H=+C?@ZAH846D=8N195Q^@/2_C"*5EI#-X!DP8,TB!"%"5&H>#=S)RX!P]-U%HN5-82SSE\IEX%-&G,SYRR*8[;G MDI _G.U8EL:AC/QG (=IP#UC63WK5XD/,&#W*KP'MG3"M+Q&S3W3H3 MYUR2SMZ<<>V\C8K#&=N,(E9%/9:;J^$M,3D6#2^:^0TY(W<2,S@WO09!F+VL M X)A9ZT\GX^N\YAMZ7WT&4PCOB=EJ3"4FJ_A0)>7]"W-Z2:MSJLKFM!";EQ[ MSMF']GV]4\,)#.19R"HNWIP5&XD%205T4D6?/CE; .#E!_3\^/D?,T>ZX]I^/T.ZL'%=N6@'E_!5^R@ MOM@7!4Q>/.G!1=T+;P%.ZB.\7J.;^F@"H1W5,ZF)<%4KB,1D_J_ 3]TO)HX\ MU0.KY<8 _O:,D[,JHIB#>TZKQ[-X7U;G%$N6#OQZW36-1S* M)N..@/3"MM]QMKU56) (0I!J+);#M*9+,\:RD^CMAF'_0_<$;^06$C&+ES81[ $+&Z9&.,C5H'-PS^QS/I MY#P33DX$.P\.8)-Y>P%Y8=4_^.Y/G._@CY+<2N#+8;P1^H]QG@E1W;#>]VE8-MEQ#*87QOP>;J(!C3.!!^DZ"I?#H\;+,\:MTV@>ZD;Y,BWC MC)7[@D)8TUL.[I<39I[RRMS[WIZA7;-FNT63%CKY&> 3@<#_&_8.=XC:?5>R MHR1T%.3S]5E&.:NC(G@T[UH-SSF!X2?VYFNN\MX+L,M1<%IJCT;-#)+0$5M] M>U;2!_$Y[60=(7C,9""K##<$T _W@;/R3N(0--ELYJ*,\J4YI6.0V ^,$B1W//'UI 1&D>[M(JR])_B1Q46<[Z%&+,>YG4# ,'4=A%Q MS^P=3 B5H$ORA3RF?DD*FD40GU4Q_N(7 K MD>9[&!=\O8(>)8FJJDC7>R'Y?9L0.AN M9P)$*75R<30!\H5*7_MR0?:_:X:RF@B"YI)9&N&2KBNN=ZI"&'ZWE+,-M_\> MZ%L:%1R]G_A_P=RI0R7;!WK"@:V-AZF^,@>N:ZF;C>#4@X1G:B"V;,"0M"BN M2(L#45B2&DU2XWGTU"N@"^X\=?]X$N8M#CE96\6&RM#KXKF_4#WD)^2+]&'I+&RPK M%O]"=D7*1?NI0>'U9XZ,++SKXD9#J[F$(UJ6L6=0YV<;5IPE;+^N-ONL?K1T M?SR;!C_RVKD"4>>7"KDZX?+UW\DF\A$=H]C&,[PO(=W,C^&G9GZ M!Y$[Y,L!?;DN7T+&>"QMX%]IBN0.F?;P2F-+9RT20?;C :Y@YJ1:P&ZGBX22 MIZ'RK&@2J<[2_&Q35UYJ8;K?$.VC&&S/M#>596ZKNB!"(N^Q2M+FY?%#;U]A MLM>_]3I@5ZN[LRL>]'T(CQ]ILL_HS>;'QJ]RLWG/\H=[6FS!N7 /[H.QV$GL M,-CC\41PSJNO*7Q O%N,X!/@=%9QI(CP-_XL\"*A@R_1R\5LK<$"]NP-/UR? M/<'I&IYN)50E&T$*4L<^8<K)T([9 )I& ?#1RH%%1?DF^^"O_ MUZ]4>ESQT\@>#\OH64YOJD=:&-_MCSR-E!#-J*[96X!=S 7Y&&G91'IYMZRZ M"EQT:A+]GF+3AF-9SM=>.UTKS M!$+1V8/FI6:L,5:!R\H>>W$USRQ0+UAD!W2=6N0:AV^)P#> ,DU4-89[;N.7 M&\J-K$1W^L0,8:]Q@194P%X$6IPLM1>P.&=$2F&-$.E@)*R,%B?206I%1#3N M4CH+C+/F<+, 0]K/VE1%K;&+J'R\RMCSX)6[X=.(36U@5->2)4!SCN+ R89# MGWS1[G@VR'33:+W/HH(D;7E"OJ>6^]TN$]L)!*PW,X8=EHDS>L&Z\BS"S1@';+/[/KT M,WDBO+3+''DX3F6?#PFH;3 =(P7J1$NY#0@KP1J,ES4 M=1W:&GO-:*]<.\Q@,9N:8B[?S-(:/T1I?I/7[HM.^:^8/=$B[2U!:_P.0A)' MQ_91*&<4B:DVMLU9?2]GE<,-/TVFG4\!#\*MY;0I5%-2'->5L2H]_0E@BZ,$==NX91R)(5Y_VXUN!V?&/"S0!\&L[L3'0 MU 4+EI[27UOF#LKRW,C($XA$D9$K;33*Q(06FT!FI\#80,9GTDPWX5MA3 3* M*R*0)@KK%6GP)AW$EY=O8Y4;>C-T["^QSWV,?V@J;%K;OP8&=;]O]0 /O%]! MQYNZ5.RKV:>&UA"W/XTNC&^^+X[*M]ME_^&Q_4A!/PX+$(;CNOFO2R9&%A8O M&B:KM=S(@TZ,&E]HB/A,YL7RLNLF5&(C-)V]#-+Y4!SNQ!.P";4G7RH4Q:[\>C)(+2S[ MQ'T:O99>I$O>W,#%S3[OE/L"7%6G*!O2A8#B4+HF8!-*NN0-)EQ@?NJ@*&3M MK4+Q%4@79MDG2A=Z+?VT/^_>NYX3[-Z!A[#,'K?<.Y[P7_,O!C:HR'';SQ81TJI$--H [(:*,Z((XE8]"X M2!:^*$GU" V!"MJV@17Q&B7=1:))$(?-S47.F?YC,P9YBID2? $WRT?E#Z!E M:UH=T#?(YH-9O"D>!^K\1KCO%K@M);$B-5I+ON^=L'8C][I3%\2-S?6]MM*W MZ&MTIJJ?B$)7*D>YO6[&V%Y6 =JTP:P@YL46^WZHAO[9<4B%)J)B@4:97<88 M,\X!!QT:KI9BEH=O\8Y6I/^8$/ M4977^2TWUEGR%TZW1W[J..>V>_1 Q8^77-<<<1:I@\[9/D]H(4JB\ ]\ MY^(#<5U\MN,<)^] D[2@,1=$\96[@X8MC/R?1.9BOK2C2GO\_P3S(5(*X/93 MSH?9:SQGIW#CEV&6H::\: W%J0(0DIV;"+9OP)1=2U[ MBQ"FG.5/M.0VA4+2JAB-#.Y'@#1(+&%3_,#1D[@I*7I54C.VNGAY,5JR7\TA M^XH5&YI6>\Y,RSMA8Y!;W/%ZRB1<-17]*OSV155?G/G,H%AD-9[14Z#-)/ MU\^O^;E5E'TMZS^67)O =)5&.W%.(?VOQCYLSBKU!52HX^=+#!9G[;W ]/4; M=2^FM"RS8P[%YQ0?/#[!"VO"L\H+*7<^S^:ZI75M''0KMI^MHPQBUL_*1RHZ M++<]?%2M]K.*U2_.LB-L075C)/AV; ]2#(:Q]#R+%J'7-6--&24 M[*]%JN<$S]=_]#F9T+(./K.I M;:7DF>US_G6>#'4JR:\WN6]I7=N5^QSZ>D'.-M\!=Q+M4D50YGQ) MP"K.1&:_#4MR+C0WMB,6JP#6XJ<.JG46;Q7XXX]SH;V[HWM![\X9^PQFCYK!?PZ/5Z:90^0_^]%WY^O M.391?%H(:-I+5O5_/7C0?8#\7*/AUUJ?2/?1K:&?F+-XZ2HMRNJ#X/DH>QOE MO]QL;K;18_0C[;DT,W\!P4/# SM/[0+HI 9/ #Z< P4&Y&>)PPCSN)\2KEYI MYS8=FFGS]^$@.S1A_R5(#;F*3:?K0NJ]O6=E:5"+2J/ '8UNN4;;1"S"55\C M7V0/,>/=!NE M>9H_7+!<*+=]E-W38GM:6W\!F,Q1!GXQ=JT8.BBMR/.IEBAJM/C>WN!%*HX8 M^>*O-"H":HA C'.J+4)R@V?-(0[+JHF)+ NKLYT'GD1*7L^(KB5#@2$[:<7! MB4TT)B&J,BZQI#WN0!F#XK>8$,:\[2O3P4(CD07X<5%B0I_'Z%LO?.'2K[69_ M&%S"UWEJI(V[_IY5478\0[='1B/08<^+@RBZ[QIU)*JPQXD"B,@&5J?&"SF;([>Z2OI]VTP3=RR4R MI,5F11I\R +GB6_HOFN@"B]%,TG^(6;;+U%-+?\"F3O_3B+&[\_D_U'X?@6C5&$YHB-S=D>U[2] MGR-948L.21M\@HJ:.?_UB.%$,OL^.]-XSY&[I.MJ./Q(_R#V!/IB0&^EVUY M1A41FX/_;'EY3\ORSZKY>A-.%>:\JF<,9DZM5^8RTGNP?43I3X0>WML;,DK? M\W2\UB-T36ETL<:W]"'-Q?69*MF\(FSPOLU"ZL2KI.WD2H_O9)%'?V1=J)MS MJ@YT14IE"8@7 O2)=U0#B@A!7VB M.:Z3I.5YS#Y"3IN3(UF?Q#]L#C%?VP;\[O,N+<1+03=@)!JA-N")Z+J/(MZ! M[^^_U_:+91F;V^\L/@AT37*>)]*&YP+.*.(_C8D^3 MVFN4TG+8U3GZ/%+PM..ZEA$%F,L#+#0-$\XX3E4VF52>&>G==I>Q Z6J4*TQ M0QF_AV2LT?%],=@SE_M2G,[7+-^'XC1S9/J4)S1.S$H8C3R.W.0 M?#0XMFMV:H 3"9W4X U;?SAB,#-Z,Q01E^9/-(\9=5JW30LG?!* G[IMSA / M''R.I9ZS$/X9-?$63BR[,?F_OMJ!>AWC)LA^*;4#9U5"?!&.Y&@#&( 4K'3G M"XQ>RR;0@WH(S3:/@L>!PA,U6QV_^.O38D."8K4&ZLC:^8[U/[*LSS^GNN(+ M^@>Q;>+T, 1 PQR%!JC)S$D4E%M\(L30Q>4ZX8HQW:0TD<&JY_$_]J(L1MZ]5.._[;1II,AH1O5U.-" QQCXUF:"N!(^;TKP$8%&&BB\8HQ' MV$1R>1:(^R)*Z(=H2\O!*P3=8T@1.!W.->\+>$0 #'LUH*4C,R7.:_$ 2>_5 MS4;\6IX_16D&V\ 5*T0HM6TWD"$XW[Z@$;06[Q :P=^K5\@Z+1&[CH!])AH\ MD"[ZI(,_61](]SDU!R(FL2(?&I>2G AI9B*B>,1<7J^7R50.;;B:)C&$9[UY MG2=TD^9I1=^G3_1%SN+;PX_1WUEQD45E.>",0HZ"U'(3H;EO'5>C&6KV=UGB?O^+>[K3YZ;_H 6+>",2!OG@9C MC%#.!Q?SG7-I>,N_?^0V2@FVW4XA(_R'U&R>KCP4TSF0S2>S[SN;:)=64?:> M\@6X66?I0WWW*&H%ZZ(.#-_"WN0,C^Z\"EZ:B\[Q&< GK$6 L")]X#_6;2X6 MQ*NF"\*05/9N-<6%.,)$V85H1Z*.*E55I.M])?SB[.7AII-VJC6B; V,MJGF M(N!K%YJ/*69W"D$?A#_C10,QNMG06.0;)6FVK[B-1DJH82XOO_[UMW_ZYLV; M?S_I)A;:66%1&)B[%7PM;7_;R)WQ@#V;X_MNT7N*AU=?K V$T<[7,-0*XVUM M\282\5?9QU@K,S:Z$P\O[2N];]I7C]S*_:?6\G<&)_ -4X//:[M::A />:!BIQ=_85GP#('SKO!Y4%J_N M>G#VJNFLT"R,DA/_$(7[4LPXVR)D0Z>-KK%G=792 ^U8Y78RW4;",+'#(-72 M5'#>F[S+35UX:\6?PF?[%&7@<^@F8081#O1B,5LKX-_'R[;T/OI,R]LH33Y0 M'1OK'\3[8$\&=']M#1!)!2!#N?IT-&3FA)E7KFRH!<='V5.D#92_XNC7'4?4 MCR?L875,3&&SN;"]5#N;B^3T7O?^J#+GTEE!(T6;S%(]1A5YCDJ2YG&V3Z"? M<$Z2DZXWA#^S;DH=\//C@9M3).$_5(QPZ=EE5%AI_)>2%D]I/";PBV L&W76 MB@&*[OB/*=N7V>&(N!4?0%5!$#YPD_I,>*'N29$X3$BB(D:_-E E1K MLZ9XF)-%][R7OZQS.6*:CK^ W-OU SO/!57-E3M\^><@>[T!;=ET@OFN]";" MVC3<<_PCMI*;&,27_T-"PW@NL'A6#*([)B%[#Z^0R#^JT]TCYJBZJH9WS(-L MF JS+.=:TW/#7([]B6-75%&:\V]N69F*<((>\WC:BP@;V R #T/7#).IIIBK M^2$8OH$,ITBR6]J,UW3#"FY+9H+YE/G\%&5[^0&^?P8CL3RR$H$. M0@%PF[R-+0$[O%/@MZ+;'2NBXD"2=,-?I&(8$&5N7?92U+\Q.5%,&7XE/6_B M-SL*%^3Y@P@RO-[NHK0 )H%*Q9JMW>05Y(8_-+0O,V (!\R.:W=."+74($ $ M!BO2XD#&)^5H;S9B(H:AHN]S%]:) X$UCTI= &+85(W67I+<[I)*T"T'*O^AAD"F[XV 91SIW0W<@@"'VILB$*' M"'S"=[I&K0^S0?1 W=_NY.U@?\S2!Y8_T1(B.2 RJ13.SN[O%ZRL/K#JK[1J M[X0TC.\O8Q#"V87LKTF!>AS8"JOS;BAQH MU2E(N2+2H[@B8G)!^P:Z$[B>?H..U_W7HB-E<.<5*]17\)PNX#L,$DO3IKW( MOGH5VSNK1>E=2W0/JXQ5R#G42NA,(V0(>B"A]J&Q#3C&=U;.?BUJ:,BP4HV: M[7\(FQES-)BWW)8CJ*CL%"S>*MZN4D/[59V:D\Q&S$ NT9&**PBN(1&+9DUFB_!*/&O?19^5(@L#;=Y]I$:XP2VZ1&Q%./:U#WBYEO@DP9AJ9$]? M/]_7'BH/X"/-9&VVQW0W?$%K\ ;V4D,_LOO >I7Q<00[[ 6L":$9@GK> T1E$V@TO+MI>XO[S[#GSI?@-W!_5E* M/4@LV$SJP=:3C32/3G-\'>>=-,5,Q!:F34HV6;\N,VB(Y>?90*/K,S.-95?0 M.)57]%M65.D_Z^OZ-N3V1#-,?@^5Q&(POFMY[B*Q@JS:!@T1MI$VB$Q/^' R MNQD9PP\/A1!A0B6+=3.&55)PK'(I98-UF4>LLD-H*9^ .P%SDX*4<7>D E1DBCTH 1ST.:P ?15(=R5A9=K%.]@4, M#0\HC,4P[:(%22J9(C4,S2RS5 )<53QQBM&2_T6AL<%ERA&HWAXXIX VBO)# M[X$']S)".9@#<:TA6DQ(C0J1N$ 9*. ]A8[ARA/-$]88;!/31]FUHYE#L[CW@5(D1HK4-T*+^!.A1F1J%G8 MQUQ2P.:.M@.B)!VBI"U1F"+*D\ VY.Z&8-\7^QQV13R[N>KDZJ8BFLR/T1>I M&W\!Z8[2#^S+Q:3' .,VLCD?Q%U9#;[C_PE4DL^ 8]ATLOF6D[2,N07!A?AF MT_4>*34'<6KEBYJKH\DZED;%2MP\Z*[%-@0>E=X M!;:+1$LKN&Y*Q&6.ZG[931KDEI,(Q@UM/[GG#.9]N>==' M_P1W-^(,//]"< M%E%VGB?GR9;K%ZA5"NT6U>KVQ\?-' 5SJ3P=FO,K9H'2BBBD5D2A)>3A&+%: M5DRC[ +-?[8++E$D*6N2/'1($AV31-U6A[C*G<&YS-)RS!+@NO7U9;2-'C@8 MJ #.\;@X<##G517%OVBE=NJK"%$U!>&\,DS=3EHB0AI,B$"%2%S0$NENFK/% ML&FDGJ:5@^V2[CFV7(,8E6MR"4?EZSU\AW4?L&+;VSK_<9;(G[[E@^N3.<-ZZ??,R( M)LOQJ)W'?$?=B_VQ&X8WW:DV,I!]OYH&H*^[RNF88>XP?I_(N9\"_V MQ,%&+6Y'$<9+AN"Q93FI20)BFB5J$?T1VM MJDQX(F2:-K16CJOT2733TS ]?B!L>?/) -WO2 H+5A?';^CRC'G&5V M2.DAZ:S[S,Y&I>H$:>\OQQY%W%?JAO302P JU G JHP4/C[ WB1FWS[6E??$ MO)A$)D1'Z1%&85,(YWD#^B! MBA\ON>0V3=6@-$'.)Y3SDX+XXF93EW)+^&\_B3+*]6C\B^;%F\WQ;R+X3Q>U M^>N;&&+C^740P&<<:I=.1TDZZP/IC5>5!=45O59$4@RJHLB9K$A--:+()A\A M0#@"!""" BO24$Y^ >5,&N*)Z#9)HN[0\&T[!+QQ^LSD"-G_GX=FULN)UOLL MXD?C)O^IKDOSK&9^%BD^>("YGR7 !VW;S%6GVD[:<$3349/^8Y]6A]KF(?2( M04Z?A^^.&W+6[\E2]?Y-IE\'+YT:>+^.62VC2&%K)0^:I*//SRTE>#IN\%P( MB4Q8BW6E.D&B=O#9N,4\QZ D="-WO5J'HR!&P8=F#$-G*^[AJEX MX<(X7,\=<1?1(@7[04))'@5J283F1&:+Q)XE^.V^3'-:EORXL4YSL66U]3;& MTIBGO8R45C,@KF6TQH)TT" M'N$+KTQ<"S:/P+YS)]IPWFZ5VDM9V%>4J.V& M^=8I6)#]44%#:+YM[GH*3+L:'INQ80D-7_N5+7PQ^U@X6B'VM_>@.+H!^$D' M99EN/#,I(0 YCBORWUN@2O"T!.MZ@+E>(?^!L4FK M-G,9))C.T69V9R+JU$^3Q45/9[IJN>V="MESR[P@W#87\8>BLVBX3 PCP6 8 MH@;R+HUXDBQYC7QYB#!\[_707 -#9W3@L95]+NZJJ*AP.(= ]UT^L6V0&;*. M781#[L!EF@)#0<-F+]DV![P&# ]C874W]1 >09 "4!=!2\=,4A6-H56@5EGL!;/ M\,.6V,=//9Q^!@I9&6>$N -,M(#J-%PY;M)J(%CAY0/X;5H--)U%GFBQ9E,W MKP]-.B5R]T6C.]VE$ 9/I,/ !%EWN_\I-[)Q6OB6*7X^2N-T%T&VWQV-]X7( M]KN$FHOI>E^)&+M/>=)^?A<5.7^V!-1%^JM.&.V-C)7B^1AXL\CGHXH22*\4 MFNV-;XO[0G1O!RMA\^^[>#;M4QC_7L;_DJ+-AY&Y5")K765RAU$1%F6$.5Q6 M_U4<+J+RD:O(IS2AR=O#IQ)B%'JRDL<+." 'PM=NF C0>5(D1X=L,O9:0Z1Z&P O MBK]K.'SV>-C(<2Q<7SLJ&D%4JWE_U$!XQB1VI$6//$O\B$*0=#$\RM(R(8FK MZ/O9G,VL+Y#WK&71-Q2*=*AT<+&S:TNWC#Z/SE[6C.M+F+4(8(35XFP0PE@W M[16;<9WD;S0;9WG98TS#)M/.]Z:JK-=;6HC$HA&K<.QQ[):H&=:UD-1P.X6X M^.FH6S0BC'TW2F8VE7;>U6_#X3)=!BQFELN-H;S9=+[3*N3)(Z!5M#$D?TK; M&"6<&G);DGCWSVP)SXO/GIQ MD)*K/@BA%>*JOOC;Q?F)%+[\8:)PM0,X/Z6??SB_//?*$3W48?HI+T/UEN9Y M'X@1[*K>/DCN*_YH=%"YJ#P0S-J,*Z%Q@GO//%2ML%7?JKT!$<]%,XT;V7N>!*(2T0)FW#@=<\Y\H6"_^6*B$+/@;( A]F% M322??]DH(+;YDLI_K_/S6.P]Y6UT #^,7DK,WL/+R_#X_A)M1Q!!"I+MV2$L MY1HFV9G,Q)W\&#(20]//LTQ=0DHO5.7)Y;4>I.APPJO*)$7Y8U3%C]#FK?/ M>9[OH^PG>5?"3]\QE(!ZT$F? PA(.;6(B2^)MH@R1O:#4@RA)12^I(L/ 8Q7 MI,&9U$@?/<4/W )OHA GIH1SI&I<2 WSL+#+4E]@W1FD$2P>JR#I=W&@?%%HBHJXJJA@^6]$) !!K<0E*A43MC=7 M*,9KYUF90)P9!)(\11GT]CVO+J*B.'!$1;R(1F&8O814"L.#^Q+\82PPPFU[ M7@@!%G&3'1Q6D$E8HU&'1X5S_QFR%<)6KZ,WYTA9J,PO 3R0IQ[ M#'_0%H]@_&=.=C:+EKX+>

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

F#\B&95?>PCB.]*!8GA'3V?)PGN$U"[ZAHR'()9[Y'4G' M.(:%*I9;W$,G*NY.@1!B^J!6BQ#:K7+'>!5&":=MSGFAT@4+E8JT_Z8QK9DQ M=W)9=?U1G@(5;_#DWN#.T.4#%/%.1^P,QA7+O.,0K@*$8^J JP7A@=CO#2L& MX1-,'L5L%G<8B?1B$E8"%1X!R;Z=>-_ZDR!9I=2-:EJV<$?SA21-N)#TGRCJ M[N?23!(^>#>YN;L(_ [;'<]QXI!"$_^PY3RM0C%V3<)<"IT1:T"P:KVMZG18 ME25\4'\3I+CVY)U.G,7$WO-&DNG4*4H;C^35T%X!1>'O&*G\!ZG@5K=LT\%M MH3]@U_E;Y5[X5=7)_33B_G3OO*W#G;N?TGU+1(L1-_TFO:MS9WYAF"9-/[J4 M,._%7J9KD]YM89?TZ$[IIK[#BM;J6_U& M9Y3[WF=A-@17"(\F$SH@(.59=.$<.F(K0NH+- ]-@V6%]]X/!J\(#\D%=G[W MUL%")XN;L3*K'6QOI&KR&6*<^!*5-> M_$P$QV*EA%.PYV I2YQY-E?MP,2E9\>"!5O _^6_'-4O*<=)HPO'E&=8DH:O M0ZU\95K?^8("/@9SIS3#IN#=96J@VB":=$,7R$M/= MH:ALS)V&@XAQ4)U-!%C&PH!5L W9*8Y6H@@%&I6>JNX-G(I8,)V>&G/7OP7Q M1,>K&64E\_]M)0":;B%O%3+QL]%^V.CMIR"IX'0]UV*GPP+A1C,FX[1C(!&7250Q'#P BXX'@C;_M!?FX(OFBU6@! GZ:)%%AUG Q)(I,>X?HJ@+&'),SM(\I># M\SU9 7P,6KJ,(3<4 ULJP+'3'?C&2V>>SK-4A$>*31PZGT<)'H5X1+_1C8) M[ Y73:]G[^6_EOM6^/77VXO[QQ2 N9 LU?J^ (&HW.O!Y[57<.DEA MFOG4V M 8.]#9!U@] '#AT7*.C&C(.OM/T7W& %@A^5Z^^Q1Z^J"T-"L MQ'2*&]_L1I#JWA.S?G-9K;X+)>WYWPZQ9YT?\19M(K M85+7'\]*'YM@NO8S9>E;CML=)!US']PSIH0*=.3H:RRK7GNJV_ADNWT#-@EV M13#5E]**3M>GKH=FWC]\N?OQ+;8>P/.3MO:OF3KSI\9OW]">6Y&\/E%>^#SS M0WP/DR_7C8O'Z\F_&I.;I^O'CX*DO4E+RW-L8P@-ZPA#2YT15@?60>^L&P'\ MI47_$Q4<=+\Z$WZ/W*5_7#U&[A+Z>T,/7KUSX/>S:0/ XG\5^N[I_A(P^U. M:[!^[&S=/TU?1E&M!> +-PY+)AO/6"P7CA70E:P>(7R6A)F)'/X7L'+/0E![ M<[=&Q>'F&'EDQXI7K'_H!RG7KMT&@;__Y1CVIS4@L ]%A@]1L.#HIV@B42Z) MM(J"4\?$'VFU10$HA'&Q^IM*C1"V@V#WZ&#CFAQMO['7-@'E@?$,)^/U0 *A MX+L/')UZ%<"@GJLVM2ZF!!X.VJ())$<-0[B!2:V$A6-B;I3MJ9%[Z:HK?Q#5 M3JE2&F]3]!*:F751:>*\=3_H,7@^NDO_-&X(.<3TZ)Z=MYH1-12_!@R[5<\L M'#\NVV@G*!+@T,.&&\?WZW[3'7MXQG%%^AUD26EH5Z]'D5"M Z:.W<=,.B== M$9Z7='X[:''(PV"7X;\\7R"=GXY<:=5#8N5;1/<6TQ694X\&LA2<%4T6@4XF M2#&2"E?*CF7#2YG+U9A4R;WN#2@:GX\<4)I.5402#CK%W^ODA?U#-EZ)+E%C M@P6?D%U,:7J02GV)[M?,X4Y>/<^10J:2H]G,LQAQ-S>2):)2"W=D+V//T ZF M&+%-M]$*_.-%,NEC$5^J&XEEG9VP^OD9MH6Y675W>\1$'M:@5W:UV<#HB"3/ M!!E^BSLO$Q,W,K#!H)&O<<#U\X:M9?S6!'M;-1F[Q;8@]$Z2, ?1-0>:8QX6 M6*;YPK;&!/(6:#L"RA03J*X=.A*]]>YIK>CM12C9L(.X90OJS+(\MQ-8#G3% MZ";Y &?FTO*&JQS>8*;27=!D1Z. <<>1XW>.KN%^XZYJ*KRA@OQ\"H^UA&>B M@>8K"4CCZE2E?F$XS9FA*2(+6NI+W-L9*!"O*KR)0D4+; 4R-4_@N%-ZPQ$ M2B'TGZ'?H\4$>CF\-S \3<+==E5LRX$W"-^8#E6GKO$XSV8O63.ZDH*BFS;Q MI4M5UQY&;Q!8EQ17ERZL'O$A5^Z>/7EGDLZYV1?[VZ) V(3)P #$CC-RHZ(( M/E>P>%CT"!<;[\J$ 3H47;%FC+3\"UT"IY^[3Z* H4N &\]H.&D5#UQ[*-X] MP M8@POLU$/_19\?>'KPRNA'45,1EP@;9FQC ?0'4Z05C:2A^][9>;?96M$] MK)+29$;TWQ32V_G ^]Z(29T-H$\N-)7FT=-MPF.*D!W-DAJ'Y)YPXC4643QW MB\KDD1[,F$P[B1T1=AQSM+_YFW,_#:9=Q71BZ9UB)Y:3F(L,@.E4/%FX8L76 M@W;:!IE!8EL1X2-Q0XQ CK[S^5:_@_L_O1'ME7Q#UW3**8-B-]?!2+SR>A=Q M=2M/7&4U=X^AL*AV!ME3V)]$,I_>C)2$U>_DF27/NTWO(JP>)ZS]"2LF2)TU M88'-2U*2UG#0J2UI'8/,ZG/2VI^THE+*\R&M&[#KTY6(=D6JD)1+6M6H@=G6 M)[F8#LUY=V/V.S'?3R^-^8+H%G6O/;*1++3.^#OZ[RXP#.5F7EK1IG]_B^F_ MOR^'=VRF'J8QZ]A<\X;-%#X-BA\A"+&]>C<706V%#$F8$PFIS2TY<>_B>\RIO[S!HL#>ZP^'!9^P7!A0\&8_5123>%5TAS"?,@&W$C"!OCH M.EZ%,LF[ROS0%@V[&30ZX5Y(U^;HK\2B7GT6EV/?T)RG9T)TD!?HJH8CI@[T M9YK!JMK+!O7SL0"3^UBVQ>AZEV5,DZ/O!?\_)2I68UCH+(676 J&+#MF,^XL MZG;>6-<8FT_6ZK&4ICM#;US/%YJQ)$2X4@$8-FP2"XD^:)A)'*A6_+ C1]BK MLUG=WK\CWBM0 *?"33$A"I./V9DMX (:Y&.#$+"B$8_+!QE"!B'$(JXL>. F M#M BD>UJSS#&&?8?7-<=O!^KLG)7BQ_B.[BQ.IKI3:-J"+'[*=T=%MNC$63Z M[XWX'.4^&QYN7Z(%&=($H^XO]!$7RPVA-T$T@Z2%V\.S:4AKP@;S_8^D#-=U MMQ=MN3&SB!#YSI*@+<<>/E!ZF&[((W#\06Y@X8'2D+N["L6]'1S[S,!(NA)7 M%;3*?R04V$WAGC$KQ4TMHK?&'!=) ZY(/&C1-\<0*#$M,;@4/ZRXVIM0ZH"? M0@_O*KV\8':"[:)6B&"-<7'F8<+<>(H)OZ+A+K"3=$GW;/$N?I-@_$FU,>YR MJ], +=PL=/&NX'-J6+L+_8)[=4B!:'L;G#$F1D^"B0MZ]'!!@W@\S\,6XSW MEX@&_R8*J\K#V"P*%&17_I5P';T/S29P =1TL>#!YI666RP ^N^P3IMHRR1! MW.'@[-S0O>$2=)B-X$]3"&&8H8LF_3 )BD+18J_+BOK@B?@#N(6F$C-A%'DX M/#NWB1Y<@!6W A&W*LW1G+ ;WHLYM\[$6@,:4=N(:_[4QZC#]9 MF)OYJF("]F3/,.DJ?=QT(])QI!C52V(/L5&4*'B55 UUU1O#I&24CH"&HY;8 M[<;*@W"ZE/=8RM3]WGC!3%"WYM5E^*NJA/TE2-//>GG.KB-VVF-Q,$Q^>H<EM(B854;PB#W QMTI(#9J1 4//'[GI M+#:4IQTD'5?(%B)IT%AQI]@>^5N$EQRM;M\61[MU^[!>'U9=/'4I:=L#L*;Q ME%4?@&%='I"V7=-O"O]VT]*8_O**:9]L=925\;@K M]@:;$9ZMI^EVR K*FTQ.K-YZ3+A@K.!JR;A2R8%7*ND'BTHMDCRH0G)K>63N MM9%U+HP,1 E]"+A_K!4Z[JR$S%]=OTI4>RTR4,=?U5J-_HV]$&PU=N7;RC45 MY6V,$QB#-&["@$8;MSMKH?#$-RTKKY6N+K?'F# 8Q=J^&$7O5 M6NU5ZSCW:M@2>\.HK:+XC-FNT>9VMM".ZJT2K)6M%J\)] M;+1 9K]T+6I0/.WE L/G8+QX#(#9/._$E%6OT,D*]^99CZ^2\&T-/V2?3>T*AM?6E4.\XJY3;L1KWK2.7\[3Q2RO2],06 MJ6@7SFEE.E/4).%" V'?^"[/#(U8]!;,+3$W%**M>@*N+#0F*M'KX!94@O[9J]W MU\>3;+-Y_8@.\_JA76'HZ*#8&=6)ZLF3VD"Y 34753$24,,\='A-%PYH1QAA MJM1Q$N&OG!#V)X1Q,H?&*1!"NSGJ<4(X44(8M)*YJHZ>$'"@4'.P&?"O.R&< M>IVCKTTR+QEK?_1J8/@5^T5QEK$_RTC8.K(&+./?/@Y22\]NKSGB>N3)TD+G M:/3(+&BAVRRZI)_30G5H(:*_8TU5R6SD0FLS=%QW6JB*G[(L;?)1M7XVIB8A MJWDPV&R; M][+"NKAQ_.V!ORSTM7+P-XK%7W?,\5<#_&6B)I6#OW$L_GJ#TO"7L(OE<71< MP*(",]JW%4SX9_75H>YU/YK?F\*320L]EVZFGNR8KW12"9E.L;>8Y(Y'@05[ ME0Z!8@;BJ46KJ"PM7O ?,U,MVS!14_0GJK,PKCQ#,/J-MEB$-[0ZLJYRT:XX M[LNXRXJHK]CXF?<3E=6U>K40.JW5Q@M88?L;\4LN6+7'JAY$T[#/7F#&+"TL M\:;B"*CO+NB;P'8;V"S"*QBA!=&6"D^HKXHH5/1]0\.P-Y$O1\\7K%T([ M4K%F@$D:'7B["C>,&RV>K+ZR_9'=J.9U.R&1Y)YM3'W.,-OZG,XPD"D][O,* M'5Y)L*N2X,X3%)^?32RJ=^O,>"%(/8[O#[<(DIU700^=,"6CT&=>NTI%H0]] M0&6.DP(GA4J1PB/!P9( IT*?BIU 3#8HNM#GHF5N%?K$#W]N]WASNJ\?5TZLD=^%WX7?Y8CNM>>O0[U+PVAX9UTGBN?"H5RWE,(1^LUL)Y)8O U=W.1B*9W'QNV"4K\*;<,);6143MBQM MZ OK*\F5GOV%2E2%Q^EV&N8:4*4UH+S:8A^B#%E[839[A:C7:XX'50 RE^(5 MVX03WLI3=P]Y?(6K1%M8V(#M_#-- MJ?*T!^*POSF8IXZ5>U6O1:N\)C6*:*U7>4W*(X >J>P1O#G!*U^L'2Q%4&I0BDQ*N+5=>B)I=6 M5EUS@>.8Y$!U;=03>]WC:,5<=76M^@Z'A$.?*J6[15!"]KI;=U1XFSVN<7#E MK=I;>>J^L1U9_]BLDCM:TIBYH38KA8+N3*BIUVY<7(]'&454$U=+D,JHB MZ V'XJ!7\%0J'N(Y4.,:1U41E*)FE5E%T&TU1Y70KJJ#W+)=N_OTSTV*TXS: M1NY$I-^/(] B [M6=$+]),?=F'Z2_>9XR/N9UHJ3]C+FI#ERT S"X@.Q6W20 MC?MM-S(Z:6] KOI74_7O5U[U#Z#H$-6_TQN+/:Y U4U@#6JB^@=0FD,!<;:HPU7_6G'241&J?S9X#:O^[52Z?T\< MM4I/B3VA<0-5G9T:(M(DFH23 &Q#"+:4MX1@.W=KCW[NOC4A"KN:NK,F M0]C5'=O.QU[8'M>GL[MNR@<37VS%+_WR"HYM-8M$5\(T>C_U2[W@NW\3"W[M MW0T^\']X/PU_%]-E?L2[S%3[>0LXIN(,?/JH)GU1Z? M9I_\/KF>4/>G+=$!36Q:_1*M-8[H_1'=:T45Y,=-[CPM1(^: M@Q)CCQS1:1#=WG-D^FDANEUJ%.+4H^F^PV6;HN9-L%3H /0=(RDX5TC.%1)V MF$C-%7B;"2[3\D-O5(.%++6TVJ"WTQ?'[8*+^#A\#X5O1*>$3%6R>L"W=W8^ M$CNC$BL7JN)*JZSZ]4H#6USWRI;\$_;Z/IC\LPBB>J'-@R55R;D+'*EID!K5 MZ#L//:M22&V+XP%':LV0&M'#(Q>5JF)('94Y/.&D\L$F%JI':;*W, /,1H49 M &42V7C18048*E]A!_YAV<$\,MC AJM\!34R04(86<*;9 G28F$:[X &FVA+ MX6\Q8;IUA2,F3?)ZOM",)2&!1,DD!H;_,V*^JC*)MC?N#)V]$GVD16V(X/>7 ML =WAOTG@<=XN^23Q2 I6?2!+)J;1"$ (#39*L_H!I+W!9'=_7XF0N!H M## $!$EX6X\N+ZCQ0W%P:,9TS$87M+7,DKLQ3/JG]*'PS#.E3.!BKLF3-D*")^@KD.X5G;XTK')RCRYC\SNS; M3DMD>;HFL9#OP,J ;=.?;3^"=D0X.D*MR0=7E-[A&-X,8"E$7U<^=&/S""+V M?7/'X7QVY"DWV4[]$6+*<5!MIVJ8O94'_^=6!^E,?&7QJR$S%0]_=:7"HNSO M!,"FOWPA.H@&;:(K$V6NZJIE8S?15W+]CKR7)"HRF&@:WI\HT;S=O57:$:/# M2.(7X[DX["STGD4;[)+U? ML!="L>6)*M=@=P58RKZ7@TX:EIB%,I3]F^^C- V:FU.'/*4I 0.+R/7<6Q4I M=P/:S)E^N&Q>/UY-_-28W3]>/'P5)>Y.6EEY[ M!GX\FS9,XXU]'OKBZ?[RJZK_%. "+,8Z6_?KT7=05&NA24O<*1 AI/&,M6=A M/RQ=@WM_X;,DS$RDTE^ JLY">'ISMT-%GP &$]D)XA7K'_IQQ[5KMYWVW_]R M#/O3VIFS#T4&!1&$H*E.T?*FE7&@!6!%-[:#_?R[Y&Z.=_ !"+A_4/I>X3:( M8@_=X0MR=R"P87([;,-V8J[ +GPC7@E#G/782354V/@ M:ZKHDF-N>5S6(<.%.^)@O-D<99?- MW8D(>NW6U(]FU]!9M!G]"CFDZ6,996+,1*#/%=?T7V"8A$G46$2W!@S1;&\$ M?W,$W)VF\!FKR;Q?HT.BH;XW9JJB$/VC=UZCL_,[X_/O>.5Y8'&!%0?7";1C MKJA'8=3I"?X4=[K^CW<-.-Z7/KQNA?^VO21S//HZCG:='Y.FS M9\#TUF/W%?+[X;)0G,".F[XT=KV!NWQ_W60>L#4TKPG]7:DU*]_/H_LZ:S=@ MN3-I";D?#< @S@Y0 >,V+]4L\T(W;T>X[RXBW+>!(1?V$5IU+C%5+U)X9 D' M0N*^4R^ %KQL(UW(LV^ )TF69<@J<"@K$RW72DLMP5DDVR\'!+"'[W"8U*>5 ME6_$RS-@QAJYG_H2G@K9"0H2V.>8ME'C@]I&T=9\7I.H_3VRO$G4R36S"9K) MK-JCH <'? *\\1''2NR#O8X A3[4;3\@T/X#A3X9FQT(V.U H/GBA3[[ ;0& M*JM.L\/58%!>AZL=H\:B^\-5IW!DUPU[.=6*>*K1EYM__MEK7-W> 4+F#5-Y M:=@SJ@4KQIPT9$T%M#? C#$<4R96X]+"< K]1V-FS[4&T:C3I3&#=6F,W\37 MH41U)#ZL3"K;YBJ>[Q\,-X<.V;Q'O^_33-+=S I?.3W$*1\=1.(E5$E+J(Z. M+*("6-7KI96<.')J1X339NM;#U_[=D1?:M$6\M1D:E011';U\@5SD'!7LTQ# MWER\GJIX;4?T^*MV']8]Z20G<=OK-,$B4,/I?#+I*O+E:H^Q.EH44EU=;5B?,P> M9L@4[B;<$GS(+I 2"IL<5:>\>HJY&'K,NPM?\3:32Y4.[%)-_9-1Y,FMJ(,B MA*VDA?XPG\+>/U<4G5:MT7,N84U[_M*<2;$J8;(2C8U8F'EO*0G:"/0 M:X_/S@T]U$4 Q5 ,%PD)Z4=\+)4CWR00^Q1--@80J47DU#+P"\5!M :KZI% M^_1AX1W3%> 0)>6_CF6S:['5@X]+&83ZBU"6T_L M6*B/P&/1!#QSF^B2+A,1ZXVQ@0->"\*&?084 MH! D!E7'QRTI+2&D\1E8Y RK 3A:*O!YN(!N)MAWT\4>% 3P39#Y I'AP MP!W8F[K5W455O._9;LHO6P\/ OI8I_)+RI=0==U>9SEJ'U1GV6GV?UVS8ME' M7NUEG]=>\GJZ7;566UWV&812^%EE?E;1!5C\K"IX5BC-3K%\L=\IL7S1,Q)< M$ZGJP]2 M%1.B' X3YK]C-R'"(K8@S0W8B/_1,'3%38E=-\Q!@H]W2?!NLDKJ> GNSR1P/.F&A(^X25$VBG;J@=VH:N-]K8@\4=3M\]XSU4=1Q,C& MO:V)/%'4Z=>W-+SF)D:46+M%ERX=J:"[,5--E9Y53;75RKL5*ZD+)!N4D)S^ MO -:[Q&_%^?N<<9=><:=;#I$P<#9G ?-@5,UX"0;AU$P<$HT.$[;RC\[__=F MMA<7Y/N3518A0>\H#O/*C[GU7GVX9!$#S 8N@Q(-+ Z7A'#)(NB7#5Q&@]J* MZIK;XV?GWV>&:3!)1:'T5.?2^O*XZ47%;'95UIG MA)<>%]?5QTM$;&9O<7T$>#EUT_H[=JA!.:W2Z:$5E]09M1;,B> 2KRZN_5\O M(MRUO^!W3Y6-A$VG1!>:-\?[[1TAS(OL'9NF(1P_^I,]^E,WTVFO%D$G=GVL M] -:[A6>'I]\97&:0++&H_&:P&&:>5OLY%J[<[R]\HX=FU&QI'W=#8=BLS7. MT]'+L5E7;$8$KO9V;1Q6LP9\,]>J-=X6<4?[E%M]QUSXECL]_BW0Y ;[J3@6 MF3J:H*E3@DU7\"/#+TVF*,>/'6S!8V'+&_AO0U9I?\0WU9X)AF,*$UN#-4JB M\(48L#Z)]D_Y)ID_9])<%.[A*U,U0OU\K%6#'7PBZPQ(,U*QHY.-JWQ3-4UX ME62<[DM7%>P]]4P FNQS0EL%N>US4+7#6$R1K7$ 4.2=MH'!QG38M['M]AN AY%M/:?/G_&VN!M/_3>B)WX_[/JFO=YYAL #Y,OUXV+Q^O)OQJ3 MFZ?KQX^"I+U)2\MC2:A@ZV1MA3/B-G1!\G/M@U]:]#]1IH/[U9GP^^;._./J M,7)GD)I#3SWSFP%Z/YY-&Z;QQCX/??%T?_E5U7\*< 'V?CE;YSOT'1356FC2 M$G=*4W72>,9F-V'F3M?@WE_X+ DS$YGF+[8AGX7P].9NAXIM'=$682>(5ZQ_ MZ)LM:]=N.^V__^48]J>U,VS1>RG+];)MRJ87$^M)B]C25=F*H[1)F ;+\<]ML7-Y<7C>&P MU6OT^NW+QJAUTV__I\UN3[ACO-M3BKN<;%>:8/\VYJCA M;:8X2"H$DH+Z6U4E7NMQ[\&HO)Y)H3ZO](3 "C5,*AL_"G0\ JITGX3-]DH? MWVG'3%\*>MJ^&C(U)>BS8'@*>:5!5IGNQRK#= &]6T?6?/<]"B)<&?H,90?C>U MB%F=<#;$O[K?_O3?.SL?=:HVQ9HCNA1$]U++LBHA&NLZ"DV:X[G8^XFY]BB0 MGEUC$7=R/INXD;;[ZKH37/F"=&IA>U]ZN7RR?E@M"#37_ M7(+?_X-HR@]DD,'NRHGLLZV/_&(:EI6V )AW&JL;+*/2[UK'!LMVB=,)JJ+I M54?"7!KSA0.ZMW!=$^%2Q62.0512XC[RQ#N%:A+M@/%<=@ MF6W.N6&R56Q\-Z;VFV3RWIAE)V$,HA(*T\@@[T0K1?Z=5I$Q)YYJ5%F41R7/ MI9%R'.5%I!\=E<'DIA]YYQYVR3'7N# -^L1%X06A4''16$EE-BJCS?)$BR[,P=UJ%* M"@Q:KKC .!(M,V[.P" J?:](^3-90>.*+$R"711AC?"W1FBZH*X$1W-O75): M)_VP4"<]'W!P:O0U+%G(EDI?@U:>K2TJ1%W<>ESWF^YC/.JDZK&XDTOK'QR: M.)*;<7"7LH?)J)NGI.?U*W4%^J&I*)4#>EOL#(^L64^$87P,S7IJ+O8#K7F> MX7VI_FAAQ^V0>*^Z5[CRR7+#F)R;>-82Y$6']T'IG9W#6KA?MU[@B4F6*1(\ M97=K.FW/;+AE3IV9]7%XC.((-B:[)07!'M@FI-LK4I/DV2B5165,-DKQJ!P6 M:M_P[)$T_C_6NR8D7'CGFNJZ088Q>2@I"#SEK/&JN2TX-*L S9@\E:*@B3ZU M/%N /;9&OWP"IM8^"XG] M84@^-RPB?U0<$YG>V7FG.6JMMST[:4=T9:'1R@,:HQAH=)N#46G0.'7EY:9. MSN3*TLP6=AHT9_:EF'$,Q;2;J\@,9Z95!L869GH ,$:M6"D[&->5E7+SMIH2 M8L.\551+AM>T!= '"#=F^5VX,S5W!V8 '@/'5UC1OT MAU)MLL!Z%-7&F'79"92B>Z=R@5(=:"8+K)<&S6[!340*$R=1\UN"HU2*FN"2 M_>L*WO\/Z=.^.XN%1K"82=($6;)FPE0SWFA)J(%S?@159W! 9)J$-8BP#5?: M"&\$^X%;<'@:_,RB06][9C@6W, +?!?P%NM3;[9XZ!3&V5OX?Q%>7-V4/U)Z MN81]N('WH4-OGN#7%YHA_W2]WR:LW[ZG?)F_:#(A2V#7""WX7?A0=MLN1,JZ"-;QZ!O6,:\_6QSU7WO56^ M$GJTUHEKJ[F6?+[L@[1$89&B567O['PPXK7T-4/0* )!K16"$M6D9(6@[MEY M?SS@"*H7@L:;"&J/?03!G\4B:#@J<=Y-50R4ZHG^6K5DJ&)D8]S*0-8'8QRW M:,D3RW:I[5X_K)PPUU9T-63&N/"O/H8Z&PDQ$XO8[&?#7:Z73[CNOK8Z6+8E56K7[L'=&&;8-WF <=([.^\/>("D M^LB*BJKMJRX5BBP4B$/N.ZD^LB*B;7LK4T4CJUTBL$X]GI)$K:AK/])*$FA$ M,#,7I2*C-HXXOX!K%%6'5;\5%;O+0Z/(LG%MGM/,.:ZRP55$/"\7?2+#KK/C M$IU^VTO5 MV CJ50[8?NM:$!I6'A.MO<887PN@T93U2C-5B>"D&+V-9R- 7) M%CZ3>7"U'T$'F<%>4;WHBLAT(IC0;8.>!2(25 XR/S^@SBWCC3ZPN@UH@OCJ M]$17(DGAFV0[L!_+F/JW/J]_JT!N]BG7Z7A]#[YNC\'N^=*\NBK_4UNEU!5Y M;E4QO#T.-QB55VD%DJ%3<5NZZEG"_5:V(Z"\V.&50^[@ED]O1'LEW^#^LY1I M#*,2LX8XH-( *JIS5") K:ET^0*KW\USQ 9/1]O%N+L59]R5]"ID.SC/290NU"VX36'4674GH1+5?RI0K'P*A?KN^TUIK'\H"(/0X,]Z?H@:Y M,N.924BZ? .>]UM][ P+X<;I,=0I,<;$E>-.G_/C_6EJE"<_OC$<,U460)MG M 50?.N,BV'$Z"&%D-M=1M5P[WL6-!YP;[TU2[5:NW%A]3:'8<&Y<(>AL3UQH M-&B>0ETX7.WUS2?8>")-;6)6G,\E#@&7@NG$JRL2^E'QY#KR*7[TA1S]:2M[ MX=T9,^9H8#?YN:JK55 MSBV"ERZ7N\=JLZF,F]]!5.JM< M[-:XH5W-M=;P[K1'="%XW!^%R9P-^"0+DUA$IPEZJMO)J.(<^TBTG ]QQ)QM MU"R82G_]+@, V/&GBWH4ZF;;DNN9TUR@WSCT2X=^/D&_3$F@V%KU\DB &SKK MALX#DY;"JZ0Y!"=2<)LG*_TUV\!DRJ)1GD9=?:#$A"'_.:0)Y?EWU&)CH"OWFSM#EC2^_T<+ ?3I_'UA;*G9KG.%W M5+82X_8N7H2%8>)15)RKGX!RV,DV7NJ>;[J^%<-"@Z3<#CHUJ+0$8QG>%N*14L4=$(G]LGU$J$[:;D+M*P8#G8^6"/FHLL+ MDZ\LCLMD6]>Z4J-3SN#(T_Y:YP[=ND;Y3PZD,;6R.T1AUG;=(0 'I7'4R5-I M3 /P*K44@H>2=SK_%?XE?%;45Z^[S,.7NQ_?8AMG>+O6:NW=2N8,GQ;7(Z@W MIDDGN*;?85'TCYDOZQ\F7ZX;%X_7DW\U)C=/UX\?!4E[DY:6AWV4I3I96^&, ML+XX'3PB5Q7XI47_$Z4EN%^=";]O[LP_KAXC=P9///14]ST#/YY-&Z;QQCX/ M??%T?_E5U7\*< $VT3E;QR9]!T6U%IJTQ)W25)TTGK%G4)B+T#6X]Q<^2\+, M1'+[Q3;DLQ">WMSM4($B550[V GB%>L?^AK*VK7;3OOO?SF&_6GMS-F'(H." M*%APT%-,8Z$=C4!KN41N0_VXDKLYWL$'(.#^08EEA=L@BCUTAR_(L7,6B_"& M.F?1228FD8FZL"U!<8C;0@NG*UO(B%%SDUY,PH8LI^N6)=6^658PB+3>?];+ M@7@R+L@C[N0K41)TS!IDVS$+/_#Z9>W/Y'B_K%/OO'2:C9=&7=YX*:L^.;T2 MHCV=U*F023EY)GURZEQ\5O/ S5'TR2F%M [*&$U"6D]O!M:AI22I3NF==LL7 M8[S;2;U(*G7>9F*2PFX5AQ 5;UE1)E%5O65%1H'5G&@O>059#(D>E%^:A$2Q M@T%Z"AWDV2:.5[OE5>WF>=BJ3M]YQ(X*HO9TL:/4::5)R3U=9D2NLV/K'@C* M_1F;[\7B'^XD??W(3) T>!-$ R28QN?0LYG^DE*_W 0P6NB ABMMX;F.,8M=VAFSN?G M\P\Q08QVF\8L?H/3?3Z/Y-=;U]WK-?OY+OPS^JI#?FI@'(9)P]H?6>@&@VV? MA+-S%U "1=3GW_&'YVNO%$G4]1\0P\)<$T%10>S:ABF\S0SAF;S@SA'S%5W> M( 5 #0.(2B8=.1<7U/HF+6DL2V3!++P%4=B[2)8@SU0R%<@[D1T;^+U@3*>J M3$P,$TXT. M)^ >1-'LF*(Z)3][^)"_R\^7FGW_V&E>W=Z HS1NF\M*P9_1D M%6-.&K*F@HAIF,2"%Y")U;BTK$?W'XV9/=<:1*.QNL8,B%5#@@4A=$Y?@,6I MI;+6H!LV74$#Y&!C81I3U19F='-DC!!:2\LF\Z9PJR/_U D3UF\J[)UJ6P+H MCB!HB?#L6/ _EN6-\J'I9.&M7L!"9G2Z#YP$SGO"T\#SAH<1*>MA'"/,<^P9X/EE%HN@>[@% BC ?& S M_?M)"&.?WR"B?8:'S CO0> ;.@+MG&;(*F ;)H!-@ M118>EBH#B5MX:^03<-GS$C<9 ^,+0J/CJQL)SZ;QD\ 9X]OC>\J&A:S%NS'] MT"2X-A&9BL>5!+P-\!O\V:MJ4;+W[XDC3]>8EG]#RV5([L8!WX*'VI1W^06' M\$B+!!C@&VQP+)?I9L]EW/4A\'S<(>R2L9S(Y[!J7.M^&OC,9T*MA$SH]NX& M)TF/Q%9K,\].C-^F7L0V;8ZX/*)MZFW;)H1M[%;U-[)N8X:"BQWK&W&-+UAI_4QP M[M#!>\DF&V_C991Y/?AO?>6]-)85NZ\,?U[[+_S@O:^?4.YS.\;I]F&:L"W^ MKM!-R8M9[F<#; Z,\FP 1I/QQCCN>=/M\7<\_.$J 36UAZ)/3I+\EP-8 JJG M.B=0O#TST(_Q2BQ[SI14Q"UU5*$S<&&2*3'Q%Y9MR#^1LEVLX7.QX8FF$4!9 M$_BZ"!Q";H*#92C_=2Q4IJEF3"PI&73 M]?/^ ?N-C'8FO>((X4 R-.6=#__GOBULW1SW<)<_"?9HP$Z295JS7]-3M1D; MQR8B"V]D?N5QL?A2J8:*1V[#*3>(',#:45Z*\J#=\O&([.7ZMKMI["%>L/,;:'J M[$AGW$MI]_1&F=L]U=F6_E:K.:2T([.,H7W=8#2G&<"=3EBQB,4V!/CE'/2?,']<9WBEFQEU#UM>&O,% 0Q3+='3 M90FY8#ZU!PWP'1VW'/&X9<9QR\YQQ"TGOF/6!9%U4L%+9A$ '[46(!1 YY6$ MOQPXL*D:KXOU6BQN_>'G;\("R(X9ZZ@B6\ZS9<-#P0X$/1C^*^A1ICIL I9- M #*J:X*["BFP4VJ&4#XJ_/#+!O=8)/6+@P@"!3A&LO:3J6 !@0@V-UGG5%> M)=" L7;35)\=? BR)Y=CF=]P%;!=H>^)*0=KN1N=A#*S XI$O[DI+G_U)%', M'DU5T[)=WUW,GD1H&\GW1#?E;?OQ37K'O#7WU:47'_9-#=2[5/@VW;) 34) M?BR92U% DP^5A 4J1;(*[ 7M4!N-+^0\\/BXO1\7@$T M_\:WT02*V/<%["$:?U23"VYZG.8[B/*2Q>Y'A,*Z8SNN@N<7VI)PG];]M%HP M6_>W?P;M1/9/!5^WL^UU=]DV@XA#N!GD$)F_ M9^Y2.E*?2]'(@581ZH02-<3\FELM@@(4I,*>DK-U\YV\H';S2*BC#3WX\+:':2,4159Y[-9:=N;MKIQ+$Q2W M@$?YS7/J*S0F:?C-"RRVJ6YN3$GN9$M]9]P=5,H0(!H6D1OJ.URM*$3_Z(G3 M\=FYH1/W\/%')IEJ!/W_[ENR X+LZ"AY?(?N*WIR#;P'^KAFF$L9@[W6++8 MR_B3)5S2?-1K/Q_U/I ?QG)55WN'PI+F'\VEG\1L[CC^[%$6[NBTUF3HXW]BS:_0^XH[&X=%5TM%-\MBCUN.[[[+:]E%+O2%UEK_PC] M769/J8VSV;.M5(J3<9M,^4_9MY]4S5M*)83%6O>H-:J*[#"5,W]G#BP:@*0O M]TPTXTUPYPAA4-%6[64#$(),SA>$F'\BF0K-S:?9*"PJ@%S+C1*#V?]"C!=3 M6H!1CS:]%-U(JEC^=:!^*<^(XFCD?NK&:RP,V%R_ ^/1)>W2L6P02C1)Y*NA MOWS%>K()W8V+Y1=_+R1M IMA;6\U-6X=U&JJ'6@M->KSUE*\M=2NUE((^&+Z M2?&SRN"L6ORLZG)6F+5RBGW:>H/R^K2YHOEC!CN?$T'PN_"[U/(NI]WR)W+^ MZ@\P,HDB?+0=<3S(4\5)T]^08[H43$>E_.ZE.%4(T\,BF_EQ M3%<6TQ%U<_LI8U7!=%<I9'Q]F"F$"JCK/# MO0LW2O4Z#<5QOU>Q7K0%3-WN"GZAH[.\?*I SOYWGBJ08:AL MM)8JH&:3'[":",\2MU.)_5%7')8Y[HX#*@V@NA& .CS@GPF@AD.QURMQ)"D' M5!I 1#1^0II!SPZ7XFHSRAFC.X!H9Y,J+;=WNS&RR.3 M)XC1J+FTAX?8L\&H.!I4+=;(45H*2B-&LV80-,\$I1UQD*N!QB/B/")^M!&8 MU#-8LW*NC+I%2A@>&JP+,,?;U:(B;.JQV"U40>? K DPQZWMFE 1'+,M]CMY M>@]Y$'K_(#0;>,3CS_PN_"X\_LSCSW6+[HSSB3\?XGGK@V4T++'DDN,H#8[R M"3L?@J/." P9CJ.:X2B?:/,!.!KWQ<&@Q*2%T[8P>(RYNI&1<3XQY@-HM0ND MRF/+')N S7QBRP=@LR^V6T66M'%L5A:;^424#[*YQ%:[:BTPN.N#!Y)K$19) M'4A.2[$]I-BAV.]M3ICB83J.Q]3QXT,D2+S5PY^)?9^M;1@AT>K4MB,Z8R/YA'[;'5&SFE93[@RC T<8Q4PP"G[E#BX2W$%&T<>V M_S2C>@\SVCJ^R!_6N/JK"J,CW=E%_AR:C1$UZR-L(I:\3A=K"]YSNJ,W2Y*R M+'+ 4>W M\+DP;D8.3-QC#WJ=9MPHB6(WX9+.^K-PV!\.NKI2+>G%)(3-,Z23V2>RC,-O MZ7AJ$.;N/W%*%O[@1M4E708J%E:#26,VB$D]E^Y6./H<&#!9YG#8@_9^;?S8 MG6$+TF*A 0;@U9H%3Z7ES",-W:QQ!&F3)4B1/&'2%(Z$'<#M3$.S*&T_F(9, M%"!HBU.TMY7J^?6KI#ET[U#/6'$]8>O>J:N-.Z+=N 6) ;+ 5(#_$R8J'AW@ M.>VNU&CW/SS_AMN#\V&_$]DQ0=.#)U^_N[-E)[*-7[?'W9[P 2]BTV/E3\$K MV&?*I]]$.I 1%BR]4,DD$'8&1!'9@_$."PD)3%WX1X._B1M%N_I^)<3<[T5Z M1S*=LC'I.K$L[VT48@']LANP*;:KIRDK,,A!,"Q\, @?) MN0:?0H\P-[ACY MC5[<[BONORAETH<&=^4WG-B.R",RF3_#!=VV2,<4-X4+R8+;.@L#9U(2U?3V MR5TB?&:1!(MD;Q^W=:OO-[8.;TK'?.)5DLWV;/>^O!$SL.%;7_'8B(BQE&\^ MLCUFX0U39M]; AO_COK7K2"@HLF)OX;X7\A:P#J,_=2#FXD5-_(U<3KV-H=NIS MN1")-@5<9?(GJ);+5Y!J#*2+5QQ.BS-5#9UJT$&]0!O ?XF-$\SGJK5ZI:8PT2Q#Q#W]+Z%^/\I:)'VYQAW# MW!Y.8>K0*>? Y%5#L7#U' MQRG#9'^(W-\J\V= Y[YF$:T!&'N1M6-Y9#HUI3EY,\R?>.[ T3>X.')KQO2[ MG^![RN9?3+J0F_^_O2/M31S)?M]?4>K52,F($&R.0$]O)'+U,)V##=F=6:U6 M+6.*X&VP&1\A[*_?]ZK*!V# W#8IJ6<"QG9=[SZ#9T_PYU.\%2B&X\%O[3'G MQ=8 D,GE0--"8FC9./23_:J9QO^T .SQYA<@*YT1@ M[RG%PVTY\^>OZJ?44 MR%V^1 $W.)[>BR#,C$0VQ?57VZ<1;OR'X_TOFP/8Y%;Q!?C[Q>&Y32D0;Z_# MTB0 6KXU'[[R^^[OFSG !X)ML8>4]<9&WF(X,#C<._2 A>I1HMXU[$$.AV3$ ME;%"+F7R^L.=HE/2"F-04KY0>$/,/R9^W.KS5E: #-H 6S/ M6@#;L1; JV.Q #X!%ME I;AW'7Z7MC\<[W<*1 .$$Z!9%MLA(]PAI X#=,9"LU:THK#>_ZVM;Q('(@(R(E9<'5.6$.V@X94&30D@X;2&C04 MGWZP8+V)4Q'BT$G,A*S#4 1+10/==\,P H8:7IA@I\WZ\PMI-!K33$0*3ID1 MG ![)L4F=F%6:%(*QR,TV2#[6#:0DQEK,W=R7EOVD)GDR5+!;7&G2GP#?FB/=_P'<\&3$=6:U-N6YS)?X2SP M!$/BDOR';R@ WI\>BMUBE<)V6CG13H7M,#);L6WPVOXXYUO9F"O38&,U;>M] M3((T0^;^PUO4@JKZIMH'2IG)#3T+/Y 7QF$\6REZXWHWK!4A.)UK&X/QC0H,/DJBMTA*&# P2LCJ?S+;J%(]6% M*LFT)_"&SX4L> M[=!LTO5,KLGFB;^7PU?C.#>YP6[XRBZ/;B+8=X(4$ECD:C?*FK?>HUG=[ M>8#.'+N?^=:2O!&@2GO38*+ "1@ZHY]=^$*1D.B GZ_P"VZC.29.B*YDU+,8 M/E$'81\PW;8&;'I 1FSJ:O:8K1BMV2:+07 !YWN>#I^1^ DCQ;@>,.PLIPO ME''ZZ,XAU;-OD3 %#6[N\ =9JAEER-T& WBR PYW ;=Q'*\>)%K<, M2AM@QD19VD?KUJ0TZU^+$6C1/=V.'D*FI=J0LH(D,Z2F(ST!*TJM":7-Z/:R M6&*/QV,@V:N;6G_L&#'")WHR2%1' M?00$FOFDF6=TYJ$GSW5.R3/>EU!83"HC2RZ2+2[BCFC_;2JSS+\6PT748S&+B)C_,7D: MF8!\/6/([*LP=Y"MR!4U00?ETCG[G:%!& 7-O@KDC3*=Y./[<,R?76WJ$:GY M00-Z8$NWU@;F&L>'!"L*";J A'8("58("9/AW0G4]":/-X:W1$T4&]#>HU;4 M\2"[5K]OC9@"Q&@\%E= \X\[J5=-GZ8>99A#D"5\)9!'_%$N)CAAQD^@+P^& MJ)*B_@6$O&?9,/4.LS=A)"NSGLV+^]SW]FS* X4[K6N83!J+]Z.MYIGDKAF# M!6FB+^9]'B-<4A_K4PQ#63SPS#S%*DK5GY+7/SM,.P(4=QK5!EW.^X7*W.[750 MT(6Y6@T+WNO 3!_:)@V+K(4L#N0$D[[V.&="J MH6WH^QU:4D=)'25US"!U/(PX&:JU^P5H.O!SUWWG[U['1R5=Y$+[NOI>Q^<& M!FY:V.O ^H3O:X\#<\/*"7T73NH#03F:P/HL,6Z_BA.WUG4-V\$0GKXW,$_W M1,[56+(;L?$FL+$D;;ZR34O,H4PLPBT88Q74AEC$@EM2 Q.PL,M^<;SAG$U$ M=P:+*Q<1\XI:^"D"4I@3<*( -, ;%GI)ME/B=__O+>VJS5+IXB)7P1KAVUW6 MDB*W&3B8^5VP#G!*Q4*^6I5GE#;D47+E:B57K5PLGH"ZS:/9C$:J 8W<,A>; M[J1QW%S,Y)E\\SE9EEC0.LUT]HYLB2=Y=K;U_5FC,8T\=GGL\M@/?^QKL-ZU MCUVJ@_,8Z51+J@QBR?RF)FE"D_FSW)6:MT:#DRR<_@8[?2 =,?D$=Z-+'BD@ M'!D9V)W"NO;YIR=0]AB#VI5\O.EZP<,$GP[<=U4>4[@+&_]_/< M<_+[/O>M6?+6AO1MX_;$\OX1!.7/A^D<&6$R=<C0'C50N57+EX$5G7Q&+F M-G7 :/T)4N"OFU=K?\4H&Y87+U(+\6(Q5R@4\+^9T3C>L"'SY(EG46@\J\_M M@9;ZVIN=0[ $-:?40*PH%NK3':, MXL;6LT67B@M3":0]PW;I3%FMX&I,$FDQGZ(P?:K&VRC>%+:N"(CQ+VL*K M,:2M=+RD+4QA#ANNDCN_GEF+VF^&_L$:,1Z*;CT8#J*S9E++\TNUE'Z)\ \7 M"V3[C5*:O%%*I"_NG<%:FF21SF5>02I)!4DJ2&E5D#):NOEMJG+S6VSAYG_* MNLVIELX6BF)&-T82\R_&"&+E- EB&Q6ZZQEMPP6*$A8,#9ET2^_1CM?/B-AU MC%B@Y&L[A!5EQJN6#()+^?(.9W6-[1O[1H<)@W%=6KE/0%]V&^D;3MBGCW7R M8T5X6+U20()WOXWI\C=AV9ZN@2Z L KJ@GY^)&SE)S'E*#!%326FW,W"*G%\ MFHV-?_MQX!S>P@L\LQ:9%BO]V DZ]0)>C(-JP6$S']ZGEX;J953GG.EWF0BU M1'=F6Q@P83PL5X.*H6M)'#HB'"JF$H=\"8@S%2J^3?$.<5FPC3;M6Z-CXPD' MULUN__BU<=4 ->KQYO8/J4)M@,X3T2^+@N%W8_(5^,2.L&VC&6@UC827MEB@ M<"Q:NI]S(%9?4]-L\18[16ZHH]O&,'F%\77A8.V8L5JBN@"'!G($-^0B#>I_\TQ*B@41'/7O MQCSC/>I7/I 7\T7\NG ,[C.H_>*0:^QKS=P,$RP4^VIP49)-0:WY3:U1B.2\ MV,)6G?TQ4<7L3N[@,GFT\@1V[ZQ8KJFUT_^@'4?BUV;XI7XD_"HFP:^K<5\; M.0DP">1%UA.&LD8S"-")D:BT,R22.+1O'"JMR*,&1J?3IUE&(\FF#H!B4V"S M.I;%PEVV$$TR*\FL#LVLC@"-BJ<__YQZC@5H4 3$N"@G08.([NVW:FC--&_@ MP4Z89Y)/ R!E6^I1"L>BFL\08OA4J57+2(B56J502@2!=4%<>1 W"#!G2NR@@=B#5MZH[0=;.0PK+WWK%2DL%]5YKY V'[::#U MM(34'(]M!7+^=T^SL8?8.,8*_G>6HH6(]2>_B_ =B,IKA4D*7_=>/5C!A?@M MM30^\ZBIGJY$X#.#FTH5!"?X_[EIZP; :+504HO?.[2KE+0D6+H8QUBZ\J-E MGMT.AGUK3",)BSRYD>=#1D2IQ4A7'V*9HMJ_(,\2RXDI8MK_0L761K%"M710J-5!- M\&/M7!^,5!# :!+,8EP!U1#+!';0!\T?()%CC4C/#;F@YW"7K&Z9INA2SQIT M(9@OQ=!Y]0:2\[\2A[+D*#G?$1Q@YQ@>%_QO*N\8)CS) SEJLI\N)C"S<*;6 M2I6*Q,S-,;/T,3"SNPIF/H?E!SA>[A8A.< DQ\JRQ,ICQ\KRD6)E!:0J$!T9 M5BJJLA5!=&XUCKV*G#"-U43.HD"N=3!(%M78+&>L+'91YHS)G+'4Y8S)P#P9 MF"<#\X[)QE@Y4ANCJA34;..FJJSHW]T_:C+G;KE:2(1:+:_M&!U#L\=+XQPD M\&P,/*L&!QP*>"YJU41A:);IH$[+0M!6*'PB(6GCV&(EGQ5"=%&[6"VD,1)G M8@L"K-8C4]@8S:A/ZATM-QT [ZY7GP!7'$5- H?9>,U\][962$^./J^?[ MT\_PX90C:K2XPY769Z7A6SU*L9[0B1%W5RM!@S%UD\(:WI7.\UIP>N>M;(US3FUC3(R]28T$!1/3/N>-H#8U%!0(DXB= _%):$?\:2P"3)B)2 UUW&D]2 MNM%4TQ64E0D_BK._.=Q,J*[D) M(SZ_GZ:]D'Y9B>+0Q5X;%OL0.!:EQVJ#RC"[K,&R9G1'*;]+8E(':#(!71FU M1M1#E,7Z1T&?9,L>LS[)>%&S;>"3[.848Z,$S95!,Y6P><=<(U@C"[U#$N". MMS*I8[S/5B8-+L94)JT<26724/-I>0-XSS@3-4BWOW%!G7>EP@9\!$%'5D5? M,<*M(B/<9(1;6B/NGQ];3?>.F_G)[0^X:C_7'ZT;] MGK1>X,+#[>-+B\A:?%L1&DK*1F'[.^S=(H!DFE4S2X5AANQV?T.S(IIKQRD& M@L,V8_:V?)#;3+_P)[1KK\]?-:]C@,[K?+>9;7B9X\T43,;4!S+5#C<]UO@X8S>N##0HZ:X#+]; MW>\&\X*M!(9QWK? ;_@"@U#R+ZK9#KF-=Q\> US&[>&E>B%A=$LPBM;QS6$S MSN'[T2 UNI.7:E5"Z)8@E#+G_P; N2RNX*,!JMC02[4F871;5%1S>M^[&'6R M"1$-0E<^&D1&MN^R&"M.2ZA< RI9;YZE%0K\V*BE<5'' &E\2RZ+L6B3QIZ\8)M$&:*%R MB.-AN+%!>9RQ>!U<;0\,QXG$U@<3R>'[(BVUXELTK]TW*Z97EG0*)G8*7DBG MH'0*2J?@=-B) W=IKF,1D^ 6[ MU6">C,]%'H_1C&2>1)A,J"R*;!2EB+Q *9]T3F,J3=^^ZSV,'_134Y1:L92; M*CY->II#.ECKG/&3#F\VQRW\.'H;& \L@N?,8P^[-NUI_:Z?5L.<9/R&'.<9 MP-,L_D+-0/N-UX>JS?$T#PV_KS]:_D^NFY^?3,+J\;9:\H.\@J M6+2A23=QI:>G"MH4-QL_M7NR(\"Z&G]>!#X_R_#;<^><;^N# 62;]LE-GOP*TN''1HF];;_<]4/L^J*TW":(A@9* M1;L[BS0:4%(G;":4*D.Q$45*UO];2(Z\M;&0&+M6'[YA8,X0)$?+=% V%$+E M3&L4!@>^]4)#B8Q- :]:_"H:,]#2T6&]O3K[%B6EP+IVADTEO[MZ?7-B %<( M^&OYVNEZM0EGVI^O9]=7"]O.^-GJ)KV@)G_0#2KO/X9UA?VY 9*TFX!1'WO6 MV[6MP.0!ABZO[>::%/ZYW(\:@&])/0R9BBTK"GH 65\8S0+AB5WV'$DP%XJ! MC.W[]2>/G]1P^UB)^<_5'9".U.E1J07=R7(03=LP=6.H]6>!=;T0[P.11,E; MY$:F:R,SQJ2_T3=039_SY)MF:T=!Z):MND5-P[+)/X'61=@RC\*AN>DZ:I)% MIY1%'Q_@3BPOD!Q?;*HYH,)SY3VZ0&XP8[--6EE+27?SI9I3KI0<@,T5C)+&6&YFNC4PS MUVNY=-BC)ODU3^XM_4=/LU>)YY:,+Z6,+Z,L+U70F$X:\^6P.1&1K/+[>NOE M+$R:C\WIOWMY7C%77>2HD^7U .*195D) $+*57_8A!G@\/'+.=OTOWPY[[F# M_N5?_@]02P$"% ,4 " #1:&146<%\S,S4W.38N:'1M4$L! A0#% @ MT6AD5-@+UP-7!P $S( T ( !- P &5X7S,S-3%\S,S4X,#,N:'1M4$L! A0#% @ T6AD M5-$5@1\_$@ .4@ T ( !PQ@ &5X7S,S-S'-D4$L! A0#% @ T6AD5,Q* M=Z&C$P (3H! !0 ( !%,L &YR8RTR,#(Q,3(S,5]C86PN M>&UL4$L! A0#% @ T6AD5+HQ/VF>8P \( ( !0 ( ! MZ=X &YR8RTR,#(Q,3(S,5]D968N>&UL4$L! A0#% @ T6AD5-D\\9@E ME +PT( !0 ( !N4(! &YR8RTR,#(Q,3(S,5]L86(N>&UL M4$L! A0#% @ T6AD5,XN=MKE: ="D) !0 ( !$-&UL4$L! A0#% @ T6AD5$N517*"UP$ MJP\7 !, ( !)T " &YR8S(P,C$Q,C,Q7S$P:RYH=&U02P4& 2 T #0 A P VA<$ end